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Abstract 
The scarring response that follows glaucoma filtration surgery (GFS), an incisional 
surgery aimed at reducing glaucoma-related pressure increases within the eye, often 
prevents a successful outcome leading to further disease progression. Whilst a number 
of drugs have been shown to regulate scarring, a number of side effects are also 
induced largely related to the delivery method.  
 
Following on from previous work initiated in the lab whereby drugs (including the 
cytotoxic drugs, 5-fluorouracil (5-FU) and mitomycin-C (MMC), the anti-vascular 
endothelial growth factor (VEGF) monoclonal antibody, bevacizumab, and the matrix 
metalloproteinase inhibitor, ilomastat) had been fabricated into solid, slow release, 
implantable tablets, a number of questions remained pertaining to their effectiveness 
within a biological context. 
 
Using 5-FU, it was shown that concentrations at which the drug is released from the 
tablet can inhibit fibroblast activity (such as proliferation) as effectively as when using 
conventional concentrations for up to a 30 day period. Furthermore, it has been shown, 
for the first time, how gene expression within healing tissue (in-vivo) is altered upon the 
application of 5-FU at currently used clinical concentrations. Results from this study 
indicated that genes involved in apoptosis such as TP53, RelA, Bax, MYC and TXN 
were downregulated indicative of a response by the cells to limit the effects of 
apoptosis on tissue exposed to 5-FU. 
 
Secondly this thesis focuses on angiogenesis where it was shown that solid-dosage 
bevacizumab tablets functioned as effectively as bevacizumab solution in-vitro, with 
excipients of this drug such as trehalose shown to have implications in modulating 
wound healing. Furthermore, VEGF was shown for the first time to be a positive-
regulator of fibroblast activity, such as in its ability to promote matrix metalloproteinase 
(MMP) production, presenting mechanisms by which anti-VEGF drugs may function to 
inhibit the wound healing process. 
 
Finally this thesis focuses on the effects of exposing cells and tissue to ilomastat, 
whereby microarray screening was utilised to uncover novel changes in gene 
expression that both regulate the direct activity of ilomastat, as well as highlight 
 v"
secondary effects of the drug. For example, a dampening of the immune response 
(such as in the downregulation of IL-1a, IL-6, IL-8, Bip and XBP1) was observed 
following ilomastat injection. Importantly however, these experiments also highlighted a 
previously uncharacterised foreign body response that was observed upon implantation 
of the ilomastat tablet in-vivo, with the widespread upregulation of genes involved in 
this process observed including TNF, FN1, IL-1β and IL-6. As such, whilst these 
experiments exposed novel mechanisms through which these drugs function, care will 
be required in moving forward with the use of such agents and delivery methods to 
ensure thatmaximum biocompatibility is achieved. 
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Chapter 1 General Introduction
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1.1 Glaucoma and aqueous humour 
1.1.1 Overview 
Glaucoma is the name assigned to a group of disorders that are, collectively, 
characterised by the slow, progressive, degeneration of the retinal ganglion cells 
(RGCs) and their axonal processes within the optic nerve (Fechtner et al., 1994; 
Weinreb et al., 2004). Whilst damage to the optic nerve head (ONH) is commonly 
observed in glaucomatous patients, the mechanisms underlying cell death is poorly 
understood. Despite this one of the leading theories is that an increase in intraocular 
pressure (IOP) leads to mechanical stress placed upon the connective tissues of the 
ONH followed by a disruption in blood flow and subsequent cell death (Burgoyne et al., 
2005; Kwon et al., 2009). However, this theory is somewhat limited as not all patients 
present with an elevated IOP such as in normal-tension glaucoma. Nonetheless, it is 
estimated that this year, 2011, over 60 million people worldwide will be suffering from 
glaucoma, with this rising to around 80 million by 2020; of these around 14% will be 
diagnosed as bilaterally blind, confirming it as the worlds second leading cause of 
blindness (Quigley et al., 2006). Despite the high incidence rate, the disease often 
goes undiagnosed for many years, with patients unaware of their gradual loss of vision. 
Due to the lack of diagnostic markers available to physicians and opticians it is 
estimated that around 50% of all glaucoma cases are still undiagnosed (The European 
Glaucoma Society, 2003). 
1.1.2 Glaucoma classification and causes 
Glaucoma, as previously stated, is not one single condition, but rather the group name 
for several optic neuropathies (Gupta, 2004). The age of onset associated with 
glaucoma can vary greatly, ranging from childbirth [as in juvenile-onset primary open 
angle glaucoma (JOAG)] through too much later in life [as in adult-onset chronic 
primary open angle glaucoma (POAG)]. Glaucoma is subject to a number of risk factors 
including race, sex, pre-existing conditions such as Diabetes as well as genetics (i.e. a 
familial history of glaucoma), with typical symptoms of including cloudy corneas, 
disruption in, or loss of, the visual field and most commonly, an elevated IOP (Elkington 
et al., 1988; Quigley, 1993; Rudnicka et al., 2006). Whilst normal IOP is around 10-21 
mmHg, an elevated pressure, or ocular hypertension (OHT), is typically defined as a 
pressure greater than 21 mmHg, which is two standard deviations above a mean IOP 
of 15.5 mmHg (Colton et al., 1980); pressure measurements greater than 20-30 mmHg 
are typically associated with chronic damage, whilst pressures of 40-50 mmHg often 
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lead to acute visual loss (Peng Tee Khaw et al., 2004). A more thorough review of the 
links between pressure and the loss of visual field can be found in a review published 
by Ivan Goldberg where it was concluded that the lower the IOP, the slower the 
progression of glaucoma would be; the higher the IOP, the more pronounced the 
damage would be (I. Goldberg, 2003). The mechanisms that underlie the rise in 
intraocular pressure are discussed in the next sections, however changes in IOP 
remain one of the limited clinical diagnostic markers of glaucoma (The European 
Glaucoma Society, 2003). A graphical representation of the changes between a healthy 
eye and a glaucomatous eye are shown in Figure 1.1. 
1.1.3 Aqueous humour outflow 
The anterior segment of the eye is characterised by a fluid filled space referred to as 
the anterior chamber (AC), with the fluid that both fills and flows through the AC called 
aqueous humour (AH): a cytokine rich fluid that provides nutrients to, and removes 
waste from, the anterior tissues of the eye such as the cornea, conjunctiva and lens 
(Welge-Lüssen et al., 2001). The production of AH takes place within the epithelial cells 
of the ciliary body, a muscular piece of tissue, that helps in controlling the shape of the 
lens for near and far vision. As fluid is produced it passes into the anterior chamber 
before leaving, predominantly, through one of two routes: a) via drainage through the 
trabecular meshwork or b) via removal through the uveoscleral outflow pathway (Rauz 
et al., 2003). It was believed that around 85-95% of all AH leaves via the trabecular 
meshwork, with 5-15% via the uveoscleral pathway (Schuenke et al., 2007) however, 
this data was based largely on a single study that calculated flow rates through the use 
of a radioactive tracer administered into patients suffering from posterior segment 
tumours prior to enucleation of the eye (Bill et al., 1971). More recent studies using 
fluorophotometry have suggested that in young healthy patients (< 40 years of age) the 
uveoscleral pathway may actually account for up to 54% of total AH drainage (Toris et 
al., 1999). The use of different methods to measure flow rate has also led to the 
production of conflicting data when investigating the impact of outside influences on AH 
production and flow. Such factors include patient age which has been investigated by 
multiple groups, leading to a variety of conclusions: Becker and Gaasterland, using a 
tomographic approach, suggested a 30% decrease in trabecular outflow is observed in 
patients under 40 compared to those over 60, whereas fluorophotometry studies have 
argued that in fact age has no impact on AH flow rates (Becker, 1958; Gaasterland et 
al., 1978; Toris et al., 1999). The Toris study does however offer one area of increased 
accuracy over the Becker and Gaasterland studies in that it is known that several 
 27 
issues exist using tomography to measure flow rate, including ocular rigidity, which has 
been shown to increase with age (Pallikaris et al., 2005). Despite this there is still no 
full agreement as to the impact of the rate of flow on intraocular pressure even within a 
diseased state, such as glaucoma. 
1.1.4 The trabecular meshwork 
In order to understand the role of the trabecular meshwork (TM) in the progression of 
glaucoma, studies have been undertaken both in-vitro and in-vivo (Gasiorowski et al., 
2009). Human trabecular meshwork (HTM) cells have been used widely in-vitro in 
order to characterise their function in normal ‘healthy’ states, simulated diseased states 
and following drug application. In order to simulate the diseased state, HTM cells can 
be treated with the steroid, dexamethasone, to produce an in-vitro glaucoma model 
(Weinreb et al., 2004). Following dexamethasone treatment a decrease in endothelin-1 
receptor B has been observed, with this receptor associated with vasodilation. A loss of 
this receptor leads to the vasoconstriction-inducing receptor, endothelin-1 receptor A, 
as the sole receptor for endothelin-1, thus causing activation of the vasoconstriction 
pathway. This alteration in receptors has been proposed as a mechanism that could 
reduce AH outflow through contraction of the HTM (Xinyu Zhang et al., 2003). 
Furthermore, the treatment of HTM cells with dexamethasone has been shown to 
increase actin networks within the cells in-vitro, although the reasoning for this remains 
unclear (A. F. Clark et al., 1994). Recent studies have demonstrated that actin 
networks are a feature found in both normal and glaucomatous eyes and although a 
higher network-to-nuclei ratio is observed within the glaucomatous patient, a functional 
link to the development of glaucoma is yet to be established (Hoare et al., 2009). 
Similarly a number of in-vitro studies in which HTM cells have been stimulated with the 
cytokine transforming growth factor beta 2 (TGF-β2) (known to be elevated within the 
AH of glaucomatous patients) have shown that HTM cells respond by increasing the 
production of various extracellular matrix components including fibronectin, collagen IV 
and VI, all which have been shown to be in-vivo markers of a glaucomatous eyes (E 
Lütjen-Drecoll et al., 1989; Ozcan et al., 2004; Elke Lütjen-Drecoll, 2005; Wordinger et 
al., 2007).  
1.1.5 The onset of glaucoma 
Glaucoma is triggered in most instances by a blockage occurring within the trabecular 
meshwork, preventing the outflow of AH from the AC and thus causing a rise in IOP 
(Rohen et al., 1993). The cause of the blockage that leads to the rise in IOP cannot be 
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traced back to one single mechanism but rather a number of different factors that each 
contribute to the pathogenesis of glaucoma such as those previously described; 
furthermore a number of different extracellular matrix (ECM) components have been 
put forward as playing a role in the development of AH outflow prevention including the 
over proliferation of endothelial cells (Potau et al., 2002) and overexpression of 
glycoproteins such as fibronectin (Chapman et al., 1996; A.-F. Li et al., 2004). With the 
increase in technological probes it is hoped that more specific genes will be identified 
(and characterised) as being critical to the development of ocular hypertension (Diskin 
et al., 2006; Fan et al., 2008); whilst some mutations have been identified, such as the 
mutations in the myocilin gene (implicated in > 10% JOAG patients) a decade of 
research has still not elucidated its exact function (Stone et al., 1997; Borrás et al., 
2006). 
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Figure 1.1 – A graphical representation of the changes in the flow of aqueous humour during 
glaucoma. 
The upper image shows a healthy eye, with continuous flow (as denoted by the black arrow) starting at the 
ciliary body, entering the anterior chamber, before leaving through the trabecular meshwork. In a 
glaucomatous eye, as in the lower image, it is common for the aqueous outflow pathway to become 
altered, largely through to a blockage within the trabecular meshwork, leading to a rise in pressure within 
the anterior chamber. This pressure increase is passed on to the posterior segment of the eye whereby 
eventually the optic nerve becomes damaged leading to a loss of vision. Image adapted from the original 
found at the cited location (Alcon, 2010). 
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1.1.6 The treatment of glaucoma 
For most glaucoma patients the treatment approach taken is assigned on a patient-
specific basis taking into account the patient’s age, needs and rate of disease 
progression (Tsai et al., 2005). As discussed previously, the most effective approach in 
maintaining visual function is through a lowering of the IOP (Tombran-Tink et al., 
2008). Even in patients suffering from normal tension glaucoma a reduction in IOP can 
still be beneficial in slowing disease progression (Hoyng et al., 2002). In order to fulfil 
such an aim, an assortment of anti-glaucoma medications are available ranging from β-
blockers aimed at reducing aqueous production to drugs designed to increase outflow 
via either the TM (miotics) or the uveoscleral outflow pathway (prostaglandin 
analogues); however, as with most medications, a number of drawbacks are present 
when using drug therapies including (The European Glaucoma Society, 2003): 
 
I. Expense: The drugs will be required over the patient’s entire lifetime; for those 
in developing countries prolonged medication regimens are simply not an 
option. 
II. Side Effects: Many agents have systemic side effects and glaucoma 
medications are no exception; drugs that do show reduced side effects such 
as the prostamides are, however, very expensive. 
III. Compliance: Many of these drugs require repeat administration and as such 
can have poor patient compliance, particularly in the elderly where self-
administration is known to be a problem. The proportion of patients incorrectly 
following medication regimens has been shown to be high in a number of 
studies, with self-reported non-compliance occurring in over ¼ (27.3%) of 
patients in one recent study conducted by Olthoff and colleagues (Gurwitz et 
al., 1998; Olthoff et al., 2005; Ngan et al., 2007; Olthoff et al., 2009). 
 
An alternative to drug based therapies is the use of laser based treatments which have 
been available since the 1980s following an initial publication by Wise and Witter, 
although recent studies have shown a decline in use of the laser-treatments due to the 
improvements in drug therapy (Wise et al., 1979; Rachmiel et al., 2006; Fraser et al., 
2008). Despite this, as the cost of medications has continued to rise combined with an 
increasing number of patients unable to meet these costs, the effectiveness of laser 
based treatments is now being re-evaluated. In 2006 McIlraith reported that the rates of 
achieving a 20% pressure reduction were almost identical in those having selective 
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laser trabeculoplasty (SLT), a technique which increases the permeability of the 
trabecular meshwork, compared to those taking Latanoprost, a commonly used 
prostaglandin analogue, with no significant differences in IOP observed after 12 
months (83% vs. 84% respectively) (Mcilraith et al., 2006). In cases where poor 
aqueous outflow is seen, SLT or other laser-based surgical techniques will continue to 
provide an alternative to drug therapy. Nonetheless, despite both drug and laser based 
therapies providing, in the short term at least, a reduction in IOP, for many patients 
incisional surgery remains the most effective method in providing long-term control of 
IOP and the prevention of vision loss (Peng Tee Khaw et al., 2000; Shaarawy et al., 
2004). 
1.1.7 Glaucoma filtration surgery 
Glaucoma filtration surgery (GFS) involves the creation of a new drainage channel 
within the eye allowing the flow of AH out of the otherwise blocked AC leading to 
reduction in the IOP. The surgical process is summarised in Figure 1.2 and the video in 
appendix 9.1 together with a more detailed methodology found in section 2.12.1; 
however in brief the surgery involves the creation of a subconjunctival space between 
the conjunctiva and sclera, followed by the removal of a portion of the anterior 
trabecular meshwork or corneo-scleral tissue, providing a direct route between the 
anterior chamber and the newly created subconjunctival space. Closure of the 
conjunctiva allows the drainage of AH into the subconjunctival space, allowing the 
formation of a bleb whereby fluid can be absorbed back into the circulatory system via 
the lymphatic or venous system (Dhingra et al., 2009). A number of studies have 
demonstrated the success rates of filtration surgery, particularly when compared to 
either laser therapy or medications, however the use of surgical intervention is not 
without it’s own complications (Migdal et al., 1994; Lichter et al., 2001). The 10-year 
results from the Advanced Glaucoma Intervention Study (AGIS) demonstrated that in 
African-American patients failure rates could be as high as 30% predominantly due to 
scar tissue formation over the drainage site, preventing aqueous outflow and 
subsequently leading to a rise in IOP (Addicks et al., 1983; Ederer et al., 2004). To 
overcome these relatively high failure rates, anti-fibrotic agents have been 
demonstrated to provide enhanced rates of success, yet these are not without their 
own complications (M. Wilkins et al., 2005); hypotony, bleb leaks and infection are all 
complications that can occur following the use of the current clinically used medications 
such as the cytotoxic agents mitomycin C (MMC) and 5-fluorouracil (5-FU); examples 
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of healthy and infected blebs are shown in Figure 1.3, with further discussion into the 
use of cytotoxic agents is present within 1.4.2 and Chapter 3. 
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Figure 1.2 – A graphical representation of a trabeculectomy. 
Following the creation of a subconjunctival space through blunt dissection between the sclera and 
conjunctiva, a channel is created between the newly created space and the anterior chamber allowing the 
release of fluid from the anterior chamber. Following the closure of the conjunctiva fluid collects within the 
space (forming the filtration bleb) before being reabsorbed into the lymphatic or venous system. Image 
adapted from the original found at the cited location (Eyecare America, 2007). 
 
Figure 1.3 – The clinical presentation of (left) a healthy, fully functioning filtration bleb compared 
to (right) a failing filtration bleb. 
Images © Professor P. T. Khaw.
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1.2 Wound healing 
The formation of scar tissue that leads to surgical failure is the final process in the 
repair of damaged tissue following injury. The wound healing cascade can be loosely 
divided into three phases: the inflammatory response, the formation of granulation 
tissue and, finally, wound contraction (Figure 1.4) (A. F. Clark, 1996). Much of our 
understanding of the wound healing process is derived from studies investigating 
cutaneous wound healing, although many of the underlying mechanisms that have 
been generated from this research have a direct application in conjunctival wound 
healing. The time scale of the events that make up the wound healing process follow a 
similar pattern from patient to patient but can be dependent on a number of factors 
including (but not limited to): age, sex, the location and size of the injury as well as 
whether any post-wounding treatments are used (S. Guo et al., 2010). Above all, 
wound healing provides the ability for an injury or insult, such as a surgical incision, to 
be repaired leading to full restoration of the structure and function of the tissue. There 
are, nonetheless, occasions when wound healing does not always produce positive 
outcomes, such as following cataract surgery, during the scarring process following 
burns, in the development of both proliferative vitreoretinopathy (PVR) and age-related 
macular degeneration (AMD) as well as being the dominant cause behind the failure of 
GFS. To that end a number of therapies have been designed to modulate the wound 
healing response at each stage during the process; however in order to be able to 
develop novel theraputics, as well as reuse existing theraputics outside of their 
designed uses, the biology underlying each stage must firstly be examined. 
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Figure 1.4 - A 
graphical 
representation of 
the wound healing 
response over time. 
Graph adapted from 
(A. F. Clark, 1996) 
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1.2.1 Inflammatory phase 
The inflammatory response is the earliest phase of wound healing and is associated 
with widespread growth factor and cytokine release, cellular activation and tissue 
cleanup; by definition, the inflammatory phase can actually be divided into two sub 
phases: the early inflammatory response and the late inflammatory response (Velnar et 
al., 2009). The first response to any insult is to generate a clot through the release of 
several mediators that lead to coagulation and increased vascular permeability, with 
the formation of this structure serving two main purposes (Martin, 1997): 
 
I. Through the generation of thrombin, derived from the clotting cascade initially 
driven via the activation of tissue factor (F3), the conversion of fibrinogen into 
fibrin is achieved, providing a matrix to which the platelets, macrophages, 
fibroblasts and endothelial cells can migrate along as well as providing an 
initial framework for later collagen deposition (Lanir et al., 1988; Mackman, 
2009). 
 
II. To provide a source of cytokines and growth factors that lead to further 
activation and stimulation of the cells present within the wound area (Anitua et 
al., 2004). 
 
Following clot formation, there is a rapid invasion of polymorphonuclear cells, in 
particular the neutrophils and eosinophils, which each provide early destruction and 
removal of parasites and bacteria (A. F. Clark, 1996). However within a few days the 
need for their presence diminishes and neutrophil infiltration ceases, with the normal 
removal of neutrophils occurring through apoptosis followed by phagocytotic clearance 
by macrophages recruited to the wound site during the initial inflammatory response 
(Chang et al., 2000). This removal of the neutrophils signals the end of the early 
inflammatory phase and the start of the late phase, characterised in part by the 
continued accumulation of macrophages and amplified release of growth factors and 
cytokines, as listed in Table 1.1. Degradation of the clot also begins to occur at this 
stage, thought to be largely mediated through a family of proteases, the matrix 
metalloproteinases (MMPs) and in particular MMP-3 (Armstrong et al., 2002). More 
detailed information regarding the MMPs is provided within Chapter 5. 
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1.2.2 Re-epithelialisation 
The migration of cells toward, and over, the wound edge marks the start of 
reepithelialisation, with alterations in cellular integrin expression and rearrangements in 
the actin cytoskeleton key features of this phase (Yves a Muller et al., 2002; Yates et 
al., 2002; Kimura et al., 2010; Rodero et al., 2010). Epithelial migration is particularly 
essential during corneal wound healing, together with changes in the basement 
membrane leading to increased expression of several ECM components including the 
MMPs, collagens I and V, fibrin and fibronectin, all critical for the next steps within the 
wound healing cascade. New drugs, including antisense oligonucleotides, are now 
being developed to target this early, critical phase with promising results (Law et al., 
2006; Nakano et al., 2008). 
1.2.3 Angiogenesis 
In order to provide both oxygen and nutrients to the regenerating tissue new blood 
vessels must form and this is achieved through the process of angiogenesis. Blood 
vessel formation is achieved not only through the sprouting of capillaries from existing 
blood vessels but also through the activation of endothelial cells from both the basal 
membrane and bone-marrow-derived endothelial stem cells (P Carmeliet et al., 2001; 
Torsney et al., 2002; Condon et al., 2004); many of the growth factors in Table 1.1 
have important roles in these processes, in particular basic fibroblast growth factor 
(bFGF) and vascular endothelial growth factor (VEGF) (Martin, 1997; Traversa et al., 
2001). The complex mix of growth factors and ECM components that underlie tight 
regulatory control over the process of angiogenesis are discussed in more detail within 
Chapter 4. 
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Mediator Effect 
EGF Involved in reepithelialisation 
FGF Involved in angiogenesis and Granulation tissue formation. 
GM-CSF Regulation of apoptosis 
IFN-γ Stimulation and priming of macrophages. 
IL-10 ↓ production of GM-CSF; regulation of IL-12 and TNF production; regulatory effect on dendritic cells. 
IL-12 Regulation of TNF, IL-1ß IL-6 and NO production; synergy with IL-18 in stimulation of IFN-γ production in BM-derived macrophages. 
IL-15 Regulatory effect on other cytokine production 
IL-18 Augmentation of IL-12 induced IFN-γ production by dendritic cells; synergy with IL-12 in stimulation IFN-γ production by bone marrow derived macrophages 
IL-1ß ↑ of production of G-CSF and IL-1ß; regulation of apoptosis. 
IL-6 ↓ of GM-CSF and TNF gene expression. 
IL-8 ↑ of production of IL-8 through CXCR1/MAPK. 
M-CSF Sensitisation to ECM proteins (inc. fibronectin and several integrins) 
MIF Regulation of TNF and toll-like receptor 4 production; inhibition of the p53 tumour suppressor. 
NO Inhibition of proinflammatory cytokine production 
PDGF Proinflammatory agent also involved throughout all stages of wound healing. 
PGE2 Regulation of proinflammatory cytokine production 
TGF-ß Regulation of proinflammatory cytokine production and macrophage differentiation 
TNF-a Proinflammatory agent that also acts as a regulator of apoptosis. 
VEGF Involved in angiogenesis 
 
Table 1.1 - A selection of growth factors released from macrophages during the inflammatory 
response. 
↑ - Increase; ↓ - Decrease. GM-CSF, granulocyte-macrophage-colony stimulating factor; TGF-ß, 
transforming growth factor-ß; IL, interleukin; MIF, macrophage migration inhibitory factor; TXA2, 
thromboxane A2; CXCR1, chemokine C-X-C receptor 1; MAPK, mitogen activated protein kinase; NO, 
Nitric Oxide; PGE2, prostaglandin-E2. 
Table data obtained from sources as cited (Ma et al., 2003; Barrientos et al., 2008). 
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1.2.4 Granulation tissue formation and tissue remodeling 
Initially stimulated by growth factors (including TGF-ß, FGF, tumor necrosis factor-α 
(TNF-ɑ), platelet-derived growth factor (PDGF) and various interleukins including IL-1 
and IL-6 as illustrated in Table 1.1), fibrocytes in the systemic circulation, as well as 
quiescent fibroblasts existing in low numbers within the connective tissue surrounding 
the site of injury, play a large role in the wound healing response through their 
differentiation into active fibroblasts. 
1.2.4.1 The fibroblast and myofibroblast 
The fibroblast, or in an inactive state the fibrocyte, is a type of cell that is identified, 
when activated, through its elongated cell body and branched processes. Whilst 
quiescent the fibroblast take on a much smaller, stellate-like cell shape (Rosenfeldt et 
al., 2000). Early in the wound healing response, the fibroblasts invade the wound site 
where they remain active, secreting proteins involved in matrix regeneration and 
remodelling until the very end of wound healing. As the wound healing cascade enters 
the granulation phase, the fibroblast undergoes differentiation into a myofibroblast, with 
myofibroblast generation critical to scar tissue formation (Darby et al., 2007). The most 
commonly accepted theory is that of a two stage transition whereby mechanical tension 
first induces the formation of a proto-myofibroblast and the initial intracellular 
production of alpha smooth muscle actin (ASMA) and fibronectin. With continued stress 
applied to the cell as well as the presence of numerous growth factors, the cell further 
differentiates into a myofibroblast with ASMA much more extensively expressed as the 
cell gains the ability to generate a greater contractile force (Tomasek et al., 2002). Due 
to the fibroblasts key role in wound healing it is often the most targeted cell in the 
modulation of wound healing either directly (such as through the use of cytotoxics to 
induce cell death) or indirectly (such as through the use of anti-inflammatory agents 
targeting cytokines that activate fibroblasts, or the targeting of proteins secreted by the 
fibroblast, such as MMPs) (Darby et al., 2007). 
1.2.4.2 Fibroblast migration 
During the first few days of the inflammatory response, the movement of fibroblasts into 
the wound site occurs. For a cell to be able to migrate it must first adhere to the matrix, 
which is primarily controlled via the cell surface receptors, the integrins. Formed from 
heterodimeric glycoproteins these receptors are targets for a number of ECM 
components including collagens, laminins and fibronectin (Kumar, 1998); the full table 
of currently known integrin subunits, and their targets, is available in a review published 
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by Wang and colleagues (Z. Wang et al., 2010). The binding of an ECM component 
(also known as a matrikine) to an integrin receptor triggers the activation of multiple 
signalling cascades involving various kinase family members such as focal adhesion 
kinase (FAK; known to be involved in the regulation of cell death), mitogen activated 
protein kinases (which form the MAPK signalling cascade) and phosphoinositide 3-
kinase (part of the PI3K signalling cascade), with each cascade triggering a variety of 
physiological processes including cellular migration, adhesion and proliferation (Ilić et 
al., 1998); more information on these signalling cascades is available in Chapter 4 and 
Chapter 5. For example, during wound healing it has been shown that the [epidermal 
growth factor (EGF)]-like repeat domains of Tenascin C, an extracellular matrikine that 
been demonstrated to be upregulated during the both the inflammatory response and 
later remodelling phases, and laminin bind the EGF receptors acting to enhance 
fibroblast migration, initially triggered by more freely circulating cytokines (Mackie et al., 
1988; Swindle et al., 2001; Tran et al., 2005). Tenascin C is also known to upregulate 
MMP expression through EGF receptor activation, with MMPs able to cleave Tenascin 
C into fragments, some of which contain the EGF-like repeat domains suggesting the 
presence of a positive feedback loop (K Wallner et al., 1999; Kurt Wallner et al., 2004). 
Collagen (also a matrikine) contains a triple helix structure that serves as a ligand for 
discoidin domain receptors 1 and 2 (DDR1 and DDR2). Activation of DDR2 following 
the cleavage of collagen (via MMP-1) sets off a feedback loop further increasing the 
level of MMP-1 expression (Vogel et al., 1997). Similarly, it has been demonstrated that 
DDR2 activation can lead to the upregulation of MMP-2, with DDR2 knockout mice 
displaying an almost complete inability to activate the MMP-2 promoter (Olaso et al., 
2001). Further information with regards to the matrikines and their physiological effects 
is available in a review by Kien Tran (Tran et al., 2005). 
1.2.4.3 Matrix contraction 
Much of current knowledge regarding the role of matrix contraction in wound healing 
has come about through the use of in-vitro studies using a model first described by Bell 
and colleagues, where cultured fibroblasts were suspended in a collagen matrix which, 
over time, reduced in size due to fibroblast mediated contraction (Bell et al., 1979). 
Using such models, we have gained an understanding of both the positive and 
negative regulators of several processes involved in wound contraction such as the 
fibroblast-myofibroblast transition. For example, during the final granulation stages of 
tissue formation where wound contraction occurs, it has been demonstrated that the 
myofibroblast is able to express a number of microfilaments that can bind to the ECM, 
 41 
producing a contraction of the matrix (Hinz et al., 2003); at the same time the 
deposition of collagen around the cells leads to the stabilisation of the contraction, 
resulting in the contracted appearance of a scar (Gabbiani, 2003). It had been 
proposed in the past that other cells could organise bundles of actin around the wound 
edge but this view is now overshadowed due to the mounting in-vitro and in-vivo 
evidence that the process of contraction is myofibroblast dependent (Bullard et al., 
1999; Tomasek et al., 2002). After sufficient collagen deposition and remodelling has 
taken place, the majority of undifferentiated fibroblasts undergo apoptosis with the 
myofibroblasts either reverting to their fibroblastic form, remaining as such, or also 
undergo apoptosis themselves (Akasaka et al., 2010). The switch for fibroblasts to stop 
producing collagen, despite the continued presence of ‘pro-collagen-production’ 
factors, is believed to be brought about (in part) through the increased expression of 
decorin, a member of a family of small leucine-rich proteoglycans which stabilise the 
ECM by binding Type I collagen leading to the downregulation of cellular migration, 
proliferation and protein synthesis (Csordás et al., 2000; Tran et al., 2005). However it 
is likely that far more regulatory switches exist, with each playing an intricate role in 
regulating cell activity. 
1.2.5 Remodeling phase 
Whilst collagen deposition takes place the remodelling phase of the wound healing 
response also begins, characterised by fibroblast mediated replacement of collagen 
type III with collagen type I, providing a stronger framework for the tissue. Despite the 
production of crosslinked, collagen bundles, scar tissue never recovers to the same 
quality and strength as it was pre-wounding (Clark, 1996; Clark, 1996; Velnar et al., 
2009). 
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1.3 Growth factors and cytokines 
Many growth factor families exist with each playing a part in the control of cellular 
functions such as proliferation, migration and apoptosis as well as in the regulation of 
gene expression and protein production during processes such as wound healing. 
Whilst many of these cytokines were previously illustrated in Table 1.1, a summary of 
the key factors is presented below. 
1.3.1 Transforming growth factor beta 
The TGF-β superfamily is a group of proteins that regulate cellular function in a number 
of ways including protein production, movement and proliferation [for a thorough 
description of all of the family members of the TGF-β superfamily please refer to the 
review of Schmierer and Hill (Schmierer et al., 2007)]. A subfamily of the same name 
is, classically, thought of as being the most important during wound healing, with a 
great deal of research having taken place into the roles of this group of cytokines that 
include TGF-β1, -β2 and -β3, with each binding to a pair of serine-threonine kinase 
receptors, TGF-β receptor 1 and TGF-β receptor 2 that signal through the activation of 
the Smad signalling pathway (5.1.2.1.4). A third TGF-β receptor exists, TGF-β receptor 
3, though this is a non-signalling receptor (Attisano et al., 1994). In relation a second 
important subfamily is the decapentaplegic-Vg-related (DVR) family, which include the 
bone morphogenic proteins (BMPs) that can negatively regulate TGF-β function. 
Research is currently ongoing as to the therapeutic potential of recombinant BMP 
proteins in the inhibition of TGF-β signalling (De Caestecker, 2004; Fuchshofer et al., 
2007). The use of in-vitro studies has demonstrated that all three isoforms of TGF-β 
can impact the activity of cells, with Cordeiro et al (Cordeiro et al., 2000) reporting that 
each of the TGF-β isoforms can stimulate fibroblast mediated collagen gel contraction, 
proliferation and migration in a dose-dependent fashion specific to each isoform. 
Similarly, experiments undertaken in-vivo have demonstrated the importance of TGF-
β2 in stimulating fibroblast recruitment and activity, such as through the enhanced 
deposition of collagen type III (Cordeiro, Reichel et al., 1999). Further information on 
the effects of TGF-β can be found in a review published by Francesca Cordeiro 
(Cordeiro, 2002), with the theraputics targeting of TGF-β2 discussed below (1.4.3.1). 
1.3.2 Platelet-derived growth factor 
The platelet derived growth factors are a family of growth factors that are produced by 
platelets, macrophages, fibroblasts and keratinocytes (Heldin et al., 2002). Similar to 
the TGF-β proteins, PDGF acts as a ligand for two transmembrane tyrosine kinases 
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that signal, primarily, through the signal transducer and activator of transcription 
(STAT) signalling cascade as documented in 5.1.2.1.3. Platelet derived growth factor is 
a multi-functional protein, initially stimulating cell migration of, and cytokine release 
from, the fibroblasts, macrophages and neutrophils as they enter the wound site (Vij et 
al., 2008). Later in wound healing, PDGF provides important stimulation for both 
angiogenesis and tissue remodelling, where PDGF is known to infer multiple effects, 
including stimulation of the fibroblast-myofibroblast differentiation. Kaur et al (Kaur et 
al., 2009) demonstrated that a blockade of PDGF family member PDGF-B led to a 
decrease in ASMA positive cells in the corneas of rabbits following laser-induced injury. 
Further effects of PDGF have been documented such as inducing the upregulation of 
MMP expression, leading to the enhanced degradation of the ECM; in-vitro a number 
of groups have shown that MMP-1 and MMP-2 production is stimulated following 
PDGF application, with gel contraction assays demonstrating that PDGF is capable of 
stimulating collagen contraction (R. A. Clark et al., 1989; Yanagi et al., 1991; Osawa et 
al., 2002). 
1.3.3 Vascular endothelial growth factor 
Vascular endothelial growth factor is the family name for a group of growth factors 
involved, primarily, in angiogenesis. Both VEGF and angiogenesis are dealt with in 
detail within Chapter 4 and as such the reader is referred to this section for more 
information. 
1.3.4 Connective tissue growth factor 
Connective tissue growth factor (CTGF) is an ECM-associated protein that functions to 
stimulate proliferation and migration of fibroblasts during, primarily, the granulation 
tissue formation phase (Leask, 2004). Connective tissue growth factor is known to 
function downstream of TGF-β with Garrett et al (Garrett et al., 2004) showing that the 
knockdown of CTGF in fibroblasts under tension can lead to a decrease in collagen 
contraction following TGF-β1 stimulation. The finding that hypertrophic scars contain 
higher levels of CTGF was not an entirely unexpected finding, with CTGF further known 
to induce ECM protein production such as collagen type I and fibronectin, both of which 
are associated with the granulation tissue formation (Frazier et al., 1996; Colwell et al., 
2005). The development of anti-CTGF treatments is currently ongoing, with Adler and 
colleagues recently reporting that phase 1 clinical trials of an anti-CTGF monoclonal 
antibodies were well tolerated when used to treat diabetic kidney disease, a condition 
marked by fibrosis within the kidney (Iwano et al., 2004; Adler et al., 2010). 
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1.3.5 Epidermal growth factor 
The epidermal growth factor family is a family of mitogens composed of several 
members including: EGF, heparin binding EGF (HB-EGF) and transforming growth 
factor α (TGF-α), which collectively function through four receptors: EGFR, HER2, 
HER3 and HER4 which collectively activate a number of downstream signalling 
cascades including the STAT and Ras cascades (Freeman, 1998; Klämbt, 2000). 
Epidermal growth factor is secreted from platelets, macrophages and fibroblasts acting 
in a paracrine fashion, with in-vitro studies demonstrating that EGF is also important in 
regulating keratinocyte proliferation and migration (Ando et al., 1993).  
1.3.6 Fibroblast growth factor 
The fibroblast growth factor (FGF) family is a 22 member group of polypeptide growth 
factors that function through four transmembrane protein tyrosine kinases, signalling 
through many of the same pathways as the other cytokines including the Ras, PI3K 
and STAT cascades (Powers et al., 2000; Barrientos et al., 2008). Of the numerous 
FGF family members, FGF2 appear to exert the most predominant effects during 
wound healing, with the FGF2 knockout mouse shown to display a delayed wound 
healing response, with late re-epithelisation observed; FGF1 knockouts meanwhile 
showed no changes in the wound healing response (Ortega et al., 1998). 
1.3.7 Inflammatory cytokines 
The inflammatory cytokines are a group of proinflammatory proteins that include the 
interleukins (some of which are shown in Table 1.1), which have previously been 
demonstrated to be upregulated in the inflammatory phase of wound healing (Hübner 
et al., 1996; Grellner et al., 2000). The use of knockout animals has provided a number 
of insights into the roles of the interleukins such as in the IL-6 knockout mouse, where 
wound healing responses were three times longer than control animals; administration 
of recombinant IL-6 one hour prior to wounding could, however, completely rescue the 
healing response (Gallucci et al., 2000). Similarly through the use of foetal wounding 
models, Liechty and colleagues were able to show that the addition of IL-6 resulted in 
scar formation in a normally scarless wound healing model presenting IL-6 as a 
potential target for the modulation of wound healing and scar formation. In-vitro studies 
have demonstrated that IL-6 is able to induce MMP-1 expression through the activation 
of the STAT3 signalling cascade, with STAT3 downregulation in keratinocytes shown to 
lead to a reduced reepithelialisation following skin wounding (Sano et al., 1999; Y. Li et 
al., 2010). Despite this it is possible a greatly reduced effect on the impact of STAT3 
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knockdown was observed in this study due to the restriction of the STAT3 knockdown 
being solely restricted to the keratinocytes; a more widespread knockdown or inhibition 
of STAT3 may lead to an enhanced impairment of wound healing.  
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1.4 The modulation of wound healing 
The modulation of wound healing is critical to providing long-term successful outcomes 
in a number of conditions, particularly following GFS. The use of cytotoxic agents has 
become the most clinically effective treatment strategy in controlling GFS related 
scarring, although a number of experimental drugs have been investigated with the aim 
of finding an agent that offers reduced toxicity together with improved surgical 
outcomes. These experimental drugs have led to both in-vivo studies and full-scale 
clinical trials, although yet no single drug has been shown to be better than the 
currently used cytotoxics when tested in human patients following GFS. 
1.4.1 Steroid and anti-inflammatory agents 
One of the major targets following any injury is that of the inflammatory response and 
as such the use of steroids and anti-inflammatory agents to inhibit downstream cell 
proliferation, angiogenesis and matrix synthesis have all been explored (Anstead, 
1998). The use of glucocorticoids in wound healing studies has been shown to reduce 
neutrophil numbers at the site of injury following a single application, with further effects 
demonstrated on vascular permeability when, through the inhibition of kinin activation 
and histamine production, a decrease in leakage of clotting factors was observed, 
reducing the clot’s ability to play a major role in the initial wound healing response 
(Pierce et al., 1989; Lama et al., 2003). Ocular corticosteroids have also been used to 
modulate wound healing following GFS, with Starita and colleagues demonstrating that 
the topical application of prednisone, a synthetic corticosteroid, could lead to a 
significant improvement in early success rates, although no additional benefits were 
gained through systemic administration (Starita et al., 1985). In 5 and 10 year follow up 
studies it was concluded that in eyes treated with a steroidal regimen post-GFS a 
significantly greater stabilisation of IOP was achieved together with a greater halt in 
disease progression and a reduction in the number of repeat surgeries required (Roth 
et al., 1991; Araujo et al., 1995). More recent studies have confirmed the potential 
benefits of pre-operative steroidal treatment with Breusegem and colleagues showing 
that patients treated with topical ketorolac or fluorometholone [a non-steroidal anti-
inflammatory drug (NSAID) and corticosteroid respectively] for one month before 
surgery were less likely to require either post-operative revision (bleb manipulation was 
required in only 5% of patients in the steroidal group vs. 24% in the control group) or 
post-operative drug treatment (24% in the control group vs. 0% in the steroidal group) 
(Breusegem et al., 2010). Whilst such results are encouraging, the use of 
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corticosteroids can in some circumstances further enhance the progression of 
glaucoma due to changes induced within the trabecular meshwork with both long term 
systemic and high dose topical corticosteroid treatment regimens having been shown 
to increase ECM protein deposition present within the TM, such as the 
glycosaminoglycans, elastin and fibronectin (R. Jones et al., 2006). Whilst these side 
effects will only be reported in a small subset of patients, without any clear treatment 
regimens currently established, further work is required to elucidate the optimal use of 
steroids post-operatively. Similarly, the use of NSAIDs to suppress the inflammatory 
response following GFS has, in a separate study by Kent et al (Kent et al., 1998), been 
shown to offer no benefit, highlighting the need for a documented treatment strategy 
and more focussed trials. In comparing the use of both the NSAID, diclofenac, and the 
corticosteroid, prednisolone, following GFS augmented with MMC, no statistically 
different outcomes were achieved with regard to either IOP control or surgical success 
at 6 months when compared to the use of MMC alone. In studies outside of the eye, 
the use of a COX-2 inhibitor was unable to alter keratinocyte proliferation and 
differentiation in the mouse epidermis following abrasion, even though the widespread 
upregulation of COX-2 is well characterised during the wound healing process (Hardy 
et al., 2003). Despite this, Wilgus et al (Wilgus et al., 2003) reported a reduction in scar 
formation in mice following topical celecoxib (an NSAID) treatment of full thickness 
incisional wounds. These mixed outcomes reported in the literature further highlight the 
requirement for more research into the role of NSAIDs modulating wound healing, 
particularly following GFS. 
1.4.2 Anti-proliferative (cytotoxic) agents 
The widespread use of antiproliferatives agents has lead to a major advancement in 
the number of successful trabeculectomies carried out worldwide each year (Peng Tee 
Khaw et al., 2000). The widespread fibrosis that is associated with wound healing 
following GFS was identified as a major target for modulation and as such led to the 
development of treatment regimens aimed at reducing either fibroblast function or 
number. Of the drugs available during this initial development, 5-fluorouracil and 
mitomycin-C were identified and became the basis for the development of a treatment 
regimen that is still in use today. The role of the cytotoxics is discussed in more detail 
within Chapter 3. 
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1.4.3 Growth factor inhibition 
As discussed previously in 1.3, the cytokines and growth factors present during wound 
healing can have great effects on the response observed. Various knockout and 
knockdown studies demonstrated that the absence of just one cytokine could severely 
retard the wound healing cascade, with such data subsequently leading to the 
development of drugs designed to specifically target single growth factors, most 
commonly through the use of monoclonal antibodies. 
1.4.3.1 CAT-152 and TGF-β2 inhibition 
As discussed in 1.3.1, TGF-β has been shown to be a highly potent stimulator of 
fibrosis and scarring, and of the three isoforms TGF-β2 was shown to be the most 
prevalent during wound healing following GFS (Cordeiro, Reichel et al., 1999). 
Following the development of the TGF-β2 neutralising, humanised monoclonal 
antibody CAT-152 (designed and produced by Cambridge Antibody Technology), in-
vitro testing established that CAT-152 was able to significantly inhibit TGF-β2 induced 
fibroblast proliferation, migration and collagen gel contraction (Cordeiro, Gay et al., 
1999). Subsequent in-vivo studies further highlighted the effectiveness of CAT-152, 
with results demonstrating significant reductions in both post-operative scarring and 
bleb failure when compared to the control group in a model of GFS (Cordeiro, Gay et 
al., 1999; A. L. Mead et al., 2003). After 30 days of study 83% of the blebs remained 
functional in the CAT-152 group compared to just 33% in the control group. 
Subsequent in-vivo studies confirmed these findings and histological analysis 
comparing CAT-152 treated eyes to those receiving 5-FU demonstrated that CAT-152 
was also less destructive to the tissue (A. Mead, 2006). From the results of these in-
vivo studies, CAT-152 was entered into clinical trials, however the results of a 388 
patient, phase III, study demonstrated that the success rate for CAT-152 was only 
60%, compared to 68% in the placebo group concluding that there was no significant 
benefit from the use of the TGF-β2 neutralising antibody. However this study failed to 
take into account a number of factors that may have resulted in the negative outcome 
observed from the study. Firstly the levels of TGF-β2 that may have been present 
within the patients prior to surgery was not assessed. Whilst the level of TGF-β2 
present post-operatively are known to be elevated, it is also known that the levels of 
TGF-β2 in patients with raised IOPs (as in POAG) are significantly higher than in 
normal eyes (Tripathi et al., 1994; Min et al., 2006). To this end the patients may simply 
have required larger doses (higher concentrations) of the drug for an effective inhibition 
of TGF-β2. Secondly, the administration of CAT-152 was only undertaken twice post-
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operatively, with the latest injection occurring one week following surgery, potentially 
missing the time when the neutralising antibody would have had its biggest impact. 
Whilst TGF-β2 is involved in the initial inflammatory response (1.2.1), during the first 
week other cytokines such as the interleukins and TNF-α play at least as great, if not 
greater, role in regulating the response to injury, with TGF largely required later in the 
response during the continued activation of fibroblasts and the induction of the 
fibroblast-to-myofibroblast transition. This expression of TGF-β2 over time was 
highlighted by Kryger et al (Kryger et al., 2007) who reported that TGF-β2 levels did not 
peak until day 15-28 in a rabbit ear model of wound healing. Why such a dosing 
regimen was chosen remains unclear, especially considering that in-vivo studies were 
undertaken with a dosing regimen that involved the injection of CAT-152 over a 14 day 
period (A. L. Mead et al., 2003). As such, the use of an alterative dosing regimen may 
have altered the outcome of this clinical trial and highlights the importance in 
understanding both drug pharmacokinetics as well as the biology behind the target of 
the drug. 
1.4.3.2 Bevacizumab 
Vascular endothelial growth factor is the major cytokine in the promotion of 
angiogenesis, as discussed previously in 1.3.3 and later in 4.1.3. Within the eye it has 
been associated with a number of diseases including macular edema, 
neovascularisation during AMD as well as the development of PVR (Grisanti et al., 
2007). Bevacizumab (Avastin) is a recombinant humanised monoclonal IgG1 antibody 
that is able to sequester VEGF inhibiting the activation of its target receptor. The use of 
bevacizumab as an adjuvant therapy to this date has not been well documented, 
although the drug is being increasingly use as a post-GFS therapeutic. The limited 
studies that have taken place have suggested that it may be able to modulate the 
wound healing response as either a single drug, or as an adjuvant therapy to the 
currently used theraputics (Z. Li et al., 2009; How et al., 2010). Further discussion with 
regards to the use of bevacizumab is available in 4.1.7.1. 
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1.5 Delivery methods 
Conventional therapies that are used peri- or postoperatively, such as those described 
in 1.4, are largely delivered via sponge application or injections. However, ocular drug 
delivery poses many difficulties, largely due to the biological barriers that exist within 
the eye such as the cornea, sclera, lens and vitreous (Urtti, 2006). An ideal ocular drug 
delivery system is one that is able to deliver the drug to the target site at a therapeutic 
concentration without causing tissue damage. Furthermore, the drug must be present 
over a sufficient period such that it can achieve its pharmacological goal without any 
local, or systemic, side effects.  
1.5.1 Current methods 
1.5.1.1 Injections 
Many drugs, particularly those used to control glaucoma, are delivered via topical 
administration (i.e. eye drops, ointments and contact lenses), however these are 
greatly limited in their effectiveness [as previously discussed (1.1.6)]. In order to be 
able to achieve more specific targeting, such as into the subconjunctival space or 
targets within the posterior segment, injections are used to deliver pharmacological 
agents. Whilst administration of drugs into the posterior section of the eye (to target, for 
example, the vitreous, retina or choroid) can be more difficult than into the front, the 
structure of the vitreous (a thick, gel like substance) allows for slow, prolonged, 
diffusion improving the half life of the drug when compared to anteriorly delivered drugs 
which are often subject to rapid fluid clearance from the eye due to the flow of AH. As 
such, in order to deliver drugs post-operatively, such as 5-FU, at levels that lead to 
sufficient inhibition of the wound healing process, very high, toxic, concentrations are 
required (i.e. 25 - 50 mg/ml). However using the drug in this way can lead to a number 
of, often severe, side effects including cell death within the conjunctival epithelial layer, 
with such a loss of cells a potential cause of late bleb leaks (a hole within the bleb wall) 
which often require surgical revision as previously documented (Geggel et al., 1984; T. 
T. L. Wong et al., 2003; Francis et al., 2005; Simsek et al., 2010). More extreme 
complications have also been documented, such as the direct injection of 5-FU into the 
anterior chamber; although sight threatening complications were eventually avoided in 
the reported cases, such mistakes can happen when using the method of 
subconjunctival injection (Mazey et al., 1994; Chalfin et al., 1995; Bhermi et al., 1999). 
Furthermore dosing regimens that involve subconjunctival injections at either daily, 
weekly or monthly basis (depending on the stage of the wound healing response) are 
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required to provide prolonged inhibition of the healing process; the development of 
such regimens are discussed further within 3.1.4 but such regimens only prolong the 
risk associated with subconjunctival injections together with prolonged discomfort for 
the patient in having to return for regular injections. 
1.5.1.2 Sponge application 
For cytotoxic drug use intraoperatively, small sponges soaked in drug are often used 
which can be placed into the subconjunctival space during surgery for around 3-5 
minutes (Siriwardena et al., 2004). From data published by Wilkins and colleagues it 
appears, however, that neither the size of the sponge, sponge material nor application 
time impact the delivery of drug beyond a maximum delivery time of 3 minutes with a 
sponge size of 2.5 x 2 mm, and 5-FU at a concentration of 25 mg/ml (M. R. Wilkins et 
al., 2000). However, even with these short application times the potential for side 
effects are rife. Due to the location of the sponge, the cytotoxic drug is exposed to the 
entirety of the subconjunctival space, leading to widespread cell death. Whilst this 
includes the targeted fibroblasts, conjunctival epithelial cells are also affected leading 
to cell death within the epithelial cell layer and the subsequent complications often 
associated with these drugs (1.4.2 and 3.1.4). Therefore, whilst sponge delivery 
provides a practical way of delivering cytotoxics during a trabeculectomy, 
improvements to the delivery method to reduce potential side effects, but retain the 
long-term effects of this dosing strategy are sought. 
1.5.2 Novel methods 
The delivery of a drug via a semi-solid or solid insert has been widely investigated and 
is discussed in more detail during the following chapters. Whilst these devices can 
improve the delivery times of drugs from several days up to several months (in-vitro), 
many of these studies have remained at a pre-clinical level with work limited to in-vitro 
or in-vivo studies requiring further work to overcome many of the obstacles associated 
with implantation devices such as the foreign body reaction and in-vivo factors which 
alter the in-vitro calculated drug release rates (Refai et al., 2010).  
One example of such a novel drug delivery comes from the use of ilomastat, a matrix 
metalloproteinase inhibitor, in the control of post-operative scarring. Whilst this topic is 
detailed in greater detail within Chapter 5, it provides an outline of the potential benefits 
of using such delivery systems. Initial studies into the use of ilomastat in the control of 
post-operative scarring required the use of repeat injections of ilomastat over a period 
of approximately one month, however after 60 days of study 43% of the blebs had 
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failed; one explanation for such a failure was the lack of drug present at the site of 
wound healing after the final injection of drug. Whilst failure was not instantaneous, and 
not observed in all groups, it is possible that such failure was seen due to the 
withdrawal of the drug indicating the requirement for the continuous presence of drug. 
Survival beyond the removal of drug does however potentially indicate that the drug 
may have remained present within the tissue, or had exerted an effect that lasted 
beyond the presence of the drug (T. Wong, 2004). In subsequent studies that used a 
solid dosage form of ilomastat that was able to continuously deliver ilomastat over a 30 
day period, 100% bleb survival was observed after 30 days of study following 
experimental GFS, indicating the benefits of sustained release. This therefore suggests 
that the benefits of sustained, prolonged, delivery of ilomastat may offer greater effects 
than that of the short term delivery seen through repeat subconjunctival injections. 
More information on these studies can be found within section 5.1.2.4.1. 
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1.6 Overall hypothesis and aims 
The background literature has outlined the importance of the wound healing process, 
and subsequent scar formation, in the outcome of GFS.  Whilst a number of drugs are 
available to clinicians, which can, successfully, control the wound healing response, a 
number of drawbacks are, nonetheless, present. For example the perioperatively used 
cytotoxic agents, such as MMC and 5-FU, are applied over a short period at high 
concentrations to ensure fibroblast activity is inhibited. However, such use is known to 
causing a number of severe side effects, including blindness. Similarly, the post 
operative use of repeat injections to deliver not only cytotoxic drugs, but antibodies and 
experimental drugs, can itself expose the patient to increased risk and discomfort. 
 
Recent studies have highlighted the potential benefits of using small, slow release, 
tablets (as in the development of the ilomastat tablet), however to this point little 
biological data as to the way they function outside of their initial mode of action (e.g. 
MMP inhibition) or the direct way in which they can prevent scarring, exists (T. Wong, 
2004; S. D. Georgoulas, 2010). Furthermore as development of these tablets has 
continued, new drugs have been used although little data is present in order to 
demonstrate their biological effectiveness (Ru, 2010; Khalili, 2011). 
 
Specific aims and experimental plans are given at the beginning of each results 
section. However, based on these previous studies it is therefore hypothesised that: 
 
i. Fabrication of tablets containing 5-FU can release drug at a concentration, and 
for a period of time, that is sufficient to inhibit fibroblast activity at least as well as 
current therapeutic regimens using 5-FU, and other cytotoxic agents such as 
MMC. Furthermore it is hypothesised that besides inhibiting fibroblast activity 
through DNA intercalation, MMC is able to alter the gene expression profile of 
cells and tissue into a state beneficial for wound healing inhibition such as 
through the decreased expression of pro-inflammatory genes. 
 
ii. The anti-VEGF drug bevacizumab, when formulated into a slow release tablet, 
can inhibit HUVEC and fibroblast activity as effectively as stock solutions of 
bevacizumab over a range of concentrations. It is further hypothesised that both 
current excipients in stock bevacizumab solution, as well as those added into the 
production of bevacizumab tablets, will remain inert and not affect cell activity 
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such as proliferation. Finally, it is hypothesised that the reason bevacizumab 
functions to inhibit wound healing is not solely due to an effect on angiogenesis 
but also a direct effect on fibroblasts themselves, with VEGF able to promote 
fibroblast activity such as proliferation and upregulate pro-wound healing genes 
and proteins such as the MMPs. 
 
iii. The matrix metalloproteinase inhibitor, ilomastat, is able to inhibit wound healing 
through secondary pathways that are a consequence of MMP inhibition. 
Previously it has been shown that MMP-1 and MMP-2 gene expression is 
downregulated following the application of ilomastat, but it is unknown whether 
this extends to not only other MMPs but other gene networks (T. Wong, 2004). It 
is therefore hypothesised that ilomastat, is able to alter fibroblast activity (such as 
proliferation) as well up/downregulate genes of multiple signalling pathways such 
as the inflammatory cascade, apoptosis and cell motility, both in-vitro and in-vivo. 
Furthermore it is hypothesised that the prolonged presence of ilomastat, as 
delivered through a slow-release tablet, will cause gene expression changes that 
further aid in the inhibition of wound healing when compared to a single dose of 
ilomastat in a model of glaucoma filtration surgery and distinct signalling patters 
will be come clear that are the result of this prolonged presence. 
 
To explore these hypotheses a range of tools will be utilised as outlined in Chapter 2, 
with both in-vitro and in-vivo analysis to be undertaken. 
Chapter 2 Methods 
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The methods section of this thesis aims to describe, clearly, the way in which work was 
carried out in the production of the results presented. This section deals entirely with 
assays that were used in each of the results chapters. 
2.1 Cell culture techniques 
2.1.1 Propagation of primary explants of human Tenon’s fibroblasts 
Experiments were carried out using human Tenon’s fibroblasts (HTFs) as they provide 
an excellent cell type to model the fibroblasts present during conjunctival wound 
healing and the subsequent scarring process (Y. Liu et al., 2008). Cells were grown 
from donor eye explants obtained from Moorfields Eye Hospital Eye Bank under the 
Tenets of the Declaration of Helsinki (1989) following previously described protocols (P 
T Khaw, Ward et al., 1992; Julie T Daniels, Cambrey et al., 2003). Explants were 
placed into 25cm2 flasks (T25, 156367, Fisher, UK) and allowed to attach before the 
addition of 5 ml of culture medium (referred to as Fibroblast Growth Medium, FGM) 
consisting of Dulbecco’s modified Eagle’s medium (DMEM, 41966-029, Invitrogen, UK) 
supplemented with 10% fetal bovine serum (F9665, Sigma, UK), 1% 200 mM L-
glutamine (25030-024, Invitrogen, UK) and 1% 100 U/ml penicillin / streptomycin 
(15140-122, Invitrogen, UK). Flasks were incubated at 37°C and 5% humidified CO2. 
The culture medium was replaced every three days. All tissue culture was performed in 
a laminar flow hood and all solutions were sterile and warmed to 37°C in a water bath 
prior to use. Serum used for all experiments was batch tested prior to use to ensure 
acceptable levels of HTF activity. The batches used during these experiments were 
015K3395 and 018K3396.  
2.1.2 Culture and maintenance of HTFs 
Explant derived fibroblasts were normally found to be confluent within four weeks of 
initial plating. Upon reaching 70 – 80% confluency, cells were either passaged into new 
flasks, following the plating densities shown in Table 2.1, or frozen down for storage in 
liquid nitrogen (see 2.1.4). Cells were detached from their flasks using trypsin 1X 
(25300-054, Invitrogen, UK). The flask was washed once in phosphate buffered saline 
(PBS, 14190-094, Invitrogen, UK), using enough PBS to ensure a coating of the flask. 
Following removal of the PBS, trypsin was added to the flask following the volume 
described in Table 2.1 and incubated at 37ºc for two minutes. Following this, the cells 
were checked for sufficient detachment under a phase contrast inverted microscope 
(Nikon Eclipse TS100, Nikon, Japan). Images, if required, were obtained with a digital 
camera with microscope attachment and stored as JPEG files (DS-Vi1 and DS-L2, 
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Nikon, Japan). If cell attachment was still visible, the flask was either tapped gently to 
encourage detachment or placed back into the incubator for an additional 20 - 30 
seconds. Trypsinisation was stopped through the addition of an equal, or greater, 
volume of FGM, before the resultant cell suspension was transferred to either a 15 or 
50 ml Falcon tube (FB55950 or 430921 respectively, Fisher, UK) and centrifuged at 
1000 g for five minutes. The resultant cell pellet was resuspended in 1 ml FGM to allow 
counting prior to plating. All fibroblasts used in this body of work were used between 
the 1st and 7th passages as cells at these passages are at their peak condition and 
behave similarly with respect to rates of cell proliferation and growth characteristics 
despite being derived from different cell donor explants (P. T. Khaw, 1995). 
Flask Size Seeding Density (cells) Growth Medium (ml) Trypsin (ml) 
T25 2.0 - 5.0 x 105 5-8 1 
T75 7.0 - 10.0 x 105 10-15 2 
T175 1.0 - 2.0 x 106 20-25 4 
Table 2.1 - Seeding Densities, growth medium and trypsin used for culturing HTFs. 
2.1.3 Culture and maintenance of human umbilical vascular endothelial cells 
Human umbilical vascular endothelial cells (HUVECs) were obtained, commercially, 
from Lonza Bio (CC-2519, Lonza, UK). Cells were provided at passage zero and 
cultured as per the manufacturer’s instructions and documented literature (Helgason et 
al., 2004). T75 flasks were plated with 1x106 HUVECs, with each flask containing 12 
ml of endothelial culture medium (EGM) composed of EBM Basal Medium 
supplemented with an EGM SingleQuot Kit Supplements and Growth Factors (CC-
3121 and CC-4143 respectively, Lonza, UK). This kit provided cells with a growth 
medium composed of 2% FBS supplemented with a source of growth factors [(Bovine 
Brain Extract (BBE)], human endothelial growth factor (hEGF), hydrocortisone, and 
antibiotics [gentamicin, amphotericin B (GA-1000)]. The HUVECs were only used 
between the 1st and 5th passages as continued passaging of HUVECs beyond this 
point has been shown to lead to senescence which, in part, is characterised by the loss 
of functional proteins such as von Willebrand factor and changes to cell telomeric DNA 
(Hastings et al., 2004; Unterluggauer et al., 2007). 
2.1.4 Storage and retrieval of liquid nitrogen frozen cells 
To provide an ongoing source of cells, a number of cell samples were frozen for 
prolonged storage in liquid nitrogen; this is able to sustain a level of cryopreservation 
for more than ten years (Hornsby et al., 1991; Baglole et al., 2005). Cell monolayers 
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were detached from their culture flasks as previously described (2.1.2) and counted. 
Cells were resuspended at a density of 1x106 per ml in a freezing mix composed of 
90% FBS and 10% cell-culture quality DMSO (D2650, Sigma, UK). The cell suspension 
was placed into a cryovial (430487, Fisher, UK) and stored at -80°C using a Mr. Frosty 
(5100-0001, Thermo Scientific Nalgene, Sigma, UK) for up to 24 hours before being 
transferred to liquid nitrogen. By using Mr. Frosty, a gradual cooling of the cells is 
achieved (-1°C per minute) limiting the impact of the cooling process on cell viability (K. 
Wilson et al., 2010). Only fibroblasts between the second and fourth passage were 
stored in liquid nitrogen for future use. Frozen fibroblasts were retrieved from liquid 
nitrogen using the following procedure: Cryovials containing frozen cells were removed 
from liquid nitrogen and thawed carefully in a pre-heated water bath (37°C). The cell 
suspension was then transferred to a 15 ml Falcon tube and 5 ml of FGM was carefully 
added before being pelleted as described previously. The storage of HUVECs was 
undertaken as previously described, although a modified freezing mix containing 80% 
EGM, 10% FBS and 10% DMSO was used; removal from liquid nitrogen was also as 
described above with the minor modification of using EGM instead of FGM. 
2.1.5 Haemocytometery 
In order to count the number of cells within a cell suspension, a haemocytometer was 
used to assess the number of cells present within a cell suspension through manual 
counting (K. Wilson et al., 2010). 20 µl of cell suspension was mixed with 20 µl of 
trypan blue (15250-061, Invitrogen, UK) within a 0.65 ml Eppendorf tube (3209, Fisher, 
UK) and allowed to mix for around 30 seconds. 10 µl of this mixture was then carefully 
applied to a haemocytometer chamber by capillary action. The number of cells present 
in a 4 x 4 square was counted (using a minimum of three, 4x4 squares) with each 4 x 4 
region equivalent to the number of cells x104/ml. Allowance for the use of trypan blue 
was taken into account in the final calculation. The use of trypan blue allows one to 
distinguish dead, unhealthy cells from living, healthy cells. If the cell suspension was 
highly concentrated it was either diluted further in growth medium, or a higher 
percentage of trypan blue was used in the counting process. 
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2.2 Monolayer assays 
2.2.1 Monolayer assays 
Monolayer experiments were performed in either 96-well plates (167008, Fisher, UK) 
for proliferation assays, T25 or six well plates (140675, Fisher, UK) for RNA / protein 
studies and 16 well, glass bottomed, chamber slides for immunocytochemistry (734-
2127, VWR, UK) 
2.3 Proliferation assays 
2.3.1 MTT proliferation assay 
Cell viability and proliferation was measured using the 3-(4,5-dimethylthiazol-2-yl)- 2,5-
diphenyl tetrazolium bromide (MTT) assay (M5655, Sigma; 5 mg/ml stock in PBS), 
following previously published protocols (Mosmann, 1983; Sladowski et al., 1993). The 
assay is dependent on the conversion of the yellow tetrazolium salt to the coloured 
formazan product within the mitochondria of active cells (Figure 2.1). The concentration 
of the coloured product can be measured spectrophotometrically and equated to cell 
number. 
 
 
 
Figure 2.1 - The reduction of MTT to Formazan via mitochondrial reductase during the MTT assay.  
Image drawn using SketchEl based upon images found within the Pubchem database (Ncbi, 2010d) 
 
At any one, single time point in the assay, the media within each well (100 µl for HTFs 
and 200 µl for HUVECs) was supplemented with 10% MTT resulting in a final working 
concentration of the MTT of 0.5 mg/ml. This was incubated at 37°C for four hours. 
Following incubation the wells were gently washed once with PBS, taking care not to 
disturb the crystals at the bottom of each well. The crystals were then dissolved in a 
200 µl, 50:50 mixture of DMSO (D5879, Sigma, UK) and ethanol (E/0650/PC17, Fisher, 
 60 
UK) and mixed, in the dark, on a rocker for 10 minutes to ensure all crystals had 
dissolved. The absorbance of the coloured solution (a purple colour) was measured 
using a Tecan Safire spectrophotometer (test wavelength: λ = 570 nm; reference 
wavelength λ = 630 nm). The spectrophotometer was operated using the XFluor 5 
software and results were extracted as an Excel formatted spreadsheet. Background 
controls were used for each condition, whereby MTT was added to media within wells 
absent of cells before being washed and treated with 200 µl of DMSO/Ethanol; this 
background reading was accounted for in the calculation of the final results.  
The MTT assay was used for in a number of investigations, as described within this 
document, with multiple cell types. Cells were seeded into 96 well plates at a specific 
densities calculated from pilot studies. For HTFs, the optimal seeding density for the 
MTT assay was found to be 1500 cells per well (range 500 – 50,000). The cell density 
was chosen as it allowed observation of changes in cell proliferation over the course of 
the study (be it a 3 or 30 day study). At initial cell densities lower than this fibroblast 
behaviour was unpredictable, and at higher densities confluency was achieved too 
early in the study period. For HUVECs, the optimal seeding density for the MTT assay 
was found to be 5000 cells per well (range 500 – 50000). The cell density was chosen 
for the same reasons as previously described. If cytokine analysis was being 
undertaken, a period of serum starvation was required following initial plating prior to 
the addition of cytokine containing media. Serum starving media was composed of 
DMEM supplemented with 0.1% BSA (A3294, Sigma, UK), 20 mM L-glutamine and 
100 U/ml penicillin / streptomycin. If cytokines were not being tested the serum-starving 
period was not required. For HUVEC studies involving the testing of bevacizumab, or 
bevacizumab related studies, cells were seeded in a modified version of EGM. The test 
media was composed of EBM supplemented with 2% FBS, Hydrocortisone, and GA-
1000 (Gentamicin, Amphotericin B), with both the BBE and hEGF were left out so as to 
not have their effects included within the study. Instead a known concentration of 
VEGF was added to the positive and testing samples, with the absence of VEGF 
dictating the negative control. All experiments were performed in sextuplicate, such that 
six wells were exposed to each test condition, and when required medium was 
replaced every three days. 
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2.3.2 Alamar blue proliferation assay 
Similar to the MTT, the Alamar Blue (BUF012B, AbD Serotec, UK) proliferation assay 
provides a measure of the metabolic activity of HTFs in either monolayer or 3D gels 
(Jonsson et al., 1997). Alamar blue is a cell viability indicator in which the active 
ingredient resazurin, a non-toxic cell permeable compound that is blue in colour, is 
reduced to resorufin upon entering the cell (Figure 2.2); resofurin forms a red colour 
that can be measured via fluorescence or absorbance. 
 
 
Figure 2.2 - The reduction of Resazurin to Resofurin during the Alamar Blue Assay.  
Image drawn using SketchEl based upon images found within the Pubchem database (Ncbi, 2010d) 
 
Assays were prepared as described in the MTT assay (2.3.1) when testing in 
monolayer conditions. Alamar Blue stock solution was added directly to the culture 
medium at 1:10 dilution (10% total volume). The solution containing Alamar Blue was 
incubated with the cells for 4 hours before reading on a plate reader (as described 
previously in 2.3.1) at an absorbance λ = 570 nm (reference 600 nm). Alamar Blue can 
also be used to evaluate the activity of cells within collagen gels. In this study, Alamar 
blue was added to the culture medium (1:10; 10% total volume) and incubated for 24 
hours. This extended incubation time was found to be required when using Alamar Blue 
with the collagen gels due to the low cell number within the gels and large volume of 
culture medium. Samples of the media were then taken in triplicate from triplicate gels 
and read on the plate reader as previously described. Following sampling of the media, 
fresh culture medium was added to the gels replacing the Alamar Blue. In both 
monolayer and 3D assays, triplicate samples of Alamar Blue were incubated for the 
required time to provide a blank background reference reading. 
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2.4 Extracellular matrix assays 
The extracellular matrix is a dynamic environment and provides it’s own effects on cell 
behaviour as well as forming a key component of the wound healing process. To such 
end the use of a collagen-based contraction model was used extensively in this thesis 
to allow the investigation of fibroblast activity during contraction in the absence and/or 
presence of drugs and cytokines. 
2.4.1 Collagen contraction assays 
First proposed by Bell and colleagues (Bell et al., 1979), the in-vitro collagen 
contraction model has become a standardised model for the investigation of cellular 
behaviour within a 3D matrix by allowing an investigator to examine the effects of cells 
in both remodelling and contraction. The model used in this assay is slightly modified 
from the original, whereby instead of the collagen lattice being anchored, it is a free-
floating lattice (Mazure et al., 1992); this alteration in assay design has since been 
replicated by many laboratories worldwide as reviewed by Dallon et al (Dallon et al., 
2008). The rate of gel contraction can be dependent on a number of factors including 
seeding density, concentration and pH of the collagen solution used as well as with the 
growth medium the gels are placed into. 
2.4.2 Preparation of full serum collagen gels 
Free-floating collagen type 1 lattices were prepared as previously described 
(Dahlmann-Noor et al., 2007): 160 µl of concentrated medium, composed of 3.5 ml 10x 
DMEM (D1408, Sigma, UK), 0.35 ml 2 mM L-glutamine and 0.9 ml 7.5 % sodium 
bicarbonate (25080-060, Invitrogen, UK), was placed into a 50 ml Falcon tube and 
combined with 830 µl rat tail type 1 collagen solution (60-30-808, First Link, UK; ~ 2.2 
mg/ml in 0.6 % acetic acid). The solution was swirled before the drop wise addition of 
approximately 78 µl, 1 M sterile sodium hydroxide (72068, Fisher, UK) leading to a 
change in pH to ~7.0 visualised by the change in colour of the solution from yellow to 
pink. Following this, 6.2x104 HTFs, resuspended in 170 µl FBS, were quickly added to 
the solution and mixed carefully to avoid bubble production but ensure cells were 
evenly distributed through the solution. Gels were then cast through the pipetting of 150 
µl of the collagen/cell mix into single wells of Mattek dishes (P35G-1.5-14-C, Mattek 
Corp, USA). Mattek dishes have the advantage over conventional plastic dishes by 
containing a glass bottomed well (14 mm diameter in this instance) in the centre of the 
dish (diameter 35 mm in this instance). Any air bubbles that were present following 
casting were removed using a 200 µl pipette tip. From the volume above six gels could 
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be cast, with the dishes incubated at 37°C to allow polymerisation over a 20-30 minute 
period. Following this the gels were released from the internal well using a 20 µl pipette 
tip and any non-polymerised solution was removed. Each gel was subsequently filled 
with 2 ml of FGM, with the culture medium replaced every three days; storage of media 
samples was undertaken when required.  
2.4.3 Preparation of serum-free collagen gels 
For cytokine testing, serum free gels were used. Gels were prepared as described 
above (2.4.2) with a few minor amendments. The cells were pre-grown and washed in 
a low percent BSA solution (0.1 - 1%) before 6.2x104 HTFs were resuspended in 170 µl 
of 1.4% BSA-DMEM solution (also containing 100 U/ml penicillin/streptomycin and 20 
mM L-glutamine). Cells, instead of being fed with FGM, were fed with 0.7% BSA-
DMEM solution (containing penicillin/streptomycin and L-glutamine as above) 
supplemented with the cytokine to be tested (Dahlmann-Noor et al., 2007). The culture 
medium was replaced every three days with storage of samples taking place when 
required. 
2.4.4 Measurement of collagen gel contraction 
Whole matrix contraction was monitored throughout the course of the experiment 
through the use of daily digital photographs (Panasonic Lumix, DMC-FZ28, Panasonic, 
UK) taken within a laminar flow hood. The Mattek dishes were placed upon a dark 
surface, providing adequate contrast against the gel. Images were then imported into 
ImageJ (Abramoff et al., 2004) and the matrix area as measured with reference to the 
inner glass bottomed well. Matrix surface area was normalised to the area calculated at 
day 0 and expressed as a percentage of the initial surface area. Each experiment was 
performed with 5 repeats of the matrices and the final lattice areas were calculated 
from the means of the pooled quintuplets and compared using ANOVA variance 
analysis. 
2.4.5 Storage of collagen gels 
Collagen gels stored for immunocytochemistry were first fixed in 4% paraformaldehyde 
(43368, Alfa Aesar, VWR, UK) and stored at 4°C for up to two weeks. Continued 
storage past this time point required the addition of a 30% sucrose solution (dissolved 
in 0.1% PFA) for 10 minutes before being transferred to a -20°C freezer. 
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2.4.6 Angiogenesis co-culture 
The anti-angiogenic effects of various compounds were analysed through the use of a 
modified co-culture assay. Originally developed by Nakatsu and colleagues (Nakatsu et 
al., 2008), the protocol described below was optimised for the use of HTFs in co-culture 
with HUVECs. The assay provides a model of monitoring tube formation in-vitro and 
subsequently the effects of agents to modulate angiogenesis. Prior to the start of the 
experiment 0.5 g of dry Cytodex 3 beads (17-0485-01, GE Healthcare, UK) were 
hydrated by being placed into a 50 ml Falcon tube to which 50 ml PBS was added and 
placed on a rocker for three hours at room temperature. Following hydration the beads 
were allowed to settle and the supernatant was removed. The beads that had settled 
were resuspended in 50 ml of fresh PBS before being allowed to settle again. The PBS 
was again removed and the beads resuspended at a concentration of 30,000 beads 
per ml through the addition of a further 50 ml of PBS. The bead suspension was 
transferred to a pre-siliconised glass bottle and autoclaved at 115°C for 15 minutes 
before being stored at 4°C; the glass bottle was silicon coated using Sigmacote® (SL2, 
Sigma, UK), whereby the inside of the glass bottle was coated with 10 ml of the 
solution before being air-dried. Excess solution was removed and the bottle dried in an 
oven at 100°C for thirty minutes. Following drying, the bottle was washed with sterile, 
deionised water. 
HUVECs were trypsinised and 1x106 beads were resuspended in 500 µl of EGM-2 
(CC-3162, Lonza, UK) and transferred to a FACS tube (325052, BD Biosciences, UK). 
2500 beads, counted using a haemocytometer, were resuspended into 1 ml of warm 
EGM-2 and added to the 500 µl HUVEC suspension. The beads and cells were 
incubated together for four hours at 37°C with the tube shaken every 20 minutes. After 
four hours of incubation the beads were transferred to a T25 flask for overnight 
incubation in the presence of 5 ml EGM-2.  
Following overnight incubation, fibrinogen type 1 (F-8630, Sigma, UK) was prepared at 
a concentration of 2 mg/ml in PBS before being sterile filtered using a 0.22 µm filter. 
0.15 units/ml of aprotinin (Stock solution 4 U/ml reconstituted in sterile deionised water; 
A-1153, Sigma, UK) was added to the fibrinogen solution to prevent bead digestion 
during the assay. 
The coated Cytodex-3 beads were transferred to a 15 ml tube and resuspended in 1 ml 
of EGM-2 and transferred to a 1.5 ml Eppendorf tube. The beads were washed three 
times in EGM-2 before being counted using a haemocytometer. The bead solution was 
resuspended at a concentration of 500 beads/ml in the fibrinogen solution.  
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To create the gel required for tube formation, 0.625 units/ml of thrombin (Stock solution 
50 U/ml reconstituted in sterile deionised water; T-4648, Sigma, UK) was added to 
each well of a 24 well plate. To this, 0.5 ml of the fibrinogen/bead solution was added 
to each well with the thrombin and fibrinogen carefully mixed to avoid bubble formation. 
This was repeated for each well before allowing the plate to air dry in the hood for five 
minutes and within an incubator at 37°C for 10-15 minutes during which time the 
formation of a clot occurred. Whilst the gels were in the incubator HTFs were 
resuspended in EGM-2 [following trypsinisation as previously described (2.1.2)], and 
upon polymerisation 20,000 fibroblasts were seeded on top of each gel in 1 ml of EGM-
2. Following seeding, the gels were monitored for branching and network development 
stemming from the bead over a 5 - 14 day period. Photographs were taken under a 
phase contrast inverted microscope when required. At certain timepoints the number of 
sprouting vessels, mean and longest vessel length were recorded for analysis; analysis 
was undertaken using 3 separate wells per group, with 4-5 beads analysed per group. 
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2.5 Tablet fabrication and release modelling 
2.5.1 Tablet Fabrication Process 
Tablets containing various compounds were created using a shared methodology. In 
brief, a required amount of compound was weighed out and the solid placed into the 
die of a punch and die system (I Holland, UK). The punch component was carefully 
slotted into the die before the entire component was placed under a hydraulic press 
(Specac, UK). A pressure of 5 – 10 bars was applied, as monitored by a pressure dial, 
for ten seconds. Tablets were carefully removed through the use of a tablet ejector, 
which allowed gentle pushing of the tablet from the die chamber. The thickness of the 
tablet was recorded using a hand held thickness gauge and the final weight recorded 
using a digital analytical balance (XS204, Mettler Toledo, UK). 
Excipient free 5-FU tablets were created as detailed above using an initial mass of 
approximately 5.5 mg 5-FU. Each tablet was composed of approximately 5.1 ± 0.4 mg 
5-FU and compressed for ten seconds at a pressure of 14 bars. The diameter of each 
tablet was 3 mm with a thickness of approximately 0.55 ± 0.06 mm. 
Ilomastat tablets were created for in-vivo studies by weighing 2 – 2.5 mg of solid 
ilomastat (UBG8237, Europa Bioproducts, UK) resulting in a similarly sized tablets of 
approximately 2.2 ± 0.1 mg with a thickness of approximately 0.4 mm; sizes used 
during in-vivo experiments are presented in Chapter 6. Pictures of an ilomastat tablet 
being created are shown in Figure 2.3. 
2.5.2 Flow model to determine tablet release 
To determine the release kinetics of implantable tablets a flow rig system was 
developed to mimic both the flow and volume that may be present within a bleb 
produced during GFS. A single tablet was placed into each rig, with up to 10 rigs 
connected to a peristaltic pump at any one time. Two plastic tubes were connected to 
each rig, one attached to the peristaltic pump and the other placed into a collection 
tube to sample fluid at various intervals. A flow rate of 2 µl per minute (PBS) was used 
to simulate the flow rate found in the eye (Prasanna et al., 2001) and the rig was 
designed to have a 200 µl capacity, an approximation (at the time of fabrication) of the 
bleb volume. The rigs were placed into a water bath to simulate the temperature of fluid 
as found in the eye (37°C). The amount of released drug was calculated by multiplying 
the volume and concentration of the outgoing fluid (with concentration determined 
through the use of HPLC as described in section 2.6). A graphical representation of the 
rig is shown in Figure 2.4. 
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Figure 2.3 – The punch and die used during tablet fabrication. 
Figure A shows the two components of the punch and die system, with figure B showing a tablet present 
within the centre of the die. 
 
 
Figure 2.4 – A graphical representation of the flow rig. 
Fluid enters the flow chamber passing over a tablet placed within the base of the chamber. Gradually 
samples are eluted from the chamber and collected in an Eppendorf prior to HPLC sampling. 
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2.6 High performance (pressure) liquid chromatography 
The use of chromatography, and specifically high performance (pressure) liquid 
chromatography (HPLC) provides a tool to identify, and calculate the concentration of, 
specific substances, impurities, drug products and changes to drug compound within 
either solutions or biological fluids. First pioneered by Hovarth and Halasz, who 
together proposed the concept of packing a column with beads to control elution time, 
HPLC has developed into one of the most important tools in analytical chemistry; a 
more complete review of HPLC history is available from Nguyen and colleagues 
(Halasz et al., 1964; Nguyen et al., 2006). The aim of HPLC is to achieve a separation 
of the components within a solution in either a liquid or gaseous phase. High-pressure 
liquid chromatography is reliant on the interaction between the different components of 
a solution within a mobile liquid phase (mobile buffer) and the stationary phase, usually 
in the form of an HPLC column. There are several versions of HPLC available to 
scientists including normal and reverse phase, size exclusion and ion exchange with 
each of these having differing applications depending on the starting solution or the 
compound of interest to be detected. However, in each of these variants of HPLC the 
transport of compounds through the HPLC column occurs entirely in the aqueous 
phase, with the flow allowing the passage of solution through an inlet toward a detector 
at the opposing end of the column. The HPLC machine itself is dependent on a number 
of components: a solvent supply, a pump, sample injector, a column, a heating 
element, a detector and a computer. At first a mobile phase is introduced to the 
system, which is passed into a high-pressure pump that controls: a) the flow rate of the 
solution (typically 1 – 2 ml/min) and b) the mobile phase composition. The mobile 
phase can be delivered as an isocratic solution (a pre-mixed solvent), or in a gradient 
fashion where the pump mixes and delivers differing compositions of the mobile phase, 
increasing and decreasing the concentrations of particular mobile phase components 
when required. The injection of samples (typically 5 – 20 µl, though this can be as high 
as 100 µl) into the mobile phase follows this, with the combined solution then entering 
the column itself. As the solution enters the column the differences between the 
polarities of the different compounds within the solution and that of the column, leads to 
the separation of the solution. As the flow continues to pass through the column those 
compounds with higher polarities will travel slower along the column than those with 
lower polarities, as such those with lower polarities will reach the detector first, and 
those more polarised will reach the detector at a later time. A number of variables can 
be altered that change the retention time including the injection volume, the type of 
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column and the polarity of the mobile phase. The detector measures the light absorbed 
by the column at a pre-specified wavelength (typically λ = 200 - 350 nm), with it’s 
output passed on to a computer which is able to integrate the signal to calculate a peak 
area. This area can be used to calculate the concentration of a particular compound 
based upon a concentration curve established with known concentrations of the 
compound of interest. A more detailed guide to HPLC is available from Agilent (Agilent, 
2009). 
2.6.1 HPLC analysis of 5-FU 
The detection of 5-Fluorouracil in various solutions was achieved through the use of an 
HPLC 1200 system (Agilent, UK) composed of a separation module for solvent and 
sample delivery, a UV detector (set to λ = 260 nm), a heat block element and automatic 
loading system. Results were collected and formatted using Chemstation software 
(Agilent, UK). For 5-FU detection a 15 cm x 4.6 mm ID, 5 µm particle size Discovery 
HS F5 HPLC column (567616-U, Sigma, UK) was used to achieve compound 
separation. A mobile phase buffer of 20 mM ammonium acetate (09688, Sigma, UK) 
with 0.6 % triethanolamine (TEA) (pH 5.0; 90278, Sigma, UK) was used as the running 
buffer. Sample injections were used at a volume of 10 µl and samples eluted at a flow 
rate of 1.0 ml/min at 40°C. 
2.6.2 HPLC analysis of ilomastat 
Ilomastat was detected in various solutions using the previously mentioned system. 
The UV detector was λ = 280 nm and a 15 cm x 4.6 mm UD, 5 µm particle size 
Discovery HS C18 HPLC (568522-U, Sigma, UK) column was used to achieve 
compound separation. A mobile phase buffer containing 20 mM ammonium acetate, 
75% 0.1% TEA and 25% acetonitrile (34998, Sigma, UK) was used as the running 
buffer. Sample injections were used at a volume of 100 µl and samples eluted at a flow 
rate of 1.2 ml/min at 40ºc. 
2.6.3 Final HPLC method developed for ilomastat detection 
Full details of the method development can be found in 5.3.4. 
I. Obtain and weigh tissue (if possible cut the tissue into small pieces). 
II. Lyophilise the tissue for 48 hours at -20°C. 
III. Place the tissue in 1 ml of collagenase solution (minimum 2 mg/ml) for 48 hours 
(or until all tissue is digested) in a shaking incubator at 37 °C at 300 RPM in a 
15 ml FACS tube. 
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IV. Pass the digested tissue through a 29 gauge or smaller needle in order to 
ensure full tissue disruption has occurred. 
V. Centrifuge samples for 5 minutes at > 10,000 RPM.  
VI. Filter the supernatant using a 0.45 µM filter. 
VII. Inject the samples into the HPLC with a UV detector (λ=280 nm). The mobile 
phase is ammonium acetate buffer (pH 5.0) with 15% acetonitrile. The flow rate 
is 1.2 ml/min. The injection volume is 100 µl. The ilomastat retention time is 
25.6 minutes.  
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2.7 Evaluation of cell death: apoptosis assay 
HTFs were evaluated for cell death within collagen gels following drug treatment, with 
levels of apoptosis assessed using the terminal deoxynucleotidyl transferase dUTP 
nick end labeling (TUNEL) assay. 
2.7.1 TUNEL assay 
The DeadEnd™ Fluorometrix TUNEL system (G3250, Promega, UK) provides a means 
to detect fragmented cell nuclei present in dead, or dying, cells. The normal cell 
process of apoptosis results in the generation of DNA fragments through the action of 
endogenous endonucleases (Schwartzman et al., 1993; Bortner et al., 1995). The DNA 
of apoptotic cells is cleaved into multimers of 180-200 base pair fragments, with these 
fragments, in the TUNEL system, measured through the incorporation of fluorescein-
12-dUTP at the 3’-OH ends of DNA ends through the use of (recombinant) terminal 
deoxynucleotidyl transferase (rTdT) (Gavrieli et al., 1992). 
Gels, which were analysed for the presence of cell death, were first fixed as described 
(2.9.1) before being transferred to individual glass slides. Using an ImmunoPen™ 
(402176-1EA, Merck, UK) a perimeter was drawn closely around each gel to prevent 
liquid loss during staining. The gels were then washed three times, for 5 minutes per 
wash, followed by the application of 100 µl of equilibration buffer placed directly on top 
of each gel for 10 minutes. Whilst equilibrating, an rTdT incubation buffer was prepared 
containing equilibration buffer, a nucleotide mix and the rTdT enzyme. Following 
equilibration, the buffer was removed using a pipette and blotting paper before the 
application of 50 µl of the rTdT incubation buffer was placed directly on top of each gel. 
The gels were covered with plastic coverslips before being incubated in a moisture 
chamber at 37°C for one hour. The reaction was stopped through the application of 2X 
sodium chloride and sodium citrate (SSC) buffer for 15 minutes at room temperature 
before a further three washes with PBS at 5-minute intervals. Tetramethylrhodamine 
isothiocyanate (TRITC)-phalloidin was applied to the gel to allow the visualisation of 
cellular actin through the addition of 50 µl of a TRITC-phalloidin/PBS solution on top of 
the gel for 50 minutes (in the dark) before a final three washes in PBS. Cells were 
mounted using Vectashield containing the nuclear marker 4',6-diamidino-2-
phenylindole (DAPI) before imaging under confocal microscopy as described in 2.9.1. 
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2.8 Protein assays 
2.8.1 Collection of conditioned medium 
In order to collect protein secreted by cells following exposure to differing treatments 
and cytokines the conditioned media was collected at various time points following 
treatment. In order to remove any potential cell contaminants samples were collected 
into 0.5, 1.5 or 2 ml Eppendorfs and centrifuged at 1000 g for 5 minutes. The resulting 
supernatant was then transferred to a new Eppendorf and stored at -80°C prior to 
testing. During sample collection all samples were kept on ice to prevent cytokine 
degradation. 
2.8.2 ELISA 
The enzyme linked immunosorbent assay (ELISA) was originally developed by Engvall 
and Perlman in 1971 to provide a method of quantifying the amount of immunoglobulin 
(Ig) G present in a mixed Ig sample (Engvall et al., 1971). The assay has since moved 
on from its original description and developed such that a wide range of antigens can 
be detected. All ELISAs were performed using either pre-coated ELISA plates direct 
from the manufacturer or through manual coating of 96 well ELISA plates. In brief, 
coated plates were exposed to 100 µl of standards and samples for 1 hour at room 
temperature, allowing the cytokine or protein of interest to bind to the immobilised 
antibody. After washing away any unbound products in the solution using a 5x wash 
buffer (PBS + 0.05% Tween 20), a detector-linked (e.g biotinylated) polyclonal antibody 
specific for the antigen previously added was introduced to the plates (100 µl per well) 
and incubated for 1 hour at room temperature. Following three washes with 5x wash-
buffer, HRP-Streptavidin was added to each well (100 µl) and incubated for thirty 
minutes at room temperature. A further 3 washes using 5x wash buffer was undertaken 
before a substrate solution was added to the wells (such as TMB) for up to 20 minutes, 
with colour development proportional to the amount of cytokine that was initially bound. 
The colour development was stopped using a stop buffer and the intensity of the colour 
measured using a microplate reader at λ = 450 nm. Measured intensities were 
converted into concentrations using a concentration curve established on the plate at 
the time of the assay. 
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2.9 Immunocytochemistry 
2.9.1 Immunocytochemical analysis of cells and collagen gels 
For immunocytochemical staining, cells were grown on collagen coated 16 well, glass 
bottomed, chamber slides, or within a 3D collagen matrix. Following treatment for the 
defined period of time, cells or gels were washed gently in PBS before being fixed in 
4% paraformaldehyde (PFA; ALFA43368.9M, VWR, UK) for 10 minutes and stored at 
4°C for up to two weeks. The PFA stock solution used was provided at a concentration 
of 16%. In order to obtain a working concentration of 4%, one vial of PFA (10 ml) was 
diluted into a total volume of 40 ml PBS. If long-term storage of fixed samples was 
required, a 30% sucrose solution was applied for 10 minutes before the slide was air 
dried and transferred to a -20°C freezer.  
Prior to staining, cells and gels were first washed three times for five minutes before 
being blocked using a solution composed of PBS containing 5% goat serum (005-000-
121, Stratech, UK) and 0.3% Triton X-100 (T8787, Sigma, UK). When staining for a 
protein that was known to be present within the cell membrane, no Triton X-100 was 
added to the solution. 
Primary antibody was dissolved into the blocking solution at the dilution factor shown in 
Table 2.2. Slides were then washed three times in PBS for five minutes before the 
application of a secondary antibody that was able to react with the species in which the 
primary antibody was raised for one to two hours at room temperature, with the 
secondaries used listed in Table 2.3. The cells/gels were then washed once again in 
PBS before being mounted using Vectashied containing DAPI (H-1200, Vectalabs, 
UK). Coverslips were applied and sealed using nail varnish before being stored at 4°C 
prior to imaging. Fluorescent images were obtained using the Zeiss 710 confocal 
microscope, with images analysed using Zen 2009 LE (Zeiss, 2010) or ImageJ. 
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Antibody Manufacturer Code Species raised in Dilution 
ASMA Sigma A2547 Mouse 1:200 
MMP-1 Millipore MAB1346 Mouse 1:200 
MMP-2 Abcam ab37150 Rabbit 1:200 
MMP-7 Millipore MAB13414 Mouse 1:200 
MMP-9 Millipore AB13458 Rabbit 1:200 
IL-6 Abcam ab6672 Rabbit 1:100 
Tenascin C Abcam ab6393 Mouse 1:200 
VEGFR2 Abcam ab39256 Rabbit 1:200 
FITC-Phalloidin Sigma P5282 - 1:1000 
TRITC-Phalloidin Sigma P1951 - 1:1000 
Table 2.2 – Primary antibodies used during immunocytochemical staining. 
 
 
 
 
 
 
 
Antibody Manufacturer Code Species raised in Dilution 
Alexa Fluor 488 (Anti-
Mouse) Invitrogen A-11029 Goat 1:500 
Alexa Fluor 488 (Anti-
Rabbit ) Invitrogen A-11034 Goat 1:500 
Alexa Fluor 594 (Anti-
Rabbit) Invitrogen A-11037 Goat 1:500 
Alexa Fluor 594 (Anti-
Mouse ) Invitrogen A-11032 Goat 1:500 
Table 2.3 – Secondary antibodies used during immunocytochemical staining. 
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2.10 RT-PCR analysis of gene expression 
2.10.1 RNA isolation 
All RNA isolation took place following the use of RNaseZap (AM9780, Ambion, UK) to 
clear surfaces, gloves and pipettes, as well as any other objects required, of RNase. All 
consumables used during RNA extraction were RNase/DNase free. 
2.10.2 RNA isolation of cells grown in monolayer 
For monolayer RNA isolation, total RNA was extracted using the RNeasy Mini kit 
(74104, Qiagen, UK) as per the manufacturers instructions (Qiagen, 2010a). Cells were 
detached using trypsin 1X as previously described (2.1.2), before being washed in PBS 
and pelleted within a 1.5 ml Eppendorf tube. Lysis buffer (RLT) containing 10 µl/ml β-
mercaptoethanol (63689, Sigma UK) was added to resuspend the pellet (700 µl for 
cells grown in a T25; 350 µl for cells grown in a 6 well plate). Cells were then 
homogenised by being passed through a 25 gauge needle five times. Samples were 
kept on ice during this step before being frozen down at -80°C for future use or 
immediately used for RNA isolation. The lysis buffer-cell suspension solution was 
mixed with an equi-volume of sterile-filtered 70% ethanol before being added onto the 
RNeasy column and centrifuged for 15 seconds at maximum speed (16.1 rcf). The 
RNeasy column is composed of a silica based membrane, which allows the binding of 
RNA using a high salt buffer system (Qiagen, 2010a).  
The RNA bound to the membrane was washed in 350 µl RW1 and centrifuged at 
maximum speed (16.1 rcf) for 15 seconds. To ensure DNA removal, samples were 
treated with DNase using the RNase Free-DNase set (79254, Qiagen, UK). The DNase 
mix was created by combining 10 µl of DNase 1 with 70 µl buffer RDD and added 
directly onto the spin column membrane of one single column. Master mixes were 
created as necessary. The samples were then incubated for 15 minutes at room 
temperature before being washed again in 350 µl buffer RW1 and centrifuged at 
maximum speed for 15 seconds. 
Two washes of the RNA with 500 µl buffer RPE were undertaken using the centrifuge, 
firstly for 30 seconds before a second wash of two-minutes (both at maximum speed), 
before the column was transferred to a new collection tube. The column bound RNA 
was then eluted via the addition of 30 µl of water to the membrane followed by 
centrifugation at maximum speed for one minute. To further concentrate the RNA, the 
eluted solution was passed through the membrane one final time at maximum speed 
for one minute. The RNA was analysed using a Nanodrop-1000 (Thermo Scientific, 
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UK) which provided a concentration of RNA (ng/µl) as well as a determination of the 
purity of the RNA through a measure of the absorbance of the solution at λ = 260 nm 
(nucleic acids) and λ = 280 nm (proteins and phenol) and a ratio between the two 
calculated. Only samples with a 260/280 ratio of 1.8-2.1 were used for further 
experimentation. Following RNA extraction, samples were stored at -80°C prior to 
further use. 
2.10.3 RNA isolation of tissue 
Tissue samples obtained from in-vivo experiments were subject to RNA isolation using 
the RNeasy kit as previously described (2.10.2) with some modifications. Tissue 
samples were removed from -80°C and kept on ice until lysis occured. The tissue was 
immediately moved to a pre-chilled, tight fitting, glass homogeniser and kept on ice. 
Four hundred microliters of buffer RLT containing 10 µl/ml of β-mercaptoethanol was 
added to the tissue and ground for 10-20 strokes. During the homogenisation of the 
tissue, cell lysis took place although the fibrous tissue remained largely in tact. The 
tissue was then moved to a pre-cooled Eppendorf, together with the 400 µl of buffer 
RLT. A fresh 200 µl volume of buffer RLT was used to rinse the glass homogeniser 
before being added to the Eppendorf for lysing with a 19 gauge needle. After 5-10 
passes through the needle the contents of the Eppendorf were transferred to a 
QIAshredder™ (79654, Qiagen UK) (including any remaining tissue fragments); the 
QIAshredder is designed to homogenise tissue lysates through the shearing of high-
molecular weight genomic DNA, as well as other cellular components in order to create 
a homogenous lysate (Qiagen, 2010b). The column was placed into a centrifuge and 
spun at maximum speed for two minutes. Following this, the QIAshredder™ column 
was removed from the collection tube and a new cap placed on top of the tube, before 
being centrifuged for three minutes at maximum speed (16.1 g). The supernatant was 
then transferred to a new Eppendorf and mixed with an equi-volume of 70% ethanol. 
Total RNA extraction was then complete using the RNeasy kit as described (2.10.2) 
with the following amendments: 
 
1. Washes with RW1 and buffer RPE were repeated twice. 
2. Following the application of the wash buffer, the spin columns were inverted 3-4 
times and rolled gently ~20 times to ensure a thorough washing of the 
membrane. 
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3. An 80% ethanol wash was performed following the final wash with buffer RPE, 
whereby 500 µl of 80% ethanol was added to the membrane and centrifuged for 
2 minutes at maximum speed (16.1 g); RNA elution using water was then 
performed as normal. 
 
These steps were undertaken following advice from Qiagen as it was observed that 
when undertaking RNA isolation from tissue an increase in phenol contamination was 
observed if these steps were not followed. 
2.10.4 Reverse transcription 
RNA (500ng-1 µg depending on RNA concentration) was transcribed into cDNA using 
the AMV Reverse Transcriptase assay (11483188001, Roche, UK). The reaction was 
performed in a final volume of 20 µl composed of: 5 mM MgCl2, 1 mM 
deoxyribonucleotide triphosphates (dNTPs), 1 U/µl RNase inhibitor, 0.8 U/µl AMV 
reverse transcriptase and 80 ng/µl oligo dT-15 primers. The mixture was incubated 
using a thermocycler (Eppendorf) for 10 minutes at 25°C, 60 minutes at 42°C, 5 
minutes at 99°C and 5 minutes at 5°C before being stored at -20°C. 
2.10.5 Polymerase chain reaction 
Semi-quantitative RT-PCR was undertaken using cDNA produced in the above RT 
reaction together with Megamix Blue PCR mix (2MMB-5, Cambio, UK). Oligonucleotide 
sequences used in the PCR reaction were obtained from either PrimerBank (Spandidos 
et al., 2010), previously published literature or through in-house design using the NCBI 
Primer Blast system (Ncbi, 2010c); all primer sequences can be found below in Table 
2.4. Primers were manufactured by Invitrogen and reconstituted to a stock 
concentration of 50 µM in RNase-free/DNase-free water (10977-049, Invitrogen, UK). 
Primers were further diluted 1:10 using the above water to generate working 
concentrations of 5 µM. The final mixture used for a single PCR reaction consisted of 
10 µl Megamix Blue, 1 µl of Forward Primer, 1 µl of Reverse Primer and 1 µl of cDNA. 
The mixture was incubated using a thermocycler (Eppendorf) at 94°C for 2 minutes 
followed by the requisite number of cycles (28 – 35) under the following conditions: 
94°C for 30 seconds, annealing temperature (usually 60°C) for 30 seconds, 72°C for 1 
minute and 1 final cycle at 72°C for 5 minutes. The PCR products were analysed on a 
2% agarose gel (V3121, Promega, UK) containing a 1:12500 dilution of GelRed™ 
nucleic acid stain (BT41002, Cambridge Biosciences, UK). Hyperladders™ (BIO-
33039, Bioline, UK) were used to provide a base pair ladder and identify product size. 
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Gels were run at 140V for 30-60 minutes (depending on the gel size) and visualised 
under a UV light controlled by Genesnap (Syngene). Auto-exposed images were used 
for densitometry analysis using ImageJ to provide semi-quantitation, with all bands 
were normalised to GAPDH or β-actin controls. 
2.10.6 RT2 Profiler PCR Array 
Changes in gene expression were also investigated using the human extracellular 
matrix and adhesion molecules PCR array (SA Bioscience, USA). cDNA was 
synthesised using RT² First Strand Kit (SA Bioscience) which was composed of (per 
reaction) 4 µl BC3 (5X RT reaction buffer 3), 1 µl P2 (primer and external control mix), 
2 µl RE3 (RT enzyme mix 3) and 3 µl water. The mixture was added to 10 µl pre-
prepared genomic-DNA (gDNA) eliminated RNA (using 5X gDNA elimination buffer) 
and incubated at 42°C for 15 minutes before the reaction was stopped by heating at 
95°C for five minutes. A total of 91 µl water was added to each reaction before the 
cDNA was mixed with 1350 µl of 2X qPCR master mix and 1248 µl of water. To each 
well of the PCR array, 25 µl of the mixture was added before being run on an ABI 7700 
light cycler under the following conditions: 95°C for 10 mintues followed by 40 cycles of 
firstly heating to 95°C for 15 seconds before cooling to 60°C for 1 minute. Delta CT 
values were exported and the data analysed using templates provided by SA 
Bioscience.
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Gene Accession Number Forward Sequence Reverse Sequence Product Length 
GAPDH NM_002046.3 CCACCCATGGCAAATTCCATGGCA TCTAGACGGCAGGTCAGGTCCACC 598 
ß-actin NM_001101 CATGTACGTTGCTATCCAGGC CTCCTTAATGTCACGCACGAT 250 
MMP-1 NM_002421.3 TTGTCCTCACTGAGGGAAAC AGGTTAGCTTACTGTCACAC 552 
MMP-2 NM_001127891.1 CCTGTTTGTGCTGAAGGACA GTACTTGCCATCCTTCTCAA 616 
MMP-3 NM_002422.3 AGCAAGGACCTCGTTTTCATT GTCAATCCCTGGAAAGTCTTCA 261 
MMP-7 NM_002423.3 AGATGTGGAGTGCCAGATGT TAGACTGCTACCATCCGTCC 357 
MMP-8 NM_002424.2 TGGACCCAATGGAATCCTTGC ATAGCCACTCAGAGCCCAGTA 544 
MMP-9 NM_004994.2 CGGTGATTGACGACGCCTTT ACCAAACTGGATGACGATGTCTG 110 
MMP-12 NM_002426.3 TGCTGATGACATACGTGGCA AGGATTTGGCAAGCGTTGG 70 
MMP-13 NM_002427.2 TTGTTGCTGCGCATGAGTTCG GGGTGCTCATATGCAGCATCA 370 
MMP-14 NM_004995.2 TCGGCCCAAAGCAGCAGCTTC CTTCATGGTGTCTGCATCAGC 180 
TIMP-1 NM_003254.2 ACTGATGGTGGGTGGATGAGTAAT AGCAACAACAGGATGCCAGAAG 208 
TIMP-2 NM_003255.4 GAAGCATTTGACCCAGAGTG CCTTTCAGACCGAACCTACT 165 
TIMP-3 NM_000362.4 GGCAAGCAGCTAGACTGGTGAA AACTGGATGGGCAGCAGGAC 199 
TIMP-4 NM_003256.2 AGGACCTGTCCTTGGTGCAGA GCCGTCAACATGCTTCATACAGA 197 
Tissue Factor NM_001178096.1 CGACGAGATTGTGAAGGATG CGGAGGCTTAGGAAAGTGTTG 252 
Table 2.4 - Primers used during PCR reactions.
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2.11 Microarray analysis of gene expression 
In order to further understand the changes induced in gene expression following drug 
exposure either in-vitro or in-vivo, microarray analysis was undertaken. In-vitro analysis 
was performed using Affymetrix microarray, whilst in-vivo analysis was undertaken 
using Agilent microarrays. 
2.11.1 Affymetrix microarray analysis 
Samples generated in-vitro were analysed using the Affymetrix GeneChip Human 
Gene 1.0 ST as further described in Appedix 9.7.1.3.  
2.11.1.1 Total RNA isolation and QC 
Total RNA was extracted as previously described (2.10.2) and quality assessed using a 
Nanodrop ND-1000 as well as using an Agilent 2100 Bioanalyzer and RNA 6000 Nano 
Chip Kit (5067-1511, Agilent, UK). The RNA 6000 Nano Chip is designed to confirm the 
quality and concentration of total RNA samples. Analysis was undertaken as per the 
manufacturers instructions (Agilent, 2006), but in brief: 
The Bioanalyzer was cleaned using an electrode cleaner filled with 350 µl of 
RNaseZAP before being rinsed with water. A gel-dye mix was prepared by placing 400 
µl of RNA gel matrix into a spin filter and centrifuged at 1500 g for ten minutes. Once 
filtered, 130 µl of the gel matrix was placed into a 1.5 ml micro centrifuge tube, to which 
2 µl of RNA dye concentrate was added and thoroughly mixed. Using a new RNA chip, 
9 µl of the gel-dye mix was added into the gel loading wells predefined on the chip 
(Figure 2.5). This was followed by 5 µl of RNA 6000 Nano Marker and 1 µl of the RNA 
6000 ladder into their predefined wells. Finally, 1 µl of each sample was added into one 
of the 12 sample wells before the chip was shaken using an IKA vortex mixer. The chip 
was placed into the Agilent Bioanalyzer and analysed using a predefined assay. Initially 
each RNA peak was shown in an overlaid manner confirming a successful running of 
the RNA ladder, before each sample was individually checked for the confirmation of 
the two ribosomal peaks (18s and 28s) together with good separation between each 
peak. From the results the software was also able to calculate the RNA concentration 
as well as an RNA Integrity Number (RIN), determining the quality of RNA on a 1-10 
scale for any one individual sample. The RIN score is calculated from the entire 
Electrophoretic trace rather than just the ratio of ribosomal bands and therefore allows 
for the presence or absence of any degradation products. An example reference 
showing the Bionalayzer trace of RNA isolated from human skeletal muscle is 
presented in Figure 2.6 (Agilent, 2010).  
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Figure 2.5 - RNA 6000 Nano Chip showing loading wells. 
 
 
 
 
 
 
 
Figure 2.6 – The Bioanalyzer trace of human skeletal muscle RNA with a RIN score of 9.5 
Trace obtained from the Agilent RIN Integrity Database (Agilent, 2010). 
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2.11.1.2 Hybridisation and array scanning 
Following pre-hybridisation QC, the samples were hybridised to the arrays. Full 
protocols for array hybridisation are available from Affymetrix, however this is detailed 
below and outlined in Figure 2.7 (Affymetrix, 2009). 
2.11.1.2.1 The preparation of cDNA 
The protocol detailed below contains the volumes required for one GeneChip but where 
possible master mixes were used for multiple chips. A maximum of 300 ng of RNA was 
added to a 2 µl mix of T7-(N)6 Primers/Poly-A RNA controls which was made up to a 
total volume of 5 µl and incubated at 70°C for 5 minutes, before being cooled for 2 
minutes at 4°C. The incorporation of the T7 promoter sequence is used to allow the in-
vitro transcription of cDNA using T7 RNA polymerase, resulting in the creation of 
multiple copies of antisense cRNA. The Poly-A probe sets that reside on the array 
provide a way of assessing the preparation quality of the labelled and hybridised cDNA. 
The probe sets have a pre-defined expected rank order in intensity of: Lys < Phe < Thr 
< Dap. Following the preparation of the primer mix the first cycle, first strand, master 
mix was created using 2 µl 5X 1st strand buffer, 1 µl DTT, 0.5 µl dNTP mix, 0.5 µl 
RNase inhibitor and 1 µl of SuperScript II; this was mixed with the T7/Poly-A/RNA 
samples and incubated at 25°C for 10 minutes, 42°C for 60 minutes and 70°C for 10 
minutes before being cooled at 4°C for 2 minutes. Upon completion second stand 
cDNA synthesis was undertaken by adding 4.8 µl water, 4 µl MgCl2, 0.4 µl dNTP mix, 
0.6 µl DNA polymerase 1 and 0.2 µl RNase H to the 10 µl of first strand cDNA 
previously created; this mixture was incubated at 16°C for 120 minutes without a 
heated lid and 75°C for 10 minutes with a heated lid. Following this, cRNA synthesis 
was undertaken via in-vitro transcription of the double-stranded cDNA: 5 µl 10X IVT 
buffer was added to 20 µl of IVT NTP mix and 5 µl of IVT enzyme mix which together 
were added to the 20 µl of double stranded cDNA created previously. The sample was 
incubated for 16 hours at 37°C before the cRNA was purified using the cRNA cleanup 
spin columns. Initially 50 µl of water was added to the cRNA mix, forming a final 
volume of 100 µl. To this 350 µl of cRNA binding buffer and 250 µl of 100% ethanol 
was added before being transferred to the IVT cRNA cleanup spin column. The spin 
column was centrifuged for 15 seconds at 10,000 g before being transferred to a new 
collection tube. 500 µl of cRNA wash buffer was added to the column, centrifuged for 
15 seconds at 10,000 g and the flow through discarded; following this a second wash 
with 80% ethanol was undertaken. Following washing, the caps of the columns were 
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opened and spun at maximum speed (16.1 g) for five minutes before the column bound 
RNA was eluted via the addition of 15 µl of water to the membrane followed by 
centrifugation at maximum speed (16.1 g) for one minute. To further concentrate the 
RNA, the eluted solution was passed through the membrane one final time at maximum 
speed for one minute. The eluted cRNA was then assessed using a Nanodrop ND-
1000 to confirm its quality and concentration. Following cRNA synthesis a second 
round of single strand cDNA synthesis was undertaken by mixing a total of 10 µg of 
cRNA with 1.5 µl of random primers in a total volume of 8 µl (water was used to take 
the volume up to 8 µl). The sample was incubated at 70°C for 5 minutes and 25°C for 5 
minutes before being cooled at 4°C for 2 minutes. After the incubation was complete 4 
µl of 5X 1st strand buffer, 2 µl of DTT, 1.25 µl of dNTP/dUTP mix and 4.75 µl of 
SuperScript II was added to the tube creating a total volume of approximately 20 µl. 
The sample was then incubated at 25°C for 10 minutes, 42°C for 90 minutes, 70°C for 
10 minutes before being cooled at 4°C for 2 minutes. During the second cycle of cDNA 
synthesis, the addition of deoxyuridine triphosphate (dUTP) led to the incorporation of 
uracil into the cDNA. In living cells one form of DNA damage is the incorporation of 
uracil into DNA (as discussed in 3.1.2.1). When this occurs in normal situations the 
enzyme uracil-DNA glycosylase (UDG) is able to rapidly hydrolyse, and thus remove, 
uracil from the DNA; this same enzyme was used later in the process for exactly this 
purpose (2.11.1.2.2). Upon completion, cRNA was removed through the use of RNase 
H, with 1 µl added to the tube and incubated at 37°C for 45 minutes, 95°C for 5 minutes 
before being cooled at 4°C for 2 minutes. Following cDNA formation, purification was 
undertaken using cDNA cleanup spin columns using a method very similar to the cRNA 
cleanup; the only difference in protocol was: a) the use of a cDNA wash buffer 
replacing the cRNA buffer; b) no alcohol wash is required and c) the elution of cDNA 
was performed using a cDNA elution buffer. The eluted cDNA was then assessed 
using a Nanodrop ND-1000 to confirm the quality and quantity of the cDNA, with 5.5 µg 
required for further use. 
2.11.1.2.2 cDNA fragmentation and hybridisation 
Upon the completion of cDNA synthesis, 5.5 µg was added to water to create a final 
volume of 21.2 µl. To this a fragmentation mix was added containing: 10 µl water, 4.7 
µl 10X cDNA fragmentation buffer, 1 µl UDG, and 1 µl APE. The use of UDG allows the 
removal of uracil that was incorporated during the second stage of cDNA synthesis, 
leading to fragmentation of the cDNA strand. At this stage an additional enzyme, 
apurinic/apyrimidinic endonuclease 1 (APE1) was added to provide catalysation of the 
 84 
endonucleolytic cleavage that occurs immediately 5’ to the site of the uracil (S. H. 
Wilson et al., 2000; Marenstein et al., 2004). The mix was incubated at 37°C for 60 
minutes, 93°C for 2 minutes before being cooled at 4°C for 2 minutes. Finally, the 
fragmented cDNA was labelled with a biotin-DNA labelling reagent with terminal 
deoxynucleotidyl transferase (TdT), a template independent polymerase that catalyzes 
the addition of deoxynucleotides to the 3’ hydroxyl terminus of single stranded DNA [as 
previously described within the TUNEL assay (2.7.1)] (Q. Bai, Salceda et al., 2007). 
The fragmented cDNA was mixed with 12 µl 5X TdT buffer, 2 µl TdT and 1 µl of DNA 
labelling reagent before being incubated at 37°C for 60 minutes, 70°C for 10 minutes 
before being cooled at 4°C for 2 minutes. Finally hybridisation of the fragmented, 
labelled, cDNA took place using a hybridisation cocktail in which 27 µl of the cDNA was 
mixed with 1.7 µl of control oligonucleotide B2, 5 µl of 20X eukaryotic hybridisation 
controls, 50 µl of 2X hybridisation mix and 7 µl of DMSO before being made up to 100 
µl with water. The cocktail was heated at 99°C for 5 minutes before being cooled at 
45°C for 5 minutes. Finally 80 µl of the hybridisation cocktail was injected into the 
microarray cartridge (GeneChip) and placed into a 45°C hybridisation oven for 17 
hours. Following hybridisation, the GeneChips were washed and stained prior to array 
imaging. In order to generate microarray signals the Affymetrix platform uses 
phycoerythrin labelled streptavidin (SAPE) to bind to the previously biotinylated cDNA, 
with each chip undergoing the fluidics protocol #FS450_0007 using the Fluidics Station 
450. Following washing, the arrays were scanned using an Affymetrix GeneChip 
Scanner 3000 7G. 
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Figure 2.7 - Affymetrix GeneChip Whole Transcript Sense Target Labelling Assay workflow. 
Image adapted from the Affymetrix User Manual (Affymetrix, 2009). 
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2.11.1.3 Post-hybridisation QC (or data pre-processing) 
Following the scanning of each chip, 3 files were generated which were used in 
downstream analysis; these are summarised in Table 2.5. 
Extension Description Comments 
*.DAT Scanned Image of the GeneChip Array 
Can only be opened in Affymetrix GeneChip 
Command Console 
*.CEL 
Cell intensity file that calculates 
the average intensities for each 
cell (probe) and assigns it to an 
x,y coordinate position 
Most commonly used for downstream 
statistical analysis - can be opened by most 
microarray statistics packages. 
*.ARR Contains experimental information 
Used in some downstream microarray 
packages 
 
Table 2.5 - Files produced following the scanning of an Affymetrix Human GeneChip ST 1.0. 
The intensity information from each probe within a microarray must first be combined 
together to produce expression values, which can then be used to determine gene 
expression. A number of models to determine such expression values are available 
including: the Model based Expression Index (MBEI) put forward by Li and Wong (C. Li 
et al., 2001), the MAS 5.0 statistical algorithm as devised by Affymetrix (Hubbell et al., 
2002) and the Robust Multi-array Average (RMA) by Irizarry and colleagues (Irizarry, 
Hobbs et al., 2003). For the QC of Affymetrix data the RMA algorithm was used 
through the use of the statistical package R (R Development Core Team, 2009) and 
various packages within this software including, Bioconductor (R. C. Gentleman et al., 
2004), AffylmGUI (G. Smyth, 2005 Limma: Linear models for microarray data), 
OneChannelGUI (Sanges et al., 2007) and their respective dependencies. The RMA 
algorithm performs three functions to the Affymetrix data: background adjustment, 
normalisation and summarisation. 
2.11.1.3.1 Background adjustment 
Background is a measurement of signal intensity that is caused by auto fluorescence of 
the array surface as well as non-specific binding that occurs on the chip. In previous 
Affymetrix expression chips, as discussed in appendix 9.7.1.3, each single probe was 
hybridised to the array twice, with one subtle, but important difference: one probe was 
a perfect match probe (PM) with the other being a mismatch probe (MM), whereby the 
13th nucleotide was altered and replaced with an incorrect nucleotide. This was 
designed such that in theory the MM probe would serve as a background correction for 
the PM probe with. Mismatch probes are still used on some Affymetrix chips for use 
within their own analysis package: Affymetrix Microarray Suite (MAS v.5.0); despite this 
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many algorithms now choosing to ignore the MM probes. One of the biggest reasons 
for abandoning the use of the mismatch probe was that intensity levels were 
demonstrated to be greater than that of the PM intensity levels in approximately 1/3 of 
all probes; if MM probes were used, negative signal values were obtained resulting in 
the loss of signal from many probes (Z. Wu, Irizarry et al., 2004). To counteract this 
algorithms were developed that completely ignore the MM probes, instead using 
mathematical models to estimate background based on the PM measured intensity. 
The complete description, and derivation of the formula used in RMA, can be obtained 
from the Iriziarry group (Bolstad et al., 2003; Irizarry, Bolstad et al., 2003; Irizarry, 
Hobbs et al., 2003). 
2.11.1.3.2 Normalisation 
The background corrected probe values were next normalised using a quantile 
normalisation. In brief, each chip was divided into quintiles and each single quantile 
averaged across all chips, with the mean for each quantile used to generate a 
normalised distribution. To normalise each individual chip, the values for each quantile 
were calculated from a distribution of probe intensities and that value matched to the 
same quantile on the normalised distribution. As such, the highest signal from each 
array was replaced by the average of all of the highest signals, the second highest from 
the average of all second highest and so on. This, therefore, allows for the variability of 
expression measures across replicate chips to be reduced. Some data can be lost at 
lower signals, however widespread testing of this method has demonstrated its 
robustness and is now widely used for Affymetrix arrays (Bolstad, 2001; Bolstad et al., 
2003). A graphical representation is in Appendix Figure 9.2. 
2.11.1.3.3 Summarisation 
Finally the log2 value for each normalised, background-adjusted signal was calculated, 
with each put through a median polish algorithm in order to calculate a single 
expression value per. A more detailed description of how this algorithm is computed is 
available in the original publication by Rafael Irizarry (Irizarry, Hobbs et al., 2003). 
2.11.1.4 Gene Expression 
Following normalisation, the generated data was analysed using the linear models for 
microarray data (LIMMA) package within Bioconductor, which allows for differential 
expression analysis. In two-group comparison, LIMMA applies a modified t-test, using a 
Bayesian approach, to make the analysis stable for small sample numbers (R. 
Gentleman et al., 2005). The Bejamini-Hochberg test for multiple corrections (Gold et 
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al., 2009) was applied to the data in order to minimise the number of falsely significant 
values before the data was exported as a tab-delimited text file ready for downstream 
analysis (2.11.3); cut-offs applied to the data were set at a fold change of ± 1.5 and a 
p-value less than 0.05. 
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2.11.2 Agilent microarray analysis 
Samples generated in-vivo were analysed using a custom designed, rabbit specific, 
Agilent 8 x 15K 60-mer oligonucleotide arrays (AMADID# 017130), which contained 
two probes for 7328 annotated genes. The very first rabbit ocular array was designed 
by the University of Florida led by Mick Popp, Greg Schultz and Mark Sherwood and 
this array used here is an improved, more fully annotated version of the chip originally 
published in 2007 (Popp et al., 2007).  
2.11.2.1 Total RNA Isolation and QC 
Total RNA was obtained from conjunctival tissue as previously described (2.10.3). 
Following RNA extraction, QC was performed on each sample using the Agilent 2100 
Bioanalyzer and RNA 6000 Nano Chip Kit as previously described (2.11.1.1). 
2.11.2.2 Hybridisation and array scanning 
Following pre-hybridisation QC, the samples were hybridised to the arrays. Full 
protocols for array hybridisation are available from Agilent (Agilent, 2008), however this 
is detailed below and outlined in Figure 2.8. 
2.11.2.2.1 The preparation of labelled cRNA 
The protocol detailed below contains the volumes required for one array but master 
mixes were used for multiple arrays. A total of 200 ng of RNA from one sample was 
added to a 2 µl of Spike A mix (similar to the Affymetrix spike ins) and this tube was 
labelled Cy-3. A second 200 ng sample of RNA (to be co-hybridised with sample 1) 
was mixed with 2 µl of Spike B mix in a separate tube labelled Cy-5. To each of these 
tubes 1.2 µl of T7 promoter primer was added and the volume made up to 11.5 µl. This 
mixture was incubated at 65°C for 10 minutes before being placed on ice for 5 minutes. 
To this mix 8.6 µl of a cDNA master mix was added, composed of: 4 µl of 5X First 
strand buffer, 2 µl DTT, 1 µl dNTP, 1 µl Moloney Murine Leukemia Virus Reverse 
Transcriptase (MMLV-RT) and 0.5 µl of RnaseOut. The mixture was incubated at 40°C 
for 2 hours, 65°C for 15 minutes before being cooled on ice for 5 minutes. 
Following cDNA synthesis the transcription to cRNA was performed through the 
addition of 60 µl of transcription master mix to the cDNA and incubated at 40°C for 2 
hours. The transcription master mix was composed of: 15.3 µl water, 20 µl 4x 
Transcription buffer, 6 µl DTT, 8 µl NTP mix, 6.4 µl 50% PEG, 0.5 µl RNaseOut, 0.6 µl 
Inorganic pyrophatase, 0.8 µl T7 RNA polymerase and 2.4 µl of either Cy-3-CTP or 
Cy5-CTP. In order to generate labelled cRNA for hybridising to the array, specific 
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nucleotides [cytidine triphosphate (CTP)] bound to either Cy3 or Cy5 were introduced 
leading to incorporation during cRNA synthesis. Following the completion of this step, 
the labelled cRNA was purified using the Qiagen RNeasy Mini kit as previously 
described (2.10.2). The quantity, and quality, of the cRNA was assessed using a 
Nanodrop ND-1000; any samples with a yield of less than 825 ng or dye activity of less 
than 8 pmol per µg of cRNA were not used and therefore reprocessed. 
2.11.2.2.2 cRNA fragmentation and hybridisation 
In order to generate fragmented samples of cRNA suitable for hybridisation, 300 ng of 
Cy-3 and Cy-5 labelled cRNA was added to a fragmentation mix composed of: 5 µl 10X 
blocking solution, 1 µl 25X Fragmentation buffer and water to make a total volume of 
25 µl. The samples were incubated at 60°C for 30 minutes, at which point 25 µl of 2X 
GEx hybridisation buffer HI-RPM was added to stop the fragmentation reaction. Finally 
40 µl of this final solution was added to the array and hybridisation undertaken over a 
17 hour period in a rotating oven set to 65°C. Once hybridised, the arrays were washed 
in a three step process using GE wash buffers 1 and 2 before being scanned using the 
Agilent Microarray Scanner. Images were obtained using the Agilent Feature Extraction 
software resulting in the generation of a number of files; of these the most important as 
a tab-delimited text file containing the expression values of each probe as well as PDF 
report providing an initial assessment of the results. 
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Figure 2.8 – Agilent two-colour microarray anti-sense labelling assay workflow. 
Image adapted from the Agilent User Manual (Agilent, 2008). 
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2.11.2.3 Post-hybridisation QC 
The approach to post-hybridisation QC was similar to that of the approach taken when 
analysing Affymetrix data (2.11.1.3). The exported raw data underwent a series of 
transformations during which background correction first took place, utilising the built in 
controls present within the array. This was followed by within- and between-array 
normalisation, which ensured that several non-biological variances were taken into 
account, including total brightness between arrays, the relative brightness of the Cy3 
vs. Cy5 and differences in background noise between arrays. Furthermore, due to the 
labeling of samples with either Cy3 or Cy5, arrays were used in a biological dye-swap 
fashion providing biological replicates to account for the effects of dye and array bias. 
The within array normalisation was undertaken to create a single expression value for 
each gene on the array through comparing the log ratio between the two intensity 
measurements (Cy3 vs. Cy5). This log ratio is referred to as the M-Value and was 
calculated using a loess normalisation method as originally defined by Yang (Y. H. 
Yang et al., 2001). Following log ratio transformation, the M-values had a distribution 
about zero. The between array normalisation was used to provide a unique single 
distribution of the data calibrated to a single pre-defined distribution (G. K. Smyth et al., 
2003). In order to achieve this aim, quantile distribution was used [as in the Affymetrix 
analysis (2.11.1.3)]. Individual probes were not summarised together, providing two 
results per gene in the final exporting of results. In the final downstream pathway 
analysis the gene with the lowest p-value of the pair was used.  
2.11.2.4 Gene expression analysis 
As with the Affymetrix data, the generated data was analysed using the LIMMA 
package within Bioconductor, which allows for differential expression analysis. In two-
group comparison, LIMMA applies a modified t-test using a Bayesian approach to 
make the analysis stable for small sample numbers (R. Gentleman et al., 2005); cut-
offs applied to the data were set at a fold change of ±1.5 and a p-value less than 0.05. 
2.11.3 Downstream analysis of microarray data 
In order to perform downstream analysis with the large data pools obtained from the 
microarray experiments a number of programs have been developed, many open-
source. The main aim of these programs is to provide a functional illustration of genes 
involved in various biological pathways. Such tools include MAPPFinder (Doniger et al., 
2003), PathVisio (Van Iersel et al., 2008) and WikiPathways (Pico et al., 2008). 
Ultimately however, after a great deal of comparison between the options available, 
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two programs were used in the generation of the final results: the Database for 
Annotation, Visualization and Integrated Discovery (DAVID) (Dennis et al., 2003; D. W. 
Huang et al., 2009) and Ingenuity Pathway Analysis (IPA, Ingenuity Systems, USA). 
2.11.3.1 The Database for annotation, visualisation and integrated discovery 
The database for Annotation, Visualization and Integrated Discovery (version 6.7) was 
used to identify significant biological clusters, processes and pathways represented in 
the sample of genes that met the requirement for differential expression (p < 0.05, FC ± 
1.5) (Dennis et al., 2003). In the calculation of gene groups, a minimum of 2 genes 
were required with an EASE score (a modified Fisher Exact p-value) of less than 0.05 
the biological clustering was based upon the gene ontology (GO) terms available in the 
GO library and pathways from Kyoto Encyclopaedia of Genes and Genomes (KEGG) 
database (Ashburner et al., 2000; Kanehisa et al., 2000). 
2.11.3.2 Ingenuity pathway analysis 
In order to confirm DAVID’s original findings, functional grouping and interaction 
networks were undertaken using Ingenuity pathway analysis (IPA). Datasets composed 
of entire probesets were entered into the IPA system and a threshold criteria of p < 
0.05 and FC ± 1.5 applied. The Fishers exact t-test was used to calculate a p-value 
that determines whether the biological function assigned to the gene is due to chance 
alone. Only p-values lower than 0.05 were used in the final results. The IPA software 
was used to generate networks based upon known gene and protein interactions, 
applying a score calculated as the negative exponent of a right-tailed Fisher's exact 
test result based upon the network size and focus of the genes (relevancy to one 
another), for example a score of 3 is calculated from a p value of 0.001 [-log(0.001)]. 
Further to this the top functions related to the network were also obtained. Networks 
were graphically presented with each node in a single network representative of an 
individual gene, with the links between each node representative of a biological 
relationship. Such interactions were generated from published literature stored within a 
database in the software; version 8.7 as used here contained 2.68 million literature 
references (Ingenuity Systems, 2010). Colouring of the networks was based upon the 
level of fold change with green representing an upregulation, red a downregulation, 
grey indicating that any change in gene expression present did not meet the required 
cut-off and white indicating the gene was not assessed within the array. 
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2.12 Glaucoma filtration surgery 
2.12.1 Surgical technique  
All in-vivo experimentation conformed to the ARVO statement for the Use of Animals in 
Ophthalmic and Visual Research (ARVO animal policy). 
Rabbits (2 – 2.5 kg, 12 -14 weeks old; Harlan, UK) were acclimatised for seven days 
prior to the start of any experiment, after which all animals underwent GFS following 
the administration of anaesthetics via an intramuscular injection into the hind leg 
muscle. To provide adequate sedation, a 50:50 mix of ketamine (25 mg/kg, Fort Dodge, 
UK) and Xxlazine (5 mg/kg, Bayer Healthcare, UK) was administered at a maximum 
dose of 1 ml per kg, after which rabbits were operated on using a Haag Streit operating 
microscope (Moeller Hi-R 900A, Haag Streit, UK). A speculum was placed under the 
eyelids of the rabbit’s left eye to open the lids and provide access to the eye. The 
nictitating membrane was carefully removed using scissors and a partial thickness 
corneal traction suture attached at an area of clear cornea, nasal to the insertion of the 
superior rectus, using 6-0 silk sutures (W812, Ethicon, UK). The traction suture was 
attached to a clamp and the eye pulled down to expose the superior conjunctiva. 
The conjunctiva was cut at the limbal edge to expose the sclera below and a fornix 
based conjunctival flap made via blunt sub-conjunctival dissection. A partial thickness 
scleral tunnel was then created approximately 4 mm from the limbus using a micro-
vitreoretinal (MVR) blade (585230, Bunzl). A 22 gauge IV Venflon (BV891451, Bunzl, 
UK) was then passed through the tunnel, until the cannula needle entered the anterior 
chamber. At this stage the anterior chamber appeared flat due to the loss of fluid 
through the tube. The Venflon was next sutured to the sclera using a 10-0 nylon suture 
(8065-198-001, Alcon, UK) passing through both the sclera and tube before the tube 
was trimmed using scissors such that only around 2 mm of tube remained visible in the 
subconjunctival space. The conjunctiva was returned to its original position and sutured 
carefully to the limbal edge using a central and peripheral mattress sutures. This form 
of closure was used to reduce the chances of leakage occurring at the limbal edge. 
Soon after closure, the formation of the bleb was visible. Finally the eye was treated 
with chloramphenicol (Martindale, UK) to help prevent any infection. During surgery 
any fluid that required removal (such as blood) was done so using PVA spears (40-
400, Altomed, UK) and eyes were kept moist through the use of Viscotears (Novartis, 
UK). 
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2.12.2 Drug treatment 
The aim of the in-vivo studies was to determine the biological effects of one, or multiple 
drugs. As such rabbits used in-vivo were treated with varying drugs that were applied 
via subconjunctival implantation, sponge application or post-operative subconjunctival 
injection. Further details with regards to the exact dosage regimens are available in the 
relevant chapters. 
2.12.3 Endpoints and clinical examination 
Rabbits were assessed daily with a number of examinations undertaken including the 
recording of the intraocular pressure of both eyes in each animal using a TonoVet 
(iCare, UK) and the measurement of bleb size (width, height and length) using callipers 
to give a size in mm. Blebs were further examined using a slit-lamp in order to 
accurately establish the location and size of the bleb. The bleb vascularity was judged 
on a pre determined criteria (0 = avascular, 1 = normal vascularity, 2 = hyperaemic, 3 = 
very hyperaemic) (T. T. L. Wong et al., 2003). The anterior chamber was also 
examined, firstly for the presence of inflammation using a predetermined scale (T. T. L. 
Wong et al., 2003) (0 = normal, 1 = presence of cells, 2= fibrin formation, 3 = hypopyon 
present), before being further assessed to examine whether the bleb was functioning, 
with a deep AC often indicative of a failed bleb; the depth of the anterior camber was 
therefore assessed as to whether it was flat, shallow or deep. 
2.12.4 Termination of the in-vivo study 
At the experimental endpoint, all animals were sacrificed following a schedule 1 
method. Animals were first sedated using the previously described anaesthetic regimen 
(2.12.1) before the administration of pentobarbitone (Euthatal, Merial Animal Health, 
UK) at a dose of 1 ml/kg into the marginal ear vein. Animals were monitored until no 
sign of life was present. 
2.12.5 Collection of tissue for RNA isolation 
Immediately following death animals were placed under the operating microscope 
where tissue was collected for RNA isolation. Three pieces of tissue from the bleb area 
were isolated per animal (central, temporal and nasal locations) with the central most 
piece an approximate size of 2 x 2 mm. Tissue was immediately placed into an RNase 
free / DNAse free 1.5 ml Eppendorf (AM12400, Ambion, UK) and snap frozen before 
being placed on dry ice and transferred to -80°C where they remained until RNA 
isolation was undertaken. 
 
Chapter 3 Cytotoxic agents 
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3.1 Introduction 
3.1.1 The cell cycle 
The eukaryotic cell cycle is divided into four stages: G1, S (DNA replication), G2 and M 
(mitosis) with each phase independently regulated (a fifth stage, G0, is present but is a 
resting phase) (Johnson et al., 1999). During G1, the gap phase, cells prepare for the 
process of DNA replication; the cell responds to either mitogenic or anti-mitogenic 
cytokines and growth factors, deciding whether to continue, pause briefly or 
alternatively completely exit the cell cycle. Between each stage, a series of checkpoints 
exists to maintain control over the events that form the cell cycle; during each of these, 
the repair of aberrations that occur during the cell cycle, such as DNA damage, can 
take place (Berk et al., 1999; Nigg, 2001; Braithwaite et al., 2006). 
Following cellular stimulation with pro-mitogenic factors, D-type cyclins are activated 
and rapidly associate with cyclin-dependent kinases (cdks): cdk4 and cdk6 (Woo et al., 
2003). The primary target of the cdks is the retinoblastoma tumour suppressor protein 
(Rb) which, in normal conditions, forms a complex with a family of transcription factors, 
E2Fs, preventing progression of the cell cycle. Upon activation of the cdks 
phosphorylation of Rb takes place, releasing it from its complex with the activator E2Fs 
(E2F-1, -2 and -3), hereon referred to as E2Fa, allowing it to regulate the transition from 
G1 to S phase (Shah et al., 2001). A second group of E2F family members also exist, 
the E2F repressors (E2F-4 through -8), hereon referred to as E2Fr, which act to 
repress cell cycle gene expression (Sherr et al., 2002). The E2Frs form a complex with 
phosphorylated Rb, indicating that the activation of Rb, through phosphoactivation 
(phosphorylation), also provides a negative feedback mechanism to control its 
activation, as well as a mechanism to fine tune the control the transition from G1 to S 
phase (Cobrinik et al., 1993; Cam et al., 2003; A. Sun et al., 2007). However when 
cells lack Rb, cell cycle progression is not halted, indicating that D-type cyclin kinase 
activity is not critical for cell cycle progression, control or prevention; furthermore the 
loss of Rb has been shown to be a common event in certain forms of breast cancer 
(Lukas et al., 1995; Herschkowitz et al., 2008). Instead the D-type cyclins are thought 
to help regulate cell cycle progression by targeting Rb and Rb-related proteins that lead 
to the initial phosphorylation of Rb (Figure 3.1) (Kato et al., 1993). The activation of the 
E2Fas leads to the progression of the cell cycle through G1, with the activation of cyclin 
E and its subsequent association with cdk2 required for cell transition from G1 into S 
phase. Further to cyclin E activation, E2Fa is also known to regulate a number of other 
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genes involved in later cell cycle events including cyclin A, cdc2, B-mub, thymidine 
kinase and DNA polymerase α (Ishida et al., 2001). 
During all phases of the cell cycle elevated levels of cyclin E are found in the nuclei of 
the proliferating cell, although the overexpression of cyclin E in quiescent cells does not 
induce proliferation directly; in order for proliferation to be restored, cdk2 activation was 
required as demonstrated by Ohtsubo and collages. Cyclin E is however required for 
cell cycle progression as the inhibition of cyclin E activity via antibodies led to no 
progression into the S phase of actively dividing cells (Ohtsubo et al., 1995). Cyclin E 
plays a further role in maintaining Rb in a hyperphosphorylated state when in a 
complex with cdk2, producing a positive feedback loop, increasing the amount of active 
E2F (Q. Liu et al., 1999).  
Cyclin A, which is also activated during G1 via E2Fa, begins accumulating as the 
transition into S phase occurs, remaining elevated throughout DNA replication. Cyclin A 
is known to initially associate with cdk2 before later in S-phase associating with, and 
activating, cdk1 (also known as CDC2) (Yam et al., 2002). The loss of cyclin A, 
demonstrated through anti-cyclin A antibodies or antisense cyclin A, prevents 
progression through the S phase, with Walker and colleagues demonstrating that a 
loss of cyclin A mRNA during metaphase arrested cells, obtained from xenopus eggs, 
could enter interphase but not initiate DNA synthesis, resulting in an incomplete S 
phase; these effects were reversed upon addition of cyclin A mRNA or protein (Girard 
et al., 1991; Walker et al., 1991). Furthermore cyclin A has been demonstrated to co-
localise with sites of DNA replication, with it’s role thought to be in restricting the 
initiation of replication to only once per cycle with Mihaylov demonstrating that the 
silencing of cyclin A led to the formation of a giant nucleus and over replication of the 
DNA (Sobczak-Thepot et al., 1993; Mihaylov et al., 2002).  
Following the synthesis of DNA the cells progress into the G2 phase, with a checkpoint 
corresponding to DNA damage present causing a delay in cell cycle progression that 
allows DNA repair to take place prior to the cell entering mitosis and completing the cell 
cycle through cell division. In healthy tissues, cells will undergo several cycles of cell 
division before reaching a point where the cell undergoes natural cell death induced 
through naturally occurring aberrations in DNA replication (Arellano et al., 1997). 
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Figure 3.1 – The cell cycle. 
Prior to activation of the cell cycle, retinoblastoma tumour suppressor protein (Rb) forms a complex with 
the transcription factor E2F. Following activation of the cyclinD/cdk4/6 complex, phosphorylation of Rb 
occurs releasing E2F and allowing downstream activation of cell cycle required genes. Together with E2F 
activation, an increase in cyclinE is also observed and when complexed with cdk2 helps retain Rb in a 
hyperphosphorylated state. Image adapted and redrawn from images found in the following citations (Berk 
et al., 1999; Braithwaite et al., 2006). 
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3.1.1.1 Apoptosis 
Apoptosis is the mechanism by which cells are able to enter controlled, programmed 
cell death with it occurring in a number of different situations (Elmore, 2007). Apoptosis 
results in a number of phenotypic changes including cell shrinkage, mitochondrial 
disruption and DNA fragmentation; however, unlike necrosis where cell death is 
uncontrolled, apoptosis allows cell death to occur in a single cell fashion without 
impeding on surrounding cells (Edinger et al., 2004; Fink et al., 2005). The control of 
apoptosis is regulated, primarily, through the activation of the caspases, a family of 
cysteine proteases that degrade a number of essential proteins; two pathways exist 
that, predominantly, control caspase activation: the intrinsic mitochondrial pathway and 
the extrinsic death receptor pathway (Burz et al., 2009). 
The apoptotic cascade is stimulated through the presence of pro-apoptotic cytokines 
leading to the activation of initiator caspases, caspase 8 and caspase 9. Their 
activation results in the downstream initiation of effector caspases through proteolytic 
cleavage (Doseff, 2004). The extrinsic signalling cascade is stimulated through 
activation of the tumour necrosis factor receptor (Fas) via the Fas ligand (FasL), the 
TNF-related apoptosis-inducing ligand (TRAIL) or cytokines such as TNF-alpha leading 
to the downstream activation of the death inducing signalling complex (DISC) and 
subsequent caspase-8 activation. The intrinsic signalling cascade meanwhile is 
induced through the release of cytochrome-c from the mitochondria of cells following, 
most commonly, drug or radiation damage. The released cytochrome-c binds to 
apoptotic protease activating factor-1 (Apaf-1), leading to co-activation of caspase 9 
(Cory et al., 2002). Upon activation of either caspase 8 or 9, cleavage of pro-caspase 3 
and 7 into their active form sees the proteolysis of several proteins take place and the 
subsequent disruption of a wide range of biological functions including chromatin 
assembly, transcription factor activation and signalling pathway transduction (Slee et 
al., 2001). 
Under normal conditions, apoptosis is a tightly regulated process as illustrated in 
Figure 3.2. One family of proteins that coordinate apoptosis are the B-cell lymphoma 2 
(Bcl-2) proteins, a family that play opposing roles in apoptosis (Zinkel et al., 2006). Bcl-
2 and B-cell lymphoma-extra large (Bcl-xl) provide inhibition of the pathway, with Bcl-2-
associated X protein (Bax) and Bcl-2 homologous antagonist killer (Bak) forming the 
pro-apoptotic family members. Bcl-2 is a regulator of the intrinsic pathway, suppressing 
the activity of Bax which, in an active form, disrupts the mitochondrial membrane 
integrity allowing the release of cytochrome-c and thus the downstream activation of 
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caspases (Cory et al., 2002; Sasi et al., 2009). A second pathway that interacts with 
Bcl-2 signalling is that of the tumour suppressor protein, tumour protein p53 (p53) 
(Zamzami et al., 2005). Under normal conditions p53 activity is inhibited through the 
formation of a with the proteins Mdm2 and Mdm; upon activation of the 
intrinsic/extrinsic signalling cascade Mdm2 and Mdmx undergo either phosphorylation 
or ubiquitination, leading to an active form of p53 present within the cell (Wade et al., 
2010). In turn, a series of events take place including activation of the intrinsic pathway 
through the repression of Bcl-2 (and thus an increased secretion of cytochrome c), as 
well as the upregulation of extrinsic pathway mediators including FasL. A more 
complete review of the role of p53 in apoptosis is available in a review by Harris and 
Levine (Harris et al., 2005). Furthermore, interaction between E2F family and p53 also 
occurs, with many of the events related to cell cycle arrest occurring through the CDK 
inhibitor p21, a p53 activated protein that disrupts the CDK-Rb-E2F pathway leading to 
E2F activity repression and cell cycle arrest (Polager et al., 2009). 
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Figure 3.2 – The activation of the intrinsic and extrinsic apoptotic pathways. 
Apoptosis can be triggered through the activation of two initially distinct, but overlapping, pathways: the 
intrinsic and extrinsic apoptotic cascades. The intrinsic pathway is initiated through the binding of ligands 
to cell surface receptors (such as Fas) leading to the activation of caspase 8 and subsequently caspase 3. 
The intrinsic pathway is induced through Bax/Bad mediated release of cytochrome c from mitochondria, 
often regulated via p53, which is upregulated in a number of situations including drug induced DNA 
damage. Cross talk between the two pathways exists, such as in the activation of Bid by caspase 8 
leading to enhanced cytochrome c release from the mitochondria. Image adapted and redrawn from 
images found in the following citations (Macfarlane et al., 2004; Sekulic et al., 2008).
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3.1.2 Therapeutics and the cell cycle 
The regulation of the cell cycle has become a key target in a number of diseases, in 
particular cancer (Vermeulen et al., 2003). The use of chemotherapeutic agents in 
cancer treatment is designed, in principle, to cause widespread cell death of the 
targeted tumour cells through interruption of the cell cycle. To that end a number of 
drugs have been developed to target each of the different phases. For example, 
cisplatin (a platinum based, small molecule) is used to treat various solid tumours and 
haematological malignancies by causing cell cycle arrest in the G2 phase as well as 
leading to interference with tubulin-associated proteins (Shah et al., 2001; Tsang et al., 
2009). The use of such drugs outside of cancer treatment has also been explored, with 
the primary uses being the induction of apoptosis and cell-cycle arrest. The most 
prominent example of those used are 5-fluorouracil and mitomycin-C, particularly in 
ophthalmology, with both having found applications in glaucoma treatment as 
discussed in section 3.1.3 (Abraham et al., 2007; Mearza et al., 2007). 
 
 
Figure 3.3 – The molecular structure of 5-fluorouracil and mitomycin-C. 
Image drawn using SketchEl based upon images found within the Pubchem database (Ncbi, 2010d). 
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3.1.2.1 5-Fluorouracil 
5-Fluorouracil is a chemotherapeutic agent that antagonises pyrimidine metabolism 
and brings about an inhibition of the cell cycle (Shah et al., 2001). 5-FU is a structural 
analogue of uracil and thymine and as such can be metabolised by the same enzymes 
that undertake the metabolism of these nucleobases (Figure 3.4). When applied to a 
cell, 5-FU rapidly enters the cell via a transmembrane carrier system where it is broken 
down by a number of enzymes (D. M. Thomas et al., 1998).  
The main conversion that takes place is that of 5-FU to fluorouridine monophosphate 
(FUMP) either directly by orotate phosphoribosyltransferase (OPRT) or through 
sequential breakdown by uridine phosphorylase (UP) and uridine kinase (UK) via a 
secondary compound, fluorouridine (FUR). Upon its formation FUMP is phosphorylated 
to form fluorouridine diphosphate (FUDP), which can be either further phosphorylated 
into the active metabolite fluorouridine triphosphate (FUTP) or converted to 
fluorodeoxyuridine diphosphate (FdUDP) by ribonucleotide reductase (RR). 
Furthermore FdUDP can be either further phosphorylated or dephosphorylated to 
generate either fluorodeoxyuridine triphosphate (FdUTP) or fluorodeoxyuridine 
monophosphate (FdUMP) respectively. Further to this a secondary pathway also exists 
whereby 5-FU can be catalysed to fluorodeoxyuridine (FUDR) via thymidine 
phosphorylase (TP) and thymidine kinase (TK). Following the above conversion of 5-
FU into FUTP, FdUTP or FdUMP damage to both RNA and DNA occurs, whereby 
these products can inhibit the nucleotide synthetic enzyme thymidylate synthase (TS) 
or be incorporated into DNA or RNA disrupting their function. Despite these 
mechanisms over 80% of 5-FU, when administered systemically, is cleared in the liver 
by dihydropyrimidine dehydrogenase (DPD), an enzyme normally involved in 
pyrimidine degradation, through the conversion of 5-FU into dihydrofluorouracil 
(Longley et al., 2003). 
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Figure 3.4 – The conversion of 5-FU into its damage inducing metabolites. 
The metabolism of 5-FU occurs via enzymatic conversion of 5-FU into three main active metabolites: 
fluorouridine triphosphate (FUTP), fluorodeoxyuridine triphosphate (FdUTP) and fluorodeoxyuridine 
monophosphate (FdUMP). 5-FU is initially converted into fluorouridine monophosphate (FUMP) via orotate 
phosphoribosyltransferase (OPRT) or uridine phosphorylase (UP) and uridine kinase (UK). Further 
phosphorylation of FUMP leads to fluorouridine diphosphate (FUDP) that is either further phosphorylated 
to form FUTP or converted to fluorodeoxyuridine diphosphate (FdUDP) via ribonucleotide reductase (RR). 
This presents two options for FdUDP, either phosphorylation to FdUTP or dephosphorylation to FdUMP. 
FdUMP can also be produced by enzymatic conversion of 5-FU to fluorodeoxyuridine (FUDR) via 
thymidine phosphorylase (TP) followed by phosphorylation to FdUMP via thymidine kinase (TK). FdUMP is 
a direct inhibitor of the enzyme thymidylate synthase (TS) leading to downstreatm damage. Image adapted 
and redrawn from images found in the following citation (Longley et al., 2003). 
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3.1.2.1.1 Inhibition of DNA repair 
In the normal cell, thymidylate synthase (TS) functions to convert dUMP to dTMP 
providing a source of thymine, essential for DNA replication and repair. In the presence 
of FdUMP this conversion is interrupted as FdUMP binds to the nucleotide-binding site 
of thymidylate synthase (TS), normally reserved for dUMP, forming a stable complex 
preventing the formation of dTMP. The synthesis of dTMP in normal conditions leads to 
the eventual formation of dTTP via thymidine kinase, providing a source of thymidine 
critical for DNA repair. With a lack of dTMP, an imbalance in the ratio of dUMP:dTMP 
causes a disruption in DNA synthesis and repair, subsequently leading to lethal DNA 
damage (Santi et al., 1974; Berger et al., 1984). A graphical representation of this 
process is shown in Figure 3.5. 
3.1.2.1.2 DNA and RNA incorporation 
Upon the inhibition of TS an increase in the ratio of dUTP is observed which, together 
with the 5-FU metabolite FdUTP, can be incorporated into DNA in error leading to 
uracil-RNA-mediated cytotoxicity (Ladner et al., 2000). Despite the repair enzyme 
uracil-DNA-glycosylase (UDG) being present, the highly elevated levels of dUTP and 
FdUTP results in further false nucleotide incorporation. Similarly the 5-FU metabolite 
FUTP is highly incorporated into RNA leading to a disruption in RNA processing and 
protein production (Doong et al., 1988; Parker et al., 1990). A graphical representation 
of this process is shown in Figure 3.5.  
3.1.2.1.3 Induction of apoptosis 
When cells are treated with 5-FU (>1 mg/ml) an increase in phosphorylated p53 is 
observed, with the p53 protein, as previously described (3.1.1.1), a key regulator of the 
expression of a number of genes, in particular those involved in apoptosis and growth 
arrest. Together with an increase in p53, a down-regulation of Bcl-2 expression is 
observed further highlighting the potential mechanism through which 5-FU induces 
apoptosis (L. Huang et al., 2010). The use of DNA microarray screening has also led to 
the identification of Fas as an inducible target of 5-FU treatment. Fas, as previously 
discussed in 3.1.1.1, is a member of the TNF receptor superfamily that is able to 
activate caspase-8 (Maxwell et al., 2003). Similarly, Backus and colleagues were able 
to show a 50% increase in staining of the Fas receptor in liver metastases from 
colorectal cancer patients that had recieved 5-FU compared to those that did not 
(Backus et al., 2001). Other studies have linked an increase in Fas signalling as a 
response to thymidylate depletion with Houghton and colleagues demonstrating that in 
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a TS-deficient colon cancer line, without thymidine supplementation, the cells would 
undergo apoptosis; upon the addition of an antibody to FasL this was inhibited. 
Furthermore upon thymidine withdrawal an increase in FasL expression was observed, 
further indicating the role of the Fas signalling cascade in regulating apoptosis due to 
thymidine depletion, as seen following 5-FU treatment (Houghton et al., 1997). 
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Figure 3.5 - 5-fluorouracil 
(5-FU) induced DNA and 
RNA damage. 
The conversion of 5-FU 
into fluorodeoxyuridine 
monophosphate (FdUMP) 
leads to the inhibition of 
thymidylate synthase (TS) 
reducing the natural 
conversion of deoxyuridine 
triphosphate (dUTP) into 
deoxythymidine 
monophosphate/ thymidine 
triphosphate 
(dTMP/dTTP), causing an 
imbalance between the 
two. This resulting 
imbalance leads to 
increased incorporation of 
uracil into DNA inducing 
cell death. The conversion 
of 5-FU into fluorouridine 
triphosphate (FUTP) 
similarly leads to cell 
damage through the 
incorporation of uracil into 
DNA/RNA. Finally 5-FU is 
also able to trigger the 
phosphoactivation of p53 
triggering the p53 
regulated apoptotic 
cascade. Image adapted 
and redrawn from images 
found in the following 
citation (Longley et al., 
2003). 
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3.1.2.2 Mitomycin-C 
Mitomycin-C is a naturally occurring antibiotic that was originally isolated from the 
Gram-negative bacteria Streptomyces caespitosus (Hata et al., 1956). Mitomycin-C 
undergoes either one or two electron reduction via a range of enzymes, with most of 
these located within the cytosol, suggesting a translocation to the nucleus is required 
for MMC to induce its primary effect (Snodgrass et al., 2010). The principle effect of 
MMC is the inhibition of DNA synthesis whereby, upon the reduction of MMC, it is able 
to bind DNA through bifunctional alkylation resulting in a crosslinking of DNA strands, 
inhibiting DNA synthesis and thus cell replication (Reddy et al., 1987; Tomasz et al., 
1987). Due to this interaction with the DNA, MMC is most effective during the late G1 
and S phases of the cell cycle (Verweij et al., 1990). 
Despite the inhibition in DNA replication, the crosslinking of DNA also gives rise to the 
induction of apoptosis through the activation of p53 (Fritsche et al., 1993), with several 
studies having shown that MMC is able to induce the activation of caspase-8 and 
caspase-9 through cytochrome-c release from the mitochondria. In particular, Seong 
and colleagues were able to demonstrate that HTFs treated with MMC, at the clinical 
concentration of 0.4 mg/ml, underwent apoptosis that coincided with an increase in 
caspase 3 and 9. Furthermore, an increase in the expression of proteins involved in the 
extrinsic pathway were also observed, such as Fas and FasL (Seong et al., 2005). The 
effects of MMC functioning in such a way have also been reported in both human RPE 
and corneal endothelial cells (S. G. Kang et al., 2001; K.-Y. Wu et al., 2008).  
3.1.3 The emergence of antifibrotic treatments as post-operative treatments 
following GFS 
The trabeculectomy, as originally described by Cairns in 1968, (Cairns, 1968) has 
undergone a number of revisions since it’s first inception, yet despite this, it has 
remained the most commonly performed incisional surgical procedure to treat 
glaucoma (Mietz et al., 2002). However, as has previously been discussed, the limiting 
factor in the success rate of GFS is subconjunctival scarring; in order to improve these 
rates a number of pharmaceutical agents were investigated, of which the most 
promising were 5-FU, as demonstrated by Gressel and Heuer, and MMC, as 
demonstrated by Chen and colleagues (C. Chen, 1983; Gressel et al., 1984; Heuer et 
al., 1984; C. W. Chen et al., 1990). Since these original publications a range of studies 
have been undertaken in which dosing regimen, dosing concentration and delivery 
method have all been altered with the aim of optimising the control of post operative 
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scarring and minimising post-operative complications typically associated with cytotoxic 
administration.  
The first pilot study by Heuer and colleagues involved the use of post-operative 
injections at a concentration of either 3 mg/ml or 5 mg/ml with twice daily injections 
over a seven-day period before a daily injection over the following seven days. A large 
scale investigation by the Fluorouracil Filtering Surgery Study group using this regimen 
produced a 5 year follow-up report, at which point only 51% of patients were classified 
as having failed, compared to 74% in the control group (Heuer et al., 1984). Importantly 
this study was able to highlight the complications associated with the use of 5-FU, for 
example it was found that 9% of patients developed a late bleb leak compared to just 
2% in the control group. When Rothman and colleagues published a nine year follow 
up to a study first started by Lebmann in 1991 (which used post-operative 
subconjunctival injections of 5-FU for up to 14 days), it became evident that despite 
short term (two year) followups indicating the effectiveness of 5-FU (100% vs. 78.9% 
surgical success rate in 5-FU patients vs. control), after five years this had fallen to 
77.8% in the 5-FU group and 62.2% in the control group (Liebmann et al., 1991; 
Rothman et al., 2000). As summarised by Lama and colleagues, this potentially 
indicates that whilst 5-FU used in this treatment regimen increased the likelihood of 
success within the first few years following GFS, long term success continues to 
decrease at a rate similar to that of the control group (Lama et al., 2003).  
Following both the limited effectiveness of subconjunctival injections and multiple in-
vitro and in-vivo studies, it was soon established that single, short term exposures of 
either 5-FU or Mitomycin-C at high concentrations (25 – 50 mg/ml 5-FU; 0.2 – 0.5 
mg/ml MMC) could lead to long term effects on the inhibition of HTF proliferation, with 
MMC having a greater effect than 5-FU (Khaw et al., 1992; P T Khaw et al., 1993). 
Single exposure treatments of cytotoxics to HTFs were shown to cause long terms 
changes in growth factor receptor expression, collagen and fibronectin production and 
cell migration (N L Occleston et al., 1997). Similar short term exposures were further 
explored in models of collagen gel-contraction, where Occelseton and colleagues were 
able to show that HTF populated collagen gels treated with MMC or 5-FU, at high 
concentrations in single five minute applications, were significantly inhibited in 
contraction compared to water controls (Occleston et al., 1994). Furthermore, Khaw 
and colleagues were able to demonstrate that the outgrowth of fibroblasts from tissue 
samples obtained from rabbits, which had been treated with 5 minute applications of 
either 50 mg/ml 5-FU or 0.4 mg/ml MMC, was significantly inhibited in those treated 
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with MMC one month after treatment, compared to a recovery from growth arrest in 
those treated with 5-FU (Khaw et al., 1992). Other approaches looking at the exposure 
time of HTFs to 5-FU have shown that when using doses of 50 mg/ml the exposure 
time actually has limited impact on the ability to regulate HTF proliferation. Merriman 
and colleagues demonstrated that in an organ culture model of HTF proliferation a one-
minute exposure to 50 mg/ml of 5-FU was as effective as a 5-minute application, with 
prolonged exposure (up to 10 minutes) providing no additional benefit (Merriman et al., 
2001). 
Whilst much of the in-vitro work that was undertaken was pioneered by Khaw and 
colleagues, the first clinical report into the use of high concentrations of these drugs 
using subconjunctival intraoperative sponge delivery was published by Dietze and 
colleagues, who in 1992 reported an 84% success rate after three months (Dietze et 
al., 1992). The use of such a sponge has remained the optimal delivery method for 
cytotoxic agents, and whilst different approaches are taken with regards to sponge 
size, shape and material, Wilkins and colleagues demonstrated that sponges soaked in 
25 mg/ml showed no differences in their ability to deliver drug to the tissue whether 
they were large sponges (7 x 4 mm) or small sponges (3.5 x 2 mm) (M. R. Wilkins et 
al., 2000). 
3.1.4 Cytotoxic side-effects 
Despite the improved treatment regimens the side effects from the use of cytotoxic 
agents are rife. The use of MMC often leads to the development of thin, avascular 
blebs which are often further associated with leakage; it has been estimated that MMC 
treatments can cause leakage as much as three times more frequently than 5-FU 
treated eyes (Greenfield et al., 1998). Despite this suggesting the slight benefit of 5-FU 
over MMC due to it’s reduced side effects, the Singapore 5-fluorouracil study group 
reported that at the three year follow up stage, despite success rates being significantly 
lower in the 5-FU group (p = 0.0154 when IOP >17 mmHg) complications were still 
highly pronounced. This study used a treatment regimen of single 50 mg/ml application 
of 5-FU over a five minute period (T. T. Wong et al., 2009). Almost twice as many 
leaking blebs were observed (13 in the 5-FU group compared to 7 in the control group) 
as well as a significantly larger proportion of patients suffering Uveitis following 5-FU 
treatment. The reasons for such complications is that the application of high doses of 
these drugs leads to instant widespread cell death of not only the fibroblasts but also 
the epithelial layer, and this has been extensively linked to bleb leakage (Geggel et al., 
1984; Francis et al., 2005). Nonetheless, despite these complications, in a study 
 112 
performed by Siriwardena and colleagues it was reported that in 2004 only 18% of 533 
UK based consultant ophthalmologists performing trabeculectomies never use any 
form of cytotoxic treatment, although of the 72% that do use such medications only 9% 
use it in more than half of their cases (Siriwardena et al., 2004). The most preferred 
antimetabolite was 5-FU (93%), with only 41% using MMC. This figure greatly differs 
from those in Japan and the USA, where the use of MMC in first time trabeculectomies 
is between 33% and 52% (P. P. Chen et al., 1997). Of those that do use MMC in the 
UK the most common doses were 0.2 and 0.4 mg/ml (52% and 30% respectively) with 
an application time of 2-3 minutes most commonly used (28 and 32% respectively). 
The commonly used 5-FU concentration is 50 mg/ml given either intra-operatively via 
sponge application (34%) or via both a combination of sponge application and post-
operative subconjunctival injection (53%) (Siriwardena et al., 2004; Dhingra et al., 
2009). 
3.1.5 Altering and Improving antimetabolite delivery methods 
One of the most critical aspects with regards to the use of antimetabolites outside of 
damage-induced side effects is the short retention time within the target area, often 
resulting in the need for bleb revision through post-operative injections. For some 
patients, the use of a single short-term application of either 5-FU or MMC is simply not 
sufficient for the maintenance of long-term surgical success (Anand et al., 2007). 
Wound healing occurs over several months and whilst a brief application of a cytotoxic 
agent may result in cell death at the first instance, it does not help with regards to 
migratory cells entering the wound area following the removal of the drug or those cells 
that are unaffected by the short term application of the cytotoxic agent. Furthermore, 
patient specific responses are also observed based upon the activity of many of the 
enzymes that regulate the cytotoxics in their mode of action. For example, in cancer 
cells an increased expression of TS resulted in an increased resistance to 5-FU (Hu et 
al., 2003; W. Wang et al., 2004). Currently no studies have looked for any links 
between thymidylate synthase activity and GFS success rates, yet it is known that 
African populations show a higher frequency of TS promoter mutations (resulting in 
increased TS activity) (Marsh et al., 2000) and it is this ethnicity that shows the highest 
failure rates following GFS (Lachkar et al., 1997). 
With regards to drug residency time, a number of studies have indicated that the time 
of 5-FU or MMC present within the subconjunctival tissue is low, with Rootman and 
colleagues indicating a peak in 5-FU concentration 30 minutes post injection with 
around a 10 times decrease in concentration after one hour (Rootman et al., 1984). 
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Similarly Huang and colleagues were able to show that in rabbits, following a 100 µl 
subconjunctival injection of tritiated-FUR (5 mg/ml), the concentration within the 
ipsilateral anterior chamber was only 10.7 µg/ml after one hour. Whilst this study did 
not look at concentration levels within the tissue it did indicate the rapid clearance of 
drugs that occurs following subconjunctival injection (D. S. Huang et al., 1988). 
Methods to increase the residency time of the antimetabolites have been investigated, 
such as the formation of a 5-FU liposomal delivery system and the development of 5-
FU loaded poly (lactic acid) discs (5-FU-PLA), although these have shown only limited 
effectiveness (Simmons et al., 1988; Cui et al., 2008). The latter system was shown in-
vitro to have a prolonged release over 100 days with a mean concentration of 60 µg/ml 
six days after release, steadily decreasing with time. However, in-vivo the 
concentration only averaged 8.7 µg/ml, falling below 1 µg/ml after one week. The study 
also found that whilst prolonged bleb survival was observed, the release of drug was 
faster than expected; by 90 days post-op all blebs were judged to have failed indicating 
a lack of complete inhibition of fibrosis. Furthermore toxic reactions due to the 
presence of PLA were found including conjunctival hyperaemia and corneal edema. 
Similar toxic effects of PLA/PLGA nanoparticles have been demonstrated in a number 
of other studies (Gould et al., 1994; Trope et al., 1994; Huhtala et al., 2009). 
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3.2 Objectives and experimental design 
Over the last 20 years a great deal of work has been undertaken to develop novel drug 
delivery systems to prolong drug residency time within target tissues. Such delivery 
methods have largely required the use of polymers or biological delivery systems, 
however many have produced poor results due to the inherent side effects induced by 
the drug carrier (Ghate et al., 2006; Choonara et al., 2010). Despite this, several 
polymers have been used safely in commercial ophthalmic products (including 
polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), dextrin, methylcellulose), providing 
an increased residency time to several drugs such as dexamethasone in the anterior 
chamber implant Surodex, fluocinolone acetonide in the retinal implant Retisert and 
ganciclovir in the retinal implant Vitrasert (Asane et al., 2008; Del Amo et al., 2008; 
Novack, 2009).  
Initial developments in our lab (led by Dr. Q. Ru) involved the generation of 5-FU gels 
and tablets in combination with ophthalmologically approved polymers: Healon (HA) 
and PVP (Ru, 2010). However following in-vitro release studies it was found that the 
presence of the polymer, whilst prolonging the release of 5-FU in comparison the 5-FU 
solution, led to 100% release of 5-FU within 24 hours. Whilst the presence of either 
polymer could prolong 5-FU by increasing viscosity within a tablet, due to hydrophilicity 
they also improved the rate of 5-FU dissolution from the tablet limiting the ability of the 
tablet to provide a prolonged release. It was therefore proposed that the release of 5-
FU could be slower without the presence of any hydrophilic polymers and as such an 
excipient free 5-FU tablet was created. Furthermore, despite the long term use of such 
agents, little is known with regards to their effects on biological pathways outside of 
their known mechanism of action as previously described (3.1.2.1 and 3.1.2.2). 
 
On this basis the aims of this chapter were: 
 
i. To determine, based upon previous in-vitro release data, the biological effects 
of 5-FU on human Tenon’s fibroblasts using various models, including 
proliferation assays (over 30 day periods), collagen gel contraction and 
immunocytochemistry when delivered at concentrations produced from 
implantable tablets compared to currently used treatment strategies. 
ii. To determine the in-vitro effects of MMC on MMP gene expression so as to 
clarify whether the anti-scarring effects of this cytotoxic drug extend beyond 
simply causing DNA intercalation, and subsequent apoptosis, in fibroblasts. 
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3.3 Results 
3.3.1 The release rates of an excipient-free 5-FU tablet 
The release rate of 5-FU tablets composed solely of 5-FU was examined by placing a 
5-FU tablet (approximately 5 mg) into a flow-rig with a 200 µl volume of PBS. The 
tablets were allowed to release over an eight-hour period. With constant flow at a rate 
of 2 µl/min it was found that 80% of the tablet had released, reaching a peak 
concentration of 6 mg/ml after three hours (Figure 3.6 and Figure 3.7). A temperature 
of 37ºc was used to simulate the temperature found in the body.  
During the release of the tablet a fully saturated concentration of 5-FU (11.1 mg/ml) 
was not observed, indicating that 5-FU dissolution from the tablet itself is the rate 
limiting step for drug release and not the solubility of the drug (maximum aqueous 
solubility of the drug at 20°c is known to be 11.1 mg/ml) (Ncbi, 2010b). This release 
rate proved slower than that of 5-FU tablets previously investigated that were 
constructed with presence of hydrophilic polymers. This data was collected and 
analysed with the aid of Dr Q. Ru (Ru, 2010). 
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Figure 3.6 – The percentage of 5-Fu tablet released over time in a flow rig. 
The release profile of the 5-FU tablet demonstrates that over 80% of the tablet had released after eight 
hours of testing. Error bars represent SD (n = 3). Data collected with the aid of Dr. Q. Ru (Ru, 2010). 
 
Figure 3.7 – The concentration of 5-FU detected during tablet release in a flow rig. 
The concentration of 5-FU present in solution sampled during the tablet release over the eight hours of 
testing as measured using HPLC. Error bars represent SD (n = 3). Data collected with the aid of Dr. Q. Ru 
(Ru, 2010).
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3.3.2 The biological effects of 5-FU tablets 
From the results of the in-vitro release study it was decided that the optimal dose of 5-
FU to use for biological testing was 6 mg/ml over an 8-hour period. Whilst ideally the 
tablet itself would have been used for biological in-vitro testing, a system to provide 
flow with cells present was not obtainable. When a tablet was placed into static (no 
flow) conditions, the release profile was very different from that of a tablet in flow 
conditions. After 24 hours incubation of 5 mg tablets in a 2 ml volume at 37ºc, the 
recorded concentration was just 1.93 mg/ml and did not rise to the expected final 
concentration of approximately 2.5 mg/ml until after this timepoint (at 72 hours the 
concentration was 2.47 mg/ml) indicating saturation was not reached until after more 
than 24 hours. 
 
Figure 3.8– The concentration of 5-FU detected during tablet release in static conditions. 
The concentration of 5-FU present in solution sampled during the tablet release over a 72 hour period as 
measured using HPLC. Error bars represent SD (n = 3). 
Due to these findings, it was decided that a single concentration would be used, 
replicating that of the concentration that the tablet released at during flow rig testing 
(Figure 3.7). Two concentrations were discussed, the mean concentration over the 
release period and the maximum concentration. It was decided that a concentration of 
6 mg/ml, the maximum concentration, would be used, as this would exploit any 
potential toxicity found at this dose when delivered over a prolonged period of time. 
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3.3.2.1 Proliferation 
In order to understand the effects on HTF proliferation, as well as any potentially toxic 
side effects, HTFs were exposed to eight hours of 6 mg/ml 5-FU and assayed using 
MTT or manual cell counting. Initial experiments were carried out using cell counting, 
with the counts of cells grown in six well plates taken every 24 hours over a 72-hour 
period after initial treatment. The manual counting of cells indicated an inhibition in cell 
growth with reduced numbers counted at each timepoint (data not shown). However 
due to the inaccuracies that can be obtained in cell counting, cells that were treated in 
the six well plate were immediately plated into 96 well plates following treatment and 
assayed over a 72 hour period using the MTT assay, with measurements taken every 
24 hours as shown in Figure 3.9. This confirmed the findings obtained through cell 
counting, with an increase in cell proliferation only observed over the first 24 hours (a 
110.7% ± 3.3% increase in absorbance from treated cells compared to 122.7% ± 5.5% 
increase in control cells). Between 24 and 72 hours an increase in absorbance of only 
4.5% ± 1.6% was found in treated cells compared to a further 59.2% ± 6.6% increase 
in untreated cells. Despite the increase in absorbance over the first 24 hours, the total 
absorbance was still significantly less than compared to the control cells (p < 0.05) 
after 24 hours, with significant differences present at all other time points (p < 0.001). 
Results are presented as mean percentage change ± SEM from three independent 
experiments (n = 6 per experiment). 
To further assess the effects of a prolonged exposure to 5-FU at a concentration 
previously undocumented, the MTT was repeated, with the cells this time treated 
directly within the 96 well plates into which they had initially been seeded. The assay 
confirmed the initial findings that whilst 5-FU cause some early cell death (a reduction 
of 24.2% ± 3.3% absorbance was seen post-treatment), it also provides a “growth 
arrest” of the cells, limiting the amount of proliferation that occurs over the tested 72-
hour period (an absorbance increase of only 51.2% ± 8.7% was found) (Figure 3.10). 
Results are presented as mean percentage change ± SEM from three independent 
experiments (n = 6 per experiment). 
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Figure 3.9 – The effects of 6 mg/ml 5-FU on HTF proliferation following treatment in a 6 well plate 
before seeding into 96 well plates. 
Following initial 5-FU treatment in a 96 well plate, cells were transferred to 96 well plates to assess their 
proliferative capacity over a further 72 hours. Whilst no differences were observed over the first 24 hours, 
after 48 hours absorbance had significantly increased by over 100% in control samples continuing through 
72 hours. Data presented is averaged from 3 independent experiments (n = 6 per experiment). Statistical 
comparisons were made using ANOVA and Bonferroni’s post-test comparing all columns. *** = p < 0.001. 
 
Figure 3.10 - The effects of 6 mg/ml 5-FU on HTF proliferation following treatment within a 96 well 
plate. 
The delivery of 5-FU at a concentration of 6 mg/ml over an eight hour period initially caused cell death as 
noted by the significant (30%) reduction in absorbance. Over the following 72 hours absorbance only 
increased 70% whilst control samples had a significant (400%) increase in absorbance.Data presented is 
averaged from 3 independent experiments (n = 6 per experiment). Statistical comparisons were made 
using ANOVA and Bonferroni’s post-test comparing all columns. ** = p < 0.01; *** = p < 0.001. 
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To compare this new treatment regimen with the current clinically used treatments of 5-
FU (25 and 50 mg/ml) and MMC (0.3 and 0.5 mg/ml) delivered over a 5 minute period, 
MTT assays were performed to assess the effects on both apoptosis and proliferation 
with the results presented in Figure 3.11. Immediately following treatment, a significant 
decrease in cell number was found in all treatments excluding those treated with PBS, 
indicating an initial wide-spread death of HTFs, even when treated with a 6 mg/ml dose 
of 5-FU for 8 hours (p < 0.001, mean 53.1% ± 3.6% decrease in absorbance). 
Following treatment, all groups produced an increase in absorbance during the first 24 
hours following treatment (a mean increase of 150.9 ± 23.0%), with similar increases 
observed between all treatment groups. However, after this initial increase in 
absorbance no significant increases were seen over the following 24 hours in any of 
the treated cells, with only the control group continuing to see rises in absorbance, and 
thus cell number.  
The cells treated with the clinical doses of 5-FU saw continued decreases in 
absorbance, with the highest doses producing the greatest changes (0.5 mg/ml MMC 
had a 45.6% ± 8.4% decrease in absorbance after 72 hours and 50 mg/ml 5-FU saw a 
39.7% ± 3.3% decrease after 72 hours). The only treatment group that continued to see 
an increase was the 6 mg/ml group, recording a 103.9% ± 14.3% increase in 
absorbance (p < 0.01) over the 72 hours. 
Throughout the study, all treatment groups showed significantly lower levels of 
absorbance than compared to the control treated cells (p < 0.001). Morphological 
appearance of the cells involved in this assay are shown in Figure 3.12 and Figure 
3.13, where clear differences in cell number are visible in the non-treated control 
samples compared to those treated with either 5-FU or MMC. Results are presented as 
mean percentage change ± SEM from two independent experiments (n = 3 per 
experiment). 
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Figure 3.11 - The effects of 6 mg/ml 5-FU on HTF proliferation compared to clinically used concentrations of 5-FU and MMC. 
The delivery of 5-FU at a concentration of 6 mg/ml over an eight hour period compared to five minute treatments of 5-FU and MMC at clinically used concentrations highlighted 
the differences in dosage of these agents. Whilst all groups had a decease in absorbance following treatment (average 53.1% ± 3.6% decrease) the only groups to show any 
proliferation after 72 hours were the 6 mg/ml group which had a 103.9% ± 14.3% increase in absorbance after 72 hours and the control group which increased by 614.1% ± 
36.5%). Significant decreases in absorbance were found between all groups as the positive control at every time point. Error bars represent the SEM (n = 6). Data presented 
are from the means of three impendent experiments (n = 6 per experiment).  
Statistical comparisons were made using ANOVA and Bonferroni’s post-test comparing all columns. *** = p < 0.001.  
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Figure 3.12 – An illustrative example of the number of MTT stained cells present within the 96 well 
plate immediately following 5-FU or MMC treatment. 
Cells treated with either PBS, 5-FU or were evaluated for signs of cell death immediately following 
treatment using the MTT assay. Prior to crystal dissolution, cells were photographed under a light 
microscope. Following treatment little cell death was observed in either the control or low dose 5-FU group, 
whilst those treated with either 5-FU or MMC at high doses displayed widespread cell death. Photographs 
representative of morphology observed in each of two experimental repeats (n = 3 per repeat). Scale bar 
represents 1000 µm. 
 123 
 
Figure 3.13 - An illustrative example of the number of MTT stained cells present within the 96 well 
plate three days after 5-FU or MMC treatment. 
Cells grown over a three day period following either PBS, 5-FU or MMC treatment were evaluated for 
changes in proliferation rates using the MTT assay. Prior to crystal dissolution, cells were photographed 
under a light microscope. Over the three day period the control cells grew toward a confluent state, whilst 
those treated exhibited a much-reduced level of proliferation. Cells treated with a prolonged, low level of 
proliferation exhibited a reduction in proliferation without having been initially killed, whilst those treated 
with high doses of 5-FU or MMC exhibited widespread cell death with little proliferation observed three 
days after treatment.  
Photographs representative of morphology observed in each of two experimental repeats (n = 3 per 
repeat). Scale bar represents 1000 µm. 
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Figure 3.14 - The effects of 6 mg/ml 5-FU on HTF proliferation over thirty days. 
The delivery of 5-FU at a concentration of 6 mg/ml over an eight hour period lead complete inhibition of cell proliferation over a thirty day period. After 30 days of growth only 
50.4% ± 10.3% increased absorbance was found in the 5-FU treated group compared to the control which had a 922.3% ± 27.1% increase. Significant differences were found 
at each time point following treatment. Error bars represent the SEM (n = 6). Data presented from a single experiment representative of triplicate repeats. Statistical 
comparisons were made using ANOVA and Bonferroni’s post-test comparing all columns. * = p < 0.05, ** = p < 0.01, *** = p < 0.001. 
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Finally, to assess the effects of a prolonged exposure to 6 mg/ml 5-FU, the MTT assay 
was performed over a 30-day period with the results shown in Figure 3.14. Absorbance 
measurements were taken 1, 2, 3, 7, 14 and 30 days post treatment with the results of 
this study showing with no significant changes in proliferation occurring between days 
seven and 30; however at all time points a significantly less number of cells was 
observed when compared to control groups (p < 0.001). Whilst as before an initial 
increase in absorbance in treated cells was observed over the first 24 hours following 
treatment (2.3% ± 3.4%), only a 50.4% ± 10.3% increase in absorbance found after the 
30 day period compared to a 922.3% ± 27.1% increase in the control cells. The cells 
grown during this study are shown in Figure 3.15 where at thirty days post treatment 
clear differences in cell number are visible, as quantified via the MTT absorbance. 
Results are presented as mean percentage change ± SEM from three independent 
experiments (n = 6 per experiment). 
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Figure 3.15 – An illustrative example of the number of MTT stained cells present within the 96 well 
plate 30 days after 5-FU treatment. 
Cells grown over a 30 day period following either PBS or 6 mg/ml 5-FU were evaluated for changes in 
proliferation rates using the MTT assay. Prior to crystal dissolution, cells were photographed under a light 
microscope. Over the thirty day period complete confluency of the control cells was observed, whilst in the 
5-FU treated cells, little proliferation was observed over the thirty day period. Photographs representative 
of morphology observed in each of three experimental repeats (n = 6 per repeat). Scale bar represents 
1000 µm. 
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3.3.2.2 Immunocytochemical analysis of HTFs grown in monolayer 
To examine the morphological differences between HTFs exposed to varying 
concentrations of 5-FU delivered over varying exposure times, immunocytochemical 
analysis of the cells was undertaken when grown in monolayer. In order to examine the 
cellular morphology of the HTFs at high magnification cells were stained with TRITC-
phalloidin to expose the actin filaments in fibroblasts at various timepoints following 
treatment (Figure 3.16). Control cells at both 24 hours and seven days post treatment 
displayed an expected fibroblastic, elongated shape, displaying long actin filaments 
throughout the cell body. Cells exposed to both forms of 5-FU exhibited a markedly 
different morphology with cells more condensed into a rounded, somewhat stellate, 
shape. As expected a decrease in cell number was observed (though not quantified) in 
cells treated with 5-FU.  
As can be seen by comparing the control cells with the treated cells, full confluency of 
the chamber slide was reached seven days following treatment, yet in treated cells 
populations of fibroblasts were largely restricted towards the edge of the well, with 
small patches located throughout the remainder of the well. Overall the cells appeared 
to stain for similar levels of F-actin, with no notable differences in fluorescence 
observed between the groups.  
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Figure 3.16 – Confocal images of F-actin staining in HTFs grown in monolayer following 5-FU treatment. 
Human Tenon’s fibroblasts grown in monolayer were fixed and stained 24 hours, and seven days, after treatment with 5-FU (6 mg/ml for 8 hours, or 50 mg/ml for five minutes). 
Cells exposed to 5-FU took on a smaller, rounded morphology compared to the elongated fibroblast shape of the control cells as evident at both 24 hours and seven days. 
Whilst the staining intensity appeared similar in both groups, clear differences in cellular morphology are seen. Staining was repeated three times with these results 
representative of the findings. Scale bars represent 100 µm in the 10x images and 20 µm in the 40x images.
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3.3.2.3 Collagen Gel Contraction 
To assess the effects of 5-FU delivered over a prolonged period of time, a 3D matrix 
model was used to assess HTF-mediated collagen contraction. 
Fibroblasts were seeded into collagen gels and immediately treated with either PBS or 
5-FU at a concentration of 6 mg/ml for 8 hours or 50 mg/ml for 5 minutes, with 
contraction monitored over a seven day period thereafter. Over the first two-three days 
of contraction, no differences in the rate of contraction were observed, with all groups 
reaching between 60 and 70% contraction after two days of growth. After this timepoint 
however the control cells continued to contract until a total contraction of 95% of the 
original size was reached, whilst the 6 mg/ml and 50 mg/ml 5-FU treated gels 
contracted only a further 11 and 14% respectively resulting in a significantly less 
contracted gel than compared to the control (p < 0.001) at day seven. 
Cells seeded into gels and allowed to grow, or activate, for a 24 hour period prior to 
treatment showed a similar response. Prior to treatment the gels had contracted 
approximately 10-25% of their original size. After seven days of growth, post treatment, 
significant reductions in total percentage contraction were found in both 5-FU groups, 
with those having had a prolonged exposure to 6 mg/ml 5-FU showing the greatest 
reduction in total contraction compared to the control (p < 0.001), with similar 
statistically significant differences found between the two 5-FU groups at day seven (p 
< 0.01). 
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Figure 3.17 – The effects of 5-FU on HTF mediated collagen gel contraction. 
HTFs were seeded into collagen gels and their ability to contact the matrix was monitored for seven days. 
Gels were treated with either PBS, 6 mg/ml 5-FU for eight hours or 50 mg/ml for five minutes. After seven 
days of contraction significantly less contraction had occurred in the 5-FU treated gels compared to the 
controls. No differences were found between the two different 5-FU treatments. Error bars represent the 
SEM (n = 5). Data presented from a single experiment representative of triplicate repeats. Statistical 
comparisons were made using ANOVA and Bonferroni’s post-test comparing all columns. *** = p < 0.001. 
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Figure 3.18 – The effects of 5-FU on HTF mediated collagen gel contraction following 24 hour pre-
activation of the cells. 
HTFs were seeded into collagen gels and allowed to grow for 24 hours. Following this period of activation 
the gels were treated with either PBS, 6 mg/ml 5-FU for eight hours or 50 mg/ml for five minutes, and the 
contraction monitored for seven days following treatment. After seven days of contraction significantly less 
contraction had occurred in the 5-FU treated gels compared to the controls, with significantly less occurring 
in the 6 mg/ml group when compared to the 50 mg/ml group Error bars represent the SEM (n = 5). Data 
presented from a single experiment representative of triplicate repeats. Statistical comparisons were made 
using ANOVA and Bonferroni’s post-test comparing all columns. *** = p < 0.001. 
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3.3.2.4 Immunocytochemical analysis of HTFs in collagen gels following 
treatment with 5-FU 
In order to understand whether phenotypic changes or reduced cell number may 
account for the reduced contraction seen in cells treated with 5-FU compared to control 
cells, immunocytochemical analysis of HTFs seeded into collagen gels was undertaken 
seven days after treatment.  
Initially cell morphology was assessed using fluorescein isothiocyanate (FITC)-labelled 
F-actin to assess the cytoskeletal shape of HTFs growing within the collagen matrix. As 
seen in Figure 3.19, the biggest difference observed between the control and 5-FU 
treated cells was the size, or width, of the fibroblasts; in control gels the cells appeared 
broad sharing similarities to that of a myofibroblast like phenotype, with tight 
compactment of cells seen due to the contraction of the gel. Cells treated with 5-FU 
however appeared thinner, elongated and more disperse throughout the gel. 
To assess the direct effects of 5-FU on the key mediators of collagen contraction, the 
MMPs, immunocytochemical staining of a range of MMPs was also undertaken. Figure 
3.20 shows the staining of MMP-1 (red) and MMP-7 (green). Both the 5-FU and control 
gels showed similar levels of staining for MMP-7, with staining observed throughout the 
entire body of the cell as well as the extending processes of the fibroblasts. However 
MMP-1 showed less staining across the gel when compared to the control cells as 
seen in the 10x magnification images. In the cells that did stain positively for MMP-1, 
similar levels of staining in the cell body was seen when compared to the control cells, 
although cells treated with 5-FU displayed decreased levels of MMP-1 staining in the 
filopodia of the fibroblasts. Figure 3.21 shows the immunocytochemical staining of 
MMP-2 (red) and α smooth muscle actin (ASMA) (green), a marker of a cell undergoing 
fibroblast to myofibroblast transition. The staining of MMP-2 was similar in both 5-FU 
and control cells, with staining observed throughout the cell, including the processes. 
Staining for ASMA was observed in both cell types, though an increase in fluorescence 
was observed in control cells, indicative of an increased level of protein; co-localisation 
of the ASMA and MMP-2 was evident in all cells, as demonstrated by the presence of 
the yellow staining. 
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Figure 3.19 – F-Actin 
immunocytochemical 
staining of HTFs in 3D 
collagen gels. 
Confocal images of HTFs 
grown in a 3D collagen matrix 
taken seven days after 
treatment with either PBS or 6 
mg/ml 5-FU. F-Actin (green) 
shows the arrangement of 
actin filaments within the cell, 
with little difference in cell 
shape observed between the 
control and treated cells. The 
presence of large gaps 
between the cells in the 5-FU 
treated cells is indicative of the 
reduced contraction that was 
observed. Nuclei are stained 
with DAPI (blue). Scale bars 
represent 100 µm in the 10x 
images and 20 µm in the 40x 
images. 
Staining was repeated three 
times with these results 
representative of the findings. 
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Figure 3.20 – MMP-1 and 
MMP-7 immunocytochemical 
staining of HTFs in 3D 
collagen gels. 
Confocal images of HTFs 
grown in a 3D collagen matrix 
taken seven days after 
treatment with either PBS or 6 
mg/ml 5-FU. MMP-7 (green) 
showed similar levels of 
staining throughout the cells 
following either treatment, with 
staining extending through the 
entire body, as well as 
extending processes of the 
HTFs. MMP-1 (red) however 
showed less staining across 
the gel as a whole in gels 
treated with 6 mg/ml 5-FU as 
seen in the 10X images. In the 
cells that did stain positively 
for MMP-1, staining was 
largely retained within the cell 
body of the 5-FU treated cells, 
with little staining observed in 
the processes of the HTFs. 
Cells treated with PBS showed 
levels of PBS consistent 
throughout the cell, including 
the cell processes. Nuclei are 
stained with DAPI (blue). Scale 
bars represent 100 µm in the 
10x images and 20 µm in the 
40x images. Staining was 
repeated three times with 
these results representative of 
the findings. 
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Figure 3.21 – MMP-2 and 
ASMA immunocytochemical 
staining of HTFs in 3D 
collagen gels. 
Confocal images of HTFs 
grown in a 3D collagen matrix 
taken seven days after 
treatment with either PBS or 6 
mg/ml 5-FU. MMP-2 (red) 
staining was seen in all cells, 
whether treated with 5-FU or 
PBS with similar staining 
profiles observed throughout 
the cell, including the 
processes of the HTFs. ASMA 
staining was observed in both 
cell types, though an 
increased fluorescence was 
observed in control cells 
indicative of the presence of 
increased levels of protein.  
Colocalisation of the ASMA 
and MMP-2 was observed in 
all of the cells, as 
demonstrated by the presence 
of the yellow colour. Nuclei are 
stained with DAPI (blue). Scale 
bars represent 100 µm in the 
10x images and 20 µm in the 
40x images. Staining was 
repeated three times with 
these results representative of 
the findings. 
 
 
 
 
 
 
 
 136 
3.3.3 The effects of MMC on gene expression in-vitro 
To assess the effects of MMC on HTFs in-vitro, HTFs were exposed to 0.5 mg/ml MMC 
for five minutes before being grown in FGM for either three or seven days. Cells were 
grown in six well plates until sufficient confluency was observed. The cells were then 
treated and allowed to grow for either three or seven days followed by RNA isolation 
and the investigation of the gene expression of selective MMPs and TIMPs via RT-
PCR.  
Photographs were taken at each stage to assess cell morphology as shown in Figure 
3.22, with widespread cell death observed (as previously described in section 3.3.2.1). 
At day three the control cells had almost reached a confluent state with some 
proliferation observed to have taken place in the MMC treated cells. Between days 
three and seven elongation of the MMC treated fibroblasts was observed, taking on a 
long, thin morphology. Control cells exhibited continued proliferation reaching a fully 
confluent state by this timepoint. 
When investigating the gene expression of HTFs treated with MMC prior to a three day 
growth period, a significant downregulation of both MMP-1 and MMP-2 [p < 0.001 and 
p < 0.05 respectively (Figure 3.23)] was observed, whilst no significant changes in 
either MMP-9 or the TIMPs was found (Figure 3.24). Cells treated with MMC prior to a 
seven day growth period exhibited a continued significant downregulation of MMP-1 [p 
< 0.05 (Figure 3.25)], whilst MMP-2 returned to similar levels as the control with both 
MMP-2 and MMP-9 showing no significant differences in levels of gene expression. 
Similarly, the TIMPs showed no significant alterations in gene expression. 
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Figure 3.22 - An illustrative example of the number of cells present within the 6 well plate following 
MMC treatment prior to RNA isolation. 
Following treatment a reduction in cell number was observed, indicative of cell death induced through 
MMC treatment. Following treatment control cells continued to grow until reaching a fully confluent state at 
day seven. Cells treated with MMC instead showed a reduced ability to repopulate the growth surface, with 
cells taking on an elongated, thin morphology seven days following treatment. Photographs representative 
of the morphology observed in each of three experimental repeats. 
Scale bar represents 1000 µm.
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Figure 3.23 - The effects of MMC on HTF gene expression of selective MMPs three days after 
treatment. 
Significant decreases in the expression levels of MMP-1 (69.2% ± 2.9% decrease) and MMP-2 (9.6% ± 
2,8% decrease) were observed following MMC treatment, with no significant changes in MMP-9 (12.0% ± 
9.2% increase) expression found. Gels show a single experiment which was repeated 3 times. Error bars 
represent SEM (experimental n=3). Statistical comparisons were made using a Student’s t-test. *** = p < 
0.001; * = p < 0.05. 
 
 
 
 
Figure 3.24 - The effects of MMC on HTF gene expression of TIMPs three days after treatment. 
Whilst reductions in gene expression were observed in a number of TIMPS, no significant changes were 
found. Error bars represent SEM (experimental n=3). Statistical comparisons were made using a Student’s 
t-test. 
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Figure 3.25 – The effects of MMC on HTF gene expression of selective MMPs seven days after 
treatment. 
A significant decrease in the expression level of MMP-1 (39% ± 3.9% decrease) was observed seven days 
after treatment, whilst no significant changes in MMP-2 or MMP-9 expression were found at this timepoint. 
Gels show a single experiment, which was repeated 3 times. Error Error bars represent SEM 
(experimental n=3). Statistical comparisons were made using a Student’s t-test. * = p < 0.05. 
 
 
 
 
 
Figure 3.26 - The effects of MMC on HTF gene expression of TIMPs seven days after treatment. 
Whilst increases in gene expression were observed in a number of TIMPS, no significant changes were 
found. Error bars represent SEM ( experimental n=3). Statistical comparisons were made using a 
Student’s t-test. 
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3.4 Discussion 
In order to overcome the effects of post-operative wound healing and the subsequent 
scarring process, cytotoxics have been demonstrated to provide improved surgical 
success rates and as such have become the standard choice of drug for surgeons. 
However the application of these drugs often leads to severe complications; current 
therapeutic application occurs through the delivery of high concentrations of either 5-
FU or MMC for very short periods of time. Subsequently this induces widespread cell 
death of not only the targeted fibroblasts, but also the epithelial layer of the conjunctiva 
leading to perforations and ensuing bleb leakage. Therefore, to overcome these effects 
it was proposed that the delivery of the antimetabolite 5-FU at a lower dose for a 
prolonged period of time could be as effective as current therapeutics, with potentially 
less side effects due to a decrease in cellular apoptosis. 
The development of a 5-FU tablet was initially undertaken with the thoughts of using a 
polymer to prolong drug delivery. However, in testing it was found that the presence of 
such excipients led to a faster release rate when compressed into a tablet. To 
overcome this excipient free tablets were produced and exhibited a release profile that 
was able to deliver 5-FU at concentrations above 1 mg/ml for over eight hours. The 
maximum concentration recorded was 6 mg/ml, far less than the saturated 
concentration of 11.1 mg/ml. As this was far less than the currently used 
concentrations, which are known to induce widespread apoptosis, a dose of 6 mg/ml 
was tested in-vitro to determine it’s biological effects (Mearza et al., 2007). At this point 
it must be noted however that whilst the rig provides a useful tool in simulating the 
release of a tablet based drug system it does not accurately represent the conditions 
found in-vivo. For example, this model is not executed in a biological context lacking 
both proteins and cells, both of which may play a major role in affecting the drug 
release (such as slowing or quickening release) as was seen in a study by Cui and 
colleagues (Cui et al., 2008). Similarly, whilst the volume of 200 µl was originally 
assessed as the bleb volume, and as such chosen as the volume for the chamber of 
the flow rig, it has since come to light that in reality the bleb volume is much lower than 
this, with the estimate from one study (using optical coherence tomography (OCT) to 
determine the bleb volume) suggesting a healthy functioning bleb may contain just 6.27 
µl of aqueous (± 8.22 µl) (Kawana et al., 2009). Similarly Gardiner and colleagues used 
an OCT calculated bleb volume of just 3.6 µl in a mathematical model of aqueous flow 
within the bleb (Gardiner et al., 2010). Further studies in determining the size of a bleb 
are clearly required, but upon their findings the flow rig must be adapted accordingly. 
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Similarly, in future experiments use of the current flow rig with the addition of serum or 
alternatively the development (or use of) of a cell based flow system [such as a 
Fibercell Bioreactor (Cadwell, 2010)] may provide enhanced understanding of the 
tablet release. Choosing a static concentration of 6 mg/ml over 8 hours to replicate the 
release of tablet in-vitro also provides a number of significant drawbacks as this 
provides only a limited insight into the effectiveness of a 5-FU tablet. Using a cell based 
flow system as previously mentioned could allow for the implantation of the tablet into 
the system and recreate accurate release of the drug (both length of time and 
concentration) in comparison to using a static concentration. Whilst replacement of the 
media at various time points could have overcome part of these problems, disruption of 
the cells over a continuous time exposes the cells to several risks (including physical 
damage and aspiration) and as such was not chosen as a method to use. 
In the determination of the effects of 5-FU and MMC on the proliferation of HTFs, the 
MTT assay was used to measure the absorbance levels of solubilised formazan 
crystals, with absorbance proportional to the number of cells present within the tested 
sample. Whilst decreases in the absorbance of control cells were seen when 
comparing pre and post treated samples, it is likely that this loss of cells was due to 
well washing following treatment; cells treated with 5-FU or MMC were similarly 
affected by the washing affect, but the fact that their decrease was so much greater 
following drug treatment indicates the rapid induction of apoptosis following drug 
treatment. 
When investigating the prolonged effects of 5-FU delivered at 6 mg/ml for eight hours it 
became apparent that prolonged growth arrested had occurred; whilst previously Khaw 
and colleagues had demonstrated the use of 5-FU at concentrations of 1 mg/ml could 
induce prolonged growth arrest following a 24 hour period of exposure in-vitro, no 
delivery method for administering 5-FU at this concentration for a 24 hour period in-vivo 
was ever proposed (P T Khaw, Ward et al., 1992). Similarly, Huang and colleagues 
have recently described the treatment of keloid fibroblasts with 5-FU leading to growth 
arrest when treated with doses of 5-FU lower than 1 mg/ml whereas doses 
conventionally used (25 mg/ml) led to widespread cell death following a 24 hour 
exposure (L. Huang et al., 2010). When Daniels and Khaw looked at the effects of 5-
FU on HTF proliferation in-vitro it was found that a 5 minute application of 5-FU could 
growth arrest fibroblasts for thirty days, whereas all other tested doses (2.5 mg/ml and 
below) led to proliferation returning to near control levels (J T Daniels et al., 1999); 
however, these studies also featured the widespread cell death known to be associated 
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with doses of 5-FU at a concentration of more than 25 mg/ml. The analysis of fibroblast 
proliferation following 5-FU treatment with a dose of 6 mg/ml for eight hours in this 
study has led to the conclusion that such a delivery of 5-FU could induce prolonged 
growth arrest with the added benefit of lowering the initial level of apoptosis when 
compared to the current clinically used formulations of 5-FU (25 mg/ml and 50 mg/ml) 
and MMC (0.3 mg/ml and 0.5 mg/ml). However, further assessment as to the level of 
apoptosis induced between each group could be made with the use of more specific 
apoptotic assays such as the TUNEL assay. Nonetheless, this difference in 
observation from the previous studies may translate to a decrease in apoptotic-related 
side effects. For example, less apoptotic activity of the conjunctival epithelial layer may 
result in a reduction in bleb thinning and leakage development due to the presence of 
fibroblasts and epithelial cells being to provide a level of wound healing that allows 
sealing of the bleb without the later generation of scar tissue. It has been previously 
demonstrated that growth arrested cells exhibited a reduction in the secretion of 
collagen and fibronectin, likely due to the interaction of the 5-FU metabolites in DNA 
and RNA processing (N L Occleston et al., 1997). Similar responses to 5-FU have also 
been reported in-vivo, with How and colleagues describing a reduction in collagen type 
I and fibronectin mRNA expression as long as 30 days after surgery (How et al., 2010). 
Further to the observations regarding fibroblast proliferation, significantly decreased 
collagen gel contraction was also found in the presence of either the 50 mg/ml 5-FU or 
6 mg/ml 5-FU treatment strategy, with no significant differences found between the two 
dosage forms in gels containing inactive fibroblasts, although these differences were 
only observed after 72 hours. Fibroblasts seeded into collagen gels, which were 
allowed to activate for a 24 hour period, again saw significant reductions in contraction, 
though in this instance the 6 mg/ml group had significantly less contraction than 
compared to the 50 mg/ml group. The initial contraction that was observed is likely, as 
previously hypothesised by Occleston and colleagues, due to a lag phase whereby 
time is required for the effects of the drug to fully take effect (Nicholas L Occleston et 
al., 1994). In the non-activated fibroblasts contraction rates began to trail off after 48 
hours, whilst the control cells showed continued contraction until day 3 or 4. In the 
activated fibroblasts less contraction had occurred prior to the cells slowing in rates of 
contraction, potentially indicating a quicker response to the 5-FU at a prolonged low 
dose than at higher doses. However, due to the contraction that was seen in both 
groups early on it may be a strategy to in future experiments seed gels in a decreased 
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quantity within the gel or feed the cells with serum-free gel to minimise contraction 
whilst the drug is administered over a 24 hour period. 
Nonetheless, in order to elucidate possible mechanisms that may be underlying the 
reduced contraction that was observed late on, in particular the 6 mg/ml group as the 
previous proliferation studies had demonstrated a minimal effect on HTF apoptosis, 
immunocytochemical analysis of non-activated collagen gels was undertaken to 
observed a range of MMPs.  
Staining showed a decreased presence of MMP-1 in 5-FU treated gels compared to 
the control cells, particularly in the protruding filopodia of the fibroblasts. Furthermore 
MMP-1 has previously been demonstrated to facilitate collagen contraction as well as 
being linked to the invasiveness of cancer cell lines during filopodia formation (Julie T 
Daniels, Schultz et al., 2003; Sossey-Alaoui et al., 2005; Machesky, 2008). Whilst a 
reduction in filopodia was not seen, the decreased staining for MMP-1 could partly 
explain the lack of contraction due to a decreased ability for the cell to migrate through, 
as well as contract, the collagen matrix. In collagen contraction models using 
endothelial cells, only siRNA knockout of MMPs 1 and 10 inhibited contraction, 
whereas those for MMP-2, MMP-9 and MMP-3 led to normal collagen contraction 
(Saunders et al., 2005). The building evidence of MMP-1 being affected by 5-FU is 
further supported when looking at the p53 pathway; activation of p53 is known to 
downregulate MMP-1 through regulation of its activator AP-1 (Ala-Aho et al., 2002; Y. 
Sun et al., 2004). Similarly, the gene expression analysis of MMC’s regulation of MMP 
expression in HTFs revealed a tight control over MMP-1 expression, with significant 
downregulation observed both three and seven days after treatment. With both 5-FU 
and MMC known to upregulate the expression of p53, it is proposed that this be a 
mechanism by which both 5-FU and MMC may alter MMP-1 expression and further 
downstream events such as collagen matrix degradation both in-vitro and in-vivo 
(Boamah et al., 2007; L. Huang et al., 2010). Further studies looking directly at the 
state of p53 would be required to confirm this. However, such studies could be 
undertaken using protein studies such as ELISAs or western blots. Furthermore, with 
the use of p53 antagonists it may be possible to reverse the effects of inhibiting 5-FU 
suppression of collagen contraction. In both 5-FU collagen gel staining and the gene 
expression analysis of MMC treated cells, the only changes in MMP-2 observed was a 
downregulation in expression three days after treatment, by day seven levels had 
returned to normal. Similarly, levels of ASMA appeared only slightly lower in 5-FU 
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treated cells, possibly due to the incomplete transformation of fibroblasts to 
myofibroblasts that was otherwise observed in the control cells.  
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3.5 Conclusion 
This study has demonstrated the potential use of an excipient free 5-FU tablet that 
delivers 5-FU at a lower concentration than is currently used within the clinic, over a 
prolonged period. This new dosing regime has proven to be as effective, if not better, in 
inducing short and prolonged growth arrest when compared to the conventional short-
term use of high doses of 5-FU or MMC. The inhibition of fibroblast proliferation, over a 
prolonged period, is critical to the abolishment of scar development with the fibroblasts 
being critical to this response. Whilst collagen contraction was assessed, the high rate 
of contraction that was observed over the initial 72 hours dampens the conclusions that 
can be drawn from these studies, but reductions in overall contraction were 
nonetheless observed indicating a further possible role in limiting the role of the 
fibroblast in wound healing.  The decreased expression of ASMA within the gels further 
shows 5-FU may have roles in the fibroblast-myofibroblast transition. 
Gene expression analysis of HTFs treated with MMC demonstrated a direct 
mechanism in which MMC may function to limit the role of the fibroblast in the wound 
healing process through the downregulation of key genes such as MMP-1 and MMP-2. 
 
Overall the results of these studies highlight the potential of the 5-FU tablet and further 
in-vivo use should be explored. The benefit of using a prolonged release, low dose of 
5-FU in-vivo will limit potentially blindness-inducing side effects whilst still inhibiting the 
wound healing process. 
  
 
Chapter 4 Inhibiting vascular endothelial growth factor 
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4.1 Introduction 
4.1.1 Angiogenesis 
Angiogenesis is, in it’s simplest terms, the development of new blood vessels and a 
subsequent vascular network from pre-existing vessels and is essential during a 
number of biological processes including development, tumour and disease 
pathogenesis and wound healing (Sheridan et al., 2006; Su et al., 2008). The process 
of angiogenesis is a highly orchestrated series of events starting with the initial dilation 
of the parent vessel in response to secreted growth factors, from which the new 
vessels grow (Cooke et al., 2006). This dilation subsequently leads to the loosening of 
the normally tight extracellular junctions and the secretion of proteins into the ECM 
including fibronectin, which is able to provide a scaffold that allows endothelial cell 
migration, and members of the matrix metalloproteinase family which degrade the 
existing matrix as endothelial cells migrate (J. Harper et al., 2006).  
In order for cell migration to occur, aside from the formation of a matrix, a 
chemoattractive gradient is established that regulates the direction of the endothelial 
cells, as well as cellular proliferation and speed of migration (Peter Carmeliet et al., 
2005; Eichmann et al., 2005; Lamalice et al., 2007; Britton, 2010).  
As the endothelial cells continue to both proliferate and migrate through the matrix tight 
junctions begin forming between the endothelial cells leading to the development of 
long, solid, structures that later fuse together to form the lumen of the new vessel 
(Strilić et al., 2009). Continued growth of the cells within the body of the lumen provide 
both vessel length and strength, whilst the endothelial cells at the tip of the growing 
vessel actively search for both guidance cues and nearby endothelial cells to which it 
can connect and thus form the initial basis of a vascular network (Eichmann et al., 
2005). The continued development of the vessel leads to the release of a number of 
pro-survival factors that help prevent apoptotic regression of the developing lumen and 
encourage the growth of neighbouring periendothelial cells which function to stabilise 
the vessels by providing both a physical support through cell:cell contact as well as 
through the secretion of ECM components that leads to the gradual development of the 
support matrix around the vessel (Conway et al., 2001; Stupack et al., 2002).  
4.1.2 Angiogenic factors and signalling 
The primary cytokine that controls angiogenesis through, predominantly, the 
proliferation of endothelial cells is vascular endothelial growth factor (VEGF) and is 
discussed in greater detail below (4.1.3). Nonetheless a number of other secreted 
  148 
growth factors and structure proteins also play important roles in the formation and 
maturation of new blood vessels. The budding process that occurs at the onset of 
angiogenesis requires the loosening of tight junctions, and for this to occur a number of 
proteins are essential in regulating this process. For example, the use of mouse 
knockout models has highlighted the role of Angiopoietin-1 (Ang1) and it’s receptor Tie-
2 in the regulation of tight junctions and later network formation with the Ang1-/- mouse 
not progressing beyond gestation and characterised by little vessel branching  with 
similar effects seen in a Tie-2 knockout mouse model (Dumont et al., 1994; Suri et al., 
1996). The exact roles of FGF, a pro-angiogenic signalling molecule (1.3.6) are still 
poorly understood, but mouse knockout models of various family members, including 
FGF-2 and FGFR1, have highlighted poor vascular network formation in their absence 
(T. P. Yamaguchi et al., 1994; D. L. Miller et al., 2000). Similarly, the importance of the 
growth factor PDGF (1.3.2) has been demonstrated in the regulation of pericyte 
recruitment during angiogenesis with mice lacking the PDGF receptor shown to have 
decreased perivascular cell support leading to vessel regression during development 
and adult mice characterised by an increase in microaneurysms and haemorrhaging 
due to a lack of stabilisation of the vessel by the perivascular cells (Hellström et al., 
1999). 
4.1.3 Vascular endothelial growth factor 
Vascular endothelial growth factor (VEGF) was first characterised as a single vascular 
cell-specific mitogen, but with further characterisation it was soon established that it 
was in fact a member of a much larger family, with each member having a range of 
effects during angiogenesis (Ferrara et al., 1989; Leung et al., 1989; Ferrara et al., 
1991). 
4.1.3.1 The vascular endothelial growth factor family 
VEGFs are family of secreted, disulphide-linked, glycoproteins with a molecular weight 
of approximately 45 kDa (Peter Carmeliet, 2005). The mammalian family of VEGF 
genes is composed of VEGF-A, -B, -C, -D, placental growth factor (PIGF) and two 
further VEGF family members, -E and -F, which are VEGF-like proteins; of the isoforms 
of VEGF that exist, VEGF-A is the most intensively studied (Xinyuan Zhang et al., 
2009). The family of VEGF isoforms bind to a similar family of receptors, VEGF 
receptor (VEGFR) -1, -2 and -3 as well as Neuropilins -1 and -2. Whilst the family 
members, outside of VEGF-A, all have roles in angiogenesis, their effects are less 
pronounced; for example VEGF-B knockout mice, whilst appearing healthy and fertile, 
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suffer some cardiac defects including a reduced heart size (Bellomo et al., 2000). Mice 
that were VEGF-C deficient did not survive past E15.5 – 17.5, with +/- mice showing a 
decrease in vessel formation within the lymphatic sac. However, following the addition 
of recombinant VEGF-C to explants obtained from VEGF-C-/- mice an upregulation of 
Prox1, a lymphatic endothelial marker, was observed giving rise to the theory that 
VEGF-C is largely associated with regulation of the lymphatic system (Karkkainen et 
al., 2004). Similarly, a previous study by Jeltsch and colleagues found that the 
overexpression of VEGF-C led to increased proliferation within the lymphatic vascular 
network, with little to no changes observed within in the circulatory vasculature (Jeltsch 
et al., 1997). Interestingly VEGF-D knockout mice were also shown to appear healthy 
post-natum with no visible changes in either the lymphatic or cardiovascular systems 
(Baldwin et al., 2005). Despite this the interest in VEGF-D has remained, in part due to 
a number of studies having documented that many tumours shown an increased level 
of VEGF-D (Stacker et al., 2001; Mccoll et al., 2007). 
4.1.3.2 Vascular endothelial growth factor-A 
VEGF-A is a dimer consisting of two polypeptides that are linked by two disulphide 
bonds, with each isoform found to have eight conserved cysteine residues that form a 
cystine-knot structure; Muller and colleagues were able to show that whilst not 
important in the thermodynamic stability of the protein, this knot is to some extent 
crucial for correct folding of the protein (Y a Muller et al., 1997). Point mutations in the 
cysteine residues results in the production of monomeric VEGF-A and without 
dimerisation the protein is unable to bind to its receptor and as such induce its 
downstream signalling (Claffey et al., 1995). The human VEGF-A gene is composed of 
eight exons (the coding region of a gene) separated by seven introns (the non-coding 
region of a gene) and can undergo alternative splicing to generate a number of 
variants, as shown in Figure 4.1. These include: VEGF-A121, -A145, -A148, -A165 (the 
first discovered and most important of the group), -A183, -A189 and -A206, with the 
subscript referring to the number of amino acids present in each secreted polypeptide 
(Tischer et al., 1991). In addition to these isoforms, a family of ‘b’ isoforms also exist 
with these characterised by an alteration in the six carboxy-terminal amino acids (S. J. 
Harper et al., 2008). One such ‘b’ isoform is VEGF-A165b, which results from the 
alternative splicing of VEGF-A165 and has been demonstrated to act in an anti-
angiogenic fashion; Bates and colleagues have demonstrated that the addition of 
recombinant VEGF-A165b can inhibit both experimental choroidal neovascularisation 
and retinal neovascularisation to an extent that rivals currently available drugs, 
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presenting itself as a potentially novel therapeutic (Konopatskaya et al., 2006; Hua et 
al., 2010). Further studies have proposed a regulatory role for VEGF-A165b during 
development with Baltes-Breitwisch and colleagues able to show that the neutralisation 
of VEGF-A165b can lead to an increase in vascular density during rat testis 
development (Baltes-Breitwisch et al., 2010).  
Mice similarly express various isoforms of VEGF with VEGF-A120, -A164 (equivalent 
to human –A165) and -A188 (equivalent to human –A189) the most prominent (Breier 
et al., 1992). Through the generation of mice expressing only a single VEGF isoform, it 
was found that of the three isoforms, VEGF-A164 was able to provide the most normal 
development when solely expressed, suggesting it to be the major modulator of 
angiogenesis during development. The sole expression of either VEGF-A120 or VEGF-
A188 led to impaired growth and development: VEGF-A120 mice survived up to two 
weeks post natum, however upon dissection a lack of myocardial angiogenesis was 
observed as well as impaired vascularisation of the retina, with mice expressing only 
VEGF-A188 undergoing termination in utero (Stalmans et al., 2002). 
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Figure 4.1 – The splice variants of the VEGF-A gene. 
The gene encoding VEGF-A is formed from eight exons that encode a range of structural motifs with the presence/absence of specific isoforms correlating, largely, with the 
receptor interaction that governs the roles of the isoforms of VEGF-A. Image adapted and redrawn from images found in the following citation (Cross et al., 2003). 
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4.1.4 The vascular endothelial growth factor receptor 
The three main receptors that are able to transduce VEGF signalling are vascular 
endothelial growth factor receptors (VEGFR)1, -2 and -3 with the receptor binding 
domain of VEGF encoded by exons 1-5; in addition two other classes of receptors 
exist, the heparan sulphate proteoglycans (HPSGs) and the neuropilins (NRPs), with 
the receptor binding domains encoded by exons 6-8. Each of the VEGFRs share a 
similar structure, with the presence of a tyrosine kinase catalytic domain underlying its 
downstream signalling mechanism (Roskoski, 2008). Vascular endothelial growth 
factor receptors are believed to act as classical receptor tyrosine kinases (RTKs), with 
the binding of VEGF leading to trans-autophosphorylation of the receptor tyrosine 
residues. This in turn produces binding sites for Src homology 2 (SH2) domain-
containing proteins, leading to the activation of downstream signalling cascades as 
discussed below (4.1.5) and shown in Figure 4.2. Much of the work in understanding 
the role of the individual receptors has been undertaken in endothelial cells that are not 
normally responsive to hVEGF-A165, such as the porcine aortic endothelial cell line 
(PAE). Overexpression of VEGFR1-3 can therefore allow the binding of VEGF and as 
such allows the investigation of the VEGF signalling pathways (Waltenberger et al., 
1994). 
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4.1.5 VEGF signal transduction and downstream cascades 
As previously discussed in 4.1.4, the VEGF receptor is a tyrosine receptor kinase that 
regulates signalling pathways very similar to those used by PDGF, FGF and EGF (1.3). 
In brief, VEGF dimers bind to extracellular receptor molecules that cause a dimerisation 
of the receptor and activation of downstream signalling through tyrosine residue 
phosphorylation. This allows proteins containing phosphotyrosine binding motifs to bind 
to the VEGF receptor and either directly translocate to the nucleus or activate other 
enzymes and proteins that transduce the downstream signal (Olsson et al., 2006). 
Such adaptor proteins include the Src homology 2 domain containing (Shc) family 
members, which have been shown to be recruited to the tyrosine-phosphorylated 
VEGFR2 resulting in themselves becoming phosphorylated before, in turn, activating 
enzymes in parallel signalling cascades as detailed below and illustrated in Figure 4.2 
(Ratcliffe et al., 2002). 
4.1.5.1.1 Phospholipase Cγ (MAPK) signalling pathway 
Phospholipase Cγ (PLCγ) is an SH2 domain-containing protein that binds directly to 
VEGFR2 where it is phosphoactivated, The resultant activated PLCγ generates 
diacylglycerol (DAG) and inositiol-1,4,5,triphosphate (IP3) from the membrane lipid 
phosphatidynlinositol-4,5-diphophate (PIP2), with IP3 causing the release of Ca2+ from 
intracellular stores within the endoplasmic reticulum (which is able to negatively 
regulate VEGF-A signalling) and DAG activating protein kinase C (PKC) leading to the 
activation of the Raf1-MEK-ERK mitogen-activated protein kinase (MAPK) cascade 
(Bruns et al., 2009; Pratilas et al., 2010). Traditionally, most ERK activation takes place 
through the adaptor protein Grb2, which binds to RTK leading to activation of Son Of 
Sevenless (SOS) and subsequently Ras, followed by Raf1, MEK and finally ERK 
resulting in the activation of transcription factors implicated in regulating the expression 
of multiple different proteins including cell cycle regulators, ECM components and ECM 
remodelling enzymes (Boucher et al., 2000).  
4.1.5.1.2 Phosphoinositidie 3-kinase signalling pathway 
The phosphoinositide 3-kinase (PI3K) is another important signalling protein in vascular 
endothelial cells. Upon VEGF stimulation, the tyrosine phosphorylation of the 
intermediate protein Shb occurs which is then able to phosphorylate PI3K in a complex 
with Sck; in turn activated PI3K phosphorylates PIP2 to PIP3 which, in a complex with 
PDK1, leads to the phospho-activation of Akt before translocating to the nucleus where 
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it regulates a number of processes including proliferation and apoptosis (K. Du et al., 
2005; Song et al., 2005). One pathway that PI3K regulates is that of the coagulation 
pathway that occurs following trauma; upon injury platelets secrete a number of factors 
that stimulate VEGF production, including tissue factor (F3), which in a positive 
feedback loop, can trigger the further release of F3 (1.2.1), with Blum and colleagues 
able to demonstrate that this loop is under the control of PI3K, with PI3K inhibitors able 
to enhance TF production; confirming this, the overexpression of Akt led to a reduction 
in VEGF stimulated TF release (Blum et al., 2001). Akt is also able to regulate 
proliferation through the activation of the transcription factor c-Myc and cyclin-D1. In 
unstimulated cells glycogen synthase kinase 3 (GSK3) phosphorylates cyclinD1 and c-
Myc preventing DNA synthesis; upon the activation of Akt a phosphorylation of GSK3 is 
observed, allowing cell cycle continuation (3.1.1) (Kou et al., 2005). Furthermore, PI3K 
is also able to activate the Rac signalling cascade, which in turn regulates cell 
movement, with further modulation of the Rac signalling pathway occurring following 
the activation of the PLC pathway through the direct action of PKC on Rac downstream 
targets, such as Raf and Ras (Maioli et al., 2004).  
4.1.5.1.3 Src signalling pathway 
The sarcoma (src) protein is a tyrosine kinase involved in a number of cell responses, 
activated via VEGF. Src is covalently linked to a fatty acid, which holds it within the 
cytoplasmic side of the plasma membrane. When the VEGFR is activated the src 
protein becomes dephosphorylated, releasing the SH2 domain allowing activation of 
downstream ligands (He et al., 1999). Of these, one of the most important is focal 
adhesion kinase (FAK), with FAK known to be a key regulator of cell migration 
(Schlaepfer et al., 1999; Schaller, 2010) as well as a regulator of Akt and Erk (Hauck et 
al., 2000; D. Huang et al., 2002). 
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Figure 4.2 – The VEGFR2 signalling cascade. 
The binding of VEGF to VEGFR2 leads to the phosphorylation of phospho-tyrosine sties present on the intracellular portion of the receptor; upon activation a number of 
signalling cascades can be activated (depending on the specific tyrosine residue phosphorylated) include the MAPK, PI3K and PKC signalling cascades. Image adapted and 
redrawn from images found in the following citations (Olsson et al., 2006).
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4.1.6 VEGF in the health and disease 
VEGF is highly implicated in both normal tissue regulation as well in a number of 
pathophysiological conditions; whilst its role in wound healing is discussed below roles 
for VEGF have been found within specific tissues, for example the expression of VEGF 
is found within the glomerular podocytes of the kidney, both during development and in 
the adult, where it is believed to promote cell survival, potentially through the regulation 
of nephrin production, a kidney specific cell adhesion molecule (Foster et al., 2005; 
Foster, 2009). However despite these seemingly regulatory roles, it has also been 
highly implicated in kidney diseases including glomerulonephritis, where elevated 
levels of VEGF were found in the renal biopsies of patients suffering from 
glomerulonephritis to control patients (S. Thomas et al., 2000). Similarly, elevated 
levels of VEGF have also been implicated in a range of ophthalmic diseases including 
diabetic retinopathy and macular degeneration (1.2), as well as in cancer where 
elevated levels of VEGF and angiogenesis characterise tumour development (Kiselyov 
et al., 2007; Grisanti et al., 2008; Crawford et al., 2009; Sung et al., 2010). 
4.1.6.1 VEGF during wound healing 
Upon the activation of the wound healing response, the release of growth factors and 
cytokines from both cells involved in the immediate inflammatory response, such as 
invading platelets, macrophages and neutrophils, leads to an increase in VEGF 
(Tonnesen et al., 2000; Bao et al., 2009); leukocytes, mast cells and macrophages 
have all been shown to express high-levels of VEGF mRNA during an inflammatory 
response (Artuc et al., 1999), with the factors involved in the upregulation of VEGF 
including many of those previously discussed such as IL-1, IL-6 and FGF (1.3). Nissen 
and colleagues were able to show that VEGF levels in wound fluid samples from 
patients undergoing either mastectomy or neck dissection steadily increased from day 
0 to a peak at day 7 (approx 8 ng/ml) with significantly more VEGF present at days 4, 6 
and 7 (Nissen et al., 1998). Similarly, following experimental GFS in rabbits VEGF 
levels in the aqueous humour have been estimated to rise from a base level of less 
than 200 pg/ml to a peak of ~ 800 pg/ml four days after surgery with levels estimated to 
be as high as ~700 pg/ml after 30 days (Z. Li et al., 2009). 
4.1.7 Anti-VEGF treatments 
Several strategies to control VEGF signalling have been developed, aimed at targeting 
either VEGF itself, the VEGF receptor or aspects of the VEGF signalling cascade. 
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Whilst an overview of these treatments is given below, more detailed reviews of these 
drugs have been documented elsewhere (Kiselyov et al., 2007; Schenone et al., 2007). 
The initial targeting of VEGF came through the use of monoclonal antibodies 
developed to specifically inhibit VEGF; when injected into mice it was found that VEGF 
inhibition could lead to a reduction in tumour vascularisation (Kim et al., 1993). Upon 
this finding research began into generating a humanised VEGF monoclonal antibody, 
and in 2004 the FDA approved bevacizumab [trade name Avastin (Genentech)] for the 
treatment of colon cancer where it has been demonstrated to improve survival 
outcomes, particularly when used in combination with cytotoxic anti-cancer 
therapeutics such as 5-FU (Us Food and Drug Administration, 2004; Mccormack et al., 
2008). Following the development of bevacizumab, further work was put into the 
development of monoclonal antibodies targeting VEGF eventually resulting in the 
development of Ranibizumab (trade name, and hereon referred to as, Lucentis), a 
monoclonal antibody fragment derived from bevacizumab, which, unlike bevacizumab, 
is clinically approved for the treatment of AMD. Despite only Lucentis having been 
approved for ophthalmological use, the off-licence use of bevacizumab is rife in spite of 
the lack of any formal clinical trials comparing the two drugs. Such use is, in part, due 
to the elevated costs of Lucentis which, annually, can be as high as $23,000 per 
patient compared to $600 when using bevacizumab (Steinbrook, 2006; Schmucker et 
al., 2010). However, large molecule antibodies are not the only treatment options being 
explored. The development of pegaptanib (trade name, and hereon referred to as, 
Macugen) as a treatment for neovascular AMD introduced the use of aptamers, RNA 
and DNA oligonucleotides, that can bind and inhibit specific proteins with both high 
specificity and affinity (Keefe et al., 2010), with Macugen designed to specifically block 
all isoforms of VEGF-A, excluding VEGF-A121. Despite having been demonstrated to 
improve visual performance through a slowing in disease progression in a review of 
clinical trial data comparing looking at trials involving both Lucentis and Macugen in the 
treatment of AMD similar results were found when using both drugs, although Lucentis 
appeared to offer slightly improved results in certain testing criteria such as letter 
recognition than Macugen, however without a formal clinical trial having taken place the 
final conclusions cannot be taken as absolute (Ng et al., 2006; Takeda et al., 2007). 
The use of more classical, small molecule drugs  have also been investigated with a 
number in clinical trials at this point (Kiselyov et al., 2007); two drugs have reached the 
clinic are Sorafenib and Sunitinib, which target the receptors of VEGF including 
VEGFR-2 and are currently used in the treatment of various cancers. 
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4.1.7.1 Bevacizumab 
The 149kD monoclonal antibody, bevacizumab, is a widely used treatment for the 
treatment of various cancers as well as AMD, diabetic retinopathy and other ocular 
diseases (as reviewed by Gunther and Altaweel), despite have not been FDA approved 
for ophthalmic use; the reasons for this have been previously explained (4.1.7) 
(Gunther et al., 2009). Despite these uses, in recent years an increasing number of 
reports have been published describing the benefits of using bevacizumab as an 
adjuvant therapy following glaucoma filtration surgery, with an increasing number of 
reports suggesting that the use of bevacizumab can improve failure rates following both 
in-vivo experimentation and within the clinic. Several studies have commented on the 
use of bevacizumab following trabeculectomies, with Gerwal and colleagues (Grewal et 
al., 2008), demonstrating in a study of 12 patients undergoing trabeculectomy 
augmented with bevacizumab, a six month post-op mean IOP reduction of 52% was 
achieved, with 11 of the 12 eyes meeting the requirement for IOP reduction. Similarly, 
How and colleagues were able to demonstrate that the use of 5-FU augmented with 
post-operative bevacizumab could improve surgical outcomes, achieving a 100% bleb 
success rates in rabbits following GFS 30 days after surgery; the success rates for the 
monotherapies was 50% in the bevacizumab group and 25% in the 5-FU group. Whilst 
investigations into the use of anti-VEGF drugs continues at this stage little is 
understood as to the way that bevacizumab modulates the wound healing cascade. To 
date, it has been demonstrated that bevacizumab is able to modulate HTF proliferation, 
with the cells confirmed to express the VEGF receptor, however doubts exist as to 
whether the effects are due to VEGF inhibition or as a result of the excipients within the 
bevacizumab solution (Z. Li et al., 2009; O'neill et al., 2010), with Takeuchi and 
colleagues able to demonstrate that trehalose is able to inhibit HTF proliferation and 
reduce scar formation following GFS, although bleb survival graphs were not provided 
in this study (Takeuchi et al., 2010). 
Nonetheless, in order to deliver bevacizumab postoperatively, as well as when 
delivering the drug to posterior segments of the eye, a needle is required with the side 
effects from using such a delivery method having been previously discussed (1.5); 
such a delivery method, combined with the quick wash out of drug from the anterior 
chamber, have led to a number of groups exploring ways to prolong the delivery time of 
bevacizumab both in anterior and posterior segments of the eye such as through the 
use of gels and bevacizumab conjugated to nanoparticles (Andrew et al., 2009; 
Molokhia et al., 2009; Hwang et al., 2010; L Zhang, Xu et al., 2010). 
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4.2 Objectives and Experimental Design 
With increasing evidence that anti-VEGF therapies may have a role to play in the 
control of post-operative wound healing, alternative delivery methods for these 
therapeutics have become a key area of research. One approach taken to improve the 
pharmacokinetics of bevacizumab was through the development of an bevacizumab 
tablet, based upon the development of similar tablets containing drugs such as 5-FU 
and ilomastat (3.3 and 5.1.2.4.1 respectively). The fabrication of the bevacizumab 
tablet was led by Dr. Ashkan Khalili who, in-vitro, was able to demonstrate that a solid 
dosage form of bevacizumab could be created without causing physical changes to the 
antibody, such as aggregation or degradation (Khalili, 2011). However, whether the 
tablet was still biologically active was an unanswered question. Furthermore, whilst the 
use of anti-angiogenic drugs for the modulation of postoperative wound healing has 
increased (4.1.7), the exact mechanisms behind its benefit are poorly understood. 
Whilst the role of VEGF in modulation of a number of biological processes has been 
well defined in endothelial cells, new targets are becoming the focus of research as 
drug use moves away from purely affecting the endothelial cells. However, to this point 
few studies have explored the exact roles that VEGF plays in regulating fibroblast 
function. All bevacizumab tablets used within this chapter were created by Dr. Ashkan 
Kahlili and his support, and guidance, was appreciated at all times during work 
involving bevacizumab. 
 
On this basis the aims of this chapter were: 
 
i. To determine the biological activity of a bevacizumab antibody-tablet following 
tablet fabrication in order to ascertain whether through production of the tablet the 
protein was damaged in such a way as to make in biologically inactive. This will 
be assessed through HUVEC and fibroblast proliferation assays, HUVEC gene 
expression analysis and using an in-vitro “angiogenesis”/branching assay. 
 
ii. To assess the effects of excipients currently found within the bevacizumab 
solution as well as those added during tablet fabrication. Reports in the literature 
have suggested that “inert” excipients such as trehalose can themselves affect 
cell activity and so both trehalose and hyaluronic acid will be investigated using 
proliferation and gel contraction assays (Takeuchi et al., 2010). 
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iii. To determine the effects of VEGF on HTF activity. Mounting evidence in the 
literature has suggested that anti-VEGF agents, such as bevacizumab, are able 
to inhibit wound healing. However it is currently unknown whether these effects 
are due directly to the inhibition of angiogenesis or whether VEGF function to 
promote fibroblast activity; as such, this will be investigated using proliferation 
and gel contraction assays, assessment of MMP gene expression and protein 
production and immunocytochemistry (Z. Li et al., 2009; O'neill et al., 2010). 
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4.3 Results 
4.3.1 The bevacizumab tablet: The determination of biological activity in-vitro 
4.3.1.1 The effects of an bevacizumab tablet compared to bevacizumab solution 
on HUVEC proliferation 
In order to understand whether bevacizumab that had been fabricated into a tablet 
could function, biologically, at a level comparable to that of standard bevacizumab 
solution, HUVECs were exposed to varying concentrations of bevacizumab-
supplemented growth medium (tablets were dissolved prior to use) and assayed using 
the MTT assay. Cells were grown in low serum media, with both the positive control 
and test samples containing 10 ng/ml VEGF, with the negative control absent of VEGF. 
Absorbance measurements were taken every 24 hours over a 72 hour period following 
initial treatment, with treatments evaluated over a serial dilution, with concentrations 
ranging from 939.6 nM to 0.9396 nM. Results for both the solution and tablet are 
presented in Figure 4.3 and Figure 4.4 respectively. The results demonstrated that 
bevacizumab could regulate HUVEC proliferation at all tested concentrations, with a 
mean increase in absorbance of 685.0% ± 14.2% across all tested groups (both 
solution and tablet. The negative control had only an 628.7% ± 31.7% whilst the 
positive control had a 1949.3% ± 95.3% increase. Significant differences were found 
between each of the concentrations of bevacizumab (both solution and tablet) and the 
positive control, whilst no significant differences were found between either the tablet 
and stock solution form of bevacizumab at equivalent concentrations, together with no 
significant differences found between the highest and lowest concentrations of 
bevacizumab. Results are presented as mean percentage change ± SEM from two 
independent experiments (n = 6 per experiment). 
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Figure 4.3 - The effect of the stock bevacizumab solution on HUVEC proliferation when grown in 
monolayer over 72 hours as assessed using the MTT assay. 
Significant differences were seen between the positive control and cells treated with stock bevacizumab 
solution at all concentrations tested (p < 0.001). The average increase in absorbance after 72 hours across 
each group containing bevacizumab was 753.7% ± 22.1% whilst the negative control 599.0% ± 44.6% and 
the positive control 1856.5% ± 26.5%. The graph shows a single experiment with errors bars representing 
the SEM (n = 6) representative of triplicate repeats. Statistical comparisons were made using ANOVA and 
Bonferroni’s post-test comparing all columns. ** = p < 0.01; *** = p < 0.001, with stars representing 
significance compared to the positive control. 
 
 
Figure 4.4 – The effect of bevacizumab that had been fabricated into a tablet on HUVEC 
proliferation when grown in monolayer over 72 hours as assessed using the MTT assay. 
Significant differences were seen between the positive control and (p < 0.001). The average increase in 
absorbance after 72 hours across each group containing bevacizumab was 616.3% ± 21.7% whilst the 
negative control 599.0% ± 44.6% and the positive control 1856.5% ± 26.5% The graph shows a single 
experiment with errors bars representing the SEM (n = 6) representative of triplicate repeats. Statistical 
comparisons were made using ANOVA and Bonferroni’s post-test comparing all columns. ** = p < 0.01; *** 
= p < 0.001, with stars representing significance compared to the positive control. 
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4.3.1.2 The effects of bevacizumab tablet excipients on HUVEC proliferation 
During the fabrication process of the bevacizumab tablet, hyaluronic acid is introduced 
to provide a structural element to the tablet; as such this introduces an extra excipient 
(Khalili, 2011). Following reports in the literature of the potential anti-fibrotic and anti-
angiogenic effects of trehalose, a pre-existing bevacizumab excipient as previously 
discussed (4.1.7.1), the effects of hyaluronic acid itself were tested alongside a 
confirmative study looking at the effects of trehalose on HUVEC proliferation. 
4.3.1.2.1 The effects of hyaluronic acid 
Due to the fabrication of the bevacizumab tablet introducing hyaluronic acid as an 
excipient, a range of concentrations of hyaluronic acid were tested to investigate their 
ability to regulate HUVEC proliferation. Cells were grown in low serum media, with both 
the positive control and test samples containing 10 ng/ml VEGF, with the negative 
control absent of VEGF. Absorbance measurements were taken every 24 hours over a 
72 hour period following initial treatment, with treatments evaluated over a serial 
dilution, with concentrations ranging from 1.75 mg/ml (the concentration found in a 
single tablet) to 0.00875 mg/ml. Results from a representative experiment are shown in 
Figure 4.5, where a significant reduction in absorbance was found following HUVEC 
treatment with amounts above 0.0875 mg when compared to the positive control. 
When cells were treated with either 0.875 mg or 1.75 mg the average increase in 
absorbance after 72 hours was 204.1% ± 14.4% compared to an increase in 
absorbance of 389.8% ± 24.3% in the positive control. As the concentrations of 
hyaluronic acid decreased a clear dose-dependent effect was also observed with an 
average absorbance of 328.3% ± 46.3%, 343.5% ± 44.6%, 397.3% ± 33.3% in the 
0.0875 mg, 0.0175 mg and 0.00875 mg groups respectively. Results are presented as 
mean percentage change ± SEM from two independent experiments (n = 6 per 
experiment). 
4.3.1.2.2 The effects of trehalose 
In order to ascertain the effects of trehalose on HUVEC proliferation in-vitro, a range of 
concentrations of trehalose were tested. Cells were grown in low serum media, with 
both the positive control and test samples containing 10 ng/ml VEGF, with the negative 
control absent of VEGF. Absorbance measurements were taken every 24 hours over a 
72 hour period following initial treatment, with treatments evaluated over a serial 
dilution, with amounts ranging from 60 mg/ml (the concentration found in a 
bevacizumab solution) to 0.3 mg/ml. Results from a representative experiment are 
  164 
shown in Figure 4.6, where only at the highest concentrations of trehalose were 
inhibitory effects observed (60 mg/ml and 30 mg/ml produced increases in absorbance 
of just 198.0% ± 12.1% and 216.7 ± 12.1% respectively compared to 390.72% ± 13.6% 
in the positive control(p < 0.001)). Beyond this, absorbance level changes were 
comparative to that of the positive control. Results are presented as mean percentage 
change ± SEM from two independent experiments (n = 6 per experiment). 
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Figure 4.5 – The effects of hyaluronic acid on HUVEC proliferation when grown in monolayer over 
72 hours as assessed using the MTT assay. 
Significant differences were seen between the positive control and amounts of hyaluronic acid above 
0.0175 mg(p < 0.001). The absorbance of the positive control was found to be 389.8% ± 24.3% whilst the 
1.75 mg and 0.0875 mg groups had a mean absorbance of just 204.1% ± 14.4%.The graph shows a single 
experiment with errors bars representing the SEM (n = 6) representative of triplicate repeats. Statistical 
comparisons were made using ANOVA and Bonferroni’s post-test comparing all columns. ** = p < 0.01; *** 
= p < 0.001, with stars representing significance compared to the positive control. 
 
Figure 4.6 – The effects of trehalose on HUVEC proliferation when grown in monolayer over 72 
hours as assessed using the MTT assay. 
Significant differences were seen between the positive control and various concentrations of trehalose. 
The 60 mg and 30 mg groups produced increases in absorbance of just 198.0% ± 12.1% and 216.7 ± 
12.1% respectively compared to 390.72% ± 13.6% in the positive control (p < 0.001). The graph shows a 
single experiment with errors bars representing the SEM (n = 6) representative of triplicate repeats. 
Statistical comparisons were made using ANOVA and Bonferroni’s post-test comparing all columns. ** = p 
< 0.01; *** = p < 0.001, with stars representing significance compared to the positive control. 
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4.3.1.3 The effects of an bevacizumab tablet on the modulation of HUVEC gene 
expression in comparison to bevacizumab solution 
In order to further examine the biological activity of bevacizumab fabricated into a 
tablet, the effects of bevacizumab in regulating the VEGF-induced upregulation of 
tissue factor (TF); TF, as previously discussed (4.1.5.1.2) is upregulated during the 
initial clotting response following the release of VEGF into the wound site 
(Mechtcheriakova et al., 1999). HUVECs were grown in six well plates overnight before 
being exposed to VEGF for 2 hours in order to induce an upregulation in the TF gene. 
Simultaneously, groups were exposed to VEGF (0.26 nM) as well as bevacizumab 
derived from either solubilised tablets or stock solution at a concentration of 200 nM 
and 100 nM. After two hours of exposure, RNA was isolated from the cells and 
analysed via semi-quantitative PCR in order to ascertain the expression level of TF in 
each group. Following analysis a significant upregulation in cells exposed solely to 
VEGF (p < 0.001) whereas in those groups exposed to EGM additionally supplemented 
with bevacizumab no significant differences in gene expression were observed when 
compared to the negative control. A graph illustrating these alterations in gene 
expression is shown in Figure 4.7. 
  
167 
 
 
Figure 4.7 – The effects of VEGF and bevacizumab in regulating the gene expression of tissue factor in HUVECs. 
A significant upregulation (p < 0.001) in TF was following a two hour treatment with VEGF, with this upregulation ablated though the addition of bevacizumab. No significant 
differences were observed between either bevacizumab solution or bevacizumab derived from an bevacizumab tablet. Error bars represent SEM (n=3). Statistical comparisons 
were made using ANOVA and Bonferroni’s post test comparing all columns. *** = p < 0.001. 
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4.3.1.4 The effects of bevacizumab solution compared to the bevacizumab 
tablet on angiogenesis using a 3D co-culture model 
In order to ascertain the biological activity of bevacizumab fabricated into a tablet, an 
in-vitro model of angiogenesis was utilised in order to determine the anti-angiogenic 
effects of bevacizumab. This model highlights some of the important aspects of 
angiogenesis including branch/vessel growth (length) and the number of branches 
sprouting from a single source. 
Cells were grown for up to ten days in EGM-2, with a standardised concentration of 
VEGF (10 ng/ml) with supplementation of bevacizumab at various concentrations from 
either a pre-dissolved tablet or from stock bevacizumab solution. Results for the assay 
were collected at days 7 and 14, at which point the maximum branch length as well as 
mean number of branches was determined.  
From the results presented below significant differences in the total number of 
branches were found in almost all samples at both days 7 and 14 (Figure 4.8 and 
Figure 4.10 respectively) when comparing the bevacizumab treated samples with the 
control, with the solution bevacizumab at a VEGF ratio of 1:2 not significant. However, 
between the comparative concentrations of bevacizumab no significant differences 
were found at either day 7 and 14. 
Similarly, whilst significant differences were found between the control and 
bevacizumab treated samples in terms of the longest branch length at both days 7 and 
14, no significant differences were found between the comparable groups of the 
respective concentrations at each time point as shown in Figure 4.9 and Figure 4.11 
respectively.   
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Figure 4.8 - The mean number of branches at seven days post seeding. 
Significant differences were seen between control and bevacizumab groups (p < 0.001) although no 
differences were observed when comparing the same concentration of bevacizumab (solution vs. tablet). 
Error bars represent SEM (n > 10).  
*** = significant differences between groups (ANOVA, p < 0.001); ** = p < 0.05. 
 
Figure 4.9 – The average longest branch length for vessel formation at seven days post seeding.  
Significant differences were seen between control and bevacizumab groups (p < 0.001) although no 
differences were observed when comparing the same concentration of bevacizumab (solution vs. tablet). 
Error bars represent SEM (n > 10). *** = significant differences between groups (ANOVA, p < 0.001). 
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Figure 4.10 – The mean number of branches at fourteen days post seeding. 
Significant differences were seen between control and bevacizumab groups (p < 0.001) although no 
differences were observed when comparing the same concentration of bevacizumab (solution vs. tablet). 
Error bars represent SEM (n > 10). *** = significant differences between groups (ANOVA, p < 0.001). 
 
 
Figure 4.11 – The average longest branch length for vessel formation at fourteen days post 
seeding.  
Significant differences were seen between control and bevacizumab groups (p < 0.001) although no 
differences were observed when comparing the same concentration of bevacizumab (solution vs. tablet). 
Error bars represent SEM (n > 10). *** = significant differences between groups (ANOVA, p < 0.001). 
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4.3.1.5 The effects of an bevacizumab tablet compared to bevacizumab solution 
on HTF proliferation 
In order to understand whether bevacizumab that had been fabricated into a tablet 
could function, biologically, at a level comparable to that of standard bevacizumab 
solution, HTFs were exposed to varying concentrations of bevacizumab-supplemented 
growth medium (tablets were dissolved prior to use) and assayed using the MTT 
assay. Cells were grown in low serum media, with both the positive control and test 
samples containing 10 ng/ml VEGF, with the negative control absent of VEGF. 
Absorbance measurements were taken every 24 hours over a 72 hour period following 
initial treatment, with treatments evaluated over a serial dilution, with concentrations 
ranging from 939.6 nM to 0.9396 nM. Results for both the solution and tablet are 
presented in Figure 4.12 and Figure 4.13 respectively. The results, whilst showing a 
reduction in proliferation did not highlight any statistically significant reduction in 
absorbance in either bevacizumab obtained from stock solution (mean increase in 
proliferation (after 72 hours) was 471.5% ± 20.1 vs. 437.5% ± 36.4% in the positive 
control) or bevacizumab from a pre-fabricated tablet (mean increase in proliferation 
(after 72 hours) was 364.7% ± 14.9 vs. 300.9% ± 23.1% in the positive control). 
Results are presented as mean percentage change ± SEM from two independent 
experiments (n = 6 per experiment). 
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Figure 4.12 - The effect of the stock bevacizumab solution on HTF proliferation when grown in 
monolayer over 72 hours as assessed using the MTT assay. 
No significant differences were found, although a reduction in proliferation was observed when HTFs were 
treated with the tested concentrations of bevacizumab. The mean increase in proliferation (after 72 hours) 
was 471.5% ± 20.1 vs. 437.5% ± 36.4% in the positive control. Statistical comparisons were made using 
ANOVA and Bonferroni’s post-test comparing all columns. The graph shows a single experiment with 
errors bars representing the SEM (n = 6) representative of triplicate repeats.  * = p < 0.05; *** = p < 0.001, 
with stars representing significance compared to the positive control.  
 
Figure 4.13 - The effect of bevacizumab that had been fabricated into a tablet on HTF proliferation 
when grown in monolayer over 72 hours as assessed using the MTT assay. 
No significant differences were found, although a reduction in proliferation was observed when HTFs were 
treated with the tested concentrations of bevacizumab. The mean increase in proliferation (after 72 hours) 
was 364.7% ± 14.9 vs. 300.9% ± 23.1% in the positive control. Statistical comparisons were made using 
ANOVA and Bonferroni’s post-test comparing all columns. The graph shows a single experiment with 
errors bars representing the SEM (n = 6) representative of triplicate repeats.  ** = p < 0.01; *** = p < 0.001, 
with stars representing significance compared to the positive control. 
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4.3.1.6 The effects of bevacizumab tablet excipients on HTF proliferation 
4.3.1.6.1 The effects of hyaluronic acid 
Due to the fabrication of the bevacizumab tablet introducing hyaluronic acid as an 
excipient, a range of concentrations of hyaluronic acid were tested to investigate their 
ability to regulate HTF proliferation. Cells were grown in low serum media, with both the 
positive control and test samples containing 10 ng/ml VEGF, with the negative control 
absent of VEGF. Absorbance measurements were taken every 24 hours over a 72 
hour period following initial treatment, with treatments evaluated over a serial dilution, 
with concentrations ranging from 1.75 mg/ml (the concentration found in a single tablet) 
to 0.00875 mg/ml. Results from a representative experiment are shown in Figure 4.14. 
A significant reduction in absorbance was found in all tested concentrations of 
hyaluronic acid when compared to the positive control. After 72 hours of treatment an 
increase in absorbance of only 110.5% ± 44.7% was found in the 1.75 mg/ml group 
compared to an increase of 363.5% ± 33.4% in the positive control. Even in the group 
treated with 0.00875 mg/ml an increase of only 241.3% ± 15.2%, which was found to 
be significantly less than compared to the control (p < 0.001). 
4.3.1.6.2 The effects of trehalose 
In order to ascertain the effects of trehalose on HTF proliferation in-vitro, a range of 
concentrations were tested. Cells were grown in low serum media, with both the 
positive control and test samples containing 10 ng/ml VEGF, with the negative control 
absent of VEGF. Absorbance measurements were taken every 24 hours over a 72 
hour period following initial treatment, with treatments evaluated over a serial dilution, 
with concentrations ranging from 60 mg/ml (the concentration found in a bevacizumab 
solution) to 0.03 mg/ml. Results from a representative experiment are shown in Figure 
4.15. Significant decreases in absorbance were found in concentrations ranging 
between 60 and 6 mg/ml, with the positive control having increased 144.2% ± 20.3% 
compared to 50.3% ± 15.9% in the 60 mg/ml group and 78.1% ± 7.7% in the 6 mg/ml 
group (p < 0.001). Beyond this concentration absorbance levels were comparative to 
that of the positive control with no significant differences observed. 
4.3.1.7 The effects of trehalose on HTF mediated collagen contraction 
The regulation of HTF mediated collagen contraction was assessed in the presence of 
varying concentrations of trehalose. Fibroblasts were seeded into collagen gels and 
exposed to FGM supplemented with varying concentrations of trehalose before being 
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monitored over a seven day period (Figure 4.16). A significant inhibition in contraction 
was observed in gels treated with 60 mg/ml, with significant differences (p < 0.001) 
found at all timepoints. After 72 hours gels treated with 60 mg/ml had only contracted 
38.21% ± 1.26% compared to 85.9% ± 0.69% in the control gels; after 172 house, 60 
mg/ml gels had contracted only 64.3% ± 1.64% whilst control gels had contracted 
95.8% ± 0.37%. Concentrations of trehalose of 6 and 0.6 mg/ml did not affect 
contraction. At day three, cells within the gel of the cells treated with 60 mg/ml 
trehalose displayed small, spindle shaped bodies, whilst those in the other groups 
appeared to extend large processes consistent with a contracting gel as shown in 
Figure 4.17; this was not seen at day seven. 
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Figure 4.14 – The effects of hyaluronic acid on HTF proliferation when grown in monolayer over 72 
hours as assessed using the MTT assay. 
Significant differences were seen between the positive control and all concentrations of hyaluronic acid. 
After 72 hours of treatment an increase in absorbance of only 110.5% ± 44.7% was found in the 1.75 
mg/ml group compared to an increase of 363.5% ± 33.4% in the positive control. Even in the group treated 
with 0.00875 mg/ml an increase of only 241.3% ± 15.2%. The graph shows a single experiment with errors 
bars representing the SEM (n = 6) representative of triplicate repeats. Statistical comparisons were made 
using ANOVA and Bonferroni’s post-test comparing all columns. ** = p < 0.01; *** = p < 0.001, with stars 
representing significance compared to the positive control. 
 
Figure 4.15 - The effects of trehalose on HTF proliferation when grown in monolayer over 72 hours 
as assessed using the MTT assay. 
Significant decreases in absorbance were found in concentrations ranging between 60 and 6 
mg/ml, with the positive control having increased 144.2% ± 20.3% compared to 50.3% ± 15.9% in 
the 60 mg/ml group and 78.1% ± 7.7% in the 6 mg/ml group (p < 0.001). The graph shows a single 
experiment with errors bars representing the SEM (n = 6) representative of duplicate triplicate. 
Statistical comparisons were made using ANOVA and Bonferroni’s post-test comparing all 
columns. ** = p < 0.01; *** = p < 0.001, with stars representing significance compared to the 
positive control. 
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Figure 4.16 – The effects of trehalose on regulating HTF mediated collagen gel contraction. 
HTFs seeded into collagen gels and exposed to either control FGM or FGM supplemented with varying 
concentrations of trehalose. After 172 house, 60 mg/ml gels had contracted only 64.3% ± 1.64% whilst 
control gels had contracted 95.8% ± 0.37% (p < 0.001). Concentrations of trehalose of 6 and 0.6 mg/ml did 
not affect contraction. Error bars represent the SEM (n = 5) of a single experiment representative of 
triplicate repeats. Statistical comparisons were made using ANOVA and Bonferroni’s post test comparing 
all columns.  
 
 
Figure 4.17 – The morphology of cells grown in gels exposed to trehalose at day three. 
Photographs representative of morphology observed in each of three experimental repeats (n = 5 per 
repeat). Scale bar represents 100 µm.
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4.3.2 The effects of VEGF on HTFs 
Despite the increasing use of bevacizumab in order to modulate post-operative wound 
healing, little is understood as to the way in which bevacizumab may be achieving its 
effects. Whilst the target of bevacizumab, VEGF, is well characterised as to its effects 
on HUVECs, little is known as to its effects on other cell types such as fibroblasts; as 
such a series of experiments were undertaken in order to shed light on some of its 
effects. 
4.3.2.1 The effects of VEGF on HTF proliferation 
In order to understand whether VEGF could regulate HTF proliferation, the MTT assay 
was used to answer this unknown. Cells were grown in serum free FGM (control) or 
serum free FGM supplemented with a range of concentrations of VEGF before the 
proliferation was assessed using MTT, with absorbance measurements taken daily 
over a 72 hour period. The results, as shown in Figure 4.18, demonstrated that VEGF, 
at concentrations of 1 ng/ml and above, could significantly increase HTF proliferation (p 
< 0.001). After 72 hours of proliferation an increase in absorbance of 137.0% ± 9.37% 
was found in control samples whilst 0.1 ng/ml mean absorbance increased by 176.2% 
± 20.0%, 1 ng/ml mean absorbance increased by 249.8% ± 24.6%, 10 ng/ml mean 
absorbance increased by 226.5% ± 5.5% and 100 ng/ml mean absorbance increased 
by 204.0% ± 15.2%. 
4.3.2.2 The effects of VEGF on HTF mediated collagen contraction 
Whilst increases in proliferation were found, the effects on VEGF on regulating 
biological processes related to wound healing were also investigated, such as through 
the use of the collagen contraction model. HTFs were loaded into gels and fed serum 
free FGM (control) or serum free FGM supplemented with a range of concentrations of 
VEGF and monitored over a seven day period. During the contraction studies it was 
found that 1 ng/ml could, initially, significantly increase the rate of contraction (p < 
0.001 up to 72 hours, p < 0.05 thereafter up to day seven); similarly an increase in total 
contraction was observed between the control gels and gels treated with 100 ng/ml 
VEGF between days four and seven (p < 0.05), whilst 10 ng/ml did not affect the rate of 
contraction. A representative set of results is shown in Figure 4.19. 
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Figure 4.18 – The effects of VEGF on regulating the proliferation of HTFs. 
Significant differences were seen between the control cells and those treated with more than 1 ng/ml 
VEGF (p < 0.001). After 72 hours of proliferation an increase in absorbance of 137.0% ± 9.37% was found 
in control samples whilst 0.1 ng/ml mean absorbance increased by 176.2% ± 20.0%, 1 ng/ml mean 
absorbance increased by 249.8% ± 24.6%, 10 ng/ml mean absorbance increased by 226.5% ± 5.5% and 
100 ng/ml mean absorbance increased by 204.0% ± 15.2%. Error bars represent the SEM (n = 6). Data 
presented from a single experiment representative of triplicate repeats. Statistical comparisons were made 
using ANOVA and Bonferroni’s post test comparing all columns. ** = p < 0.01. 
 
Figure 4.19 – The effects of VEGF on regulating HTF mediated collagen contraction. 
HTFs seeded into collagen gels and exposed to either serum free FGM or serum free FGM containing 
VEGF were analysed over a seven-day period. Significant differences in the rate of contraction were 
observed, although have not been shown on the graph due to the difficulty in presenting the data (results 
can be found in the text). Error bars represent the SEM (n = 5). Data presented from a single experiment 
representative of triplicate repeats. Statistical comparisons were made using ANOVA and Bonferroni’s post 
test comparing all columns.
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4.3.2.3 The effects of VEGF on HTF gene expression 
To assess the effects of VEGF on HTFs in-vitro, HTFs were exposed to a range of 
concentrations of VEGF for 72 hours, where cells were grown in six well plates until 
sufficiently confluent before being treated with either serum free FGM or serum free 
FGM supplemented with VEGF; after 72 hours RNA was isolated and the expression 
levels of MMPs and TIMPs were analysed via RT-PCR. 
Whilst a range of genes were analysed, it was often found that only one or two 
concentrations of VEGF altered the expression levels of any single gene. For example, 
as shown in Figure 4.20 and Figure 4.21, whilst an increase in the expression of TIMP-
1 was found following treatment with 0.1 ng/ml of VEGF, no other concentrations 
greatly affected its expression. Similarly, whilst a downregulation in MMP-2 expression 
following treatment with 1 ng/ml of VEGF was observed, a significant increase in 
expression was observed following treatment with 100 ng/ml (p < 0.01). Furthermore a 
significant increase in MMP-9 and TIMP-2 expression was observed following 
treatment with 100 ng/ml (p < 0.05 and p < 0.01 respectively). 
4.3.2.4 The effects of VEGF on HTF protein production 
To assess the effects of VEGF on HTF mediated MMP/TIMP production in-vitro, HTFs 
were exposed to VEGF at varying concentrations for either 24 or 72 hours before the 
media was collected and analysed via ELISAs. After 24 hours of exposure, no MMP-1 
was detected in control samples, with approximately 3 ng/ml detected following 
treatment with 1 ng/ml VEGF (p < 0.05). No significant differences were found in MMP-
2 expression nor TIMP-1 expression, although downregulation of TIMP-1 following 
treatment with both 10 and 100 ng/ml VEGF was observed. After 72 hours a 
significantly elevated level of MMP-1 was observed following 10 ng/ml treatment (p < 
0.05), with no differences in MMP-2 observed. Whilst no significant changes in TIMP-1 
expression was observed, a continued downregulation of TIMP-1 following 10 ng/ml 
and 100 ng/ml treatment was observed.  
Of note, MMP-9 was also tested but levels were undetectable outside of 100 ng/ml 
treatment, which after 72 hours led to very low levels of detection, but clearly sufficient 
to produce a response. 
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Figure 4.20 – The effects of varying concentrations of VEGF on MMP/TIMP gene expression following 72 hours of exposure. 
Whilst no significant differences were observed, an upregulation of TIMP-1 was found following treatment with 0.1 ng/ml of VEGF (101.4% ± 42.5%). Bars normalised to control 
samples with band density normalised to 1 for control samples. Error bars represent SEM (n=3). Statistical comparisons were made using ANOVA and Bonferroni’s post test 
comparing all columns.
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Figure 4.21 - The effects of varying concentrations of VEGF on MMP/TIMP gene expression following 72 hours of exposure. 
Significant upregulation in MMP-2 (100 ng/ml: 49.7% ± 10.4%), MMP-9 (100 ng/ml: 75.1% ± 8.9%) and TIMP-2 (100 ng/ml: 37.6% + 7.6%) was observed following treatment 
with 100 ng/ml VEGF, no other differences in gene expression were found to be statistically significant despite MMP-1 having a decrease of 25%. Bars normalised to control 
samples with band density normalised to 1 for control samples. Error bars represent SEM (n=3). Statistical comparisons were made using ANOVA and Bonferroni’s post test 
comparing all columns. ** = p < 0.01, * = p < 0.05.
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Figure 4.22 – Levels of MMP/TIMP protein in media collected from HTFs grown in the presence of 
varying concentrations of VEGF for 24 hours. 
A significant increase in MMP-1 was found following treatment with 1 ng/ml VEGF, although no other 
differences were found to be statistically significant. Error bars represent SEM (n=3). Statistical 
comparisons were made using ANOVA and Bonferroni’s post test comparing all columns. * = p < 0.05. 
 
 
Figure 4.23 - Levels of MMP/TIMP protein in media collected from HTFs grown in the presence of 
varying concentrations of VEGF for 72 hours. 
A significant increase in MMP-1 was found following treatment with 1 ng/ml VEGF, although no other 
differences were found to be statistically significant. Error bars represent SEM (n=3). Statistical 
comparisons were made using ANOVA and Bonferroni’s post test comparing all columns. * = p < 0.05. 
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4.3.2.5 Immunocytochemical analysis of HTFs following exposure to VEGF 
In order to visualise protein expression within the cells, immunocytochemical analysis 
of HTFs grown in the presence of VEGF was undertaken. Cells were grown on 
collagen type I coated chamber slides for 72 hours in the presence of either control 
serum free FGM or serum free FGM supplemented with varying concentrations of 
VEGF. After 72 hours cells were fixed and stained. 
Figure 4.24 and Figure 4.25 show the immunocytochemical staining of fibroblasts for 
the structural protein F-actin or the VEGF receptor, VEGFR2. Staining for both proteins 
was largely consistent in all cells, with these pictures demonstrating the presence of 
VEGFR2 both within the membrane and intracellular compartments of the cell, such as 
in the cytoplasm. Figure 4.24A and C show the 10x and 40x magnification of the 
control cells, respectively, with Figure 4.24B and D representing cells grown in 1 ng/ml 
VEGF. Similarly, Figure 4.25A and C shows the staining of cells grown in 10 ng/ml 
VEGF, with Figure 4.25B and D showing the staining of cells grown in 100 ng/ml 
VEGF. Apart from changes in cell number, which can be observed, little in the way of 
expression was seen in the staining of VEGFR2. 
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Figure 4.24 – F-actin and 
VEGFR-2 
immunocytochemical 
staining of HTFs. 
Confocal images of HTFs 
grown in monolayer on 
collagen surface taken 
three days after exposure 
to either serum free FGM 
or serum free FGM 
supplemented with VEGF. 
Images A and B represent 
10x magnification of the 
control and 1 ng/ml treated 
cells respectively, with 
images C and D 
representing 40x 
magnification. F-actin 
staining (green) clearly 
shows cell shape and 
provides an indication of 
the cell number, with 
VEGFR2 (red) staining 
found both on the 
membrane and 
intracellularly. Nuclei are 
stained with DAPI (blue). 
Staining was repeated 
three times with these 
results representative of 
the findings.  Scale bars 
represent 100 µm in the 
10x images and 20 µm in 
the 40x images. 
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Figure 4.25 - F-actin and 
VEGFR-2 
immunocytochemical 
staining of HTFs. 
Confocal images of HTFs 
grown in monolayer on 
collagen surface taken three 
days after exposure to serum 
free FGM supplemented with 
VEGF. Images A and B 
represent 10x magnification 
of the 10 ng/ml and 100 
ng/ml treated cells 
respectively, with images C 
and D representing 40x 
magnification. F-actin 
staining (green) clearly 
shows cell shape and 
provides an indication of the 
cell number, with VEGFR2 
(red) staining found both on 
the membrane and 
intracellularly. Nuclei are 
stained with DAPI (blue). 
Staining was repeated three 
times with these results 
representative of the findings. 
Scale bars represent 100 µm 
in the 10x images and 20 µm 
in the 40x images. 
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4.4 Discussion 
With the aim of improving the success rates of glaucoma filtration surgery, and 
reducing the number of post-operative failures that are due to scarring, many surgeons 
have turned to novel theraputics due to their, perceived, increased safety and reduced 
side effects; one such example is bevacizumab, which a number of clinicians are now 
using to provide enhanced post-operative care as opposed to, or in conjunction with, 
currently used anti-metabolites. However, despite this a number of problems with 
bevacizumab currently remain including both its mode of delivery (intraocular / 
subconjunctival injections) and its residency time at its site of action. Whilst this second 
point is somewhat less of an issue in regions such as the posterior segment where the 
thick, gel-like, vitreous can slow diffusion, in areas of rapid fluid turnover (such as in the 
bleb), the rapid washout of injected drugs can be critical to how successful a treatment 
it can be. As such, and following on from the work of our group, a solid dosage form of 
bevacizumab was created by our group (principally led by Dr Ashkan Khalili) which was 
able to provide a gradual release of bevacizumab (approximately 150 hours or around 
5-6 days). However, whilst chemical testing of bevacizumab had determined that the 
antibody had remained intact without aggregating or breaking down, the question still 
remained as to whether it was biologically viable. Furthermore, would the introduction 
of secondary excipients themselves impact upon its biological activity. As such a series 
of experiments, as documented in this thesis, were undertaken to determine the 
biological activity of bevacizumab that had previously been fabricated into a tablet. The 
effects of bevacizumab were assessed, predominantly, using endothelial cells 
(HUVECs), however assessments as to its activity were also explored by investing 
effects on the key cell involved in conjunctival scarring, the tenon’s fibroblast. 
To determine the biological activity of bevacizumab pre-fabricated into tablets, the 
proliferative capacity of HUVECs was first explored, with such endothelial cells having 
previously been shown to be regulated by VEGF (Soker et al., 1997). In comparative 
studies looking at bevacizumab solubilised from pre-fabricated tablets compared to 
stock solutions of bevacizumab it was found that bevacizumab fabricated into a tablet 
could suppress VEGF induced proliferation as effectively as stock bevacizumab, with 
no significant differences found between the two forms of bevacizumab (proliferation 
was effected at all concentrations tested with p-values < 0.001) suggesting that, in 
agreement with the chemical studies, the antibody remained active at levels 
comparable to that of the stock solution (Khalili, 2011). However, during the 
development of the tablet it was found an excipient was required for both tablet stability 
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and protein protection, and as such hyaluronic acid was incorporated. Therefore, to 
assess the effects of hyaluronic acid directly on the proliferative capacity of HUVECs, 
studies were undertaken which highlighted an anti-proliferative capacity at all tested 
concentrations. However, what is currently unknown is the exact levels of hyaluronic 
acid that are released from the tablet – whilst each tablet contains 1.75 mg, the exact 
rate of release of hyaluronic acid requires calculating; a clear drop off in the 
effectiveness of hyaluronic acid to regulate HUVEC proliferation was seen with 
proliferation less affected as the concentration of hyaluronic acid tested fell. As such, 
future studies looking directly at the level of hyaluronic acid released from the tablet 
should be assessed. Nonetheless, such anti-proliferative effects have been previously 
documented (especially when using high molecular weight hyaluronic acid such as the 
Healon GV used in the fabrication of the tablets); Sheehan and colleagues were able to 
demonstrate that when using 1 mg/ml of high-molecular weight hyaluronic acid 
proliferation of macrophage cells could be inhibited over a 72 hour period, with cell 
death actually induced beyond this point. Whilst an inhibition in proliferation has also 
been observed in this study, cell death was not assessed. As such future studies may 
be important to understand whether prolonged exposure to such levels of hyaluronic 
acid also induces cell death in other cell types such as HUVECs (Sheehan et al., 
2004). It was proposed in the above paper that hyaluronic acid induced such effects 
through the interaction with CD44, a cell surface protein known to be expressed on 
HUVECs, highlighting the importance of further investigation. A number of studies have 
previously implicated CD44 activation in the upregulation of pro-apoptotic proteins such 
as Fas (Fujii et al., 2001; J. F. Murphy et al., 2005). Despite these findings the second 
excipient that is present in bevacizumab proved to only effect proliferation of the 
HUVECs at the very highest of concentrations that would likely not be observed in-vivo. 
However this does highlight the importance of confirming the exact levels present 
during tablet release as well as the effects of hyaluronic acid fragments on HUVEC 
activity. Similar effects were also observed when tested on HTFs, where hyaluronic 
acid was shown to suppress fibroblast proliferation, and whilst this goes against 
several studies that have shown hyaluronic acid can actually increase fibroblast activity 
(proliferation, migration etc), such studies have often used intermediates such as TGF-
beta to induce hyaluronic acid production by the cell itself, rendering identifying the 
molecular weight of the hyaluronic acid produced difficult (I. R. Ellis et al., 1996; Denk 
et al., 2000).  
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Whilst trehalose was shown here to inhibit proliferation of both HUVECS and HTFs, it 
was limited to only the highest of concentrations, however these concentrations 
interestingly correlate with concentrations of bevacizumab, which in the past others 
have suggested inhibit HTF proliferation (Z. Li et al., 2009; O'neill et al., 2010). As such 
this presents the possibility that the results found in the previously cited papers were in 
fact the effects of trehalose in the bevacizumab solution rather than the effects of the 
antibody itself; the dose-dependent effect seen in these papers almost mimics the 
dose-dependent effect of the trehalose shown in this study. O’Neill and colleagues also 
presented gel contraction data whereby they suggested bevacizumab was able to 
inhibit fibroblast mediated collagen contraction; however once again the rates of 
contraction (and inhibition) once again bare great similarities with that of the trehalose 
inhibition presented in this study. Interestingly the use of trehalose itself as an anti-
fibrotic agent is currently being explored with Takeuchi and colleagues having 
demonstrated at high concentrations trehalose can inhibit keratinocyte and fibroblast 
proliferation, and when used in-vivo could prolong bleb survival and although no 
survival curves were provided in the dataset, the IOP of animals given topical trehalose 
treatment remained significantly lower than control animals over a 70 day period 
(Takeuchi et al., 2010). However this study does not fully answer the question of how 
trehalose may be exerting these effects, and whilst the shape of the cell was distinctly 
altered three days after treatment it was unclear as to whether this was due to a direct 
effect on the cell or whether a downregulation in proteins critical to contraction such as 
actin formation in the processes of the fibroblast, or in proteins that digest the matrix 
such as MMPs were effected. This therefore highlights a novel area for further study in 
characterising the direct mechanisms through which trehalose may alter fibroblast 
activity. Besides these studies, the ability for bevacizumab to regulate VEGF-induced 
upregulation of TF was further demonstrated to be unaffected following being 
fabricated, as was the inhibition of angiogenesis following the in-vitro angiogenesis 
assay whereby vessel formation was inhibited by bevacizumab, previously fabricated 
into tissue tablets, at a level comparable to that of the stock solution. Whilst a great 
deal of time was invested into trying to generate GFP positive HUVECs in order to 
provide a way of imaging the gels with confocal microscopy this aim was not achieved, 
however such a tool would provide greater ability in order to fully assess the ability of 
the HUVECs to generate sprouts in the presence of either form of bevacizumab. 
Finally, the effects of the excipients, trehalose and hyaluronic acid, were not tested in 
either the gene expression or angiogenesis assays but performing both experiments 
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may once again further highlight any potential effects these compounds have on 
regulating HUVEC activity and demonstrate the importance of understanding the role of 
the perceived excipients. 
Nonetheless, the increasing use of bevacizumab as a post-operative therapeutic as 
well as the results of in-vivo experiments performed by several groups around the 
world, including ours, has demonstrated that the drug does demonstrate an ability to 
modulate the wound healing process. As such, in order to determine potential roles of 
VEGF in the wound healing response (the natural target of bevacizumab), the effects of 
VEGF on fibroblast activity were explored. This study has shown that fibroblasts 
express the VEGF receptor, VEGFR2, with this finding supporting recently published 
data indicating that VEGF is potentially able to activate downstream signalling events 
within the fibroblast. However, to this stage no studies (including this one) have shown 
that activation of the VEGFR2 induced signalling cascades actually occurs following 
VEGF stimulation and as such protein based techniques (such as through the use of 
phospho-antibodies in western blots or ELISAs) are required to confirm VEGFR2 
activity. Despite this, following VEGF treatment increases in the ability for HTFs to both 
proliferate and contraction a collagen gel were both observed in this study. One 
drawback in this dataset is the high rate of contraction observed, despite using a BSA 
only media supplemented with VEGF; although this was repeated, a higher than 
normal cell number was required per gel in order to generate a rate of contraction, with 
normal seeding densities eliciting no contraction in even the positive (TGF-β2) controls. 
Further repeats of these studies may prove useful, although significant differences 
were observed in each of the experimental repeats in a dose-dependent fashion. 
However, this findings only offer insights into the end-point effects of VEGF on HTF 
activity; the finding that VEGF was able to modulate MMP gene expression and protein 
production is potentially the most interesting of this study. The finding that both 1 ng/ml 
and 10 ng/ml VEGF (at different time points) can significantly upregulate MMP-1 
highlights a novel role through which bevacizumab may regulate HTF activity in-vivo, 
and subsequently the wound healing process. Future studies looking directly at MMP 
levels following bevacizumab treatment (using either ELISAs or other antibody based 
techniques) may highlight ways in which the drug is regulating the wound healing 
process; ideally this thesis would have incorporated a bevacizumab microarray study, 
either in-vitro or in-vivo, however for a number of reasons these studies have yet to be 
undertaken although are planned for future work and may highlight clear mechanisms 
through which VEGF functions to regulate the wound healing process outside of 
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angiogenesis. Despite this, these results present novel roles for VEGF in regulating 
fibroblast-mediated activity (either directly in stimulating proliferation, or indirectly 
through altering MMP expression) and as such offer novel mechanisms by which anti-
VEGF drugs may regulate the wound healing process. 
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4.5 Conclusion 
This study has demonstrated the ability for bevacizumab, pre-fabricated into a slow 
release tablet, to still function as well as stock bevacizumab solution through numerous 
in-vitro assays. Whilst excipients within the tablet have similarly been shown to exert 
an effect on cellular activity, the doses tested may well be higher than would ever be 
physiologically found, requiring further analysis of levels of hyaluronic acid and 
trehalose released during the solubilisation of the tablet. Furthermore, this study has 
highlighted novel roles for VEGF in regulating fibroblast activity all key to the wound 
healing process, potentially highlighting mechanisms through which bevacizumab may 
regulate the wound healing process outside of the inhibition of angiogenesis. Future 
studies will further highlight such mechanisms, in particular the use of screening tools 
such as microarray studies. 
  
Chapter 5 The matrix metalloproteinases 
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5.1 Introduction 
5.1.1 The matrix metalloproteinase family 
The MMPs are a large family of enzymes that, collectively, share a number of common 
features including the presence of a catalytic domain, underpinning a basic structure 
that requires the binding of a zinc ion to an activation site in order to allow enzymatic 
activity (Hideaki Nagase et al., 2006). Originally identified as a single protein [interstitial 
collagenase 1 (MMP-1)] within the tails of tadpoles that are lost during metamorphosis 
(Gross et al., 1962), today 24 mammalian MMPs have been identified which are, 
classically, divided into five main sub groups based upon the substrate with which they 
interact and subsequently degrade. The target specificity of each MMP is defined by 
the carboxy terminal domain of the protein (see Table 5.1 and Table 5.2). Two further 
families of related metalloproteinases have also been identified, the ADAMs and the 
ADAMTs as discussed below (5.1.1.7) (Blobel, 2002; Cal et al., 2002). Whilst the 
majority of MMPs are secreted from the cells in an active state, those forming the MT-
MMPs are instead placed into the membrane where they interact with either the matrix 
directly adjacent to the cell or freely available targets such as proproteins (secreted 
proteins that reside in the ECM in an inactivate state, requiring proteolytic cleavage for 
activation) (Berk et al., 1999). 
5.1.1.1 The Collagenases 
The collagenase family, composed of MMPs -1, -3 and -8, are so named due to their 
ability to degrade fibrous collagen including type I, II, III, V and IX; upon interacting with 
collagen, the fibre is broken down into ¼ and ¾ fragments which, at room temperature, 
form gelatin which can be further degraded by the gelatinases (Ohuchi et al., 1997; 
Chung et al., 2004). 
5.1.1.1.1 MMP-1 
As well as being the first collagenase identified through the work of Gross and Lapiere 
(Gross et al., 1962), MMP-1 was also the first human MMP to be identified (G. I. 
Goldberg et al., 1986). Since its discovery it has been shown to be expressed in a 
number of cells in-vitro including fibroblasts, endothelial and epithelial cells, 
keratinocytes and macrophages (Birkedal-Hansen et al., 1993). During wound healing, 
MMP-1 is highly upregulated where, aside from collagen degradation (MMP-1 favours 
type III, but can digest all of the previously mentioned collagens), it can also cleave 
several non-structural ECM substrates including the TNF precursor, the insulin-like 
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growth factor-binding protein (IGFBP) and glycoproteins such as tenascin and 
fibrinogen (Mccawley et al., 2001). 
5.1.1.1.2 MMP-8 
With the close interaction that occurs between the wound healing response and MMP 
expression, a number of cells largely associated with the early events of wound healing 
also express elevated levels of MMPs (1.2.4). For example, MMP-8 is also known as 
neutrophil collagenase, as it was once thought to be exclusively expressed within 
neutrophils where it can be stored within granules and released when required; 
however, it has since been shown to be expressed in other inflammatory cells including 
macrophages and T-cells, as well as more common cells such as fibroblasts and 
endothelial cells (Van Lint et al., 2006). Upon the knockout of MMP-8, an increase in 
skin tumours was observed, although bone marrow transplantation was able to restore 
natural protection against tumour development, suggesting that MMP-8 expression is 
protective against cancer development (Balbín et al., 2003). However within the same 
mouse model, increased inflammation was observed and although the initiation of the 
inflammatory response was initially delayed, a similar delay in resolution was also 
observed suggesting MMP-8 may be critical for the both establishment and resolution 
of the inflammatory response; as in the cancer model, the use of bone marrow 
transplantation was able to restore the inflammatory response to that of the wild type 
animal (Balbín et al., 2003; Gutiérrez-Fernández et al., 2007). 
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Enzyme Name 
MMP 
Abbreviation Substrate Specificity 
Collagenases     
Interstitial collagenase 1 MMP-1 
Collagen I, II, III, VII, VIII, X; aggrecan, entactin, serpins, α2-macroglobulin, perlecan, 
vitronectin, Tenascin, fibrinogen, TNF precursor, IGFBP, progelatinase B 
Interstitial collagenase 2 MMP-8 Collagen I, II, III, aggrecan, serpins, α2-macroglobulin, fibrinogen 
Collagenase 3 MMP-13 
Collagen I, II, III, IV, IX, X, XIV; aggrecan, fibrillin, fibronectin, gelatin, lamnin, Tenascin, 
serpins, fibronogen, progelatinase B 
     
Gelatinase     
Gelatinase A MMP-2 
Collagen I, IV, V, VII, X, gelatin, fibronectin, Tenascin, fibrillin, osteonectin, entactin, 
aggrecan, vitronectin, decorin, plasminogen, α2-macroglobulin, IGFBP, TNF precursor, 
pro-TGF-ß, progelatinase B, procollagenase 3 
Gelatinase B MMP-9 
Collagen I, IV, V, VII, XI, XIV, gelatin, elastin, fibrillin, osteonectin, aggrecan, fibronectin, 
vitronectin, decorin, α2-macroglobulin, TNF precursor, IGFBP, plasminogen, pro-TGF-ß 
Stromelysins     
Stromelysin 1 MMP-3 
Collagen III, IV, V, VII, IX, X, elastin, fibronectin, fibrillin, fibrinogen, gelatin, aggrecan, 
vitronectin, decorin, Tenascin, TNF precursor, E-cadherin, IGFBP, plasminogen, 
procollagenase 1, procollagenase 2, procollagenase 3, progelatinase B 
Stromelysin 2 MMP-10 
Collagen III, IV, V, IX, X, elastin, fibronectin, gelatin, aggrecan, procollageanse 1, 
procollagenase 2, progelatinase B, promatrylisin 1 
Matrilysins     
Matrilysin 1 MMP-7 
Collagen IV, elastin, fibronectin, entactin, Tenascin, aggrecan, vitronectin, decorin, 
versican, E-cadherin, plasminogen, ß4 integrin, Fas ligand, pro-TNF-α, procollagenase 
1, progelatinase A, progelatinase B 
Matrilysin 2 MMP-26 Collagen IV, gelatin, fibronectin, fibrin, ß-casein, TACE-substrate, proGelatinase B 
Stromelysin 3 MMP-11 IGFBP 
Table 5.1 – Matrix metalloproteinase families, members and target substrates (Part A). 
This table shows four of the five classic MMP families: the collagenases, the gelatinases, the stromelysins and the matrilysins. The MMPs, whilst sharing may target substrates 
also display high specificity for certain components as shown in the table. Aside from ECM proteins such as collagen and fibronectin the MMPs are also able to activate the 
latent forms of proteins such as proTGF and proTNF. 
IGFBP = Insulin-Like Growth Factor-Binding Protein; TNF = TGF; TGF = Transforming growth factor; TACE = tumor necrosis factor-α-converting enzyme. 
Table adapted from findings presented in the following citations (Mccawley et al., 2001; Vincenti et al., 2002; Seiki, 2003; Xue et al., 2006). 
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Enzyme Name 
MMP 
Abbreviation Substrate Specificity 
Membrane Type MMPs     
MT1-MMP MMP-14 
Collagen I, II, III, gelatin, fibronectin, vitronectin, aggrecan, Tenascin, perlecan, 
fibrinogen/fibrin, fibrillin, α2-macroglobulin, procollagenase 3, progelatinase A, 
progelatinase B 
MT2-MMP MMP-15 Fibronectin, gelatin, aggrecan, Tenascin, perlecan, vitronectin, tTG 
MT3-MMP MMP-16 Collagen III, fibronectin, gelatin, laminin, aggrecan, casein, vitronectin, α2-macroglobulin 
MT5-MMP MMP-24 Fibronectin, progelatinase A 
MT4-MMP MMP-17 Gelatin, TNF-α precursor, fibrillin, fibronectin 
MT6-MMP MMP-25 Progelatinase A 
     
Others     
Macrophage Elastase MMP-12 
Elastin, collagen IV, fibronectin, gelatin, vitronectin, entactin, proteoglycan, heparan and 
chondroitin sulphates, TNF precursor, plasminogen, fibrillin, fibrinogen 
Enamelysin MMP-20 Aggrecan 
Cystein Array (CA)-MMP MMP-23 Gelatin 
Epilysin MMP-28 Casein 
Rheumatoid arthritis 
synovium inflamed-1 (RASI-1) MMP-19 Collagen IV, gelatin, Tenascin, fibronectin, aggrecan, fibrinogen 
- MMP-21 α-1-antitrypsin 
- MMP-27 Fibronectin, lamnin, gelatin 
Table 5.2 - Matrix metalloproteinase families, members and target substrates (Part B). 
This table shows the final of the five classic MMP families: the membrane-type MMPs. This table expands upon the list shown in Table 5.1. 
IGFBP = Insulin-Like Growth Factor-Binding Protein; TNF = TGF; TGF = Transforming growth factor; TACE = tumor necrosis factor-α-converting enzyme. 
Table adapted from findings presented in the following citations (Mccawley et al., 2001; Vincenti et al., 2002; Seiki, 2003; Xue et al., 2006).
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5.1.1.1.3 MMP-13  
Matrix metalloproteinase 13 was first cloned from a breast cancer cDNA library and has 
since been found to be expressed by a wide range of cells, including endothelial cells, 
fibroblasts and macrophages (Freije et al., 1994). Initially MMP-13 is secreted in an 
inactive pro- form but is rapidly cleaved by a number of enzymes including MMP-2, -3 
and -14 as well as itself (Knäuper et al., 2002). The preferential substrate for MMP-13 
is known to be collagen type II, which is largely found within cartilage and as such is 
highly expressed in developing bone as well as osteoarthritic and damaged cartilage. 
Supporting these findings, MMP-13 null mice were found to suffer from growth plate 
defects and significant collagen accumulation within atherosclerotic plaques (Inada et 
al., 2004). One explanation put forward for this specificity is the presence of the Runt-
related transcription factor 2 (RUNX-2) site within the promoter of MMP-13 which is 
known to be highly expressed within bone and tissue cartilage cells where it is 
essential for bone and tooth maintenance (Mengshol et al., 2001; Jonason et al., 
2009). However, despite this, MMP-13 is highly implicated within the wound healing 
process, particularly during the initial inflammatory response where it has been shown 
to regulate both the beginning and termination of the inflammatory response; a loss of 
MMP-13 has been shown to both prolong the inflammatory response and increase the 
level of fibrosis in the liver during cholestasis (a condition that prevents bile from 
leaving the liver) (De Aquino et al., 2009). 
5.1.1.2 The Gelatinases 
Only two members of the gelatinase family exist, MMP-2 and -9, which cleave the 
peptide bonds in denatured collagen leading to small fragmented peptides (Chung et 
al., 2004). The gelatinases are secreted into the ECM in an inactive pro- form requiring 
cleavage to become active; a number of MMPs can regulate this process as shown in 
Table 5.1 and Table 5.2. 
5.1.1.2.1 MMP-2 
Gelatinase A, or MMP-2, is the smaller of the gelatinases at 72 kDa, but is 
constitutively expressed within a range of cells including fibroblasts, macrophages and 
endothelial cells. A number of growth factors and pro-MMPs are controlled though 
MMP-2 cleavage including proMMP-1, -2 -3, pro-TNF-α and pro-TGF-β2 (Gearing et 
al., 1994; Schönbeck et al., 1998; Bäck et al., 2010). Knockout studies using MMP-2 
null mice have highlighted the roles of MMP-2, in particular during angiogenesis where 
reduced vascularisation was observed in both tumour models and when using a 
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corneal vascularisation model, together with a decrease in the ability for tumours to 
metastasise (T Itoh et al., 1998; Samolov et al., 2005). However, increased 
inflammatory responses were also observed in the MMP-2 null mice, including 
enhanced myocardial inflammation and increased immune-mediated arthritis (Takeshi 
Itoh et al., 2002; Matsusaka et al., 2005). Similarly, the increased inflammatory 
response seen in MMP-2 knockout mice has been shown to be a critical factor behind 
the delay in neovascularisation seen within the cornea following wounding, with 
Somolov and colleagues demonstrating that at nine days into the wounding response a 
significantly less percentage of neovascularisation had taken place (Samolov et al., 
2005). 
5.1.1.2.2 MMP-9 
Gelatinase B, or MMP-9, is a 92 kDa protein that is expressed within a wide range of 
cells with constitutive expression normally associated with cancerous tumours and 
cancer cell lines (Devarajan et al., 1992) although such expression has also been 
associated with murine macrophages (B. Xie et al., 1994). The substrates of MMP-9 
are highly similar to those of MMP-2 (Table 5.1 and Table 5.2) but it has also been 
demonstrated to induce the release of VEGF during angiogenesis (Bergers et al., 
2000). The MMP-9 knockout mouse produced a number of conflicting reports with 
regards to its effects during an inflammatory response, with Castenada and colleagues 
reporting a reduced inflammatory response in experimental colitis (an inflammation of 
the colon) and Luttun and colleagues similarly demonstrating a reduced macrophage 
infiltration during atherosclerosis (Luttun et al., 2004; Castaneda et al., 2005). In 
contrast to this though when using the same MMP-9 null mice within a model of lung 
inflammation, an enhanced inflammatory response was observed with increased 
eosinophils and Th2 cells present in the knockout mice; interestingly Lanone and 
colleagues, whilst not finding an increase in eosinophils during IL-13 mediated 
inflammation of the lung, did instead report an increased number of neutrophils 
(Lanone et al., 2002; Mcmillan et al., 2004). Despite these conflicting studies the 
knockout of MMP-9 has been widely associated with reduced angiogenesis and whilst 
the knockout mice display no abnormalities in their vasculature during embryonic 
development, a reduction in angiogenesis was observed in both the development of 
neuroblastomas as well as in the neovascularisation of the cornea that occurs in 
response to the herpes simplex virus, highlighting the potentially critical role of MMP-9 
mediated angiogenesis in situations where blood vessel formation is required post-
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natum such as in tumour growth and wound healing (S. Lee et al., 2002; Chantrain et 
al., 2004; Chantrain et al., 2006). 
5.1.1.3 The Stromelysins 
The stromelysins are composed of MMPs -3, -10 and -11, with each of the MMPs 
having a wide range of targets including fibronectin and lamnin. Outside of ECM 
regulation the stromelysins are highly implicated in the activation of many pro-proteins 
including many of the proMMPs, in particular proMMP-1, as well as inflammatory 
cytokines and growth factors such as pro-HB-EGF (K. Suzuki et al., 1990; M. Suzuki et 
al., 1997). Knockout studies have implicated MMP-3 as being critical for the structural 
formation of neuromuscular junctions and branching within the mammary gland (as 
was also seen in MMP-11 knockouts), whereas MMP-10 null mice displayed increased 
inflammation following wounding (Page-Mccaw et al., 2007). 
5.1.1.4 The Matrilysins 
The matrilysins are composed of MMP-7 and MMP-26 and are associated with the 
enzymatic degradation of a range of substrates including many collagens, Tenascin, 
fibrin and lamnin. Further to this, MMP-7 is also able to activate the apoptotic cascade 
through the cleavage of FasL bound to the cell surface as well as activation of TNF-α, 
an upstream activator of the apoptotic cascade (as described in 3.1.1.1 and shown in 
Figure 3.2) (B. R. Wong et al., 1997; Haro et al., 2000). The knockout of MMP-7 has 
been shown to cause immune defects following intestinal infection as well as reduced 
lung inflammation and delayed re-epithelialisation following allergen challenge or injury 
(Parks et al., 2001).  
5.1.1.5 Membrane-type MMPs 
The membrane bound MMPs (MMPs -14, -15, -16, -17 and -24) are largely involved in 
the activation of other MMPs, although they do play a role in ECM-degradation, with 
MMP-14 able to breakdown a number of different types of collagen. Of the MT-MMPs, 
MMP-14 is the most studied, with it’s activation known to occur through interaction with 
plasmin and furin, although studies have suggested that direct interactions between 
collagen and MT1-MMP may also occur activating a feedback loop that further controls 
the activity of MMP-2 (Stetler-Stevenson, 2008). Tam and colleagues were able to 
demonstrate that the presence of collagen type I can induce the presence of MT1-MMP 
which in turn cleaves proMMP-2 leading to an increase in MMP-2 activity, although this 
can be controlled through natural inhibition via the tissue inhibitor of metalloproteinases 
2 (TIMP-2, see 5.1.2.3 for more details) binding to the MT1-MMP-proMMP-2 complex. 
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As the collagen is degraded, the need for MT1-MMP decreases leading to autolysis of 
MT1-MMP and the generation of a 44 kDa fragment that lacks the extracellular 
cleavage domain; this fragment replaces MT1-MMP within the membrane and thus 
prevents further proMMP-2 cleavage (Tam et al., 2002). The knockout of MMP-14 was 
shown to impair angiogenesis during wound healing when using a model of corneal 
neovascularisation, although other tissues developed normally during development 
suggesting that this was a tissue specific response, with either MMP-14 required for 
corneal vascularisation directly, or through the activation of MMP-2 (Z. Zhou et al., 
2000). However, as previously discussed (5.1.1.2.1) the knockout of MMP-2 led only to 
a delayed vascularisation of the cornea rather than complete impairment (after 12 days 
complete vascularisation was observed), whilst the MMP-14 knockout study presented 
a continued lack of vessel growth 3 weeks after the initial injury suggesting a more 
critical role for MMP-14 in modulating corneal angiogenesis than simply limiting the 
activation of MMP-2 (Z. Zhou et al., 2000; Samolov et al., 2005).  
5.1.1.6 Other MMPs 
Aside from those which have classically been assigned into the five groups, a number 
of other MMPs also exist, including macrophage metalloelastase (MMP-12) which is 
expressed predominantly by macrophages during an inflammatory response, as well as 
cancerous tumours, where it is involved in the degradation of a number of extracellular 
matrix proteins including collagen type IV, lamnin, fibronectin and Tenascin. Xie and 
colleagues demonstrated that the addition of IL-1β to smooth muscle cells could lead to 
an increase in MMP-12 expression in-vitro, thus exacerbating a potential inflammatory 
response through the downstream activation of neutrophils (S. Xie et al., 2005; 
Manicone et al., 2008). Corresponding with these observations, knockout MMP-12 
mice show a decreased response to inflammatory stimulators, including a reduced 
macrophage and neutrophil presence within the injured site (Hautamaki et al., 1997; 
Wells et al., 2003). Despite these observations it has also been demonstrated that in 
some conditions the loss of MMP-12 does not always affect the inflammatory response, 
with Matute-Bello and colleagues showing an inflammatory response similar to that of 
the wild type upon antibody driven Fas activation in MMP-12-/- mice, with Fas a known 
inducer of lung inflammation and fibrosis (Matute-Bello et al., 2007). Nonetheless this 
study demonstrated a marked reduction in fibrosis in the knockout when compared to 
the wild type, suggesting MMP-12 plays a critical role in regulating downstream Fas-
induced fibrosis within the lung. 
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5.1.1.7 The ADAMs and ADAMTS 
Related to the MMPs are two families of metalloproteinases named a) the adamalysins 
[a disintegrin and metalloproteinase (ADAMs)] and b) a disintegrin and 
metalloproteinase with thrombospondin type-1 motifs (ADAMTS), which collectively 
contain both a metalloproteinase and disintegrin domain. The metalloproteinase region 
has high homology with the MMPs whilst the disintegrin has an integrin-like-binding 
domain. The ADAMs, meanwhile, are membrane bound proteins that have multiple 
substrates including the processing of ECM components and proteolytic cleavage of 
other membrane bound proteins. One example of this is in the activation of proTNF-α, 
which takes place through cleavage of its prodomain by ADAM-17, otherwise known as 
TNF-α converting enzyme (TACE) (Black et al., 1997). The ADAMTS meanwhile are a 
secreted family that are largely involved in the regulation of glycosaminoglycans within 
the ECM, such as in the cleavage of aggrecan by ADAMTS-4, a protein critical to the 
structure of cartilage (Miwa et al., 2006). Further discussion of the roles of the ADAMs 
and ADAMTS can be found within the reviews of Edwards and Porter respectively 
(Porter et al., 2005; Edwards et al., 2008). 
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5.1.2 Matrix metalloproteinase regulation 
The MMPs are able to alter cell behaviour in a number of ways, from modulation of the 
ECM that interacts with membrane bound receptors to altering the levels of active 
cytokines within the ECM through cleavage of their inactive forms (Ra et al., 2007). 
Despite this regulatory role, the MMPs can themselves be regulated with this taking 
place through one of four routes: transcriptional regulation, direct-activation, 
endogenous enzyme inactivation and synthetic inhibition. 
5.1.2.1 Transcriptional regulation 
The transcriptional control of MMP expression is not a single, unified, mechanism but 
rather a complex series of events that are triggered in response to a cytokine or growth 
factor. Whilst most MMPs have a low level of expression under quiescent conditions, 
upon being stimulated a rapid upregulation in expression can be achieved (Brinckerhoff 
et al., 2002). The majority of MMPs share common cis-acting elements in their 
promoter region and consequently often become activated as a group; despite this, fine 
tuning of MMP activation can be achieved through the activation of specific pathways 
and subsequently specific transcription factors that are able to regulate the expression 
of only a small subset of MMPs, such as the Runx2 binding site specific to MMP-13 
(5.1.1.1.3). As more has been learnt about MMP activation, a new classification system 
for the MMPs has been developed, based upon the mechanisms regulating their 
expression, with this shown in Table 5.3 (Yan et al., 2007). The inflammatory signals 
that are known to regulate MMP expression include IL-1β, IL-6 and TNF-α, which act 
through a number of cascades including the NF-κB, MAPK, SMAD and STAT signalling 
pathways, with the downstream targets of these signalling cascades the 
aforementioned cis-elements, such as the TATA box, the AP-1 binding site and the E-
twenty six (Ets) transcription factor binding sites, which includes the polyoma enhancer 
A binding protein-3 (PEA3) binding site (Vincenti et al., 2007). 
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Group MMPs Present Distinguishing Feature 
1 MMP-1, MMP-3, MMP-7, MMP-9, MMP-12, MMP-13, MMP-19 and MMP-26 
Presence of a TATA box and AP-1 
site binding to the members of the Fos 
and Jun families of transcription 
factors 
2 MMP-8, MMP-11 and MMP-21 
Presence of a TATA box and AP-1 
site, but are often constitutively 
expressed with elevated levels 
present in disease situations 
3 MMP-2, MMP-14 and MMP-28 
No TATA box or AP-1 site, but are 
often constitutively expressed with 
elevated levels present in disease 
situations 
Table 5.3 – The grouping of MMPs based upon transcription factor activation. 
This method of group differs from that of the groupings shown in Table 5.1 and Table 5.2, which is based 
upon target specificity. Groups shown as first published by Yan and Boyd (Yan et al., 2007). 
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5.1.2.1.1 The NF-κB signalling pathway 
The regulation of MMPs through nuclear factor κ-light-chain-enhancer of activated B 
cells (NF-κB) signalling has been widely demonstrated, particularly with regard to the 
regulation of MMP-1. The NF-κB pathway involves a number of transcription factors, 
including NF-κB1 and NF-κB2, which, in response to pathway activation, undergo 
proteolytic cleavage of their cytoplasmic domain allowing protein translocation to the 
nucleus (Vincenti et al., 2007). In order to activate transcription, the NF-κB transcription 
factors must associate with other proteins including RelA and Bcl-3; upon binding to 
RelA, a secondary complex forms through the binding of the inhibitor of kappa B (ikB), 
which is able to retain the NF-κB-RelA complex within the cytoplasm (Elliott et al., 
2002). In order to release the NF-κB-RelA complex and allow translocation to the 
nucleus, phosphorylation of IkB must take place via IkB kinases (IKK) (Karin et al., 
2004). The NF-κB proteins can also form a complex with Bcl-3, which is able to act as 
a docking station for transcriptional co-activators such as TIP60 and CBP/p300 
(Dechend et al., 1999). Elliott and colleagues were able to show that Bcl-3 can mediate 
IL-1β induced MMP-1 gene expression, although it was later shown that in order to 
achieve maximum IL-1β induced MMP-1 expression, a sustained phosphorylation of 
RelA is required, with a loss of RelA leading to a downregulation in MMP-1 expression 
even in the presence of IL-1β (Elliott et al., 2002; Raymond et al., 2007; Vincenti et al., 
2007). A graphical representation of the NF-κB signalling cascade is shown in Figure 
5.1. 
5.1.2.1.2 The MAPK signalling pathway 
Mitogen activated proteins kinases (MAPK) are a family of serine threonine protein 
kinases that mediate gene expression through the MAPK cascade, with the MAPK 
family divided into extracellular-regulated kinases (ERKs), the p38 protein kinases and 
c-Jun N-terminal kinases (JNKs) (Berk et al., 1999). The ERK pathway is most 
commonly used by growth factors such as EGF and FGF, functioning through RTKs 
that phosphorylate and recruit adaptor proteins such as Shc, Grb2 and Sos (4.1.5); 
these adaptor proteins further activate a set of downstream targets including Raf, Mek1 
and ERK1/2 resulting in the phosphorylation of a number of transcription factors 
including C/EBP-β, Ets, Fos and Jun (Lopez-Ilasaca, 1998; Mulder, 2000). The 
activation of the ERK pathway, via EGF, has been demonstrated to upregulate a 
number of MMPs including MMP-1, -3, -7, -9 and -14. Inflammatory cytokines can also 
utilise the MAPK pathway, such as IL-1β, which has been shown to stimulate MMP-1 
transcription and as such has become the target for drug research in the treatment of 
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inflammatory conditions such as arthritis (Noh et al., 2009). Interleukin-1β can further 
upregulate MMP expression, particularly that of MMP-1, through the activation of both 
the p38 protein kinase pathway and JNK pathway, however in chondrosarcoma cells it 
has been shown that the JNK pathway is not required for IL-1β induction of MMP-1 
suggesting that the cytokine regulation of MMP-1 may be cell specific (Mengshol et al., 
2001; Liang et al., 2007; Vincenti et al., 2007). A graphical representation of the MAPK 
signalling cascade is shown in Figure 4.2. 
5.1.2.1.3 The Jak/STAT signalling pathway 
The signal transducers and activators of transcription (STAT) proteins are transcription 
factors that become phosphorylated via Janus Kinases (Jak) and tyrosine receptor 
kinase adaptor proteins (4.1.5) (C. L. Yu et al., 1995; Berk et al., 1999). Cytokine 
receptors, such as the IL-6 receptor, are composed of gp130 homodimers that bind 
and phosphorylate Jak which is then able to phosphorylate STAT3 and trigger the 
downstream signalling cascade via nuclear translocation (Heinrich et al., 2003; Yahata 
et al., 2003). Interleukin-6 signalling has been implicated in STAT3 mediated MMP-1 
expression, as well as in the promotion of epithelial migration and the regulation of 
several genes that regulate the wound healing cascade such as ICAM1, BCL3 and the 
IL-6 receptor (Dauer et al., 2005; Jiang et al., 2010; Y. Li et al., 2010). The loss of 
STAT3 in keratinocytes led to impaired cell migration and wound healing in a STAT3 
disrupted mouse model (Sano et al., 1999). A graphical representation of the Jak/STAT 
signalling cascade is shown in Figure 5.1. 
5.1.2.1.4 The Smad signalling pathway 
The signalling of the TGF-β family (1.3.1) can take place through the Smad signalling 
pathway. Initially regulated by serine/threonine kinases that, upon activation, trigger the 
phosphorylation of receptor-regulated Smads leading to Smad dimerisation. The 
signalling of TGF-β is key to regulating MMP gene expression during wound healing 
and, as previously discussed, has been the target of therapeutics with the aim of 
modulating wound healing (1.4.3.1). Whilst TGF-β has been shown to upregulate MMP 
expression, for example in human trabecular meshwork cells where TGF-β2 has been 
shown to induce the expression of MMP-2, it has also been widely shown to be able to 
downregulate MMP expression (Fuchshofer et al., 2003). Yuan and Varga were able to 
demonstrate that MMP-1 is downregulated through the activation of Smad3 and 
Smad4, with Risigner similarly demonstrating that TGF-β was able to suppress PDGF 
induced upregulation of MMP-2 (Yuan et al., 2001; Risinger et al., 2010). This data 
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suggests that TGF is able to carefully balance the expression of MMPs, particularly 
during times of inflammation where many inflammatory signals (such as IL-1 and IL-6) 
are working to upregulate MMP expression. A graphical representation of the Smad 
signalling cascade is shown in Figure 5.1. 
5.1.2.2 Direct activation 
Whilst many MMPs are secreted from the cell in an active form, a number are secreted 
as proenzymes, an inactive form that requires cleavage of an NH2-terminal propeptide 
(H Nagase et al., 1999). The presence of the propeptide leads to a sealing of the 
catalytic Zn2+ region, with the removal of the propeptide allowing access to the catalytic 
region; this mechanism is otherwise referred to as a cystein-switch (Van Wart et al., 
1990). Besides direct MMP cleavage, proMMPs can also be partially activated through 
other proteases such as furin and plasmin, with these proteases themselves regulated, 
such as the regulation of plasmin via the urokinase-type plasminogen activator (uPA) 
(G. Murphy et al., 1999). However activation by such proteases requires a final 
cleavage to achieve full activation with this largely taking place via an MMP, such as 
the requirement of MMP-3 during proMMP-1 activation. This step is thought to provide 
a greater control over MMP activity. Whilst proteases such as plasmin and furin are 
commonly found within the ECM, MMPs are not and as such the MMP-regulated 
activation takes place during very specific circumstances where MMP upregulation is 
observed. This mechanism of activation underpins the phenotypic changes observed in 
some of the knockout mouse models previously discussed, such as the lack of MT1-
MMP in the MT1-MMP knockout mouse, resulting in an accumulation of proMMP-2 and 
lack of activation (5.1.1.5). 
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Figure 5.1 – A graphical representation of the NF-κB, Smad and STAT signalling pathways. 
IL-1 binding to tits receptor stimulates the TGF-activated kinase (TAK) that leads to the downstreatm activation of the NF-κB signalling pathway through the binding of NF-κB 
with RelA and Bcl-3 which both translocate to the nucleus for downstreatm gene activation. The activation of the Smad signalling cascade occurs through the phosphorylation 
and dimerisation of Smad proteins which translocate to the nucleus where they phosphoactivate transcription factors such as Ets, Fos and Jun. Finally the activation of the Jak-
STAT signalling cascade occurs through the phosphoactivation of STAT proteins that lead to the phosphoactivation of CBP/P300 as well as the aforementioned transcription 
factors. Image adapted and redrawn from images found in the following citation (Vincenti et al., 2007).
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5.1.2.3 Natural inhibition 
The regulation of MMP activity can be achieved through either the secretion of natural, 
specific, MMP inhibitors, the tissue inhibitors of MMPs (TIMPs), or several non-specific 
inhibitors, such as α1-antiprotease and α2-macroglobulin, a naturally occurring 
abundant protein that, besides regulating protease activity, functions in a number of 
ways including cytokine sequestration and  coagulation inhibition (Borth, 1992; 
Tchetverikov et al., 2003). The TIMPs meanwhile are a family of secreted proteins that 
inhibit the MMPs through non-covalent binding of the pro or active forms of the MMPs 
(Stetler-Stevenson, 2008). A total of four TIMPs exist that are, themselves, regulated 
via cytokines and growth factors, with signalling occurring through many of the same 
transcription factors that regulate MMP expression (I. M. Clark et al., 2008). Cytokines 
including TGF-β, IL-1β and TNF-α have all been shown to regulate TIMP expression, 
with TNF-α shown to stimulate TIMP-1 production at low concentrations, yet at high 
concentrations suppresses its production in accordance with its regulation of the MMPs 
(A. Ito et al., 1990; I. M. Clark et al., 2008; Stetler-Stevenson, 2008). Each TIMP has 
preferential MMP inhibition with, for example, TIMP-1 having a greatest preference for 
proMMP-9 and TIMP-2 favouring proMMP-2; TIMP-3 meanwhile binds both pro 
enzymes. Unlike TIMP-1 however, TIMP-2 and TIMP-3 can also inhibit the MT-MMPs, 
with TIMP-3 further able to inhibit members of the ADAM family including ADAM 17 
and 10 and ADAMTS-4 and -5; TIMP-4 is also able to bind the C-terminal of MMP-2. A 
more detailed review of the binding interactions of the TIMPS can be found in the 
reviews published by Settler-Stevenson and Brew respectively (Stetler-Stevenson, 
2008; Brew et al., 2010). Whilst the primary function of the TIMPs is to inhibit MMP 
activity, biological functions for the TIMPs have also been established, such as the 
regulation of the cell cycle through TIMP-1, with Taube and colleagues demonstrating 
that TIMP-1 is able to cause both a downregulation of cyclin D1 as well as 
hypophosphorylation of Rb (Taube et al., 2006). Conversely apoptosis has been shown 
to be affected by the TIMPS, with TIMP-3 thought to cause the stabilisation of the Fas-
activated apoptotic cascade (Wetzel et al., 2008). In contrast TIMP-1 is thought to 
inhibit apoptosis, as demonstrated by Lee and colleagues, who found that TIMP-1 
decreased apoptosis in breast carcinoma cells, through a mechanism thought to be 
mediated by the activation of Akt and PI3kinase; such a role for TIMP-1 may partly 
explain the high levels of TIMP-1 mRNA have previously been shown to be present 
within metastatic cancers (Ree et al., 1997; Bond et al., 2002; S.-J. Lee et al., 2003; E. 
Lambert et al., 2004). 
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5.1.2.4 Synthetic inhibition 
Outside of the natural regulation of MMPs that occurs through either transcriptional 
regulation and through the body’s use of natural inhibitors, a number of synthetic MMP 
inhibitors (MMPis) have been generated. Synthetic MMPis are predominantly low 
molecular weight compounds that feature a structure designed for specific interaction 
with the catalytic site, as well as a functional group that is capable of binding and 
chelating the active site zinc ion (Hidalgo et al., 2001). Broadly, MMPis can be 
classified into two main categories: peptidomimetics and non-peptidomimetics. In brief, 
the peptidomimetics are pseudopeptide derivatives that were originally produced to 
mimic the structure of collagen, the target of many MMPs, with the MMPis often 
featuring a hydroxamic acid, zinc-binding group that binds competitively, but strongly, 
to the active site of MMPs. Such examples include batimastat (BB-94), a broad 
spectrum MMP inhibitor, and its direct derivative marimastat (BB-2516). Batimastat is 
an inhibitor of MMP-1, -2, -3, -7 and -9 but struggled in clinical trials due, in part, to a 
poor solubility requiring intraperitoneal administration (S Zucker et al., 2000). This, 
therefore, led to the development of marimastat, a more soluble inhibitor which, whilst 
initially shown to increase survival and delay of disease progression in patients 
suffering from advanced gastric cancer (Bramhall, Hallissey et al., 2002), failed in late 
clinical trials, with the data suggesting a clear lack of effectiveness (Sparano et al., 
2004). Furthermore these MMPis were also often associated, when delivered orally, 
with joint pain, edema, reduced mobility and skin discoloration (Bramhall, Hallissey et 
al., 2002; Bramhall, Schulz et al., 2002). Non-peptidomimetic inhibitors have been 
designed using an approach that allows for the generation of drugs with increased 
target specificity, improved pharmacokinetics and bioavailability. Many of these are still 
undergoing testing, although one of the more promising compounds, BAY-129566 
(tanomastat), an MMPi selective for MMP-2, -3 and -9 previously shown to not cause 
the aforementioned musculoskeletal side effects, was found in clinical trials to have 
once again failed to provide the required effectiveness to warrant further investigation 
or clinical use; consequently further development of tanomastat was abandoned 
(Pavlaki et al., 2003; Hirte et al., 2005; Hirte et al., 2006). More recent work has 
focussed on the generation of monoclonal antibodies and peptide based inhibitors that 
offer even greater target specificity when compared to conventional small molecule 
drugs which, it is hoped, will offer a greater clinical impact than current compounds 
(Stanley Zucker et al., 2009). 
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5.1.2.4.1 Ilomastat 
Ilomastat (PubChem CID #132519; molecular structure shown in Figure 5.2) is a 
synthetically derived hydroxamic acid MMP inhibitor that was first documented in 1992 
(Grobelny et al., 1992). Also known as Galardin, or GM6001, ilomastat is able inhibit a 
number of MMPs, with the published Ki values of: MMP-1 (0.4 nM), MMP-2 (0.5 nM), 
MMP-3 (27 nM), MMP-8 (0.1 nM) and MMP-9 (0.2 nM). Ilomastat functions through 
competitive inhibition of the active-site, with its isobutyl group and tryptophan side 
chain able to bind to the sub-sites on the target enzymes that normally interact with 
ECM proteins (R.E Galardy, 1993; Kocer et al., 2005). A number of non-binding targets 
have been demonstrated to be effected upon the application of ilomastat, including the 
disruption of EGF signalling, thought to be through the inhibition of pro-HB-EGF 
cleavage (Y. Zhao et al., 2006; F. Wang et al., 2007), disruption of the MAPK signalling 
cascade (Pai et al., 2002; Razandi et al., 2003) and decreases in the production of 
various cytokines including TNF-α, IL-1β and IL-8 (Ramesh et al., 2002; Mascia et al., 
2003; Murray et al., 2010). In conjunction with these findings its effects on various 
models (in-vitro and in-vivo) has also been demonstrated including the inhibition of 
collagen contraction, the downregulation of MMP-1 and MMP-2 gene expression, and 
the promotion of rat sciatic nerve regeneration (thought to be through the promotion of 
Schwann cell differentiation with particular emphasis upon the inhibition of MMP-9) 
(Julie T Daniels, Cambrey et al., 2003; T. Wong, 2004; Jeng et al., 2006; Sounni et al., 
2010). Similarly, the use of ilomastat as a therapeutic agent has also been explored, for 
example as a treatment following mustard gas induced injuries (D. R. Anderson et al., 
2009; Mol et al., 2009), cisplatin-induced nephrotoxicity (Ramesh et al., 2002), as well 
as a treatment for various corneal injuries, with the only clinical trial of ilomastat to date 
exploring its effects in the treatment of corneal ulcers. However, following a phase II/III 
trial, despite showing potential clinical effectiveness, further work was abandoned 
following the buyout of the drug company running the trial, Glycomed (Glycomed, 1994; 
Ligand Pharmaceuticals Inc., 1995). Due to the roles of ilomastat, particularly in its 
direct modulation of collagen contraction, ilomastat was tested in-vivo following 
experimental GFS, where it was found that it could significantly prolong bleb survival, 
lower IOP and decrease the number of myofibroblasts present within the conjunctival 
tissue when compared to a control group (T. T. L. Wong et al., 2003). This initial 
investigation was followed by a larger study that produced similarly encouraging 
results, and importantly was shown to be at least as effective as MMC in prolonging 
bleb survival, with an added benefit of not inducing widespread cell death associated 
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with MMC (3.1.4) (T. T. L. Wong et al., 2005). Both studies were undertaken using 100 
µl injections of ilomastat delivered at its maximum aqueous solubility of 100 µM through 
subconjunctival injections. The treatment regimen involved the use of daily injections 
over the first nine days followed by twice weekly injections for two weeks and weekly 
injections for a further two weeks. However despite this dosing regimen failure occurred 
in 43% of blebs after 60 days. One explanation for this late failure was based upon the 
pharmacokinetics of the anterior segment of the eye which, as previously discussed 
(1.5.1.1), causes the rapid clearance of drug from the subconjunctival space); without a 
prolonged, near continuous, presence of ilomastat until the end of the wound healing 
cascade, a number of cells can continue to function in a fibrotic state and thus cause 
late surgical failure. Based upon the work described in Chapter 3, excipient free tablets 
containing ilomastat were created that could provide sustained release (in-vitro 
experimentation estimated the tablet could release the drug at concentration of 80 µM 
for up to 30 days) following subconjunctival implantation. The use of in-vivo studies 
demonstrated the potential of the ilomastat tablet, with 100% bleb survival after 30 
days post surgery compared to 25% in the MMC group, as well as a histological profile 
consistent with a healthy, functional, bleb showing no signs of any side effects (S. 
Georgoulas et al., 2008; S. D. Georgoulas, 2010). These results have led to the 
continued investigation and development of an ilomastat tablet, an aspect of which is 
presented in both this, and the subsequent, chapters. 
 
Figure 5.2 - The molecular structure of ilomastat (N^-[2R-2-(Hydroxamidocarbonymethyl)-4-
methylpentanoyl)]- L-tryptophan Methylamide). 
Image drawn using SketchEl based on the structure presented in the cited publication (R E Galardy, 
Cassabonne et al., 1994). 
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5.1.3 Biological effects of MMPs 
5.1.3.1 Cell proliferation and migration 
In order to successfully carry out the normal physiological processes that cells are 
involved in, such as wound healing and angiogenesis, cells must be able to migrate 
through the ECM surrounding them, with such events dependent on the remodelling of 
the matrix. For example, during angiogenesis the migration of endothelial cells is 
essential for both initial sprouting and later vessel development (4.1.1). Smooth muscle 
cells (SMC), which migrate into the damaged areas of arteries, were found to be reliant 
on MMP-9 for migration and subsequent repair. When MMP-9-/- mice were subject to 
an injury within their arteries it was found that SMC replication was significantly lower 
eight days after injury compared to the wild type, with SMC migration also significantly 
impaired. Similar effects were found when cells isolated from MMP-9-/- mice arteries 
were cultured in-vitro (Cho et al., 2002). Furthermore, SMCs have been shown to 
upregulate MMP-1 following the use of an in-vitro model of vascular damage, with the 
upregulation associated with an increase in ERK1/2 phosphorylation; upon the addition 
of an ERK inhibitor both SMC migration and MMP-1 expression were completely 
abolished (Shi et al., 2010). 
5.1.3.2 Cell death 
Both MMPs and TIMPs have been implicated in the regulation of the cell cycle and cell 
death, with Conant and colleagues demonstrating that neurons expressing the α2-β1 
integrin could enter an apoptotic cascade through the formation of a complex between 
the α2-β1 and pro-MMP-1; upon formation of the complex, a dephosphorylation of Akt 
was observed followed by caspase activation (3.1.1.1) (Mccawley et al., 2001; Conant 
et al., 2004). Similarly, Schedin and colleagues found that fibronectin fragments were 
able to induce MMP activity leading to cell death, thought to be mediated through the 
Fas signalling cascade, with the broad spectrum MMP inhibitor, BB-24, able to reverse 
this effect (Schedin et al., 2000). Menon and colleagues demonstrated that MMP-2 
expression is implicated in the apoptosis of rat ventricular monocytes, whereby 
stimulation of the β-adrenergic receptors, which normally activates the apoptotic 
cascade, also brings about an increase in MMP-2 expression which is thought to 
mediate the apoptotic cascade through interactions with integrins, in particular β-1 
integrin, disrupting pro-survival signalling pathways. Treatment of the cells with 
ilomastat was able to prevent β-adrenergic receptor mediated apoptosis (Menon et al., 
2005). However, conflicting data does exist: whilst MMPs have been implicated in 
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directly regulating apoptosis, data has also shown that the MMPs can function as anti-
apoptotic proteins. For example, Cowan and colleagues showed that through the use of 
GM6001, whilst a markedly reduced amount of Tenascin C was observed, the 
induction of widespread apoptosis was also seen (assessed using the TUNEL assay) 
in a rat pulmonary artery organ culture; similar effects were found in cell culture, 
whereby the application of ilomastat led to the induction in cell death of smooth muscle 
cells with approximately 50% cell loss observed over 48 hours (Cowan et al., 2000). 
Similarly, other synthetic MMP inhibitors have been demonstrated to be pro-apoptotic 
with Daniel and colleagues able to demonstrate that the use of the MMP inhibitor BB-
1101 was able to induce cell cycle arrest and apoptosis in a model of experimental 
glomerulonephritis, with similar effects seen when batimastat was used in models of 
ovarian cancer (Erba et al., 1999; Daniel et al., 2001). 
5.1.3.3 MMPs in the eye 
The MMPs play a number of critical roles within the eye both during development, 
normal physiology and pathological conditions. The role of the MMPs, as well as other 
proteases, have been implicated within many of the major structural components of the 
eye including the lens, where MMPs are highly involved in cataract formation; the 
retina, where during development the MMPs play a critical role during retinal axon 
guidance, as well as during the neovascularisation that occurs during AMD (V. Lambert 
et al., 2003). Many of these roles are beyond the scope of this thesis but further 
information can be found within the published reviews of Michael Wride and Jeremy 
Sivak (Sivak et al., 2002; Wride et al., 2006). Nonetheless this some of the roles of 
MMPs within the development of glaucoma are discussed below. 
5.1.3.3.1 Glaucoma and MMPs 
The presence of matrix metalloproteinases (MMPs) within the trabecular meshwork is 
known to be critical in the regulation of TM outflow channels (1.1.4). Stretch-induced 
stress has been documented to regulate MMP expression with both MMP-2 and MT1-
MMP having been shown to be upregulated and TIMP-2 downregulated; such 
mechanical changes are known to occur within the TM as the increased pressure 
within the AC, often associated with glaucoma, causes an increase the stress on TM 
cells (Okada et al., 1998; Bradley et al., 2001). Following the application of cytokines, 
such as TNF-α and IL-1 changes in MMP expression with TM cells cultured in-vitro 
were also seen, characterised by the upregulation of MMP-1, -3, -9 and TIMP-1 
together with a further downregulation of TIMP-2; however since these publications it 
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has been demonstrated, in a single study, that the only interleukin significantly 
upregulated within the aqueous of glaucomatous eyes was IL-8 [the elevated presence 
of IL-6 was also detected, although quantification did not find the elevation to be 
significant; similarly no increases in TNF-α or Interferon-gamma (IFN-gamma) were 
found] (J P Alexander et al., 2001; Pang et al., 2003; Kuchtey et al., 2010). Despite 
this, the levels of TNF-α are known to be highly upregulated during the inflammatory 
response following treatments such as SLT and incision surgery, and as such research 
has continued with Alexander and colleagues showing that TNF-α induced upregulation 
of the MMPs can be ablated through the use of MAPK (ERK) antagonists (J Preston 
Alexander et al., 2003). However pathways not involving the Mek/Erk cascade are also 
involved in MMP activation within the TM, such as PKC, with its inhibition shown to be 
able to decrease MMP/TIMP expression following the exposure of TM cells to TNF-α (J 
P Alexander et al., 2001). In samples of aqueous humour collected from glaucoma 
patients undergoing surgery, significantly elevated levels of TIMP-2 were found to be 
present and despite MMP-2 being the most active gelatinase in the aqueous sampled, 
this could partly explain why a lack of type I collagen degradation was observed within 
the trabecular meshwork (a feature commonly associated with POAG patients) (Määttä 
et al., 2005). Whilst Weinstein and colleagues, also found an increase in MMP-2 levels 
in the aqueous humour of dogs, they failed to look at the TIMP levels and as such, 
despite a rise in MMP-2, it cannot be ruled out that an increase in TIMP-2 regulating 
MMP-2 activity could also be present as in the Määttä study (Weinstein et al., 2007). 
Similarly, Rönkkö reported that in immunohistochemical staining of MMPs and TIMPS 
within the chamber angle of both normal and POAG patients, MMP-1 and MMP-3 
staining was significantly greater in the POAG patients, with significantly more MMP-1 
present than it’s inhibitor, TIMP-1, although in aqueous samples from POAG patients, 
significantly increased levels of TIMP-1 were present than compared to the control 
group (Rönkkö et al., 2007). It is possible, that whilst the aqueous levels of TIMP-1 are 
elevated, within the actual tissue the levels are much lower than compared to the 
MMPs. Whilst no conclusive answers have yet been found, the role of ECM 
degradation via MMPs remains an important area of research, with MMP expression 
highly implicated in the morphological changes of the TM that underlie the 
pathogenesis of glaucoma. 
5.1.3.3.2 MMPs in ocular wound healing 
As previously discussed, the MMPs play critical roles during wound healing and are a 
major cause of the scarring response observed during the failure of GFS; however, as 
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has also been discussed, the modulation of these MMPs with inhibitors has been 
shown to be able to improve surgical success rates during in-vivo testing (5.1.2.4.1). 
Further discussion as to the exact roles of the MMPs within the wound healing process, 
such as following GFS are discussed in 6.1.1. 
5.1.4 Drug pharmacokinetics 
The labelling of compounds is vital in understanding the pharmacokinetics of a drug; 
knowing both the location and concentration is imperative to not only determining if the 
drug is functioning correctly, but whether it is accumulating in unpredicted sites leading 
to potential side effects (Meibohm, 2006). Many studies that analyze the bio-distribution 
of drugs use one of two markers: a) fluorescent probes or b) radiolabeling.  
5.1.4.1 Fluorescence 
The use of fluorescent labelling has become a popular choice when performing 
pharmacokinetic studies due to the ability to perform live imaging (Neyfakh, 1988). 
However many of the commercially available fluorophores are large molecules, with the 
smallest probes available (members of the coumarin family) having a molecular weight 
of around 300 g/mol (Invitrogen, 2010), and although carboxylic acids have been 
attached to coumarin-type reagents for analytical analysis, the impact on the 
compound within a biological situation is currently unknown (Gikas et al., 2003). The 
use of quantum dots has also become a favoured tool for the imaging of cellular 
targets, cells and drugs, with large protein antibodies proving an ideal candidate for 
quantum dot labelling. However the conjugation of a quantum dot with small molecules 
without affecting the efficacy of the drug is known to be difficult and as such is a 
significant obstacle that has yet to be overcome (A. M. Smith, Duan et al., 2008). 
Similarly whilst antibody based drugs can be detected in histological sections through 
the use of secondary antibodies (as in the detection of bevacizumab within the retina 
as undertaken by Heiduschka and colleagues), such an approach cannot be 
undertaken using small molecule inhibitors (Heiduschka et al., 2007). 
5.1.4.2 Radiolabeling 
Due to the difficulties in using fluorescence to label small molecules, radiolabeling is 
often the label of choice (Singhvi et al., 1985). Radiolabeling has been used in a 
number of ocular studies to determine drug distribution, including the use of 
radiolabeled 5-FU for the determination of the optimal delivery time of the drug during a 
trabeculectomy, as well as the use of tritiated bevasiranib [a VEGF-A small interfering 
RNA (siRNA)] to determine its ocular biodistribution following intravitreal injection (M. 
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Wilkins et al., 2005; Dejneka et al., 2008). Radiolabeling can be achieved through one 
of two ways: either the direct creation of the compound using a radiolabeled molecule 
[such as carbon-14 (14C)] or through the substitution of a radiolabeled molecule into an 
existing compound [such as tritium (3H)] (Voges et al., 2009). However the use of 
radiolabeled compounds is often prohibitive to investigators due to the high costs and 
time consuming processes involved in the generation of stable compounds as well as 
the specialist equipment required for downstream studies (Lappin et al., 2006).  
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5.2 Objectives and experimental design 
The wound healing response relies heavily on the interaction between the cells and the 
support structure surrounding them, the ECM (Agren et al., 2007). The ECM provides 
not only a foundation over which the cells can grow and migrate but also, through the 
fine tuning of the proteins expressed within the matrix, a way of regulating gene 
expression and protein production within those cells. As such cell behaviour is highly 
tuned based on a balance between matrix turnover and remodelling, which is achieved 
through the synthesis and degradation of the ECM (Schultz et al., 2009). For this 
balance be achieved a number of proteins are involved in the degradation of unwanted 
ECM components, with the matrix metalloproteinase (MMP) family one of the most 
important enzyme families involved in this process (Xue et al., 2006). Whilst essential 
in normal functioning, the MMPs have also been shown to be required in a number of 
diseases including the metastasis of cancerous tumours. Due to this, great emphasis 
was given to the development of MMP inhibitors (MMPis) as anticancer therapeutics 
(Overall et al., 2002) and recent work has demonstrated the potential use of MMP 
inhibitors as a method of modulating the wound healing process, with improved 
delivery methods strengthening their potential (T. T. L. Wong et al., 2005; S. 
Georgoulas et al., 2008; Ru, 2010).  
 
This chapter aims to build on the work of Wong, Ru and Georgoulas who have 
demonstrated that in-vivo the application of the MMP inhibitor, ilomastat, is effective in 
overcoming pathological tissue fibrosis and scarring when used in a model of GFS. In 
particular, the recent development of a slow release, excipient-free tablet (similar to 
those discussed in Chapter 3 and Chapter 4) was shown to be even more effective 
than repeat injections as first described by Wong  (T. T. L. Wong et al., 2005; S. 
Georgoulas et al., 2008; Ru, 2010).  
 
Whilst the effects of ilomastat have been well demonstrated in-vivo, little is known 
about its biological effects outside of MMP inhibition, either in-vitro or in-vivo, together 
with little knowledge existing as to the pharmacokinetics of the drug. 
  218 
On this basis the objectives of this chapter were: 
 
i. To assess whether ilomastat is able to inhibit fibroblast proliferation, fibroblast 
mediated collagen gel contraction, apoptosis, gene expression and protein 
production using proliferation assays, contraction assays, immunocytochemical 
analysis, PCR and ELISAs. 
 
ii. To investigate whether ilomastat is able to modulate the gene expression of 
multiple signalling pathways and whether these underlie findings from aim (i) 
such as proliferation and motility, through genome wide gene expression 
analysis of fibroblasts exposed to ilomastat.  
 
iii. To develop a method that could improve the sensitivity of ilomastat HPLC 
detection in order to allow the detection of ilomastat at low concentrations from 
within ocular tissues. 
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5.3 Results 
5.3.1 The effects of ilomastat on cells grown in monolayer 
5.3.1.1 The effects of ilomastat on HTF proliferation 
In order to understand the effects of ilomastat on HTF proliferation, HTFs were 
exposed to ilomastat for a predefined period of time before an assessment of the cell 
number was undertaken. Initial experiments were performed using manual cell counting 
whereby cells grown in six well plates were trypsinised at the required time point before 
being counted with a haemocytometer. The manual counting of cells indicated an 
inhibition in cell growth, with a significantly lower number of cells present after seven 
days growth in 100 µM ilomastat when compared to the control cells (p < 0.05). No 
statistically significant differences were observed between the 10 µM group and control 
cells (Figure 5.3). The morphological appearance of the HTFs also demonstrated this 
observation (as shown in Figure 5.4), with control cells (A) showing a typical fibroblast 
morphology of long, elongated cells tightly packed over the surface of the six well plate 
whilst the ilomastat treated cells displayed a broader, flattened morphology with large 
gaps present between populations of cells (C and D). However due to the inaccuracies 
that can be obtained in cell counting, proliferation of the HTFs were also assessed 
using the MTT assay, through comparison of the measured absorbance level of the 
solubilised MTT crystal. The results of these assays, as shown in Figure 5.5, with a 
significant reduced level of absorbance measured between the 100 µM group and the 
control cells (p < 0.01) three days after treatment; this trend continued in subsequent 
studies where proliferation was studied for up to seven days (Figure 5.6), at which point 
significant differences in absorbance were found between the control cells and cells 
treated with 100 µM of ilomastat. 
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Figure 5.3 - The number of cells present when grown as a monolayers in the presence / absence of 
ilomastat after 7 days of growth. 
HTF proliferation was investigated via the manual counting of cells grown in 6 well plates. A significantly 
lower number of cells were found when treated with 100 µM of ilomastat when compared to control cells. 
Error bars represent the SEM (n = 3). Data presented from a single experiment representative of triplicate 
repeats. Statistical comparisons were made using ANOVA and Bonferroni’s post test comparing all 
columns. * = p < 0.05. 
 
Figure 5.4 - The morphology of HTFs when grown as a monolayer in the presence / absence of 
ilomastat after 7 days of growth. 
Figure A shows control cells, with elongated cell bodies typical of a fibroblast, with tight packing of cells 
observed over the surface of the well. Figures B and C show ilomastat treated cells (10 and 100 µM 
respectively) with large gaps present between the populations of cells. Scale bar represents 500 µm. 
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Figure 5.5 - The effects of ilomastat on HTF proliferation when grown in monolayer over 72 hours 
as assessed using the MTT assay. 
Significant differences were seen between the control cells and those treated with 100 µM of ilomastat (p < 
0.01) whereby a 30% reduction in absorbance was observed. Error bars represent the SEM (n = 6). Data 
presented from a single experiment representative of triplicate repeats. Statistical comparisons were made 
using ANOVA and Bonferroni’s post test comparing all columns. ** = p < 0.01. 
 
 
Figure 5.6 - The effects of ilomastat on HTF proliferation when grown in monolayer over 7 days as 
assessed using the MTT assay. 
Significant differences were seen between the control cells and those treated with 100 µM of ilomastat (p < 
0.01) where after 7 days 90% less absorbance was observed. Error bars represent the SEM (n = 6). Data 
presented from a single experiment representative of triplicate repeats. Statistical comparisons were made 
using ANOVA and Bonferroni’s post test comparing all columns. * = p < 0.05. 
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5.3.1.2 Immunocytochemical analysis of HTF proliferation and morphology 
A final assessment as to the effects of ilomastat on HTF proliferation was made using 
immunocytochemical analysis. Cells grown in monolayer on collagen coated glass 
chamber slides for 7 days were fixed and stained for Ki-67 and the DNA/nuclear 
marker DAPI, with whole well images obtained and analysed using ImageJ’s particle 
analysis plug-in to count the number of nuclei and the number of Ki67 positive cells. 
Figure 5.7 shows that following 7 days treatment with 100 µM ilomastat the number of 
nuclei stained positive for DAPI was significantly reduced (p < 0.001). The number of 
Ki67 positive cells were similar in both treated and untreated cells at around 25% of 
total nuclei (data not shown). Figure 5.8 provides an example of the images used to 
calculate these results with A and B showing control cells and C and D showing cells 
following treatment with 100 µM ilomastat for 7 days. 
The assessment of cellular morphology using phalloidin to stain the F-actin filaments of 
the cell revealed the markedly different morphologies in cells treated with ilomastat. As 
shown in Figure 5.9, cells grown in control conditions (as shown in images A, C and E) 
displayed the characteristic morphologies of fibroblasts, with long elongated processes 
exhibiting a broad cell body. Furthermore strong F-Actin staining was associated with 
both the cell membrane, as well as the intracellular fibres. However, cells treated with 
100 µm of ilomastat over a three day period exhibited markedly different morphologies 
(as shown in images B, D and F), with cells smaller and rounded. Those cells that did 
extend processes often had very thin, elongated, cell bodies, though as shown in figure 
F, many were characterised with a “growth-cone” like structure that was not observed 
within the control cells (Luo, 2000). 
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Figure 5.7 –DAPI staining of a representative control well as analysed in ImageJ in the 
quantification of cell proliferation.  
Images A and B are representative images that were used for particle analysis. DAPI staining is clearly 
reduced in the ilomastat treated well (B). Images are tiled scans composed of 5 x 5 images. Staining was 
repeated three times with these results representative of the repeats. 
Scale bar represents 100 µm. 
 
Figure 5.8 – The average cell count as determined using particle analysis of DAPI stained nuclei 
using ImageJ.  
A significantly lower number of cells were found when cells were cultured in 100 µM of ilomastat for seven 
days. Error bars represent the SEM (n = 3). Statistical comparisons were made using a Student’s t-test. *** 
= p < 0.0001. 
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Figure 5.9 – F-actin staining HTFs grown in monolayer after three days growth. 
Human tenon’s fibroblasts grown in monolayer were fixed and stained with F-actin after three days of 
growth in the absence or presence of 100 µM ilomastat. Figures A and B represent a 10x image; C and D 
represent a 40x image; E and F represent a 63x image. The cells grown in ilomastat were found to have a 
markedly different morphology, with smaller, rounded cells expressing less F-Actin than those grown under 
control conditions. Those cells that were elongated, as seen in F, were often very thin with a large growth-
cone like structure at the end of the fibroblast process. Staining was repeated three times with these 
results representative of the findings. Scale bars represent 200 µm in the 10x images, 100 µm in the 40x 
images and 50 µm in the 63x images.
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5.3.2 The effects of ilomastat in 3D matrix 
5.3.2.1 Collagen contraction 
The regulation of HTF mediated collagen contraction was assessed in the presence of 
varying concentrations of ilomastat. Fibroblasts were seeded into collagen gels and 
exposed to FGM supplemented with varying concentrations of ilomastat. The standard 
contraction profile obtained when using ilomastat is shown in Figure 5.10, with 100 µM 
of ilomastat typically allowing less than 30% total contraction over a seven day period, 
with significant differences in total contraction present at every time point (p < 0.001). 
However upon removal of the FGM it was found that contraction continued to remain 
inhibited (data not shown) and as such the reversibility of ilomastat was questioned. To 
explore this, cells were grown in six well plates and treated with control FGM or 
ilomastat supplemented FGM at a concentration of either 10 or 100 µM. After seven 
days of growth the cells were seeded into the collagen gels, which were fed with 
control FGM. The results, as shown in Figure 5.11, demonstrated that the fibroblasts 
previously treated with 100 µM of ilomastat were unable to contract the collagen gel to 
the same extent as either the control or 10 µM treated cells over a seven day period, 
with significant differences in the total percentage contraction found at every time point 
(p < 0.05 – p < 0.001). Observing the morphology of cells three days after growth within 
the gel (Figure 5.12) all cells appeared similar, although those in figures A and B 
(control and 10 µM) respectively showed increased development in their filopodia 
compared to the more rounded cells shown in figure C; seven days later the cells in the 
control and 10 µM group (Figure 5.13 A and B respectively) show elongated fibroblasts 
consistent with a contracting gel, whilst the cells pre-exposed to 100 µM ilomastat 
remained small and rounded, with only a small number showing an extension of their 
filopodia (Figure 5.13 C). After ~ 14 days contraction had resumed in all gels with an 
expected 80-90% total contraction observed by day 21. 
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Figure 5.10 – The effects of ilomastat on HTF mediated collagen gel contraction. 
HTFs seeded into collagen gels and exposed to either control FGM or FGM supplemented with ilomastat. 
Gels treated with ilomastat displayed an inhibited contractile profile compared to the control cells. Error 
bars represent the SEM (n = 5). Data presented from a single experiment representative of triplicate 
repeats. Statistical comparisons were made using ANOVA and Bonferroni’s post test comparing all 
columns. Both 10 µM and 100 µM were statistically significant at all timepoints when compared to the 
control (p < 0.001). 
 
Figure 5.11– The effects of pre-treating HTFs prior to collagen gel contraction. 
HTFs grown in six well plates for seven days in the presence or absence of ilomastat were transferred to 
collagen gels and fed with control FGM. The contractile profile was monitored over seven days, with 
significantly less contraction occurring in gels containing cells that had been pre-exposed to 100 µM of 
ilomastat. Error bars represent the SEM (n = 5). Data presented from a single experiment representative of 
triplicate repeats. Statistical comparisons were made using ANOVA and Bonferroni’s post test comparing 
all columns. * = p < 0.05; ** = p < 0.01; *** = p < 0.001. 
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Figure 5.12 - Morphology of cells within a gel three days after seeding.  
Cells had previously been exposed to control FGM (A), 10 µM ilomastat (B) or 100 µM ilomastat (C) for 
seven days. After 72 hours within the gel, the cells appeared similar in morphology although processes 
within A and B appeared longer with more rounded cells remaining in C.  All gels were grown in control 
FGM. Photographs representative of morphology observed in each of three experimental repeats (n = 5 
per repeat). Scale bar represents 500 µm. 
 
Figure 5.13 - Morphology of cells within a gel seven days after seeding.  
Cells had previously been exposed to control FGM (A), 10 µM ilomastat (B) or 100 µM ilomastat (C) for 
seven days. After seven days within the gel having been fed control FGM, the cells in pictures A and B 
show long fibroblast elongation associated with a contracting gel and the development of a myofibroblast. 
Cells within C remained small or rounded, typical of cells exposed to ilomastat. All gels were grown in 
control FGM. Photographs representative of morphology observed in each of three experimental repeats 
(n = 5 per repeat).Scale bar represents 500 µm. 
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5.3.2.2 TUNEL analysis 
Whilst it was shown that ilomastat could inhibit matrix contraction, as represented in 
Figure 5.10, it was not entirely clear whether the treatment of HTFs with ilomastat was 
leading to apoptosis whilst in the matrix, with a number of conflicting reports present in 
the literature describing both the pro- and anti-apoptotic effects of ilomastat (Cowan et 
al., 2000; Menon et al., 2005). In order to assess any potential cell death, the TUNEL 
assay was used to observe any DNA fragmentation, a sign of an apoptotic cell. Gels 
were analysed using confocal microscopy with Z-stacks created throughout the gel 
across different regions of the gel. Maximum intensity projections of the stacks were 
generated and assessed for TUNEL positive nuclei. Orthogonal sections were also 
created to assess overlap between any TUNEL positive staining and the DAPI stained 
nuclei. Cells within the positive controls (Figure 5.14) confirmed the staining of DNA 
fragmentation, where cells had been treated with DNase prior to staining. A clear 
overlap between the DAPI stained nuclei (blue) and the presence of DNA 
fragmentation (green) is seen in images A-D. The orthogonal slices (E and F) further 
demonstrate the overlap of the staining between of the fragmented DNA and the 
nucleus. Figure 5.15 shows an example of the control gels, which after 7 days had fully 
contracted and as such were highly compact. Phalloidin staining indicated the 
presence of fully developed fibroblasts with long, broad, elongated cell bodies. Only a 
small proportion of cells (~10%) were found to be TUNEL positive as would be 
expected in a healthy, contracting, gel. Figure 5.16 shows the ilomastat treated gels, 
where the cells are much more spaced out than in the control gel, as associated with a 
non-contracted gel. Cell morphology appeared very different from that of controls, with 
cells appearing largely small and rounded, though some small, thin projections were 
found. Nonetheless, little TUNEL staining was observed, with only small numbers of 
cells positive (similar in proportion to those in the control gels). 
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Figure 5.14 - TUNEL staining of the positive control gel (images A-F).  
Nuclei are stained with blue using DAPI (A) and DNA fragmentation is stained green (B). Cell cytoskeletal 
actin (F-actin) is stained red with phalloidin (C) with image D providing a merge of the three pictures. 
Images E and F have an orthogonal view of the staining showing clear overlap between the nuclei and 
staining for DNA fragmentation. The positive control shows that all nuclei stained positive for DNA 
fragmentation due to DNA disruption with DNase treatment. Staining was repeated three times with these 
results representative of the findings. Scale bar represents 100 µm. 
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Figure 5.15 - TUNEL staining of the control gel (images A-F).  
Nuclei are stained with blue using DAPI (A) and DNA fragmentation is stained green (B). Cell cytoskeletal 
actin (F-actin) is stained red with phalloidin (C) with image D providing a merge of the three pictures. 
Images E and F have an orthogonal view of the staining showing clear overlap between the nuclei and 
staining for DNA fragmentation. The control shows very limited staining for TUNEL positive nuclei, 
indicating a very low proportion of cell death in gels grown for seven days in FGM. Staining was repeated 
three times with these results representative of the findings. Scale bar represents 100 µm. 
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Figure 5.16 - TUNEL staining of gels grown for seven days in the presence of 100 µM of ilomastat 
(images A-F).  
Nuclei are stained with blue using DAPI (A) and DNA fragmentation is stained green (B). Cell cytoskeletal 
actin (F-actin) is stained red with phalloidin (C) with image D providing a merge of the three pictures. 
Images E and F have an orthogonal view of the staining showing clear overlap between the nuclei and 
staining for DNA fragmentation. As in the control, limited staining for TUNEL positive cells was found, with 
no more present than in the control. Staining was repeated three times with these results representative of 
the findings. Scale bar represents 100 µm. 
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5.3.2.3 Immunocytochemical analysis 
In order to visualise changes in protein expression, immunocytochemical analysis of 
HTFs grown in the presence of ilomastat was undertaken. Cells were grown on collage 
type I coated chamber slides for seven days in either control FGM or FGM 
supplemented with 100 µM.  
Firstly the levels of MMP-1 and IL-6 were assessed with Figure 5.17 showing the 
results of these experiments. Figures A and C show control cells at 10x and 40x 
magnification respectively, with figures B and D showing the ilomastat treated cells at 
the same, respective, magnifications. The staining for MMP-1 (red) was greatly 
reduced in the ilomastat treated cells, both intracellularly and within the matrix 
surrounding the cells, with both the cells and matrix in the control wells staining 
brightly. Il-6 (green) staining was also much more pronounced within the control cells, 
with clear staining present within the cell bodies in the control cells compared to only 
limited staining seen in the ilomastat treated cells. Figure D shows the sparse 
intracellular staining found within the ilomastat cells whilst staining within the control 
cells (figure B) characterises the intracellular staining of IL-6.The staining of MMP-2 
(red) and ASMA (green), as shown in Figure 5.18, highlights the limited changes that 
occurred in either protein. Similar levels of both proteins were found in the control (A 
and C) and ilomastat treated (B and D) cells. However within this the staining the 
altered morphology of ilomastat treated cells is further evident, with cells taking on a 
small, more compact morphology following ilomastat treatment compared to the broad, 
elongated, morphology of the control cells. The staining of Tenascin-C (red) and MMP-
9 (green) again showed somewhat limited differences between the control and 
ilomastat treated cells, although the nuclear staining of Tenascin C was far more 
pronounced in the control cells than in the ilomastat treated cells as indicated by the 
co-localisation of the DAPI positive nuclei and Tenascin C resulting in purple coloured 
nuclei in the control cells; limited co-localisation was observed in the ilomastat treated 
cells. 
The F-actin staining of fibroblasts within collagen gels is shown in Figure 5.20, where 
tiled (2 x 2) images were collected from both ilomastat and control treated gels. The 
control gels (A, B, C) shows cells with broad morphologies and elongated processes. 
The ilomastat cells (D, E, F), instead, display a compact cellular morphology, with only 
limited process formation in a stellate-like shape; fibroblasts that did extend processes 
instead took on a neuronal-like morphology, with very think processes attached to a 
central cell body. 
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Figure 5.17 – MMP-1 and IL-6 immunocytochemical staining of HTFs. 
Confocal images of HTFs grown in monolayer on collagen surface taken seven days after treatment with 
either control FGM or FGM supplemented with 100 µM ilomastat. Images A and B represent 10x 
magnification of the control and ilomastat treated cells respectively, with images C and D representing 40x 
magnification. MMP-1 (red) staining was seen in all cells, although less staining was observed in the 
ilomastat cells, with little MMP-1 staining found within the ECM of the ilomastat treated cells as otherwise 
seen in the control cells. Similarly, Il-6 (green) staining was greatly reduced in the ilomastat treated cells. 
Nuclei are stained with DAPI (blue).  
Scale bars represent 100 µm in the 10x images and 20 µm in the 40x images.
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Figure 5.18 – MMP-2 and ASMA immunocytochemical staining of HTFs. 
Confocal images of HTFs grown in monolayer on collagen surface taken seven days after treatment with 
either control FGM or FGM supplemented with 100 µM ilomastat. Images A and B represent 10x 
magnification of the control and ilomastat treated cells respectively, with images C and D representing 40x 
magnification. MMP-2 (red) staining was seen in all cells with similar staining intensities found in both the 
control and ilomastat treated cells, Similarly, ASMA (green) staining was largely the same in both the 
control and ilomastat cells. Despite this these images show the altered cellular morphology of the ilomastat 
treated cells with a smaller appearance than the elongated cells found in the control group. Nuclei are 
stained with DAPI (blue). Scale bars represent 100 µm in the 10x images and 20 µm in the 40x images.
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Figure 5.19 – Tenascin C and MMP-9 immunocytochemical staining of HTFs. 
Confocal images of HTFs grown in monolayer on collagen surface taken seven days after treatment with 
either control FGM or FGM supplemented with 100 µM ilomastat. Images A and B represent 10x 
magnification of the control and ilomastat treated cells respectively, with images C and D representing 40x 
magnification. Tenascin C (red) staining was seen in all cells with similar staining intensities found in both 
the control and ilomastat treated cells; clear nuclear staining was observed in both cells groups, with 
colocalisation observed with the DAPI stained nuclei (blue), MMP-9 (green) staining was sparse in both 
cell types although slightly more staining was observed in the ilomastat treated cells. Nuclei are stained 
with DAPI (blue). Scale bars represent 100 µm in the 10x images and 20 µm in the 40x images.
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Figure 5.20 - F-Actin immunocytochemical staining of HTFs in 3D collagen gels. 
Confocal images (10x magnification, 2 x 2 tile) of HTFs grown in a 3D collagen matrix taken seven days 
after growth in either control FGM [A (DAPI), B (F-Actin), C (Merge)] or ilomastat supplemented FGM [D 
(DAPI), E (F-Actin), F (Merge)]. F-Actin (green) shows the difference in cell morphology between the 
control cells and the ilomastat treated cells; control cells appeared elongated, with broad cell bodies and 
due to the contraction that had occurred were tightly packed together. The ilomastat treated gels were 
meanwhile dispersed throughout the gel displaying either rounded cell bodies or very thin, neuronal-like, 
processes. Nuclei are stained with DAPI (blue). Scale bars represent 200 µm. 
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5.3.2.4 Angiogenesis 3D co-culture 
Using the 3D co-culture, the anti-angiogenic effects of ilomastat were explored when 
compared to control and bevacizumab treated cells. Cells were grown for up to ten 
days in EGM-2 with supplementation of either bevacizumab (939.6 nM) or ilomastat at 
concentrations of 10 µM and 100 µM. The HUVECs used for this study were marked 
with CellTracker™ Red CMTPX to provide added visualisation of the cells during 
analysis, with Figure 5.21 showing the state of angiogenesis at five days into the study. 
Figure 5.22 shows the average branch length for the vessels in each treatment group, 
with Figure 5.23 and Figure 5.24 showing the number of branches per bead and the 
longest branch found in the analysed beads respectively. Figure 5.21A shows the 
control treated cells with large vessels having formed together with multiple branching 
around the beads. Average branch length was found to be 46.95 pixels with an 
average 14 branches per bead. The longest branch found from beads analysed was 
147.16 pixels in length. Figure 5.21B shows cells treated with bevacizumab, which 
produced only limited sprouting and no clear vessel development. Average branch 
length was found to be significantly smaller than the control (p < 0.001) at only 24.47 
pixels in length. The number of branches were also fewer with a 67.86% decrease. 
Cells remained on the beads with only limited growth into the matrix. Figures C and D 
show ilomastat treated HUVECS, with C showing 10 µM treated cells and D showing 
100 µM treated cells. In both groups a reduction in number of branches was found (4.5 
and 2.5 respectively compared to 14 per bead in the control), with average branch 
length significantly reduced in both groups (p < 0.001). Average branch length in both 
ilomastat treated groups was 72% lower than in the control. 
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Figure 5.21 – The inhibition of tube formation using ilomastat.  
Cells are red due to the presence of a cell tracker within the cells. Image A shows the control cells after 5 
days growth with multiple branches and long vessel development. Figure B shows cells grown in the 
presence of bevacizumab (939.6 nM), with angiogenesis occurring though it is greatly reduced compare to 
the control. Figures C and D show cells grown in the presence of 10 and 100 µM of ilomastat respectively, 
with only very limited sprouting occurring around these beads and no signs of vessel formation. Scale bar 
represents 100 µm. 
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Figure 5.22 – The average branch length for vessel formation at day five post seeding.  
Significant differences were seen between control and bevacizumab and both ilomastat groups (p < 
0.001). Error bars represent SEM (5 beads counted per experiment, 3 repeats of each experiment). *** = 
significant differences between groups (ANOVA, p < 0.001). 
 
 
Figure 5.23 - The number of branches present in each treatment group at day five post seeding.  
No significant differences were seen between any of the groups. Error bars represent SEM (5 beads 
counted per experiment, 3 repeats of each experiment). *** = significant differences between groups 
(ANOVA, p < 0.001). 
 
 
Figure 5.24 – The longest branch found in each treatment group.  
The longest branch length was found in the control samples with bevacizumab treated and ilomastat 
treated cells all having similar longest branch length. Error bars represent SEM (5 beads counted per 
experiment, 3 repeats of each experiment). *** = significant differences between groups (ANOVA, p < 
0.001). 
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5.3.3 Microarray analysis of HTFs following ilomastat treatment 
In order to ascertain the genes affected by ilomastat on a whole genome level, global 
gene expression analysis was carried out on HTFs exposed to 100 µM of ilomastat for 
72 hours. Using the Affymetrix Human Gene ST 1.0 GeneChip (2.11.1), the changes in 
gene expression induced by ilomastat treatment were obtained; to further extend this 
analysis, downstream pathway analysis was undertaken. 
5.3.3.1 Quality control results 
Following hybridisation and scanning, microarrays underwent a series of quality control 
checks, as previously described (2.11.1.3), with all quality control (QC) undertaken 
using Bioconductor and the software package AffylmGui. For the QC work the 
individual samples were relabelled as shown in Table 5.4. 
 
Chip Name Condition 
G305_1.CEL Treated1 Treated 
G305_2.CEL Treated2 Treated 
G305_3.CEL Treated3 Treated 
G305_4.CEL Control1 Control 
G305_5.CEL Control2 Control 
G305_6.CEL Control3 Control 
Table 5.4 – The sample names for microarray analysis of HTFs grown in-vitro with or without 
ilomastat treatment. 
Expression values underwent normalisation, using RMA, and box-plots of the raw and 
normalised data were generated showing the median and interquartile ranges. The 
figures for this section are found within the appendix The intensity within the two 
groups was of a high quality match, with normalisation only further strengthening the 
data by providing the samples with similar inter-quartile ranges and medians (Appendix 
Figure 9.3A). The intensity distribution graph (Appendix Figure 9.3B) shows the density 
of the probe intensities. Samples showed high levels of overlap between each array. 
The MA plots (Appendix Figure 9.3C and D) were plotted to assess the reproducibility 
of biological replicates providing an indication of whether to expect large differences in 
gene expression between the samples within each group. The graph is composed of 
the y-axis, representing the M-value (log2 fold change between the intensity value of 
each probeset from each chip of the two samples plotted), with the x-axis representing 
  241 
the A values, or the average intensity of each probe-set across the chips as obtained 
during normalisation. The plots showed symmetry around the x-axis with the loess lines 
(red on the graphs) not deviating significantly from the x-axis. Furthermore, at high log 
intensities the points are close to the x-axis, indicating good agreement between the 
biological replicates (Yee Hwa Yang et al., 2002). As most samples from within the 
same group should have similar gene expression profiles most genes should lie around 
0 (no change in gene expression). As the signal intensity decreases, increased values 
for M are to be expected as variation in intensity has a much greater effect on the M 
value. Outliers are further expected due to the number of data points that are being 
investigated. 
The control probe-set analysis (Figure 9.4) indicated that all samples hybridised 
correctly to the chip with the built in biological controls producing no errors. All arrays 
had similar positive and negative control signal values and the area under the curve fell 
between the 0.8 and 1 range demonstrating a good separation between positive and 
negative controls (Figure 9.4A). Bac and poly-A control probe-sets (Figure 9.4B and C) 
had a similar value across the samples and displayed the expected rank order (2.11.1).  
The correlation plot showing the heat map of the array-array Spearman rank correlation 
coefficients (Figure 9.5) demonstrated that all samples were highly correlated, with no 
outliers detected within the data sets. 
5.3.3.2 Summary of expression changes 
As all six arrays passed the required quality control checks, differential expression 
between the two groups was examined. Genes were considered differentially 
expressed between the two groups if there was a fold change greater than 1.5 with a 
FDR corrected p value of ≤ 0.05. The volcano plot (Figure 9.6) graphically highlights in 
red those genes fulfilling this criteria with fold change shown on the x-axis and the log p 
value shown on the y-axis. The total breakdown of differential expression found a total 
of 1180 genes having a p value ≤ 0.05 and of those 753 were downregulated (63.9%) 
and 427 upregulated (36.1%) in the treated samples compared to the control. When a 
fold change cut off of 1.5 was applied, 136 (32.3%) genes were found to be 
upregulated and 285 (67.7) downregulated. The entire set of genes with differential 
gene expression is shown in appendix 9.2. 
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Gene Title Gene Symbol Fold Change P Value 
FK506 binding protein 5 /// hypothetical 
LOC285847 
FKBP5 /// 
LOC285847 5.05 1.88E-05 
Family with sequence similarity 105, 
member A FAM105A 3.85 0.000744912 
Zinc finger and BTB domain containing 
16 ZBTB16 3.81 0.000131284 
KIAA0746 protein KIAA0746 3.09 0.000116142 
TSC22 domain family, member 3 TSC22D3 3.02 0.000104768 
Neuronal cell adhesion molecule NRCAM 3 0.0007054 
Ectonucleotide 
pyrophosphatase/phosphodiesterase 2 ENPP2 2.91 0.000116142 
ATP-binding cassette, sub-family C 
(CFTR/MRP), member 3 ABCC3 2.71 0.000133452 
Fraser syndrome 1 FRAS1 2.62 0.00029261 
Angiopoietin 1 ANGPT1 2.56 0.001547833 
Table 5.5 - The top 10 genes upregulated in HTFs following exposure to 100 µM ilomastat for 72 
hours. 
 
 
 
 
 
Gene Title Gene Symbol Fold Change P Value 
Wingless-type MMTV integration site 
family member 2 WNT2 -4.44 0.001506146 
Cellular retinoic acid binding protein 2 CRABP2 -4.35 3.06E-05 
Tenascin C TNC -4.26 3.06E-05 
Matrix metallopeptidase 1 (interstitial 
collagenase) MMP-1 -3.98 3.19E-05 
RAS guanyl releasing protein 1 (calcium 
and DAG-regulated) RASGRP1 -3.63 0.000153732 
RAS guanyl releasing protein 3 (calcium 
and DAG-regulated) RASGRP3 -3.59 0.000115124 
MSTP131 MST131 -3.58 0.000116142 
ATP-binding cassette, sub-family C 
(CFTR/MRP), member 9 ABCC9 -3.47 3.06E-05 
Keratin 19 KRT19 -3.43 0.000229641 
Brain expressed, X-linked 1 BEX1 -3.38 0.000141633 
Table 5.6 - The top 10 genes downregulated in HTFs following exposure to 100 µM ilomastat for 72 
hours 
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Figure 5.25 – IPA functional classification of genes altered following HTF treatment with 100 µM ilomastat.  
The top 20, statistically significant, functional groups containing genes identified as meeting the cut-off criteria (FC ± 1.5, p < 0.05). Groups are ranked according to p value 
significance with the p value threshold (0.05) shown via the yellow line. The groupings indicate that ilomastat has affected a number of genes involved in cell proliferation and 
death, together with cell growth, and movement. 
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Figure 5.26 – IPA canonical pathway analysis of genes altered following HTF treatment with 100 µM ilomastat. 
Pathways are ranked by ratio (secondary x-axis), which represents the total number of molecules in a given pathway. Pathways are ranked according to p value significance 
with the p value threshold (0.05) shown via the yellow line. The top pathways were largely associated with signalling responses, including the IL-6 and IL-10 signalling 
pathways, as well as the hepatic fibrosis signalling pathway. 
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5.3.3.3 Functional pathway analysis 
Data analysis of the gene expression changes in cells treated for three days with 100 
µM of ilomastat was undertaken using both DAVID and IPA. The top 10 differentially 
expressed genes following HTF exposure are shown in Table 5.5 and Table 5.6 
(upregulated and downregulated respectively).  
The genes within these lists highlighted some of the initial direct effects of inhibiting 
MMP function, such as the downregulation of MMP-1, Tenascin C and members of the 
Ras signalling pathway such as RASGRP1 and RASGRP3, which are critical to the 
regulation of various signalling cascades including MAPK and PKC. For example, 
Teixeira and colleagues were able to demonstrate that for correct functioning of 
diacylglycerol (DAG) a phosphorylation of RasGRP3 must occur which is mediated by 
PKC. In fibroblasts, DAG has previously been shown to be involved in the regulation of 
growth factor induced growth and proliferation (Bagnato et al., 2003; Teixeira et al., 
2003). Of the genes upregulated, assigning a reason on an individual basis was 
difficult, but the upregulation of neuronal cell adhesion molecule (N-CAM) is 
highlighted; whilst N-CAM is more usually associated with neuronal cells, although 
fibroblasts that proliferate in denervated areas known to express N-CAM (Gatchalian et 
al., 1989).  
Nonetheless, in order to gain further understanding of the genes in biological 
processes, functional classification was carried out in order to group genes based upon 
the gene ontology of a single gene; this was undertaken using both DAVID and the 
software package (IPA) (see 2.11.3 for more details). For a gene to be included in a 
grouping, the cut-off criteria of a fold change ±1.5 and a p-value less than 0.05 was 
applied with each group subject to a right tailed fisher’s exact t-test to determine 
whether the group was statistically relevant. 
The functional grouping, as shown in Figure 5.25, sorted genes into functions largely 
associated with cellular growth, proliferation, movement and death, with both IPA and 
DAVID complementing one another in their findings. A further function of IPA is to 
classify genes into known pathways, and the top 20 are shown in Figure 5.26, where 
the primary y axis represents the ratio of genes affected by ilomastat compared to the 
total number within the known pathway; the secondary y axis represents the -log(p 
value) and the x-axis providing the name of each group. However the data can be 
skewed to some extent based on the size of the pathway; for example the top hit, 
“airway pathology in chronic obstructive pulmonary disease” contains only 9 genes and 
of these only MMP-1 was effected, however this resulted in a ratio of 0.111 making it 
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the most affected pathway. Despite this, those pathways that were highly effected 
included IL-6 and IL-10 signalling. Ingenuity pathway analysis is also able to group 
collections of molecules into networks based upon known interactions generated from a 
database of published literature. In total 25 networks were generated, of which 22 had 
an IPA score of greater than three. The top 5 networks are shown in Figure 5.27, 
Figure 5.28 and Figure 5.29, with the remaining 19 listed within in appendix 9.3. 
 
The first network, Figure 5.27(1), is centred on three primary nodes consisting of the 
NF-κB complex, cytokeratin and FGF1; of these, both FGF1 and cytokeratin were 
found to be significantly downregulated. Fibroblast Growth Factor 1 is a growth factor 
known to stimulate fibroblast proliferation and migration, with members of the 
cytokeratin family involved in cell structure, although keratin expression is more 
normally associated with epithelial tissue where they have become markers for a 
number of tumours, including breast and lung cancer (Moll, 1994; Linder, 2007). Of 
further note within this pathway is the downregulation of FGF5, a growth factor that 
works in similar ways to FGF1, the downregulation of the inflammatory cytokine IL-32, 
as well as the upregulation of TGF-β2 and ADAMTS-9. 
 
The second network, Figure 5.27(2), was a network created of proteins highly involved 
in cellular development, assembly and organisation, with nodes cantered around MMP-
1, which was significantly downregulated, as well as EGF, which whilst was unaltered 
on the microarray, saw several proteins that it is known to normally upregulate or 
interact with also become downregulated, including RASGRP3, a modulator of the Ras 
mediated PLCgamma signalling pathway which is known to regulate cell proliferation, 
and S100A4, a calcium binding protein that is involved in a wide range of cellular 
processes including growth, signalling and movement and has been demonstrated to 
be highly upregulated following corneal injury where widespread expression was seen 
in corneal fibroblasts (although its function is though to be in stimulating post-wounding 
apoptosis in the fibroblasts), as well as in synovial fibroblasts, where S100A4 was 
demonstrated to trigger the upregulation of MMP-1, -3, -9 and -13 required for joint 
destruction associated with arthritis (Bagnato et al., 2003; Ryan et al., 2003; Teixeira et 
al., 2003). Of the genes upregulated, EFEMP1 is a member of the fibulin family, which 
is known to bind and activate the EGF receptor, though EGF like repeats (similar to 
those found in Tenascin C) and a C-terminus fibulin-like-domain (Camaj et al., 2009).  
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Network 3 [Figure 5.28(3)] is predominantly cantered around PLC gamma and ERK, 
which whilst not directly altered, various proteins which activate and regulate these 
signalling pathways are, including FGF. Interestingly VEGF is centred within this 
network and whilst not being directly affected has a number of genes it regulates, or is 
regulated by, affected. These include CCRL1, a chemokine receptor; ITGB8, an 
integrin involved in vascular morphogenesis (with knockout mice leading to embryonic 
termination) (Zhu et al., 2002) as well as regulation of the Rac signalling cascade 
(Lakhe-Reddy et al., 2006).  
 
Network 4, Figure 5.28(4), contains a number of molecules involved in the inflammatory 
signalling response, in particular IL-6, which acts as a central node, together with 
ICAM1 and FSH, although FSH is unaltered within the data set. Interleukin-6 is known 
to directly regulate MMP-1 expression, and the downregulation of this protein presents 
a mechanism by which MMP-1 expression may be modulated during ilomastat 
treatment. Whilst this network is relatively small, it is one of the more interesting 
networks with downregulation of TK1 which encodes thymidine kinase 1, a key protein 
involved in the cell cycle (3.1.1) (N. Wang, He et al., 2001); ACTG2, otherwise known 
as actin-gamma 2, a monomeric component of F-Actin (Schoenenberger et al., 1999); 
ACTA2, the gene encoding α smooth muscle actin and RASSF2, a regulator of the 
tumour suppressor protein PAR-4 (Vos et al., 2003; Donninger et al., 2010). 
Interestingly, the gene ENPP2, which encodes the protein Autotaxin (ATX), was 
upregulated with Autotaxin a known mediator of uPA activity as well as an inducer of 
lysophosphatidic acid synthesis (LPA), which has been shown to induce MMP 
expression and pro-MMP activation (Fishman et al., 2001; Haga et al., 2009). Such 
effects are particularly important during cancer cell invasion where it also promotes cell 
motility (Kishi et al., 2006) and is required for blood vessel formation, though this is 
thought to be dependent on the initial expression of ATX, as ATX knockout mice die at 
e10.5 dure to a lack of blood vessel formation (M. Tanaka et al., 2006; Okudaira et al., 
2010). 
 
Network 5, Figure 5.29, represents a set of genes implicated in cellular movement, with 
ERK and IGF central to this pathway. Two IGF binding proteins (IGFBP3 and IGFBP5), 
which function to sequester IGF within the ECM preventing its interactions with IGF 
receptors, are shown to be downregulated; both of these proteins are known to be 
cleaved by MMP-1 allowing the release of otherwise inactive cytokines (Fowlkes et al., 
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1999). Similarly, semaphorin 3A (Sema3A) (4.1.1) is highly downregulated, which in 
corneal fibroblasts has been shown to be upregulated in response to EGF in culture, as 
well as following wounding in-vivo, although the exact function is unknown (Ko et al., 
2008; Morishige et al., 2010). This network also highlights the downregulation of the 
ECM protein, Tenascin C, a known regulator of MMP-1 expression through the MAPK 
pathway (Galoian et al., 2007). 
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Figure 5.27 - Significant signalling networks mapped using the differential gene expression found 
following HTF exposure to ilomastat in-vitro. 
Associated functions with the genes within the networks included: Network 1: Cell Death and cellular 
assembly and organisation; Network 2: Cellular development and cell death. 
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Figure 5.28 – Significant signalling networks mapped using the differential gene expression found 
following HTF exposure to ilomastat in-vitro. 
Associated functions with the genes within the networks included: Network 3: Cellular development; 
Network 4: Lipid metabolism and molecular transport. 
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Figure 5.29 - Significant signalling networks mapped using the differential gene expression found 
following HTF exposure to ilomastat in-vitro. 
Associated functions with the genes within the networks included: Network 5: Cellular growth and 
proliferation.
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5.3.3.4 RT-PCR analysis of HTF MMP gene expression 
To assess the effects of ilomastat on HTFs in-vitro, HTFs were exposed to either 10 or 
100 µM of ilomastat for either three or seven days. Cells were grown in six well plates 
until sufficient confluency was observed.  The cells were then treated and allowed to 
grow for either three or seven days followed by RNA isolation and the investigation of 
the gene expression of selective MMPs and TIMPs via RT-PCR.  
Confirming the microarray results, little difference in MMP expression was observed at 
day three, although a significant downregulation in MMP-1 expression was observed. 
Whilst MMP-3, MMP-7 and MMP-12 were downregulated based on band densitometry, 
no statistically different findings were observed. Results from the PCR array analysing 
ECM-related genes showed a similar trend, but confirmed the downregulation of 
several MMPs including MMP1, MMP3, MMP7 and MMP12.  However at day seven 
continued MMP-1 downregulation was observed, in both the 10 µM and 100 µM 
concentration groups, with MMP-9 also downregulated at this timepoint. At day seven a 
significant upregulation in MMP-7 expression was also found, and whilst at day three 
MMP-7 had shown a small, but non-significant, upregulation, at day seven this was far 
more pronounced. A downregulation of TIMP-1 was also observed at this timepoint, 
though no statistically significant differences were observed. At neither day 3 nor day 7 
was the presence of MMP-13 detected (in either control or ilomastat treated cells) and 
as such is not represented in the graphs. 
5.3.3.5 ELISA analysis of HTF MMP and cytokine production 
To assess the effects of ilomastat on HTF-mediated MMP production in-vitro, HTFs 
were exposed to 100 µM of ilomastat for three days before the media was collected 
and analysed via ELISAs. Confirming both the microarray and PCR results, a 
significant reduction in MMP-1 production was observed (p < 0.01), with small, but 
significant, decrease in the level of MMP-2 (p < 0.05) secretion also observed; both 
MMP-9 and TIMP-1 unaltered following ilomastat treatment (Figure 5.34. Similarly, a 
significant reduction in IL-6 secretion from HTFs was also observed following ilomastat 
treatment (p < 0.01, Figure 5.35). 
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Figure 5.30 – The effects of ilomastat on HTF gene expression after three days exposure. 
A significant downregulation was seen in MMP-1 gene expression following three days exposure to ilomastat. No differences in gene expression were otherwise found to be 
statistically significant. Bars normalised to control samples with band density normalised to 1 for control samples. Error bars represent SEM (n=3). Statistical comparisons were 
made using ANOVA and Bonferroni’s post test comparing all columns. * = p < 0.05. 
 
Figure 5.31 – The effects of ilomastat on HTF gene expression after seven days exposure. 
A significant downregulation was seen in MMP-1 gene expression following seven days exposure to ilomastat, as well as a significant upregulation of MMP-7 following 10 µM 
treatment. No differences in gene expression were otherwise found to be statistically significant. Bars normalised to control samples with band density normalised to 1 for 
control samples. Error bars represent SEM (n=3). Statistical comparisons were made using ANOVA and Bonferroni’s post test comparing all columns. * = p < 0.05.
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Figure 5.32 - Agarose gels for gene expression in HTFs three days after ilomastat exposure. 
 
 
 
Figure 5.33 - Agarose gels for gene expression analysis in HTFs seven days after ilomastat 
exposure. 
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Figure 5.34 – The effects of ilomastat on MMP and TIMP production in-vitro. 
A significant reduction in the levels of both MMP-1 and MMP-2 were found in the media of samples 
collected following 72 hours of treatment with 100 µM ilomastat. Error bars represent SEM (n=3). 
Statistical comparisons were made using ANOVA and Bonferroni’s post test comparing all columns. * = p < 
0.05. 
 
 
Figure 5.35 - The effects of ilomastat on IL-6 production in-vitro. 
A significant reduction in the level of IL-6 was observed following treatment with 100 µM ilomastat over a 
72 hour period. Error bars represent SEM (n=3). Statistical comparisons were made using ANOVA and 
Bonferroni’s post test comparing all columns. ** = p < 0.01. 
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5.3.4 The pharmacokinetics of ilomastat: The development of a method to 
allow detection within tissue 
5.3.4.1 Increasing the sensitivity of the HPLC method 
Building upon the previously described HPLC method (2.6.2), a number of variables 
were altered with the aim of improving the detection of ilomastat. Firstly the injection 
volume was increased from 10 to 100 µl such that the amount of ilomastat within a 
single injection, and subsequently entering the column, would be increased. With the 
increased injection volume an increased flow rate was used, 1.2 ml/min, with the aim of 
minimising any broadening of the peak that would have occurred had the initial flow 
rate been used. These small, but significant changes, led to the detection limit 
increasing from 5 µM to 100 nM, with Figure 5.36 showing the calibration curve 
developed for the new method, with the lowest detected peak area of 2.7 equating to a 
concentration of 97.66 nM. 
5.3.4.2 Tissue digestion 
To determine the ilomastat concentration within ocular tissues, the extraction method 
required careful refining to ensure several conditions were met. Firstly, the tissue had 
to be well digested with all tissues (including the fibrous regions) broken down as fully 
as possible. Secondly, the method of digestion had to be demonstrated to not have an 
effect on the integrity of ilomastat; and thirdly that the method of digestion did not 
involve the use of reagents that would overlap with the ilomastat peak on an HPLC 
chromatogram. As such several methods were trialled including a range of chemical, 
biological and mechanical methods with a summary presented in Table 5.7. A range of 
tissues were used during these trials, obtained from dissected rabbit eyes, including 
the cornea, lens, conjunctiva, iris, sclera, muscle and vitreous. Whilst several methods 
provided excellent homogenisation (such as following the use of TRIZOL and 
proteinase K), a significant degradation of ilomastat was observed following HPLC 
testing. Overall, the use of collagenase D proved to provide optimal digestion without 
affecting the integrity of ilomastat, and as such was chosen as the final digestion tool. 
In brief, tissue was washed in PBS before being placed into 1 ml collagenase D at a 
concentration of 2 mg/ml (all within a 15 ml FACS tube). The tubes were placed into a 
shaking incubator set at 300 RPM and a temperature of 37°c. Samples were checked 
every six to twelve hours; with all samples found to have digested within 48 hours. 
Samples were then passed through a 29 G needle to further disrupt any potential 
fragments.  
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5.3.4.3 The use of an internal standard  
During the extraction process, an internal standard is typically used to correct for the 
loss of any target compound during the sample preparation prior to detection. To this 
end the internal standard must share a number of common similarities with the target 
compound, including a similar molecular weight and structure. Using several 
databases, including PubChem, ChemSpider and SciFinder, the only commercially 
available compound with properties similar to ilomastat was Leu-Trp, although unlike 
ilomastat, Leu-Trp was found to be insoluble in either water or the HPLC mobile phase, 
but could be solubilised in DMSO. Despite this, upon mixing ilomastat and Leu-Trp it 
was found that ilomastat overlaid with an impurity of Leu-Trp in HPLC chromatograms 
(Figure 5.37 and Figure 5.38 and whilst alternative gradient methods could not 
separate the peaks, it was found that through the use of an isocratic method peak 
separation could be achieved (Figure 5.39). 
 
 
Figure 5.36 – The calibration curve developed during the optimisation of ilomastat HPLC detection. 
The lowest detected peak area (2.7) equated to a concentration of 97.66 nM. The r2 for the graph was 
0.99999. 
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Mechanism of 
Homogenisation Extra Products Used Positive Results Negative results 
Acid/Base   Led to the degradation of ilomastat 
Laemelli Buffer  Inexpensive reagent Led to little degradation unless used in conjunction with mechanical degradation 
Homogenise directly 
Laemelli Buffer Mortar and Pestle 
Liquid Nitrogen 
 Inconsistencies in homogenisation from sample to sample; easy to lose sample, particularly if frozen 
Various sized probes  Loss of tissue in the probe 
With Laemelli Buffer  Poor homogenisation in Laemelli Buffer Homogeniser 
With TRIZOL Good homogenisation in TRIZOL Led to the degradation of ilomastat 
Various speeds in PBS Rapid Tissue degradation Sclera not homogenised 
Centrifuge Beads Various speeds in 
Laemelli Buffer Rapid Tissue degradation Sclera not homogenised 
TRIZOL  Excellent tissue degradation, particularly with mechanical input Led to the degradation of ilomastat 
56°C Excellent tissue degradation after 24 hours Led to the degradation of ilomastat 
Proteinase K 37°c, 300 RPM  Little tissue degradation observed after 48 hours 
Collagenase D 37°c, 300 RPM Excellent tissue digestion after max. 48 hours  
Table 5.7 – Methods tested during the establishment of a protocol to digest tissue. 
Whilst a number of methods provided good, general, homogenisation, specific tissues proved difficult to break down. Similarly, although methods such as TRIZOL digested the 
tissue very efficiently a breakdown in ilomastat was also observed. Of the methods tested only collagenase D was able to digest all tissues without degrading ilomastat.
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Figure 5.37 – A chromatogram showing the overlap between ilomastat and an impurity of Leu-Trp 
when using a gradient method (A). 
This chromatogram shows the direct overlap between ilomastat (blue) and Leu-Trp (black) when using a 
gradient method. 
 
 
Figure 5.38 - A chromatogram showing the overlap between ilomastat and an impurity of Leu-Trp 
when using a gradient method (B). 
This chromatogram is a magnified version of Figure 5.37, which shows the direct overlap between 
ilomastat (blue) and Leu-Trp (black) when using a gradient method. 
 
 
Figure 5.39 - A chromatogram showing the removal of the overlap between ilomastat and an 
impurity of Leu-Trp through the use of an isocratic method. 
This chromatogram illustrates that through the use of an isocratic method the overlap between ilomastat 
(blue) and an impurity of Leu-Trp was removed.
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5.3.4.4 Tissue soaked in ilomastat 
Following tissue digestion of various ocular tissues (using the method previously 
described), it was found that ilomastat could be detected within all of the ocular tissues 
excluding the lens with no overlay peaks between any tissue components and 
ilomastat observed. However the total volume of liquid could not be quantified and as 
such the total volume was unknown, leading to an inaccurate concentration calculation.  
To overcome this obstacle it was decided that the tissue supernatant, following 
digestion, would be freeze-dried and resuspended in a known volume of liquid; as such 
a lyophilisation step was included in the design of the final protocol, whereby following 
digestion samples were transferred to a freeze dryer for 48 hours at -20°c. Aqueous 
samples of ilomastat were also subject to being freeze-dried to ensure this process did 
not cause any degradation to ilomastat as demonstrated in Figure 5.40. 
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Figure 5.40 – A chromatogram showing the effects of lyophilisation on ilomastat integrity. 
Ilomastat dissolved in DMSO (red) was compared to ilomastat that was lyophilised (blue) prior to being 
dissolved in DMSO; no degradation of ilomastat was observed in the chromatogram. 
 
 
Figure 5.41 – The bleb formed during ex-vivo modelling. 
This figure shows the formation of a “filtering bleb” (denoted by the white arrow) in an ex-vivo model of 
GFS. The use of a contrast agent, rhodamine, allowed visualisation of the bleb as well as the confirmation 
that a tight seal had been made, with no leakage observed.
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Figure 5.42 – A chromatogram showing various tissues together with an ilomastat peak. 
The tissues displayed on the chromatogram are represented by the different coloured traces: conjunctiva 
(red), sclera (green) and muscle (pink). A control sample of ilomastat was also overlaid.  
 
 
Figure 5.43 – The concentration of ilomastat detected in different ocular tissues. 
Ilomastat was detected in various ocular tissues both following either the soaking of tissue in ilomastat or 
through the use of an ex-vivo bleb. The blue bars represent tissue dissected from ex-vivo eyes after 4 
hours (n = 3); the red bars represent tissue dissected from ex-vivo eyes after 24 hours (n = 3); the green 
bars represent tissue soaked in 100 µM of ilomastat solution for 24 hours (n = 1).
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5.3.4.5 Ex-vivo modelling of the bleb 
Through the previous experiments it had been confirmed that a) ocular tissues could be 
thoroughly digested without causing degradation of ilomastat; and b) accumulation of 
ilomastat within the tissue could occur which, importantly, was at a high enough level 
so as to allow HPLC detection. However the soaking of tissue within a high 
concentration of ilomastat does not replicate the release of ilomastat from a tablet; 
therefore in order to simulate the in-vivo conditions, excised rabbit eyes were used to 
model filtration blebs. A 5 – 10 cm cut was made at the conjunctival/limbal edge and 
pocket created posteriorly via blunt dissection, followed by the placement of a tablet 
under the conjunctiva before a tube was inserted into the pocket and the conjunctiva 
sealed over the tube / attached to the sclera, using glue to create a watertight bleb. To 
ensure a watertight pocket was being created, a contrast agent (rhodamine) was 
injected into a sample eye as shown in Figure 5.41, with the distribution of the dye 
showing both the formation and size of the bleb, consistent with in-vivo bleb size; 
furthermore no leaks were observed. The end of the tube was connected to a peristaltic 
pump, which was set to a rate of 2 µl per minute pumping PBS through the eye, with 
the eyes kept moist during the experiment through the use of a saline drip providing 
constant moisture. Three eyes with ilomastat tablets were dissected after four hours 
with a further three eyes dissected after 24 hours, along with 2 control eyes that did not 
contain a tablet. The eyes were dissected into the aforementioned sections (5.3.4.2) 
and all samples were briefly washed in PBS before being placed into an Eppendorf 
tube and weighed (the tube was weighed prior to tissue being added, with the 
difference accounting for the weight of the tissue). Finally the tissues were stored at -
20°C prior to digestion. The tissue samples were transferred to 15 ml Falcon tubes and 
0.9 ml of collagenase D was added along with 0.1 ml of Leu-Trp and digested as 
previously described (5.3.4.2). Following digestion and lyophilisation the tissue 
samples were resuspended in DMSO, the only solvent available to dissolve the Leu-
Trp. However upon addition of DMSO it was found that the tissue supernatants were 
poorly soluble in DMSO, but dissolved very well in water. The use of the internal 
standard/DMSO was therefore abandoned at this stage. Following dissolving, the 
samples were filtered using 0.22 µm filters and analysed using HPLC using the 
isocratic method previously described (5.3.4.1), resulting in HPLC chromatograms 
similar to those found from tissue soaked in ilomastat solution. 
 The detection of ilomastat was achieved in the conjunctiva, sclera and muscle located 
near the bleb site, though no significant differences were found between the 24 and 
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four hour samples. The ilomastat concentration within the conjunctiva was estimated to 
be 0.5 µM per mg, with concentrations around 10-20 times within the sclera and 
muscle. No detection of ilomastat was observed within the iris, cornea or vitreous body 
of samples from the ex-vivo model (Figure 5.42 and Figure 5.43).  However, these 
concentrations cannot be classed as entirely accurate due to the use of water as the 
dissolving agent, leading to incomplete solubility of the Leu-Trp. Whilst Leu-Trp peaks 
were detected, they could not be relied upon and consequently the loss of ilomastat 
during tissue preparation could not be established. Despite this it was confirmed that: 
a) Collagenase was able to digest tough ocular tissue without interference to ilomastat, 
and b) ilomastat accumulated in the ex-vivo eyes could be detected using our HPLC 
method with a sensitivity minimum of 100 nM. 
5.3.4.6 Further improvements 
To overcome the problem of losing the internal standard, it was decided that if the 
tissue could be freeze dried prior to digestion, the sample could be digested in a known 
volume of collagenase, and as such a known total volume. Tissue samples obtained 
from excised rabbit eyes were soaked in ilomastat, as was first previously described 
(5.3.4.4). Following soaking the samples were washed in PBS before being freeze-
dried at -20°C for 48 hours. Following lyophilisation the samples were subject to the 
standard digestion process as previously described (5.3.4.2) using a 1 ml of 
collagenase D. The resulting HPLC chromatograms were very similar to those 
previously obtained (Figure 5.42), although through the use of an aqueous sample of 
ilomastat it was estimated that a loss of 10% ilomastat was observed during sample 
preparation. 
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5.4 Discussion 
5.4.1 The in-vitro effects of ilomastat 
Initial experiments undertaken in-vitro were aimed at demonstrating the effects of 
ilomastat on HTF activity. Whilst previous studies have demonstrated that ilomastat 
could inhibit collagen contraction, conflicting reports remained as to its effects on 
proliferation (Julie T Daniels, Cambrey et al., 2003; Townley et al., 2009). The 
experiments in this study have shown that significantly less cell proliferation occurs in 
the presence of ilomastat, with both the MTT and immuno-based studies confirming 
these results. These confirm the previous findings of other groups who suggested that 
ilomastat was able to inhibit cell proliferation. The microarray results also highlighted 
the downregulation of genes related to cell proliferation, including the downregulation of 
several IGF binding proteins which function to provide a source of growth factors that 
stimulate cell growth and proliferation (Fowlkes et al., 1999). Interestingly TUNEL 
staining of collagen gels revealed no differences in positively stained nuclei between 
control and ilomastat treated cells, suggesting that ilomastat does not induce cell death 
and the previously aforementioned changes in proliferation observed using the MTT 
assays are not because of cellular apoptosis. Similarly, the downregulation of members 
of the actin-cytoskeletal processing family potentially underlies the changes in 
morphology observed in the fibroblasts when stained with F-Actin. Fibroblasts grown in 
the presence of ilomastat exhibited a markedly different morphology whereby instead 
of extending board, elongated cell bodies the cells appeared rounder and stellate within 
gels and thin and short on a monolayer surface. The downregulation of a number of 
genes within the microarray again potentially underlie these changes, with 
downregulation of ACTG2 a key component of F-Actin assembly. Similarly the 
downregulation of genes such as CXCL12, ACTA2, and other members of the Rho and 
Ras signalling cascades, which all play a part in actin-formation within the cell. 
Akamata and colleagues have previously shown that CXCL12 expression is important 
for cell adhesion through the upregulation of integrins and increases in the 
polymerisation of actin (Amakata et al., 2007). Such downregulation may underlie many 
of the morphological changes seen within the fibroblasts upon exposure to ilomastat, 
but further antibody-based studies may be able to confirm these results. The presence 
of a “growth-cone” like structure that was seen on a number of fibroblasts when 
examined with F-Actin was not seen in control cells, but suggests that the fibroblasts 
are trying to grow or migrate along the collagen coated surface. 
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The examination of ilomastat on angiogenesis using the angiogenesis 3D co-culture 
revealed that ilomastat could act as a potent inhibitor of angiogenesis, with its effects 
comparable to that of the anti-angiogenic treatment bevacizumab, confirming the data 
of previous studies that have used ilomastat in studies of angiogenesis. Such inhibition 
highlights a further mechanism by which ilomastat may act as such a potent inhibitor of 
wound healing, through direct inhibition of the MMPs required for angiogenesis (as 
previously discussed) (R E Galardy, Grobelny et al., 1994; Haas et al., 2000; Friehs et 
al., 2006). 
The downregulation of MMP expression from monolayer revealed a highly significant 
downregulation of MMP-1 both in the array and with RT-PCR analysis, with MMP-1 
regulation known to be effected by a number of other genes affected within the 
microarray dataset such as tenascin C and IL-6 (Galoian et al., 2007; Y. Li et al., 2010). 
Interestingly, a downregulation of Il-6 staining was observed in cells grown in the 
presence of ilomastat, whilst no differences in the intracellular staining of Tenascin C 
was observed. Of further note, tenascin C staining was found to be colocalised within 
the nuclei of cells, although its exact role here remains unclear with the intracellular role 
of tenascin C having not been well documented within the literature. Further protein-
based studies may be able to elucidate a role for this protein, where it perhaps acts as 
a chaperone for other proteins. The downregulation of MMP-1 may in part underlie the 
lack of contraction observed following experiments to examine the reversibility effects 
of ilomastat. When grown in monolayer for seven days in the presence of ilomastat 
before being placed into a collagen gel, little contraction was observed over a seven-
day period. Whilst gene expression analysis of the gels was not undertaken, it would 
be interesting to explore whether there are prolonged changes in gene expression 
underlying the lack of reversibility seen in collagen gel contraction. The 
immunocytochemical staining of MMP-1 further confirmed the changes observed 
through the RNA studies, with far less MMP-1 staining observed within both the ECM 
and intracellularly in cells grown on collagen type I surfaces over a seven day period. 
Similarly ELISA based protein studies confirmed these findings with a significant 
reduction in MMP-1 production observed. Whilst the in-vitro microarray study provided 
some insight in the ways ilomastat modulates HTF expression, the lack of study in 3D 
must be taken into account. When in a 3D matrix, the interactions that take place 
between the matrix and the cell will itself induce a different set of gene expression 
responses and as such cellular behaviour. It may be that when analysing the RNA of 
cells grown in 3D increased differences in MMP gene expression will be observed due 
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the cell requiring the upregulation of MMP gene expression during this time, as 
previously shown by Wong, who described that MMP-2 downregulation was also 
significantly seen (aside from MMP-1) when assessed using RNA obtained from 3D 
gels. Whilst using RNA from 3D gels was discussed, it was decided that the biological 
responses obtained in-vitro on a monolayer surface would provide its own insight; 
many similar microarray studies have been undertaken on a monolayer surface as 
direct comparison between the treated and non-treated cells can be made; in order to 
assess 3D gene expression changes it would be useful to include a third group to 
examine the gene expression changes that occur in HTFs purely from being within the 
collagen gel through comparison between cells grown in monolayer and in 3D. 
5.4.2 Pharmacokinetics 
The aim of this experiment was to determine the concentration of ilomastat within 
ocular tissues using a non radioactive / non-fluorescent method. A number of obstacles 
presented themselves during the development of the method, with the most 
challenging being that of finding a method that could provide thorough tissue digestion 
without impacting the integrity of the target compound. Whilst previous publications had 
provided clues as to potential ways to digest the tissue, including acids, bases and 
mechanical methods, these publications often only required the digestion of a single 
specific tissue, or were detecting a highly resilient compound (Knapp et al., 2003). 
Whilst multiple digestion methods were tested, as outlined in Table 5.7, many proved to 
be unusable. The lack of having an internal standard in the final protocol is somewhat 
troubling, as it prevents a final accurate concentration to be calculated. It is possible 
that, despite the method aiming to minimise sample loss, during the centrifugation step, 
ilomastat bound to proteins released during digestion may be lost; similarly, whilst the 
detection of the HPLC method has been greatly improved, it may still be insufficient to 
detect the very low levels of ilomastat present within other tissues. An HPLC-Mass 
Spectrometry method is currently under development within the group, which hopes to 
provide a sensitivity of 2.57 nM. Whilst the aim was to create, as accurately as 
possible, an ex-vivo model of the bleb, our model falls short in certain aspects including 
the absence of circulation within the tissues, and as such certain dynamic aspects of 
the living eye are lost, in particular any transport to the posterior segment of the eye 
and active transport between active barriers. This could therefore go some way to 
explaining why ilomastat was undetectable within the vitreous body of the ex-vivo eye. 
An interesting finding was observed in the ilomastat concentration in the conjunctiva, 
with Figure 5.43 showing that the ilomastat seemed to be more concentrated in the 
  268 
conjunctiva from the ex-vivo eye rather than from the dissected tissue that was soaked 
in ilomastat solution. One possible explanation could be that the tissue was not 
correctly washed, with fragments of the ilomastat tablet remaining within/on the tissue 
during digestion. Alternatively it is possible that ilomastat simply accumulated within the 
tissue upon release from the tablet, and that the released concentration from the tablet 
exceeded 100 µM (the concentration of the static solution). From the release profiles of 
tablets containing either ilomastat or 5-FU previously been described it is known that 
the concentration can increase upon a decrease in the size of the compartment into 
which the tablet was placed, for example release studies with 5-FU indicated that a rig 
chamber with a volume of 50 µl could result in a higher concentration of 5-FU being 
collected than that of a 200 µl chamber (S. D. Georgoulas, 2010; Ru, 2010). Whilst 
experiments with ilomastat tablets in smaller chambers have not yet been performed, it 
would provide an interesting observation as to whether concentrations increase in a 
similar manner. A further limitation of the study included the temperature of the tissue, 
which was at room temperature, as opposed to 37°c; whilst ideally this temperature 
would have been used it was beyond the capabilities of the tools available. Finally the 
solution used during flow, PBS, is markedly different from that of the aqueous that 
normally flows through the eye. Whether the proteins contained within this tissue have 
an impact on the release of a tablet is currently unknown; similarly, this study has not 
simulated the conditions present when a tablet is placed into the bleb following surgery, 
such as the large inflammatory response. The cells that are introduced may impact 
upon the release of the tablet as previously described in 3.4. A summary of the final 
method is shown in 2.6.3. 
  269 
  
5.5 Conclusion 
These in-vitro studies have provided insights into the role of ilomastat in regulating HTF 
behaviour following exposure to varying concentrations of the drug. This study has 
documented that ilomastat can decrease cellular proliferation, alter HTF morphology 
and protein production as well as restrict its ability to contract a collagen gel even after 
a prolonged exposure before the drug is removed. Explanations for these changes 
have been provided through the use of an in-vitro microarray study, which highlighted 
changes in proliferation and cellular growth as being some of those most affected as 
well as providing clues as to signalling pathways that may regulate the changes in 
expression seen in-vitro. Finally this chapter has also provided, despite its limitations, a 
novel way to detect the concentration of ilomastat in tissue obtained from an in-vivo 
situation without the requirement of using a labelled compound, with this study 
indicating that drug may be restricted in it’s movement to the areas directly adjacent to 
the tablet location. 
  
Chapter 6 In-vivo microarray analysis of conjunctival 
tissue following glaucoma filtration surgery 
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6.1 Introduction 
Whilst in-vitro experiments have given rise to an increased understanding of both 
currently used and experimental therapeutics which have been designed to modulate 
the wound healing response, these models provide only a limited insight due to the 
difficulty in modelling the numerous factors that play a role within the would healing 
process in-vivo.  The requirement for in-vivo studies is therefore critical to determine 
both the effectiveness, and limitations, of experimental therapeutics for the modulation 
of the wound healing response following GFS. Numerous tools are available in order to 
provide this assessment in-vivo, including observation-based assessments such as the 
measurement in size of a filtration bleb and measurements of intraocular pressure, as 
well as end-point histological analysis. However, these observation based studies offer 
little insight into the exact mechanisms underlying the effectiveness/limitations of the 
drug (and delivery regimen), and although time course studies have been undertaken, 
for example in the quantification of the levels of cytokines within aqueous humour, 
these are often protein based studies limited in their scope due to the requirement of 
single experiments for the assessment of single proteins (H. J. Lee et al., 2008; 
Kuchtey et al., 2010). The emergence of the microarray has allowed for increased 
scope in analysis of the wound healing response and as such has been used in a 
number of studies to explore the gene expression changes at various time points within 
the wound healing response (Esson et al., 2004; Popp et al., 2007; J. C. Smith, Boone 
et al., 2008). Following on from the in-vitro analysis of the previous chapters, 
microarrays were chosen to provide in-vivo analysis of the effects of differing drugs and 
dosing regimens on the gene expression obtained from conjunctival samples following 
GFS; as such, this became the basis of the aims of this chapter. 
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6.1.1 Ocular wound healing 
The wound healing process, including scarring, is involved in the pathogenesis of a 
number of conditions that lead to either visual impairment or total blindness (T. T. L. 
Wong et al., 2002). These conditions can occur in both the anterior and posterior 
segments of the eye, either as a direct result of injury or trauma, or as a postoperative 
complication. For example, the development of posterior capsule opacification (PCO) 
following cataract surgery can occur in as many as 20 - 40% of patients and is 
dependent upon the transformation of lens epithelial cells (LECs) into myofibroblasts, 
with Saika and colleagues demonstrating that implanted intraocular lenses become 
coated with matrix depositions expressing elevated levels of TGF-β [a known stimulant 
of the myofibroblast transition (1.2.4.1)] (Saika et al., 2000; Hewitt et al., 2002; Awasthi 
et al., 2009). Similarly the growth factors FGF, EGF and hepatocyte growth factor 
(HGF) have all been implicated in the proliferation of LECs and the maturation of the 
PCO (I M Wormstone et al., 2001; Choi et al., 2004; I Michael Wormstone et al., 2006). 
Similarly, a number of these growth factors, and others such as VEGF, have been 
implicated in the scarring that occurs within the retina following retinal detachment, 
stimulating the growth and proliferation of retinal pigmented epithelial (RPE) cells, 
fibroblasts and fibroblast-like neuron support cells, the Müller glia. The growth of these 
cells leads to the development of an epiretinal membrane, leading to vision loss or 
visual distortion (Harada et al., 2006; J. S. Ellis et al., 2009). However, despite these 
conditions much of our understanding of the ocular wound healing process comes from 
studies investigating the healing of the conjunctiva directly, or the wound healing that 
takes place within the cornea. 
6.1.1.1 Corneal wound healing 
An injury to the cornea can trigger a number of wound healing responses dependant 
upon the area of injury, for example epithelial damage will trigger a re-epithelisation 
response largely governed by nearby epithelial cells, whereas damage to the stroma 
will cause the activation of keratocytes which enter the wound area below the epithelial 
cells, eventually differentiating into myofibroblasts (Myrna et al., 2009; F.-S. X. Yu et 
al., 2010). A number of MMPs have been implicated in both responses with, for 
example, Mullholland and colleagues demonstrating the expression of a range of 
MMPs following keratectomy induced wounding (laser induced changes to the cornea). 
Using immunohistochemical staining, it was shown that high levels of MMP-1 were 
found along the leading edge of migrating epithelial cells with MMPs-2 and -9 located 
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behind the migrating cells. MMP-2 was further found to be expressed within the stroma, 
although no staining was observed for either MMP-1 or MMP-9 within this location 
(Mulholland et al., 2005). This study confirmed the previous work Daniels and 
colleagues who demonstrated that MMP-1 is required for corneal epithelial migration on 
a collagen I surface, with the neutralisation of MMP-1 leading to both significantly 
reduced epithelial migration and scratch wound closure (Julie T Daniels, Limb et al., 
2003). Many of these increases in MMP expression are associated with the 
upregulation of various growth factors including EGF, HGF and importantly TGF-β, 
which whilst essential for the keratocyte-myofibroblast transition has little effect on 
epithelial migration, with TGF-β1 having been shown to actually slow reepithelialisation 
(Folger et al., 2001; Garrett et al., 2004; Carrington et al., 2006; F.-S. X. Yu et al., 
2010). Further information with regards to the specific effects of the various growth 
factors involved in corneal wound healing can be found within the previously cited 
review by Yu and colleagues.  
6.1.1.2 Conjunctival wound healing 
The conjunctival wound healing response follows the standard healing response that 
was previously described in chapter 1.2, however a number of studies have described 
distinct conjunctival responses that occur following injury. Of particular interest, Shima 
and colleagues were able to demonstrate the specific expression changes in MMPs 
following experimental GFS in rabbits. Using a histochemical approach, staining for 
MMPs-1, -2, -3, -9 and -14 was undertaken at various time points following surgery. At 
day 1 post surgery no staining was observed in any of the operated eyes, with day 3 
showing positive staining for all of the MMPs tested, though it appeared that expression 
was limited to the invading macrophages. At days 7 and 14 spindle shaped cells 
became evident which stained weakly for all of the MMPs, as well as endothelial cells 
showing similar staining patterns excluding MMP-3. When quantifying the number of 
cells found to be stained positive, MMP-1 and MMP-14 were found to be most 
expressed at day three (Shima et al., 2007). Similar immunocytochemical studies on 
human patient samples of scarred or normal conjunctiva revealed differential 
expression of the BMPs, with BMP-6 and activin-A (a TGF receptor) found to be 
significantly overexpressed within the scarred tissue. Interestingly, activin A has 
become a target for theraputics with in-vitro testing of the Activin-A inhibitor, follistatin, 
shown to inhibit the TGF-β induced fibroblast to myofibroblast transition with in-vivo 
testing having concluded that follistatin is able to inhibit TGF-β induced fibroblast 
activation following bleomycin induced lung injury (You et al., 2002; Aoki et al., 2005). 
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Similarly, an inhibitor to activin receptor-like kinase 5 was shown to attenuate the 
effects of bleomycin induced lung fibrosis, with significant reductions in collagen I, III 
and fibronectin mRNA expression observed (Higashiyama et al., 2007).  
Furthermore, Cvenkel and colleagues, whilst not looking directly within the bleb, were 
able to demonstrate the high levels of particular cytokines associated with failing blebs 
by investigating their levels within the aqueous humour, concluding that elevated levels 
of both TNF-α and IL-6 were significantly elevated in three month old failed blebs 
(Cvenkel et al., 2010). The direct modulation of TGF itself has also been explored, as 
previously discussed (1.4.3.1), though clinical trials did not demonstrate effectiveness 
in improving the failure rates of GFS. Despite the ongoing investigations into 
conjunctival wound healing as yet no drug has shown to be better than either 5-FU or 
MMC, yet despite the use of these treatments subconjunctival scarring remains a major 
obstacle to achieving long term pressure control in glaucomatous eyes. 
6.1.2 Microarray analysis of the wound healing response 
Whilst many studies have explored the various aspects of the wound healing response 
through immunohistochemical analysis, or single gene mRNA quantification, the 
development of the microarray has given researchers greater scope in understanding 
the wound healing response following injury. A number of studies have been 
undertaken, albeit largely following dermal injury, ranging from the analysis of wound 
response 30 minutes after trauma (Cole et al., 2001) through to the analysis of 
hypertrophic scars, several months after the initial injury (J. Wu, Ma et al., 2004). 
Microarrays have further been used to understand the changes observed in ocular 
wound healing events such as following GFS and corneal trauma. Both of the 
published microarray-based reports into the wound healing response following GFS 
were undertaken at the University of Florida, firstly through the analysis of filtration 
blebs of rats at days 2, 5 and 12 (Esson et al., 2004) before the development of a 
rabbit specific microarray, with which they analysed the filtration blebs of rabbits 14 
days after surgery (Popp et al., 2007). Some correlation was observed between the rat 
day 12 array and rabbit day 14 array, including the upregulation of lumican and 
fibronectin, although differences were found including an upregulated state of MMP-9 
at day 14 in the rabbit array that was not observed within the rat array. However the 
rabbit model of GFS provides a better model of the trabeculectomy due to the anatomy 
of the rabbit eye more closely resembling that of the human eye when compared to that 
of the rat and as such is better able to reflect the gene expression changes that may be 
observed in human conjunctival wound healing (M. H. Miller et al., 1989; Popp et al., 
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2007). However, to this point no studies have looked directly at the impact of 
theraputics used to modulate wound healing on the gene expression profile of the 
healing conjunctival tissue following experimental GFS; as such this became the basis 
of the study documented within this chapter. 
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6.2 Objectives and experimental design 
Whilst in-vitro analysis of ilomastat-induced changes in gene expression have provided 
some insight as to the potential mechanisms through which ilomastat is able to 
modulate cell activity (as described in Chapter 5), in-vivo experiments will always 
present a number of different responses conditions that simply cannot be replicated in-
vitro. Using a custom designed rabbit microarray chip [the publication of Michael Popp 
and colleagues provides further details as to the construction of a preceding rabbit chip 
(Popp et al., 2007)] analysis of the gene expression changes that took place five days 
into the wound healing response was undertaken. Using the Agilent two-colour 
microarray system (2.11.2) a microarray experiment was carefully planned, taking into 
account both biological and technical replicates (dye swap), which would allow the 
comparison of the effects of multiple treatments on the wound healing process. The 
experiment was designed to firstly examine the changes induced by surgery alone 
through comparison of the operated conjunctival tissue against unoperated control 
samples. The second condition was designed to allow the comparison of MMC treated 
blebs with the operated control; the third condition, the comparison of a single, post 
operative, injection of ilomastat; and the fourth condition, the comparison of an 
implanted tablet containing ilomastat. Application of these drugs took place in three 
different forms: 
1. Mitomycin C 
MMC (MITV102, Movianto, UK) was prepared at a concentration of 0.5 mg/ml 
through the addition of 4 ml of sterile water to a single 2 mg vial of MMC. The 
solution was mixed to ensure the powder had fully dissolved prior to use, with 
MMC applied prior to the sclera being punctured. Following conjunctival 
retraction a Corneal Shield was soaked in 0.5 mg/ml MMC for 20-30 seconds 
before being placed into the subconjunctival space. The conjunctiva was 
brought forward over the sponge, where it was left for three minutes. Following 
removal after this time period, the eye was thoroughly irrigated using 20 ml of 
PBS to ensure the removal of any residual MMC. The surgery then continued 
as previously described. 
2. Ilomastat Injection 
A 100 µM solution of ilomastat was prepared by dissolving ilomastat (G8237, 
US Biological, USA) in sterile water. The solution was stirred for 24 hours in the 
dark at 4°c using an autoclaved magnetic stirrer. The solution was sterile 
filtered using a 0.22 µm filter and stored at 4°c prior to use. Solutions were kept 
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no more than 24 hours prior to use. Following closure of the conjunctiva and the 
formation of the bleb a 0.1 ml injection of ilomastat was administered 
subconjuctivally using a 29-gauge insulin syringe (BD, UK). 
3. Ilomastat Tablet 
Tablets for use in this study were prepared in advance using the previously described 
method (2.5.1). A number of tablets were prepared, with three chosen prior to surgery 
due to the similar size and shape (Table 6.1). All tablets were prepared using ilomastat 
of the same batch as in the injection. Prior to the study, tablets were irradiated with 25 
kiloGrays to ensure sterility. 
Animals treated with a tablet form of ilomastat were operated on as previously 
described, however prior to closure of the conjunctiva, a tablet was placed posterior to 
the tube before the conjunctiva was sutured closed. 
Weight (mg) Thickness (mm) Diameter (mm) 
2.22 3.15 3 
2.23 3.35 3 
2.22 3.6 3 
Table 6.1 - The tablets used during the in-vivo study to determine gene expression changes 
following GFS 
Five days after surgery conjunctival samples, approximately 2 x 2 mm in size, were 
taken from the centre of the bleb and the RNA isolated before being processed for 
microarray analysis. Based upon the Nanodrop assessed RNA qualities, two of the 
three samples were used for final microarray analysis. 
 
Upon the extraction of the gene expression values, the aims of this chapter were: 
 
I. To examine which signalling pathways (and single genes) were up/downregulated at 
day 5 in the wound healing process within the conjunctiva of a rabbit given 
experimental glaucoma filtration surgery. 
 
II. To examine, through global gene expression analysis, which signalling pathways, or 
single genes, were altered upon the application of MMC, a single injection of 
ilomastat or an ilomastat tablet. 
 
III. To identify, through gene expression, previously undocumented side effects (both 
positive and negative) brought about as a direct result of the treatment regimen
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6.3 Results 
6.3.1 Post-operative observations 
In total 12 rabbits were subject to GFS, in which their left eye was used as the operated 
eye, with three rabbits randomly assigned to each of the treatment groups. The blebs 
were assessed on a daily basis following surgery, with the size of the bleb, vascularity 
and IOP all recorded during these observations. Photographs taken on day five, the 
endpoint of the experiment, characterise the appearance of the blebs as shown in 
Figure 6.1. The eyes of rabbits that underwent GFS but did not receive any treatment 
exhibited markedly vascularised blebs when compared to the three treatment groups 
(Figure 6.4). The blebs of both the untreated and injected ilomastat groups were the 
smallest of the treatment groups, though at day five no statistically significant 
differences were found in bleb area. The blebs of both the MMC and ilomastat tablet 
treated rabbits were large, marked by the presence of generally avascular surfaces; a 
similar streak of avascularity was seen within two of the blebs treated with an ilomastat 
injection. Whilst the surgery caused an initial reduction in IOP in all groups, no 
significant differences were found between the groups over the course of the 
experiment. 
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Figure 6.1 - The morphology of the filtration blebs five days after surgery. 
The normal conjunctiva, as shown in figure A, is a transparent tissue with the white appearance due to the 
sclera below. Rabbits operated on and not given a post-operative treatment, as shown in B, at day five 
presented highly vascularised blebs typical of a scarring bleb that is likely to fail. Figure C shows the 
largely avascular bleb of the ilomastat tablet treated rabbits, highly similar in morphology to the MMC 
treated rabbits (E). Blebs were large, fluid filled pockets indicative of a fully functioning bleb. Figure D 
demonstrates the bleb of a rabbit having had a single injection of ilomastat, with a streak of avascularity 
present toward the front of the bleb, though high levels of vascularisation were present on the remainder of 
the bleb. 
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Figure 6.2 - The area of the blebs over the five days of the experiment. 
Bleb area was calculated from measurements of the width and length of the bleb with the results 
suggesting the tablet and MMC treated eyes function best at day five, with the injection and no treatment 
groups presenting blebs small in size indicative of a failing bleb. 
 
Figure 6.3 - The height of the blebs over the five days of the experiment. 
Bleb height was measured as a marker of the functionality of the bleb, with taller blebs normally associated 
with blebs filled with aqueous, thus suggesting a fully functional bleb. In accordance with the bleb area 
measurements, untreated and ilomastat injection treated eyes had the lowest bleb heights, with the tablet 
and MMC groups presenting large blebs. 
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Figure 6.4 - The vascularity of the blebs over the five days of the experiment. 
Bleb vascularity was judged using a 3 point scale, with zero representing an avascular bleb and three a 
highly vascularised bleb. The presence of an avascular blebs was largely seen in the rabbits given a drug 
treatment, with the untreated rabbit eyes exhibiting a markedly vascularised bleb. 
 
Figure 6.5 - The intraocular pressure recorded over the five days of the experiment. 
Following surgery a reduction in IOP was seen in all rabbits, though this was not statistically significant; 
over the course of the experiment pressures remained low in all groups.
0!
0.5!
1!
1.5!
2!
2.5!
0! 1! 2! 3! 4! 5!
Va
sc
ul
ar
ity
 (u
si
ng
 0
-3
 s
ca
le
)!
Day!
Tablet!
Injection!
MMC!
Nil!
0!
2!
4!
6!
8!
10!
12!
14!
0! 1! 2! 3! 4! 5!
In
tra
oc
ul
ar
 P
re
ss
ur
e 
(m
m
Hg
)!
Day!
Tablet!
Injection!
MMC!
Nil!
  282 
6.3.2 Post-hybridisation quality control 
Following RNA isolation, pre-hybridisation QC, hybridisation and scanning of the 
microarrays, the extracted data was subject to post-hybridisation quality control using 
Bioconductor (2.11.1.3). For reference purposes NanoChip traces of the RNA samples 
are shown in appendix 9.4. Upon analysing the data it was found that one MMC array 
had performed inadequately, producing a significant outlier in the data when being 
normalised (Figure 9.7). It was therefore decided, at this stage, to exclude this single 
array due to the skew on data it would present, and as such the following data includes 
a sample size of only one for the MMC group. Differential gene expression analysis 
was performed with the second MMC group and the data is included within appendix 
9.5 for reference purposes but was not used in downstream analysis. Whilst the data of 
the other groups was not, on the whole, greatly affected by this outlier (expression 
values were comparable to analysis performed without the outlying array), the MMC 
data was greatly affected. As the outlying data was inconsistent with the other seven 
arrays it was chosen as likely to represent incorrect expression values and as such it 
was that array that was removed. The remaining MMC array produced expression 
intensity levels consistent with the other arrays. During the final QC work inter- and 
intra-normalisation was undertaken, as previously discussed (2.11.2.3) with the MA 
graphs, box plots and probe density graphs shown in Figure 9.8 and Figure 9.9. The 
results displayed good agreement of the means within the box blots. The MA graphs 
showed good agreement around the x-axis with and the density distribution graph 
following normalisation was indicative of comparable samples, indicating a successful 
normalisation of the data. 
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6.3.3 Summary of expression changes 
Following normalisation, differential gene expression between various groups was 
computed, with genes considered to be differentially expressed if the cut-off criteria of a 
fold change greater than 1.5 together with a p-value less than 0.05 was met. The total 
breakdown of genes meeting this criteria are shown in Table 6.2 and Table 6.3. 
Various groups were compared starting with the operated eyes vs. unoperated eyes, 
allowing a background analysis of the genes up/downregulated at day five in the wound 
healing response. This was followed by comparisons between each treatment group 
and the operated samples, allowing genes that were differentially expressed following 
treatment to be determined when compared to the operated sample. Upregulation in 
gene expression is indicative of the treatment inducing an increase in expression, 
pertinent to it’s mechanism of action, with the inverse applicable to any downregulated 
genes. Further comparisons were made by directly comparing the treatment groups to 
observe direct differences between the treatments. Fully annotated gene lists for each 
of the comparisons are available in appendix 9.5, with the following analysis based 
upon those lists. Downstream analysis was undertaken using IPA (2.11.3.2), through 
which grouping of genes by their classical function was undertaken as well as an 
assessment of specific pathways affected. Further to this, networks based upon 
published interactions were produced with full listings of each network available in 
appendix 9.6; legends for the networks are provided in the 5th network of each 
comparison group (e.g. Figure 6.14). 
One key area of interest, are the MMPs and Figure 6.6 - Figure 6.9 show the changes 
in gene expression of the MMPs in each of the treatments. Following surgery a 4 fold 
upregulation of MMP-1 was seen, as well as upregulation of MMP-3, MMP-9, MMP-12 
and MMP-13. Following the treatment with MMC, a downregulation in all MMPs, in 
particular MMP-1, MMP-3, MMP-12 and MMP-13 was observed. The ilomastat 
injection group had little change in MMP expression aside from an increase in MMP-9 
and a downregulation of MMP-1, although the fold change did not quite meet the 
threshold of 1.5. The tablet treated group meanwhile had a significant upregulation of 
MMP-9, MMP-12 and MMP-13. 
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Operated 
vs. 
Unoperated 
MMC vs. 
Operated 
ILOI vs. 
Operated 
ILOT vs. 
Operated 
Genes Upregulated 446 616 81 332 
Genes Downregulated 579 808 170 320 
Total differentially expressed 
genes 1025 1424 251 652 
Table 6.2 – A Summary of differentially expressed genes meeting the cutoff criteria of a fold 
change ± 1.5 and p value < 0.05 (part A). 
 
 
 
 
 
 ILOI vs. ILOT MMC vs. ILOT MMC vs. ILOI 
Genes Upregulated 183 711 452 
Genes Downregulated 287 1108 508 
Total differentially expressed 
genes 470 1819 960 
Table 6.3 – A Summary of differentially expressed genes meeting the cutoff criteria of a fold 
change ± 1.5 and p value < 0.05 (part B). 
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Figure 6.6 - Gene expression changes found between operated rabbits and unoperated control 
rabbits.  
The red lines indicate cutoff thresholds for fold change of +- 1.5. * = p < 0.05, ** = p < 0.01. 
 
 
Figure 6.7 - Gene expression changes found between MMC treated rabbits and operated control 
rabbits.  
The red line indicates the cutoff threshold for fold change of -1.5. * = p < 0.05. 
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Figure 6.8 - Gene expression changes found between rabbits treated postoperative with an 
ilomastat injection and operated control rabbits.  
The red lines indicate cutoff thresholds for fold change of +- 1.5. No changes were statistically significant. 
 
 
Figure 6.9 - Gene expression changes found between rabbits treated perioperatively with an 
ilomastat tablet and operated control rabbits. 
The red line indicates the cutoff threshold for fold change of -1.5. * = p < 0.05, ** = p < 0.01. 
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6.3.3.1 Operated control vs. Unoperated control 
Data analysis of the gene expression changes within conjunctival tissue obtained from 
the filtration blebs of rabbits that had not received any pharmaceutical intervention 
following surgery was undertaken through direct comparison with unoperated 
conjunctiva obtained from control eyes.  
At day five in the wound healing response initial analysis of the top 10 
up/downregulated genes (Table 6.4 and Table 6.5) was suggestive of an ongoing 
inflammatory response, with upregulation of the inflammatory cytokines IL-1α and TNF-
α induced protein (TNFAIP), members of the S100 family of proteins [markers of 
neutrophil activity (Goyette et al., 2010)] as well as the tissue plasminogen activator 
(tPA), a serine protease that, whilst most commonly associated with the conversion of 
plasminogen to plasmin during the breakdown of a clot, is associated with the 
activation and release of MMPs (in particular MMP-9) from a number of cells including 
neutrophils and endothelial cells during an inflammatory response such as cerebral 
ischemia (X. Wang et al., 2003; Cuadrado et al., 2008). Similarly, the chemokine ligand 
CXCL5, a known mitogen, was highly upregulated, as was MMP-13 and serum amyloid 
A1, which has previously been shown to be upregulated in rabbits following an 
inflammatory response, where it is a known component of the acute phase 
inflammatory response functioning in a number of roles including macrophage 
recruitment and MMP activation (Steel et al., 1994; Ray et al., 1999; Vlasova et al., 
2006).  
The most significantly downregulated genes were highly associated with cell 
morphology, with a number of cytoskeletal genes downregulated including nebulin, 
myosin and actin-α1; these genes grouped together in network 10 (see below) with 
similar downregulation documented following ear tissue damage in mice, where 
samples were analysed four days after injury using microarrays (Canhamero et al., 
2010). 
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Gene Title Gene Symbol FC P value 
Interleukin 1α IL1A 23.18 0.00498 
S100 calcium binding protein A12 S100A12 13.16 0.00135 
Tumor necrosis factor, α-induced protein 6 TNFAIP6 9.03 0.03966 
Chemokine (C-X-C motif) ligand 5 CXCL5 8.83 0.00028 
Serine incorporator 2 SERINC2 8.67 0.01583 
Plasminogen activator, tissue PLAT 7.65 0.0034 
Serum amyloid A1 SAA1 7.28 0.02097 
Plasminogen activator, tissue PLAT 6.99 0.00116 
Matrix metallopeptidase 13 (collagenase 3) MMP-13 6.36 0.02868 
S100 calcium binding protein A9 S100A9 5.66 0.00025 
Collagen, type XII, α1 COL12A1 5.03 0.03379 
Table 6.4 - The top 10 genes upregulated in conjunctival samples analysed five days after 
glaucoma filtration surgery without the use of post-operative theraputics. 
 
 
 
 
 
Gene Title Gene Symbol FC P value 
Nebulin NEB -22.74 0.01108 
Eukaryotic translation initiation factor 2C, 2 EIF2C2 -11.49 6.00E-05 
Myosin, heavy chain 1, skeletal muscle, adult MYH1 -9.90 0.03337 
Creatine kinase, mitochondrial 2 (sarcomeric) CKMT2 -8.64 0.0293 
Phospholipase A2, group IIA (platelets, 
synovial fluid) PLA2G2A -8.43 0.00179 
Actin, α1, skeletal muscle ACTA1 -7.79 0.04362 
Myosin, light chain 1, alkali; skeletal, fast MYL1 -7.53 0.01507 
Titin-cap (telethonin) TCAP -7.15 0.04932 
Synaptophysin-like 2 SYPL2 -7.03 0.04777 
Chromosome 4 open reading frame 49 C4orf49 -7.01 0.00546 
Table 6.5 - The top 10 genes downregulated in conjunctival samples analysed five days after 
glaucoma filtration surgery without the use of post-operative theraputics. 
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In order to gain a further understanding of the genes within biological processes, genes 
meeting the cutoff criteria were assigned into groups based upon their known functions, 
as shown in Figure 6.10. The functions that ranked within the top 20 were typical of the 
wound healing response with cell death, cell movement, immune cell trafficking, tissue 
development and tissue morphology all significantly represented. Within the cell death 
group of genes were 17 directly interacting genes pertinent to the induction of cell 
death, primarily through the activation of caspase 3, with known activators upregulated 
including uPA and FAS. Within this population of genes, two negative regulators of 
apoptosis were identified, including CRYAB (3.48 fold downregulated), the gene 
encoding α-B-crystallin (a known cleaver of pro-caspase3), and PEA15 (1.6 fold 
upregulated), a gene encoding a protein of the same name, that functions as an anti-
apoptotic protein though the regulation of the TNF/FAS response (3.1.2.1.3)(Condorelli 
et al., 1999).  
Canonical pathway analysis further highlighted the continued inflammatory response 
with the pathways of IL-6, hepatic fibrosis and leukocyte signalling all significantly 
affected. Whilst labelled the IL-6 pathway, it also includes the signalling mechanism of 
IL-1 and TNF-α, which can both utilise the MAPK signalling cascade (4.1.5.1.1) of 
which the members NIK and p38 MAPK were identified as being upregulated, together 
with products of this signalling mechanism, such as TNF-α induced protein 6, and 
MDR1, an ATP regulated glycoprotein pump involved in the active transport of proteins 
and phospholipids out of the cell as well as being highly implicated in drug resistance 
(Dolis et al., 1997; Berk et al., 1999). Interestingly α2 macroglobulin was shown to be 
significantly downregulated, despite this protein being more typically associated with 
upregulation during an acute-phase inflammatory response (Y. Du et al., 1998; Janka 
et al., 2002). 
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Figure 6.10 - IPA functional classification of genes differentially expressed in conjunctiva that was untreated following GFS.  
The top 20, statistically significant, functional groups containing genes identified as meeting the cut-off criteria (FC ± 1.5, p < 0.05). Groups are ranked according to p value 
significance with the p value threshold (0.05) shown via the yellow line. The groupings indicate that most differences in gene expression were in genes related to cell death, 
molecular transport and cellular movement. 
 
Figure 6.11 - IPA canonical pathway analysis of genes differentially expressed in conjunctiva that was untreated following GFS. 
Pathways are ranked by ratio (secondary x-axis), which represents the total number of molecules in a given pathway, with all pathways having met a p value threshold of 0.05 
as indicated by the lower yellow line. The top pathways that were affected included hepatic fibrosis, IL-6 signalling and leukocyte extravasation. 
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The network analysis of genes altered following surgery first highlighted a network 
associated with cellular compromise, centred around the NF-κB complex, which whilst 
not itself being differentially expressed, saw several genes it regulates altered, 
including the upregulation of ADAMTS9, an ADAMTS family member that is typically 
associated with an inflammatory response where it is known to cleave large 
aggregating proteins (Demircan et al., 2005; Zeng et al., 2006; Rasheed et al., 2009). 
Similarly, the activators of the NF-κB complex, such as TNF and IL-1 were themselves 
shown to be upregulated (Verstrepen et al., 2008). However, this network is largely 
characterised by widespread downregulation, particularly of the glutathione s-
transferase (GST) family of genes as well as alcohol dehydrogenase 1 which are highly 
involved in the regulation oxidate stress induced damage (Townsend et al., 2003); both 
sets of genes have also been documented to become altered following laser 
keratectomy within guinea pigs likely due to the increased presence of free radicals in 
the cornea (Bilgihan et al., 1998).  
Network two centres around the highly upregulated cytokine, IL-1β which was found to 
be 5.3 fold upregulated. The network highlights several of the interactions with IL-1β, 
including the upregulation of hyaluronan synthase (HAS2), where hyaluronan is known 
stimulator of inflammation as well as a promoter of fibroblast proliferation and migration 
(W. Y. Chen et al., 1999), and the S100 calcium binding protein 10 (S100A10), which is 
able to bind to members of the annexin family such as annexin A1 and A2 (Rezvanpour 
et al., 2009); whilst it has previously been shown to be upregulated during wound 
healing its exact function is still unknown although more recent studies have suggested 
it may potentiate the inflammatory response through activation of macrophages as well 
modulate the repair and structure of the cell membrane (Munz et al., 1997; Eckert et 
al., 2004; Y. Huang et al., 2007). Similarly, the induction of the TNFAIP6, which has 
been demonstrated to be upregulated by IL-1β, is shown here together with the 
downstream activation of ITIH3, a further marker of an ongoing inflammatory response 
that has been characterised within cases of myocardial infarction; current research has 
shown that is can form a complex with hyaluronan in the regulation of inflammatory 
cells (M. Rossi et al., 2005).   
A further population of genes that were demonstrated to be altered were the TSPAN 
genes that encode tetraspanin proteins, which interact with various integrins aiding in 
cell adhesion and migration; a number of studies have demonstrated the role of 
tetrapanins in wound healing both during the early inflammatory response (M. D. 
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Wright et al., 2004) and later wound remodelling [as reviewed by Berditchevski] 
(Berditchevski, 2001).  
Network 3 demonstrates the upregulation of members of the tubulin family, a set of 
proteins involved in microtubule formation, with the same upregulation of tubulin also 
pertinent in network 4, where CRYAB, a downregulated protein in the pathway, is 
shown to interact with tubulin, suppressing tubulin aggregation (Arai et al., 1997). 
Central to network four is caspase 3, though this network does not offer much 
additional information to that which has previously been discussed.  
Network 5 centres around MAPK14, a gene encoding p38 MAPK, which is critical to 
the functioning of the MAPK cascade and in this network, is linked to CD44, a 
hyaluronan induced gene that is capable of regulating MAPK.  
A further network of interest is Network 17, assigned the function of tissue morphology. 
This network is centred on MMP-1 (4.6 fold upregulated), which has a number of 
interactions including collagen I, IGFBP (which it activates through proteolytic 
cleavage) and MMP-3 which has been shown to be required for MMP-1 activation (G. 
Murphy et al., 1987; G. Murphy et al., 1988). Furthermore, this network highlights the 
upregulation of FGF, which as denoted in the network, is a known upregulator of 
various MMPs as well as uPA. The presence of two chemokine related proteins is also 
evident within the network, with CXCL5 shown to be upregulated together with the CXC 
receptor CXCR1; the activation of CXCR1 has been demonstrated to potentiate 
multiple responses, predominantly through the PI3K signalling cascade, including the 
activation of MMPs such as MMP-12, which itself was found to be upregulated (S. Ito et 
al., 2007; Awad et al., 2010). An MMP was also shown to be upregulated in network 8, 
where MMP-13s interaction with the upregulated TIMP-1 was demonstrated (Liang 
Zhang, Yang et al., 2010). Furthermore this network highlights the upregulation of the 
coagulation factor, thrombin and several of its interactions, including an upregulation of 
collagen IV (Mclaughlin et al., 2005), SERPINB2 [a protein that provides cellular 
protection from TNF-α induced apoptosis (Fish et al., 2006)] and the tissue 
plasminogen activator. 
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Figure 6.12 - Significant signalling networks mapped using the differential gene expression found 
in conjunctiva that was untreated following GFS. 
Associated functions with the genes within the networks included: Network 1: Cellular compromise and 
free radical scavenging; Network 2: Cell signalling.
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Figure 6.13 - Significant signalling networks mapped using the differential gene expression found 
in conjunctiva that was untreated following GFS. 
Associated functions with the genes within the networks included: Network 3: Small molecule biochemistry; 
Network 4: Cellular Compromise.
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Figure 6.14 - Significant signalling networks mapped using the differential gene expression found 
in conjunctiva that was untreated following GFS. 
Associated functions with the genes within the network included: Network 5: Cellular growth and 
proliferation and cell cycle.
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6.3.3.2 MMC vs. Operated control 
Data analysis of the gene expression changes within conjunctival tissue obtained from 
the filtration blebs of rabbits that had been treated, perioperatively, with 0.5 mg/ml 
MMC for three minutes was undertaken through direct comparison with operated 
conjunctival samples.  
At day five in the wound healing response initial analysis of the top ten 
up/downregulated genes (Table 6.6 and Table 6.7) was suggestive of a downregulation 
of the proinflammatory cascade, represented in changes such as the downregulation of 
IL-1α and the tissue plasminogen activator as well as the upregulation proapoptotic 
cascade members, such as the death associated protein-like 1 (DAPL1) (Ashburner et 
al., 2000).  
However, many of these top genes, when analysed on an individual basis, provided 
little clues as to the processes altered following MMC treatment.  Therefore, genes 
were firstly classified based upon their biological processes whereby it was identified 
that the processes most associated were related largely to cell proliferation/death as 
well as protein synthesis, including post-translational modification and protein folding. 
Similarly molecular transport was also effected with several downregulated genes 
associated with this function including BAX, IKBKB, MYC, RELA, TP53, TRAF2 and 
TXN with many of these also involved in apoptosis.  
The roles of Bax and TP53 (p53) have been previously discussed in Chapter 3, 
however IKBKB encodes the protein IKK-β which functions as an inhibitor of the TNF-α 
induced extrinsic apoptotic cascade, potentially thought to be through interference of 
Jak signalling (Z. W. Li et al., 1999; Maeda et al., 2003). MYC encodes the 
transcription factor c-Myc, which has been demonstrated to both induce apoptosis as 
well as induce cell cycle arrest through DNA damage both mediated through the 
accumulation of reactive oxygen species (ROS, also known as free radicals) (H. 
Tanaka et al., 2002; Vafa et al., 2002). RELA encodes the transcription factor p65 
(RelA) which can inhibit apoptosis through disruption of the Jnk signalling pathway 
(Vaira et al., 2008). TRAF2 encodes the TNF-associated factor 2 which serves as a 
mediating protein between the activation of the TNF-α receptor and downstream 
pathway activation as well as a specific target for ROS in the induction of apoptosis 
(Shen et al., 2004; Xia et al., 2005).  
Finally, TXN encodes the protein thioredoxin, a redox protein that reduces the 
presence of ROS through a nicotinamide adenine dinucleotide phosphate (NAPDH) 
regulated mechanism; it has however been shown that TXN can itself induce apoptosis 
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when drugs (including many anticancer agents such as Cisplatin) bind to the protein 
preventing reduction (Lillig et al., 2007).  
Analysis of genes associated with apoptosis revealed a downregulation of many of the 
pro-apoptotic genes, relating to both the extrinsic and intrinsic pathways such as Fas 
and Calpain 2, a calcium activated protein that has a multifunctional role in apoptosis 
including cleavage of pro-caspases (Goll et al., 2003). Canonical pathway analysis 
further highlighted these affected responses, with the most significant pathway affected 
that of oxidative phosphorylation where a number of NADH dehydrogenase subunits 
displayed differential expression; similarly mitochondrial dysfunction was significantly 
altered sharing a number of similar genes. Significant disruptions in the p38 MAPK 
signalling pathway (4.1.5.1.1) were also found including the signalling cascade 
members TRAF2, FAK1, MKK3, MAPKAPK2 as well as the final transcription factors 
including CREB, MEF2 and c-Myc; furthermore expression of the genes encoding the 
ligands TGF-β2 and IL-1α were also downregulated. 
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Gene Title Gene Symbol FC P value 
Ribosomal protein L17 RPL17 9.55 0.04788 
S100 calcium binding protein A12 S100A12 8.22 0.02047 
Advillin AVIL 7.29 0.00485 
Family with sequence similarity 62 (C2 
domain containing) member B FAM62B 7.23 0.00045 
S100 calcium binding protein A12 S100A12 6.28 0.01987 
Chromosome 14 open reading frame 
43 C14orf43 5.88 0.03214 
Aldolase B, fructose-bisphosphate ALDOB 5.85 0.03385 
Chromosome 10 open reading frame 
58 C10orf58 5.63 0.01007 
Neurofilament, light polypeptide 68kDa NEFL 5.54 0.00595 
Death associated protein-like 1 DAPL1 5.21 0.04941 
Table 6.6 - The top 10 genes upregulated in conjunctival samples analysed five days after 
glaucoma filtration surgery augmented with perioperative MMC. 
 
 
 
 
 
Gene Title Gene Symbol FC P value 
Serum/glucocorticoid regulated kinase SGK -20.97 0.01259 
Interleukin 1, α IL1A -14.16 0.03342 
Epsin 2 EPN2 -12.26 0.04917 
Actin related protein 2/3 complex, 
subunit 5, 16kDa ARPC5 -9.25 0.02172 
Ribosomal protein L12 RPL12 -8.99 0.00064 
Kruppel-like factor 13 KLF13 -7.92 0.02246 
Plasminogen activator, tissue PLAT -7.84 0.01255 
Podoplanin PDPN -7.75 0.01485 
Procollagen C-endopeptidase 
enhancer PCOLCE -7.53 0.03454 
Serpin peptidase inhibitor, clade B 
(ovalbumin), member 2 SERPINB2 -7.31 0.00168 
Table 6.7 - The top 10 genes downregulated in conjunctival samples analysed five days after 
glaucoma filtration surgery augmented with perioperative MMC.
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Figure 6.15 - IPA functional classification of genes differentially expressed in conjunctiva treated with MMC following GFS. 
The top 20, statistically significant, functional groups containing genes identified as meeting the cut-off criteria (FC ± 1.5, p < 0.05). Groups are ranked according to p value 
significance with the p value threshold (0.05) shown via the yellow line. The groupings indicate that most differences in gene expression were in genes related to cell death, 
cellular growth and protein synthesis. 
 
Figure 6.16 - IPA canonical pathway analysis of genes differentially expressed in conjunctiva treated with MMC following GFS. 
Pathways are ranked by ratio (secondary x-axis), which represents the total number of molecules in a given pathway, with all pathways having met a p value threshold of 0.05 
as indicated by the lower yellow line. The top pathways that were affected included oxidative phosphorylation, p38 MAPK signalling and ILK signalling.
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Network analysis based upon gene interactions also highlighted similar effects with the 
top three networks containing a number of genes related to small molecule 
biochemistry, DNA replication, cellular compromise and energy production. Three 
central nodes primarily dominate network 1: MAPKAPK2, UBQLN4 and peptidylprolyl 
isomerase. Stemming from the MAPKAPK2 gene are members of the actin complex 
ARP, with a number of members downregulated as well as the gene WASF2. Each of 
these genes encodes proteins involved in actin fibre formation and lamellipodia 
extension critical to cell migration and growth (Bannigan et al., 2005; Ibarra et al., 
2005).  
The genes centred around the UBQLN4 node, a gene encoding for the protein ubiquilin 
4 [also known as ataxin-1-interacting protein (A1Up)], part of a family of proteins 
involved in protein production within the endoplasmic reticulum although A1Up has 
been proposed to be involved in the chaperone of ataxin-1 into the nucleus where it 
may mediate RNA processing (Davidson et al., 2000; Irwin et al., 2005). A number of 
genes shown interacting with the central node, such as FKBP2 and PIN1 are members 
of the peptidyloprolyl isomerase family with these proteins involved in protein 
production where they are able to bind target proteins and direct them for either 
intracellular localisation, dephosphorylation, ubiquitylation or transactivation (Shaw, 
2002). 
Network two centres around the PKC signalling pathway as well as the MAP3K7 gene. 
The network highlights the downregulation of two heat shock proteins, HSPB1 and 
Hsp27, which are implicated in apoptosis, where Hsp27 functions to inhibit the 
activation of pro-caspase 9 through disruption of the cytochrome-C/APAF-1 complex 
(Pandey et al., 2000). A number of nuclear located proteins are also shown to be 
downregulated, such as SFRS11 and TARBP2, which have been demonstrated to be 
involved in RNA processing and alternative splicing (Bannwarth et al., 2001; J. Y. Wu 
et al., 2006).  
Network 3 is centred on two central nodes composed of the NF-κB complex and, firstly, 
the ATP synthase complex. This complex is dominated by the upregulation of a 
number of ATPase enzymes, each of which are involved in the catalysation of ATP into 
ADP; under acute oxidative stress these enzymes have been shown to be upregulated 
(Dargelos et al., 2010) with type 2 diabetes patients known to have decreased ATP 
synthase activity coincided with increased ROS formation [as reviewed by Christen 
Anderson (C. Anderson, 1999)]. The downregulation of the NF-κB complex members 
RelA and LITAF (a TNF-α secreting promoter) underlies a number of the associated 
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downregulated genes presented, including the downregulation of HDGF for which the 
presence of RelA is required for its own upregulation (Hinata et al., 2003). Similarly, the 
downregulation of CARD10 underlies the downregulation of the NF-κB complex, as 
CARD10 has been shown to be involved in BCL10 mediated activation of NF-κB (L. 
Wang, Guo et al., 2001). Further downregulated proteins within this network include the 
downregulation of HTRA1, the gene encoding serine protease 11, which has been 
implicated in enhancing the induction of MMP-1 and MMP-3 in synovial fibroblasts 
though fibronectin fragmentation, as well as inhibiting TGF-β family members including 
TGF-β1 (Oka et al., 2004; Grau et al., 2006; Milner et al., 2008).  
Network four focuses around the roles of the gene encoding the tumour suppressor 
protein p53 as well as highlighting the downregulation of the eukaryotic translation 
initiation factors (EIFs), a group of proteins that are involved in the translation of 
mRNA. A number of genes are shown within this network to be downregulated. The 
exact roles of the EIF proteins is beyond the scope of this thesis but more information 
can be found within the reviews of Sonenberg and Hernández (Sonenberg et al., 2003; 
Hernández et al., 2005). The downregulation of TP53 is displayed with a range of non-
apoptotic related interactions associated with this protein including a number of 
transcription factors such as Transcriptional enhancer factor TEF-4  (TEAD2) and 
chromosome 16 open reading frame 53 (C16ORF53, or more commonly known as 
PA1).  
At the centre of network 5 is ITGB3, the gene encoding integrin β 3, as well as 
members of the calpain family and VEGFA; each of were shown to be downregulated, 
as were many of their network neighbours.  The downregulation of VEGF was 
associated with the downregulation of HK1, hexokinase 1, a member of the hexokinase 
family of proteins which are involved in a number of metabolic processes including 
glycolysis and as a consequence, protein synthesis (Golshani-Hebroni et al., 1997; 
Kawai et al., 2005). The presence of VEGF has been shown to increase HK1 
expression in HUVECs, mediated through the AKT3 signalling cascade (G. L. Wright et 
al., 2008). A further network of interest is network 8, associated with cellular 
movement. However, this network highlights the downregulation of both the urokinase 
and tissue plasminogen activators as well as MMP-1 and the transcription factor, ETS1 
which regulates the expression of a number of MMPs including MMP-1, MMP-2 and 
MMP-9, each of which was downregulated in the dataset although only MMP-1 was 
found to be significant (Trojanowska, 2000). The network also highlights the 
downregulation of the TGF family members BMP1, a protein capable of cleaving 
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Procollagen I, II and III (Trackman, 2005), and BMP7, an inhibitor of TGF-β2 signalling 
(Fuchshofer et al., 2007). 
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Figure 6.17 - Significant signalling networks mapped using the differential gene expression found 
in conjunctiva treated with MMC following GFS. 
Associated functions with the genes within the networks included: Network 1: Drug metabolism and DNA 
replication; Network 2: Cellular compromise and protein synthesis.
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Figure 6.18 - Significant signalling networks mapped using the differential gene expression found 
in conjunctiva treated with MMC following GFS. 
Associated functions with the genes within the networks included: Network 3: Energy production and 
nucleic acid metabolism; Network 4: Protein synthesis. 
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Figure 6.19 - Significant signalling networks mapped using the differential gene expression found 
in conjunctiva treated with MMC following GFS. 
Associated functions with the genes within the network included: Network 5: Cellular movement and cell-
to-cell signalling and interaction. 
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6.3.3.3 Ilomastat injection vs. Operated control 
Data analysis of the gene expression changes within conjunctival tissue obtained from 
the filtration blebs of rabbits that had been treated, postoperatively, with a 0.1 ml 
injection of 100 µM ilomastat was undertaken through direct comparison with operated 
conjunctival samples.  
At day five in the wound healing response initial analysis of the top ten 
up/downregulated genes (Table 6.8 and Table 6.9) was suggestive of a downregulation 
within the proinflammatory cascade through the downregulation of genes such as IL-1α 
and the urokinase plasminogen activator. Within the upregulated genes, two stood out 
due to their familial relationship: WNT5A and DKK1. The Wnt family member WNT5A is 
part of a group of proteins that are highly implicated in the developmental process; 
however, outside of this WNT5A has been shown to stimulate lamellipodia formation in-
vitro with signalling mediated through the Jnk transcription factors important for the 
migration of wound healing cells (Nishita et al., 2006; Nomachi et al., 2008; Nishita et 
al., 2010). Dickkopf-related protein 1  (DKK1) is an inhibitor of Wnt signalling and has 
been shown to block WNT5A induced macrophage invasion in-vitro (Pukrop et al., 
2006) as well as being critical for the regulation of skin thickness where, in the dermis, 
it is secreted from fibroblasts to promote keratinocyte proliferation through increased 
expression of keratin 9 and decreased expression of β-catenin (which incidentally, was 
observed to be downregulated in the data set) (Y. Yamaguchi et al., 2008). 
Furthermore, DKK1 has also been demonstrated to function as a tumour suppressor 
with the ability to induce apoptosis, although this has only been shown in cancer cells 
(Hirata et al., 2010). Despite these genes little else within the top ten genes could be 
identified as being significantly important without further analysis.  
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Gene Title Gene Symbol FC P value 
Family with sequence similarity 62 (C2 
domain containing) member B FAM62B 6.21 0.00014 
Dickkopf homolog 1 (Xenopus laevis) DKK1 4.79 0.01207 
Secretoglobin, family 2A, member 1 SCGB2A1 3.57 0.03359 
Platelet factor 4 (chemokine (C-X-C motif) 
ligand 4) PF4 3.06 0.01191 
Wingless-type MMTV integration site family, 
member 5A WNT5A 2.76 0.04837 
Phosphoinositide-3-kinase interacting protein 
1 PIK3IP1 2.62 0.00172 
Coenzyme Q2 homolog, prenyltransferase 
(yeast) COQ2 2.54 0.0026 
Protein kinase, cAMP-dependent, regulatory, 
type II, β PRKAR2B 2.47 0.01522 
Mitochondrial ribosomal protein L17 MRPL17 2.44 0.03588 
Ribosomal protein L17 RPL17 2.43 0.01688 
Table 6.8 - The top 10 genes upregulated in conjunctival samples analysed five days after 
glaucoma filtration surgery augmented with a single postoperative injection of ilomastat. 
 
 
 
 
 
Gene Title Gene Symbol FC P value 
Relaxin 2 RLN2 -14.76 0.03197 
Interleukin 1, α IL1A -7.84 0.02412 
Serpin peptidase inhibitor, clade B 
(ovalbumin), member 2 SERPINB2 -5.26 0.0009 
Serum/glucocorticoid regulated kinase SGK -4.21 0.04906 
Apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide 1 APOBEC1 -3.45 0.00855 
CDV3 homolog (mouse) CDV3 -3.40 0.00205 
ATP-binding cassette, sub-family A (ABC1), 
member 8 ABCA8 -3.35 0.03559 
Epithelial membrane protein 1 EMP1 -3.09 0.00006 
Plasminogen activator, urokinase PLAU -3.03 0.03001 
UDP-glucose dehydrogenase UGDH -2.82 0.02944 
Table 6.9 - The top 10 genes downregulated in conjunctival samples analysed five days after 
glaucoma filtration surgery augmented with a single postoperative injection of ilomastat. 
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Therefore, as previously described, functional grouping of the differentially expressed 
genes was undertaken with the most significantly affected functions related to cell 
death, growth and proliferation as well as cell morphology. Within the cell death group, 
a mixture of up and down regulation was observed, with members of the extrinsic 
pathway largely downregulated, such as the downregulation of Fas and IKBKB, with 
upregulation seen in CASP3, the gene encoding caspase 3. The amyloid precursor 
protein, APP, was also upregulated which has been shown to induce apoptosis through 
an increase in β-amyloid production (which was itself upregulated in the dataset) 
following caspase-3 cleavage of APP leading to the formation of a positive feedback 
loop (Gervais et al., 1999; Tanzi, 1999). The retinoic acid induced transcription factor 
RAI14 and the ribosomal binding protein RPL37 were similarly both upregulated and 
have previously been indentified as being upregulated in fibroblast apoptosis (Hitomi et 
al., 2008). 
Canonical pathway analysis found pathways related to endoplasmic reticulum (ER) 
stress and protein ubiquitination to be significantly affected. Within the ER stress 
pathway, two primary proteins were underlying the significance found, with these the 
BiP (HSPA5) gene and XBP1 gene, both of which were downregulated. BiP encodes 
heat shock protein 70 (Hsp70) which, whilst having a wide range of roles, is 
predominantly involved in the transportation of proteins throughout the cell; however, 
studies have demonstrated that the knockdown of Hsp70 can promote cell survival in 
fibroblast-like synoviocytes though disruption of Akt mediated apoptosis (E. H. Kang et 
al., 2009). The x-box binding protein 1 (XBP1) transcription factor is involved in 
regulating the expression of, amongst other inflammatory cytokines, IL-6 (Iwakoshi et 
al., 2003). The treatment of human fetal lung fibroblasts with TGF-β1 has also been 
shown to trigger an increase in XBP1 expression (Chambers et al., 2003).  
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Figure 6.20 - IPA functional classification of genes differentially expressed in conjunctiva treated with an injection of ilomastat.  
The top 20, statistically significant, functional groups containing genes identified as meeting the cut-off criteria (FC ± 1.5, p < 0.05). Groups are ranked according to p value 
significance with the p value threshold (0.05) shown via the yellow line. The groupings indicate that most differences in gene expression were in genes related to cell death, 
cellular growth and proliferation and cellular movement. 
 
Figure 6.21 - IPA canonical pathway analysis of genes differentially expressed in conjunctiva treated with an injection of ilomastat. 
Pathways are ranked by ratio (secondary x-axis), which represents the total number of molecules in a given pathway, with all pathways having met a p value threshold of 0.05 
as indicated by the lower yellow line. The top pathways that were affected included endoplasmic reticulum stress pathway, the protein ubiquitination pathway and the 
coagulation system. 
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Network 1, which is associated with cellular assembly and organisation, as well as 
cellular compromise, highlights the downregulation of both the FAS receptor and tPA, 
the ECM component SerpinB2 as well as the upregulation of clusterin [an anti-
apoptosis protein that is able to inhibit activated Bax (H. Zhang, Kim et al., 2005)], 
cytochrome C oxidase subunit 2 (MT-CO2) and the macrophage scavenger receptor 1 
(MSR1), a largely macrophage associated protein involved in the uptake of low-density 
lipoprotein that has previously been identified as being upregulated during the wound 
healing process, with its presence detected as late as 168 hours in a study by Gerecke 
(Deonarine et al., 2007; Gerecke et al., 2007).  
Network 2 centres around the downregulated YWHAQ, a gene that encodes the 14-3-3 
protein theta that is able to mediate the signal transduction of the PKC signalling 
cascade, which has previously been shown to be upregulated in fibroblast mediated 
remodelling of the uterine cervix during pregnancy (Malmström et al., 2007); despite 
this its exact function has yet to be fully determined, although it has been implicated in 
a range of functions including apoptotic control through a direct binding of Bax 
preventing apoptosis. However Bax activation can be achieved via the activation of the 
extrinsic apoptotic cascade, which leads to the caspase-mediated cleavage of the 14-
3-3 theta-Bax complex, releasing Bax to perform its pro-apoptotic roles (Nomura et al., 
2003; Mhawech, 2005).  
Network 3, containing genes largely associated with the cell cycle, is actually centred 
around the transcription factor HNF4A, a gene that was not tested for on the array. 
However, several genes that it either interacts with, or regulates, were altered including 
the downregulation of the DNA polymerase subunit Pole3 which has been shown to 
associate with E2F1 and 4 as well as MyC to positively regulate the cell cycle, with 
upregulation in NIH3T3 mouse fibroblasts correlating with the onset of the S phase 
(Bolognese et al., 2006). A further nuclear protein that was downregulated but has 
been shown to interact with HNF4A is symplekin, SYMPK, a protein that has been 
associated with the polyadenylation of mRNA as well as mitotic spindle formation 
(Cappell et al., 2010). The network also highlights the upregulation of CRELD1, the 
gene encoding an ECM protein that contains EGF like repeats which has been largely 
associated with developmental processes within the cardiovascular system and limb 
buds (Rupp et al., 2002).  
Network 4 highlights the downregulation of a number of genes involved in post-
translation modification and cell death, with many of the previously mentioned genes 
implicated in this network such as caspase 3 and IKBKB. Further pertinent to the 
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induction of cell death was the downregulation of the anti-apoptotic gene BAG1 which 
encodes a protein of the same name that interacts with Bcl-2 to promote Bcl-2s anti-
apoptotic effect; the overexpression of BAG1 has been identified within a number of 
cancer cell lines including both pituitary tumour and colon tumour formation (X. Yang et 
al., 1999; Y.-X. Bai, Yi et al., 2007; Evans et al., 2008). Similarly, the network is 
characterised by the downregulation of another anti-apoptotic gene SGK1, which 
encodes a serine/threonine protein kinase sharing 50% homology with Akt, a similarly 
anti-apoptotic kinase (Luft, 2007) that is known to control the downstream signalling of 
the cytokine IL-2 which functions as a pro-survival cytokine in T-lymphocytes, although 
it’s receptor has been identified to be present on other cell types, including fibroblasts 
(Gruss et al., 1996; Benczik et al., 2004). The role of Sgk1 is thought to be similar to 
that of Akt, with Amato and colleagues demonstrating that IL-2 inhibition of apoptosis is 
mediated through Sgk1 in a renal carcinoma cell line (Amato et al., 2007). The network 
also highlights the downregulation of several heat shock protein encoding genes, 
including Hsp5, Hsp8 and Hsp70. 
Network 5, whilst associated with cellular development, only contains a small number 
of differentially expressed genes with a number already discussed. However, the 
network does highlight the downregulation of DDX5, a gene encoding the protein p68 
RNA helicase that has been demonstrated to coactivate the p53 tumour suppressor, 
with RNAi downregulation of p68 shown to decrease p53-mediated apoptosis (Bates et 
al., 2005). A network of further interest is network 9, which is associated with cell-to-cell 
signalling and tissue development. The network displays the downregulation of IL-α 
and IFN gamma antagonist (IK), together with an upregulation of the IGFBP5 gene. 
The network also includes the MMP node, which whilst not shown to be 
downregulated, upon analysis of the MMP genes it was found that the expression of 
MMP-1 was downregulated 1.7 fold, although did not meet the significant cut off value 
due to its p value of 0.0825. 
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Figure 6.22 - Significant signalling networks mapped using the differential gene expression found 
in conjunctiva treated with an injection of ilomastat following GFS 
Associated functions with the genes within the networks included: Network 1: Cellular assembly and 
organisation; Network 2: Cell-to-cell signalling and interaction. 
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Figure 6.23 - Significant signalling networks mapped using the differential gene expression found 
in conjunctiva treated with an injection of ilomastat following GFS 
Associated functions with the genes within the networks included: Network 3: Cell cycle; Network 4: Post-
Translational modification and cell death.
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Figure 6.24 - Significant signalling networks mapped using the differential gene expression found 
in conjunctiva treated with an injection of ilomastat following GFS 
Associated functions with the genes within the network included: Network 5: Cellular development.
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6.3.3.4 Ilomastat tablet vs. Operated control 
Data analysis of the gene expression changes with conjunctival tissue obtained from 
the filtration blebs of rabbits that had been treated, perioperatively, with the 
implantation of an ilomastat tablet, was undertaken with direct comparison with 
operated conjunctival samples.  
At day five in the wound healing response initial analysis of the top ten 
up/downregulated genes (Table 6.10 and Table 6.11) was suggestive of an enhanced 
inflammatory response beyond that of normal wound healing. Within the top 10 
upregulated genes were three MMPs: MMP-9, -12 and -13 with fold change increases 
of 10.8, 19.1 and 4.57 respectively as well as upregulation of the inflammatory related 
collagens, including collagen XII and collagen VIII where is thought to be important for 
neutrophil accumulation (Shuttleworth, 1997; Illidge et al., 1998). Similarly the 
upregulation of PDCD4, a gene encoding the programmed cell death protein 4, is 
largely associated with cytokine release from inflammatory cells; the presence of an 
NF-κB binding site, which is predicated to be in its promoter, provides a mechanism by 
which it can positively influence TNF-induced activation of NF-κB; when cells lacking 
PDCD4 were subject to LPS treatment (which normally induces cell death) it was found 
that the cells were protected from entering the apoptotic cascade, with PDCD4 mice 
resistant to some models of inflammatory disease including streptozotocin-induced 
diabetes which causes persistent inflammation following the induction of uveitis. 
(Onishi et al., 1998; S. Rossi et al., 2006; Lankat-Buttgereit et al., 2009).  
Genes downregulated included a 12 fold downregulation of CYCS, the gene encoding 
cytochrome C, and a 7 fold downregulation of the complement component 1 gene, 
C1S, which encodes the C1s serine protease which is involved in the direct activation 
of the complement system through the formation of the C1 complex. C1S has also 
been implicated in the cleavage of type I and II collagen and IGFBP5, incidentally, 
which was upregulated within the data set.  
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Gene Title Gene Symbol FC P value 
Matrix metallopeptidase 12 (macrophage 
elastase) MMP-12 19.12 0.00288 
Matrix metallopeptidase 9 (gelatinase B, 
92kDa gelatinase, 92kDa type IV 
collagenase) 
MMP-9 10.80 0.00111 
Lysyl oxidase LOX 6.52 0.02074 
Family with sequence similarity 62 (C2 
domain containing) member B FAM62B 6.21 0.00014 
Secretoglobin, family 2A, member 1 SCGB2A1 5.61 0.01157 
Collagen, type VIII, α 2 COL8A2 5.05 0.03654 
Programmed cell death 4 (neoplastic 
transformation inhibitor) PDCD4 4.60 0.0011 
Matrix metallopeptidase 13 (collagenase 3) MMP-13 4.57 0.03061 
Collagen, type XII, α 1 COL12A1 4.56 0.04608 
Heat shock 27kDa protein 1 HSPB1 4.31 0.00842 
Table 6.10 - The top 10 genes upregulated in conjunctival samples analysed five days after 
glaucoma filtration surgery augmented with the perioperative implantation of an ilomastat tablet. 
 
 
 
 
 
Gene Title Gene Symbol FC P value 
Cytochrome c, somatic CYCS -12.61 0.03282 
Complement component 1, s subcomponent C1S -7.21 0.03575 
Carboxypeptidase E CPE -6.55 0.02994 
Mitochondrial ribosomal protein S33 MRPS33 -4.04 0.01863 
Inhibitor of κ light polypeptide gene enhancer 
in B-cells, kinase β IKBKB -3.47 0.00007 
PDZ and LIM domain 3 PDLIM3 -3.28 0.01064 
CUG triplet repeat, RNA binding protein 2 CUGBP2 -3.22 0.03197 
PDZ and LIM domain 3 PDLIM3 -3.12 0.00848 
Signal transducing adaptor molecule (SH3 
domain and ITAM motif) 2 STAM2 -3.11 0.03421 
Fibroblast growth factor 13 FGF13 -3.07 0.04215 
Table 6.11 - The top 10 genes downregulated in conjunctival samples analysed five days after 
glaucoma filtration surgery augmented with the perioperative implantation of an ilomastat tablet. 
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Functional grouping of the differentially expressed genes highlighted the groups 
associated with cell death, movement, growth and proliferation as being the most 
significantly affected. Within the cell death group a number apoptotic related genes 
were upregulated including CASP3, TNF, CTNNB1 (β-catenin) and FN1 (fibronectin). 
Whilst genes such as CAPS3 and TNF are pro-apoptotic, the upregulation of FN1, 
fibronectin 1, has previously been associated with protection from Fas induced 
apoptosis (Kitagawa et al., 2006).  
Canonical pathway analysis of the differentially expressed genes found pathways 
related to oxidative stress and acute phase response signalling to be the most 
significantly altered pathways, together with IL-6 signalling. The oxidative 
phosphorylation pathway highlights the downregulation of a number of the genes 
involved in the complexes that make up the electron transport chain, such as the 
downregulation of NADH dehydrogenase encoding genes found within complex I, 
cytochrome c oxidase encoding genes found within complex IV as well as genes 
related to complex III and V such as ubiquinol-cytochrome-c reductase (UQCRB) and 
adenosine-tetraphosphatase (ATP5L). The acute phase response signalling cascade 
highlighted the upregulation of both TNF-α and IL-1β, together with the IL-6 signalling 
pathway mediator STAT3, the MAPK signalling cascade member HSP27 and the 
lipopolysaccharide receptor CD14, a receptor that is present on the cell surface of 
macrophages and stimulates their activation. Further highlighted within the IL-6 
signalling cascade was the downregulation of the Ras components Ras-related protein 
R-Ras2 (RRAS2 / TC21) and Neuroblastoma RAS viral oncogene homolog (NRAS), 
with RRAS2 known to induce activation of both the MAPK and PI3K signalling 
cascades (Rosário et al., 1999; Rong et al., 2002). Many of these functional changes 
were similarly reflected within the networks generated using the differentially expressed 
genes.  
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Figure 6.25 - IPA functional classification of genes differentially expressed in conjunctiva treated with an ilomastat tablet.  
The top 20, statistically significant, functional groups containing genes identified as meeting the cut-off criteria (FC ± 1.5, p < 0.05). Groups are ranked according to p value 
significance with the p value threshold (0.05) shown via the yellow line. The groupings indicate that most differences in gene expression were in genes related to cell death, 
cellular growth and proliferation and cellular movement. 
 
Figure 6.26 - IPA canonical pathway analysis of genes differentially expressed in conjunctiva treated with an ilomastat tablet. 
Pathways are ranked by ratio (secondary x-axis), which represents the total number of molecules in a given pathway, with all pathways having met a p value threshold of 0.05 
as indicated by the lower yellow line. The top pathways that were affected included oxidative phosphorylation, acute phase response signalling and the hepatic fibrosis 
pathway. 
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Network 1, which is functionally associated with cell death, is centred around the 
upregulated caspase 3 and β-catenin genes. The network further highlights the 
downregulation of IKBKB, which is known to phosphorylate β-catenin suppressing its 
pro-apoptotic function (Lamberti et al., 2001). The network also highlights the 
downregulation of proteasome encoding genes, such as PSMA3 (a member of the 20s 
proteasome complex), which can become upregulated through an antioxidant response 
element in order to degrade oxidised proteins (Merker et al., 2000).  
Network 2 further highlights the role of oxidative stress, with downregulation seen in a 
number of cytochrome c oxidase related proteins including COX7C, COX6C and 
COX7B; cytochrome c oxidase where, in the electron transport chain, it converts 
oxygen into water, is critical to controlling the generation of ROS, with deficiencies 
associated with the increased oxidative stress and amyloid formation in a mouse model 
of Alzheimer’s (Fukui et al., 2007; Pickrell et al., 2009). Of more interest however is the 
link between MMPs and ROS generation, with MMP-1, -2, -7, and -9 all having been 
shown to be upregulated through ROS induced increases in AP-1 and NF-κB (Nelson 
et al., 2004; Nelson et al., 2006). The downregulation of calcineurin is also displayed 
within the network, although inflammatory conditions are more typically associated with 
an upregulation, such as in arthritis where the activation of calcineurin has been highly 
implicated in the induction of inflammatory cytokine and MMP production (Yoo et al., 
2006). The upregulation of the heat shock protein 27 is also noted through the 
upregulation of the HSP27 and HSPB1 nodes, together with further markers of an 
acute phase inflammatory response such as the upregulation of ferritin and it’s related 
genes. Both IL-1β and TNF-α increase the synthesis of ferritin, with ferritin known to 
increase IL-1β secretion through activation of NF-κB via the PKC signalling cascade in 
a positive feedback loop (Ruddell et al., 2009). Network 3 is centred around IL-13 and 
β-estradiol, neither of which were tested for on the array, although a number of genes 
that they are known to regulate were found to be differentially expressed. Interleukin-
13, an inflammatory response protein, has been shown to induce human fibroblast 
proliferation in-vitro as well as upregulate the expression of MMP-2, -12, -13 and -14 
following the induction of an inflammatory response (Lanone et al., 2002; Ingram et al., 
2004). The cathepsin genes CTSB and CTSL2 were also found to be upregulated, 
which have, similarly, been shown previously to be upregulated following an IL-13 
overexpressed inflammatory response (Zheng et al., 2000). The cathepsin B protein 
(CTSB) functions in a number of ways including the initiation of a uPA mediated 
cascade that is able to activated pro-TGF-β (M. Guo et al., 2002); within the dataset an 
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upregulation of TGF-β1 was also found, suggesting an increased role for TGF β 
signalling. Network four centres around STAT3, PKC and the side group members of 
the NADH pathway. The STAT signalling cascade is dependent on STAT3, which can 
be activated by a number of cytokines and growth factors, including IL-1 and IL-6. The 
upregulation of RBM8A, a gene that encodes the protein Y14, underlies the interaction 
between STAT3 and Y14, with binding between the two able to positively regulate the 
phospho-activation of the STAT3; in Y14 knockdown cells the continuous stimulation 
with IL-6, a STAT3 activator, eventually led to a decrease in STAT3 within the nucleus 
indicating that Y14 may be critical in restraining STAT3 in the nucleus (Ohbayashi et 
al., 2008). The widespread downregulation of various NADH protein encoding genes is 
demonstrated to the left of the central network. The NADH proteins are required during 
the electron transport chain as was previously illustrated within the oxidative stress 
pathway. A downregulation of the NADH genes has previously been shown to occur 
during tumour formation, such as within basal cell carcinoma development (Mamelak et 
al., 2005). The presence of the NDUFA1 gene has previously been proposed to be 
critical for regulating electron flow, with disruption in complex I activity leading to 
increased ROS formation and subsequent downstream damage, such as activation of 
the intrinsic apoptotic cascade (Wallace, 1999; T. Tanaka et al., 2000; Novo et al., 
2008). Whilst VEGF acts as a central node, it itself was not altered on the array, 
although EMP1, an endothelial junction protein was found to be downregulated, 
although little literature exists as to its exact function; current reports suggest it 
localises with endothelial cell tight junctions where it may be involved in the loosening 
of tight junctions between endothelial cells (Bangsow et al., 2008; Soulet et al., 2010).  
Network 5 centres directly around the upregulated TNF-α molecule, which itself affects 
many of the previously described functions including its stimulatory role in ROS 
generation, STAT3 transcription and activation of both the intrinsic and extrinsic 
apoptotic cascades. Whilst several nodes within this network have previously been 
discussed, it does highlight several interesting links including the activation of NUAK1, 
a gene that encodes SNF1-like kinase, which interacts with myosin phosphatase in the 
regulation of cell adhesion; phosphorylation of myosin phosphatase complex member 
MYPT1 leads to the inhibition of complex formation and subsequently causes myosin-
related cell detachment (Banno et al., 2004; Zagórska et al., 2010).  
The network also highlights the downregulation of the glutathione peroxidase members 
GSTT1 and GPX3, a family of proteins that catalyse the reduction of hydrogen 
peroxide, as such protecting against their damaging effects (Barnett et al., 1995). 
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Two additional networks of further interest were networks 9 and 10, associated with 
tissue morphology and drug metabolism respectively. At the centre of network 9 is the 
upregulated MMP-9 together with the upregulated TIMP family member, TIMP-1. Both 
of these genes are linked to TSP-1 (thrombospondin), which again was upregulated 
within the array; the Tuszynski group have previously demonstrated that the 
exogenous addition of TSP-1 to endothelial cells can upregulate TIMP-1 and MMP-9, 
highlighting a potential mechanism for MMP-9 upregulation during angiogenesis (Qian 
et al., 1997; John et al., 2009). Furthermore, thrombospondin has been demonstrated 
to promote the recruitment of macrophages during an inflammatory response (Reed et 
al., 1993). Whilst the TNF gene was previously shown to be upregulated, the TNF 
receptor superfamily member 11B (TNFRSF11B) was found to be downregulated, 
although this receptor is more often expressed within regenerating bone (Nakamura et 
al., 2003). The network also highlights the upregulation of lysyl oxidase, an enzyme 
that crosslinks ECM proteins such as collagen, with its effects further enhanced 
through TGF-β1 stimulation (Shanley et al., 1997; Hong et al., 1999). Network 10 
further highlights the roles of the MMPs, with MMP-12 and -13 shown to be 
upregulated, together with CTGF and IGFBP5. Related to these proteins is the 
upregulation of SRGN (serglycin), a proteoglycan that is secreted by macrophages 
during an inflammatory response and is able to cleave proMMPs, including proMMP-9 
(Zernichow et al., 2006; Ra et al., 2007). The network also displays the downregulation 
of SERPINB2, a gene that encodes the plasminogen activator inhibitor-2, a protein that 
inhibits the activity of both tPA and uPA as well as causing the downregulation of the 
MMP transcription factors TCF and LEF as well as the downregulation of the growth 
factor, FGF13. 
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Figure 6.27 - Significant signalling networks mapped using the differential gene expression found 
in conjunctiva treated with an ilomastat tablet following GFS 
Associated functions with the genes within the networks included: Network 1: Inflammatory disease; 
Network 2: Cellular development and cellular growth / proliferation.
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Figure 6.28 - Significant signalling networks mapped using the differential gene expression found 
in conjunctiva treated with an ilomastat tablet following GFS 
Associated functions with the genes within the networks included: Network 3: Cellular development and 
cell death; Network 4: Cell death.
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Figure 6.29 - Significant signalling networks mapped using the differential gene expression found 
in conjunctiva treated with an ilomastat tablet following GFS 
Associated functions with the genes within the network included: Network 5: Cell-to-cell signalling and 
interaction and cellular compromise.
  325 
6.3.3.5 Ilomastat tablet vs. ilomastat injection 
In order to compare the effects of the ilomastat tablet against that of the injection the 
expression values from the two groups were compared directly.  
At day five in the wound healing response the top ten genes (Table 6.12 and Table 
6.13) that were differentially expressed highlighted the enhanced, ongoing, 
inflammatory response present within the tablet treated filtration blebs with the elevated 
levels of both IL-1α and IL-1β characterising this response, together with the 
upregulated levels of MMP-9, -12, CTSB and FN1. Functional grouping of the 
differentially expressed genes highlighted functions within lipid metabolism and 
molecular transport as being most affected, with the canonical pathway analysis 
highlighting significant differences in the IL-10, IL-6 and oxidative phosphorylation 
pathways.  
The major differences within the interleukin signalling cascades are the enhanced 
upregulation of STAT3, TNF, IL-1 and MAP2K1 (Mek); although not significant a 4.6 
fold increase in IL-6 was also detected. These changes were largely reflected within 
the network analysis, with network 1 centred on the upregulated TNF gene as well as 
the downregulated cytochrome c oxidase.  
Network 2, related to cellular assembly and organisation is centred on the 
downregulated APP gene within the ilomastat tablet group, together with the 
downregulated state of the glutathione peroxidase genes.  
Network 3 contains genes largely associated with tissue morphology, further 
highlighting the upregulated state of STAT3 and MAP2K1.  
Networks 4 and 5 display a number of genes all previously discussed, with functions 
related to an inflammatory response together with cellular assembly and organisation 
respectively. Further genes of interest that were upregulated within the ilomastat tablet 
group included the increased expression of TGF-βR1 and IL-8. 
  326 
Gene Title Gene Symbol FC P value 
Matrix metallopeptidase 12 (macrophage 
elastase) MMP-12 17.03 0.01306 
Interleukin 1, α IL1A 11.03 0.04519 
Thrombospondin 1 THBS1 6.68 0.02662 
Matrix metallopeptidase 9 (gelatinase B, 
92kDa gelatinase, 92kDa type IV 
collagenase) 
MMP-9 5.73 0.01528 
ATP synthase, H+ transporting, mitochondrial 
F1 complex, α subunit 1, cardiac muscle ATP5A1 4.08 0.01492 
Programmed cell death 4 (neoplastic 
transformation inhibitor) PDCD4 3.67 0.00863 
Interleukin 1, β IL1B 3.65 0.00565 
Apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide 1 APOBEC1 3.14 0.03844 
Cathepsin B CTSB 3.12 0.0029 
Fibronectin 1 FN1 3.07 0.0199 
Table 6.12 - The top 10 genes upregulated in conjunctival samples obtained five days after 
glaucoma filtration surgery augmented with a perioperative implantation of an ilomastat tablet 
compared to conjunctival samples treated with a single postoperative injection of ilomastat. 
 
 
 
 
 
Gene Title Gene Symbol FC P value 
Mitochondrial ribosomal protein S33 MRPS33 -4.17 0.04803 
Procollagen-proline, 2-oxoglutarate 4-
dioxygenase (proline 4-hydroxylase), β 
polypeptide 
P4HB -3.71 0.04668 
Quiescin Q6 sulfhydryl oxidase 1 QSOX1 -3.51 0.00072 
Nuclear receptor subfamily 2, group F, 
member 1 NR2F1 -3.46 0.04274 
Chromosome 4 open reading frame 49 C4orf49 -3.36 0.00935 
Glutathione S-transferase theta 1 GSTT1 -3.31 0.00119 
Kinesin family member 21A KIF21A -3.21 0.04508 
Growth differentiation factor 10 GDF10 -3.08 0.01514 
Peripherin 2 (retinal degeneration, slow) PRPH2 -3.07 0.04565 
Calcium channel, voltage-dependent, L type, 
α 1C subunit CACNA1C -2.87 0.04762 
Table 6.13 - The top 10 genes downregulated in conjunctival samples obtained five days after 
glaucoma filtration surgery augmented with a perioperative implantation of an ilomastat tablet 
compared to conjunctival samples treated with a single postoperative injection of ilomastat.
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Figure 6.30 - IPA functional classification of genes differentially expressed in conjunctiva treated with an ilomastat tablet compared to an injection of ilomastat.  
The top 20, statistically significant, functional groups containing genes identified as meeting the cut-off criteria (FC ± 1.5, p < 0.05). Groups are ranked according to p value 
significance with the p value threshold (0.05) shown via the yellow line. The groupings indicate that most differences in gene expression were in genes related to lipid 
metabolism, molecular transport and small molecule biochemistry. 
 
Figure 6.31 - IPA canonical pathway analysis of genes differentially expressed in conjunctiva treated with an ilomastat tablet compared to an injection of 
ilomastat. Pathways are ranked by ratio (secondary x-axis), which represents the total number of molecules in a given pathway, with all pathways having met a p value 
threshold of 0.05 as indicated by the lower yellow line. The top pathways that were affected in tablet treated conjunctiva compared to injection treated conjunctiva included 
oxidative phosphorylation, mitochondrial dysfunction and interleukin signalling.  
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Figure 6.32 - Significant signalling networks mapped using the differential gene expression found 
in conjunctiva treated with an ilomastat tablet compared to an injection of ilomastat.  
Associated functions with the genes within the networks included: Network 1: Cellular assembly, 
organisation and compromise; Network 2: Cell death and cellular assembly and organisation.
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Figure 6.33 - Significant signalling networks mapped using the differential gene expression found 
in conjunctiva treated with an ilomastat tablet compared to an injection of ilomastat.  
Associated functions with the genes within the networks included: Network 3: Tissue morphology; Network 
4: Inflammatory response.
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Figure 6.34 - Significant signalling networks mapped using the differential gene expression found 
in conjunctiva treated with an ilomastat tablet compared to an injection of ilomastat.  
Associated functions with the genes within the network included: Network 5: Cellular assembly and 
organisation.
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6.4 Discussion 
The regulation of gene expression, and subsequently protein expression, is critical to 
the wound healing response, with temporal changes underlying the stage of wound 
healing that the tissue is currently in. This study has highlighted the changes in wound 
healing that occur early in the response, together with the effects of different drugs and 
dosing regimens in modulating this effect.  
The surgery itself produced results that correlated with previous studies that have used 
either MMC, ilomastat injections or ilomastat tablets, with the avascular area shown in 
the day five photos correlating with previously observed findings (T. T. L. Wong et al., 
2005; S. Georgoulas et al., 2008; S. D. Georgoulas, 2010). Similarly, the size of the 
blebs at day five correlated with these studies, with the control (untreated) bleb 
appearing to be on a path to surgical failure, whilst the ilomastat and MMC treated 
blebs continued to present as healthy, functioning blebs. The isolation and quality of 
the RNA was confirmed in all samples to be excellent, and whilst the study was limited 
in its design due to the number of arrays available, it was established in such a way as 
to allow multiple comparisons whilst trying to retain a balance of both technical and 
biological replicates. Despite this, the exclusion of one array led to the MMC group 
containing only a single sample, and as such warrants further investigation or validation 
to confirm its findings, though the results presented correlate with previous, albeit 
limited, publications that have investigated the gene expression changes induced by 
MMC (Crowston et al., 2002; Granada et al., 2005). 
The reason for this poorly functioning array is likely due to a technical issue, either due 
to poor labelling of the RNA, poor hybridisation, or a fault on the array, however a 
biological reason cannot be excluded, particularly when using MMC. The concentration 
of MMC used here was the maximum possible, at 0.5 mg/ml. Whilst other in-vivo 
studies (as previously cited) have used lower 0.2 - 0.4 mg/ml doses, 0.5 mg/ml is a 
clinically relevant dose (Siriwardena et al., 2004) and was chosen so as to allow the 
examination of the maximum effects of MMC on gene expression; whilst this may 
induce some biological variation (as seen in humans, with some patients suffering 
postoperative complications and others not) the differences observed during 
normalisation are more likely to have been induced due to technical error, particularly 
as RNA levels were normalised prior to labelling. Such labelling errors are not 
uncommon, with many publications in the literature falling foul of poor hybridisation on 
single arrays on multi-array chips; these errors are not unknown and a common hazard 
in using the microarray (Simon et al., 2004; Leder et al., 2009). During observation of 
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the rabbits, no complications in the bleb were observed, further discrediting the 
possibility that this was due to biological variation. Despite this one complication within 
the analysis, upon exclusion of the outlying array, the normalisation process proceeded 
correctly, exhibiting expected results that met the standards required for downstream 
analysis.  
Many details of the individual genes were described within the results section, although 
not all genes were discussed due to the impracticalities of the numbers involved. 
Instead the genes most relevant to the treatment were discussed, as well as those 
most differentially expressed or within the top networks. The discussion below will aim 
to give further biological context to the observed findings. Furthermore whilst the 
expression values provide an insight into the mechanisms being regulated during the 
wound healing process, the changes may not be reflected in the protein expression 
and as such further studies will be required to confirm this through techniques such as 
ELISA, immunohistochemistry, western blotting or more advanced proteomic 
techniques such as iTRAQ as performed by Zhou and colleagues in the analysis of 
corneal wound closure (L. Zhou et al., 2007). However, as previously documented, the 
difficulty of doing such studies in-vivo is a major obstacle due to the limited amount of 
tissue available and the manner in which protein detection must be undertaken. 
Nonetheless, with advancing array based technology, or the iTRAQ system, future 
developments may allow for such analysis. 
6.4.1 Operated vs. Unoperated 
The results from the analysis of the operated conjunctiva compared to unoperated 
controls largely correlated with the previous findings of other in-vivo wound healing 
studies, including those of Popp and colleagues, with similarities found between both 
the rabbit and rat experiments including the upregulation of MMP-3, MMP-9 and MMP-
13 (Popp et al., 2007). Although no increase in MMP-2 expression was detected in our 
array, whereas in the rat study it was found to be significantly upregulated, other 
microarray wound healing studies have similarly found upregulation of MMP-1, -3 and -
9 without an upregulation of MMP-2 until later (day 8) in the wound healing process 
(Deonarine et al., 2007; Greco et al., 2010). 
Other genes shown to be upregulated only later in the wound healing response were 
similarly absent from this day 5 dataset, including CTGF and IL-10. The upregulation of 
these MMPs correlates with the upregulation of several known activators of MMP 
expression, including the CXCL5 chemokine, with activation of its receptor, CXCR2, 
known to lead to an upregulation in MMP-9 expression; blocking of CXCR2 has been 
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shown to significantly reduce MMP-9 secretion, and the knockout of CXCR2 has been 
similarly shown to delay wound healing through defective neutrophil recruitment 
(Devalaraja et al., 2000; Chakrabarti et al., 2005). A further activator of CXCR2 
signalling is IL-8, which again on the array was shown to be significantly upregulated, 
presenting itself as a potential target for future therapeutic targeting. Related to IL-8, IL-
6 upregulation was also observed (>3 fold) although it was not found to be significant. 
Both genes signal through the STAT3 mediated signalling cascade, further highlighting 
this as a potential target for future therapies (Vij et al., 2008).  
A further family member, IL-1, was also found to be upregulated with IL-1α the most 
upregulated gene on the array. Interleukin-1 has previously been shown to be critical 
for wound healing, with IL-1R type 1 knockout mice shown to exhibit significantly 
reduced rates of wound healing in intraoral wounds, with Thomay et al demonstrating 
that the same knockout mouse had skin wounds with lower levels of collagen, despite 
an otherwise normal healing process suggesting that IL-1 inhibition can ameliorate the 
widespread fibrosis associated with some healing responses and as such could 
become a viable target in controlling wound healing following GFS (Graves et al., 2001; 
Thomay et al., 2009). Despite the presence of the IL-1 receptor antagonist available as 
a licensed drug, no studies have yet explored its use in GFS although it has been 
shown to significantly reduce CD11 positive cells (a marker of neutrophils, monocytes 
and macrophages) entering the cornea following epithelial injury (Stapleton et al., 
2008). In agreement with these inflammatory genes, the remainder of the differentially 
expressed genes were, as previously stated, largely expected merely serving to 
confirm, and in some places expand, upon the work of previous publications. 
6.4.2 MMC 
Whilst, as previously stated, the MMC group was limited due to having only a single 
analysed treatment group, observations can be made with regards to the effects 
induced following MMC treatment. Most apparent within the array was the response of 
the tissue to apoptosis, with a number of pro-apoptotic genes downregulated. 
Mitomycin-C is a known inducer of apoptosis (3.1.2.23) and as such, the 
downregulation of pro-apoptotic genes likely represents a response to the increase in 
apoptosis seen. By limiting the gene expression of these genes it is possible that a 
decrease in the protein level would be seen, and as such limit the ability of the intrinsic 
and extrinsic signalling pathways to function.  Pathways disrupted associated with this 
function included the 14-3-3 signalling pathway and the p38 MAPK pathway, which 
both highlighted the downregulation of pathway mediators and transcription factor 
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binding proteins, which are known to regulate the expression of genes such as Bax. 
Responses such as this have previously been demonstrated in cancers that become 
resistant to anti-cancer theraputics such as cisplatin, where downregulation of the pro-
apoptotic cascades have been implicated in the build up of resistance (Gadducci et al., 
2002). This suggests that such disruption is an important pro-survival mechanism that 
has been introduced to overcome the effects of the pro-apoptotic drug.  
A number of phenotypic changes are seen in cells following MMC treatment in-vitro, 
including the rounding up of cells and the dataset provides a number of insights into the 
regulation of this, primarily through the widespread downregulation of genes associated 
with the actin cytoskeleton including WAVE, the ARP2/3 complex, Actin and ROCK 
which are all implicated in a range of processes including focal adhesion formation and 
actin polymerisation, a critical process for filopodia formation, lamellipodia formation 
and stress fibre formation (Alberts et al., 2002; Disanza et al., 2005). Similarly, the 
downregulation of MMPs was widespread, with MMPs-1, -2, -3 -12 and -13 all 
downregulated more than 1.5 fold, although only MMP-1 was shown to be significantly 
affected; however, this does correlate with the previously described in-vitro findings 
although further studies will be required to validate these findings at the protein level. 
Whilst in-vitro studies have previously documented that cells treated with MMC showed 
a long term recovery in receptor expression, an initial downregulation was observed (J 
T Daniels et al., 1999) and similar findings were found here, including the 
downregulation of the FGF, TGF and EGF receptors, together with significant 
disruption of their signalling cascades through the MAPK signalling pathway.  
Overall this dataset has highlighted the changes in gene expression that seemingly 
underlie many of the changes seen both in-vitro and in-vivo as well as suggesting 
mechanisms by which cells try protect themselves from continued apoptosis. Whilst no 
specific insight can be drawn into the long term effects of MMC leading to generation of 
side effects, or the reasons behind eventual failure, the ability for populations of cells to 
prevent apoptosis suggests that a number of cells can retain a basic function which, 
over time, may allow for a continued fibrotic wound healing response. 
6.4.3 Injection 
Analysis of the ilomastat injection group revealed the fewest changes in gene 
expression, yet revealed several interesting features pertinent to the modulation of the 
wound healing response. The upregulation of the two Wnt related genes, WNT5A and 
DKK, together with a downregulation in IL-1a, correlated with a resolution of the 
inflammatory response and the activation of later events such as the differentiation, 
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growth and increased proliferation of both epithelial cells and fibroblasts (Fathke et al., 
2006) (Vuga et al., 2009). Whilst increased expression of caspase 3 was observed, a 
decrease in FAS expression was found suggesting a potential limiting of the extrinsic 
apoptotic cascade. Whilst no changes in apoptosis were observed in-vitro, such 
analysis has not taken place in-vivo. However, a further complication could be that the 
cells isolated during tissue extraction may not have been solely conjunctival cells (such 
as fibroblasts and epithelial cells) but may also have included the remnants of the 
inflammatory response (such as neutrophils and macrophages) which are known to 
enter into an apoptotic state toward the end of the inflammatory response (Greenhalgh, 
1998).  
Similarly the downregulation of the BiP and XBP1 genes further suggests a reduction in 
inflammation, with these two genes (when upregulated) associated with activation of 
the unfolded protein response (UPR) pathway and the downstream activation of the 
NF-κB, the transcription factor for many pro-inflammatory genes (Pahl et al., 1997; 
Ewbank et al., 2010). The UPR is a response to a disruption in endoplasmic reticulum 
homeostasis, with the UPR serving to counteract cell stress and its related events, 
such as apoptosis, through an alteration in transcription and translation (Butler et al., 
2009). The UPR have been well documented to occur during an inflammatory response 
(Hotamisligil, 2010) with BiP critical to this response with findings suggesting this is due 
to a repression of the ER stress-signal transducers such as protein kinase RNA-like 
endoplasmic reticulum kinase (PERK) and inositol-requiring 1 (IRE1). Interestingly, 
IKBKB adds further weight to this response, with IKBKB, encoding the IKK β protein 
which is required for the transduction of the NF-κB response, also found to be 
downregulated within the dataset (Renard et al., 1999). However, the exact mechanism 
that underlies a potential downregulation in the inflammatory response is unclear in 
terms of the role of ilomastat. Whilst no MMPs met the significant cut off level, MMP-1 
was 1.8 fold downregulated but not significant (Renard et al., 1999). Despite this, 
ilomastat has previously been demonstrated to prevent the activation of NF-κB through 
inhibition of the phosphorylation of the EGF receptor, with the EGF/NF-κB signalling 
pathway known to cause the upregulation of MMP-1 (Vincenti et al., 2002; Q. Zhang, 
Adiseshaiah et al., 2005; Lemarié et al., 2006). No studies have yet explored the gene 
expression of IKBKB in relation to the EGF signalling pathway, however the EGF 
signalling pathway is dependent on the correct functioning of NF-κB (L. Huang et al., 
2008).  
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Interestingly the downregulation of the urokinase plasminogen activator correlated 
highly with the in-vitro array data, presenting a route through which ilomastat may 
further modulate MMP activity in-vitro. The fact that this gene was still downregulated 
long after the injection of ilomastat is potentially testament to the effects of ilomastat 
over a prolonged period of time following a single exposure.  
Despite these observations many of the genes that were altered in this array proved 
difficult to link together. The downregulation of the interleukin genes IL-1, IL-6 and IL-8 
together with other inflammatory cytokines such as TNFAIP6 are important to the 
pathogenesis of the healing bleb and suggest that ilomastat has reduced the 
inflammatory response consistent with previous publications; for example Zheng and 
colleagues were able to show that the use of ilomastat was able to decrease IL-13 
expression as well decrease the number of infiltrating macrophages and leukocytes by 
90% when assessed in a mouse model of chronic obstructive pulmonary disease, with 
similar findings reported by Wang and Tsirka when using ilomastat to control 
inflammation following intracerebral haemorrhage (Jian Wang et al., 2005). Lin and 
colleagues demonstrated a significant downregulation in IL-1β following ilomastat 
administration to LPA stimulated HUVECs in-vitro, with LPA known to activate the 
EGFR suggesting once again a modulation of the EGF pathway (Lin et al., 2011). 
Whilst more specific functions of ilomastat are difficult to pin down from this data set, 
the reduced inflammatory response alone is a noteworthy effect due to the dosing 
regimen used here; despite the injection having occurred five days prior to RNA 
isolation, a reduction in the inflammatory response was still observed highlighting the 
role of ilomastat as an anti-inflammatory agent. 
6.4.4 Tablet 
Upon analysing the ilomastat tablet treated conjunctiva it became evident that the gene 
expression profile was indicative of a side effect to the implantation of a foreign body 
(the tablet) as characterised by the upregulation of MMP-9, -12 and -13 all within the 10 
most upregulated genes. This was further coupled with a number of inflammatory 
related genes such as TNF, FN1, IL-1β, IL-6, CTNNB1 and STAT3. The differences 
were highlighted in comparison to both the operated conjunctival samples and 
ilomastat injection treated conjunctival samples, with no real overlap found between the 
two different ilomastat treatment regimens. In order to understand the potential causes 
of this inflammatory response careful consideration was given as to what the presence 
of an implanted tablet could trigger, with a foreign body reaction (FBR) identified as the 
most logical answer (James M Anderson et al., 2008). The FBR undergoes a number 
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of steps beginning with an acute inflammatory response, before progressing through to 
a stage of granulation tissue formation and the development of fibrotic tissue over the 
foreign body, made up of many of the same ECM components found in scar tissue; the 
FBR as a whole bares many similarities to that of the wound healing process as shown 
in Figure 6.35 (J M Anderson, 1988). 
Upon the implantation of a foreign body, serum proteins including fibrinogen, 
fibronectin, IgG and complement factors adsorb onto the surface, leading to the 
generation of soluble protein fragments that are able to attract and mediate the 
adhesion and migration of macrophages, leukocytes and neutrophils (Tang et al., 1993; 
A K Mcnally et al., 1994; Keselowsky et al., 2007). Similarly the increased expression 
of the integrins β1 and β2 of the surface of the primary invading inflammatory response 
related cells, as well as the secretion of IL-8, have been shown to be important in the 
identification of the foreign material, further aiding in the continued recruitment of 
macrophages (Amy K Mcnally et al., 2002; J. A. Jones et al., 2007). As increased 
binding of macrophages to the foreign body continues, a change in cytokine secretion 
occurs with levels of TNF-α and IL-6 particularly critical to the continued development 
of the FBR (Higgins et al., 2009). A number of the above genes were found to be 
upregulated within the data set, although neither the integrin β1/2 nor the complement 
factor genes were found to be differentially expressed, suggestive of a move away from 
the initial inflammatory response to the secondary, or tertiary stage, of FBR that 
includes the generation of foreign body giant cells (FBGC) and the formation of the 
fibrous capsule (James M Anderson et al., 2008). Similarly no increase in either IL-6 or 
TNF-α was found within the surgically operated group, to which the dataset comparison 
was made, indicative of the response having moved on to a later stages where these 
cytokines become critical.  
A further bi-product of macrophage recruitment is the generation and release of free 
radicals, leading to the activation of the apoptotic cascade [furthermore, upon the 
formation of the FBGC free radical production has been shown to increase by as much 
as 20 - 30 times (Kreipe et al., 1988; Q. Zhao et al., 1991)]. The dataset demonstrated 
a downregulation of a number of genes related to the oxidative-stress signalling 
pathway, potentially demonstrating a response to the increased presence of these 
radicals by minimising the sensitivity to stress-induced apoptosis (Schreck et al., 1992). 
The process of FBGC formation is not yet fully understood, but involves the fusion of 
macrophages into multinucleated cells, although the upregulation of a range of 
cytokines has been demonstrated as being important for fusion to occur, with IL-4 and 
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IL-13 typically identified as two of the more important genes (Helming et al., 2007; 
Ward et al., 2008). However, IL-4 was not found to be upregulated at this time, and IL-
13 was untested on the array although as previously shown by Zheng, ilomastat is 
known to modulate IL-13 expression in-vivo (Zheng et al., 2000). Similarly, no 
upregulation of vitronectin was found in either data set, an ECM component that is 
known to be important in FBGC formation, although it is possible that vitronectin 
release preceded day 5 and was secreted from invading inflammatory cells as opposed 
to the cells within the conjunctival tissue for adsorption onto the surface of the ilomastat 
tablet (Amy K Mcnally et al., 2008). 
Despite this, it has been demonstrated that the surface chemistry of the implanted 
foreign body can further alter macrophage mRNA expression values, protein secretion 
and attraction, with studies suggesting that in some situations IL-1, IL-6 and TNF-α are 
more important in the initial foreign body reaction (for example, both Bonfield and 
Marques have found IL-6 to be the most secreted protein following in-vitro testing); as 
such, further analysis into the interaction of macrophages and the ilomastat tablet may 
prove useful in understanding the foreign body reaction as seen in this study (Bonfield 
et al., 1992; Marques et al., 2004). Nonetheless, as the multinucleated cells begin to 
surround the implanted foreign body, the tissue modelling stage beings, with this stage 
characterised by the upregulation of MMPs and subsequent collagen deposition and 
remodelling, all of which had components upregulated within the data set. Analysis of 
cell-culture supernatants by Jones and colleagues using an in-vitro FBR model 
implicated MMPs -9, -13, TIMP-1 and TIMP-2 as being critical to the FBR, although the 
sensitivity limits of the protein array used within this study may have limited the 
detection capabilities of other MMPs (J. A. Jones et al., 2008).  
The use of a broad-spectrum inhibitor known to inhibit MMP-1 reduced FBGC formation 
in the same study, although due to its non specific MMP targeting it is difficult to state 
that MMP-1 is required for this the FBR as put forward by the author; instead specific 
inhibition or knockdown studies would be required in order to decipher the role of MMP-
1. Furthermore, although a range of substrates were analysed in the Jones study, the 
lack of knowledge as to the interaction of macrophages with the ilomastat tablet limits 
the conclusions that can be drawn from such studies in the application to this dataset. 
Other publications, such as that by Luttikhuizen and colleagues instead demonstrated 
the importance of MMP-2, together with the aforementioned MMPs -9, -12 and -13, as 
well as the upregulation of IL-1, TNF-α and IL-6 using an in-vivo model of the FBR 
(Luttikhuizen et al., 2006). Similarly Junge and colleagues were able to show that 
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following hernia repair using polymer meshes that are known to induce an FBR, high 
levels of MMP-1 staining was observed within the reaction area.  
Despite these mixed, inconclusive, reports in the literature, within this ilomastat study 
no elevation in either MMP-1 or -2 was observed suggesting one of two outcomes: a) 
these MMPs are not required during the FBR to an ilomastat tablet at day 5, or b) that 
ilomastat was able to modulate the expression of these MMPs [as was previously been 
shown in-vitro (5.3.3.4), as well as potentially in the injection group of this study]. The 
MMPs that did show increased expression (MMP-9, -12 and -13) have previously been 
demonstrated to not have their gene expression altered following in-vitro ilomastat 
treatment (5.3.3.4). In order to fully assess whether, despite the foreign body reaction, 
the ilomastat tablet remained functional in releasing ilomastat either direct protein 
quantification of the MMP levels within the tissue via ELISA, immunohistochemical 
analysis, or in-situ zymographic analysis would be required; alternatively sampling of 
the aqeous for drug detection  [such as through the use of the HPLC method 
developed in chapter 5 (5.3.4)] may prove useful, although the detection limit of such 
methods may not currently be low enough.  
Alternatively, the radiolabeling of ilomastat would provide an improved method of 
detection within tissue, but is faced with many of the issues previously discussed 
(5.1.4.2). Since this study was undertaken it has been demonstrated on more than one 
occasion that capsule formation is indeed occurring, with both visual (Figure 6.36) and 
histological confirmation having taken place (data collected by A. Lockwood, not 
shown), a finding that had not been documented in previous in-vivo studies when 
testing the ilomastat tablet (S. D. Georgoulas, 2010). With the emergence in our 
understanding of the capsule formation, it is now of interest to find out whether the 
tablet remains functional despite being encapsulated. Further histological analysis of 
the bleb after thirty days of study will be required to fully determine whether the 
ilomastat bleb is functioning after 30 or more days; however, using the current gradient 
system, despite the capsule formation, it suggests that the tablet does continue to 
release drug with blebs appearing functional after such a period of study (S. D. 
Georgoulas, 2010). Nonetheless the dataset analysed here has served as important 
tool in identifying the early markers of this potential side effect of the tablet. Subsequent 
studies, and further continuation of the development of the ilomastat tablet, will likely 
require the use of excipients within the tablet to improve its solubility, or alternatively, 
the use of a secondary therapeutic to control the FBR. This study has highlighted a 
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number of targets that could serve to control this response and as such is an area that 
warrants further investigation. 
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Figure 6.35 - A graphical representation of the foreign body reaction. 
The foreign body reaction takes place over several weeks (in humans) in a process that bares high similarities to that of the wound healing response. Initial inflammatory 
stages are marked by the invasion of macrophages which, following the upregulation of various inflammatory cytokines as denoted in the graphic, form foreign body giant cells, 
which form over the surface of the foreign body. Over time the deposition of ECM components including different collagens leads to the formation of dense, crosslinked, 
collagenous capsule surrounding the foreign body. Image adapted and redrawn from images found in the following citation (Van Bilsen, 2008).
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Figure 6.36 - Capsule formation sound the ilomastat tablet following GFS. 
Figure A shows the location of the tablet in the subconjunctival space prior to removal, with the tablet 
located toward to the rear of the bleb as denoted by the white arrow. Figure B shows a magnified view of 
the table following the removal of the conjunctiva allowing visualisation of the fibrotic capsule. Figures C 
and D show the tablet following removal with the fibrotic capsule present around the tablet. Images 
supplied by Dr Sumit Dhingra.
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6.5 Conclusion 
In summary this chapter has described novel pathways which MMC and ilomastat 
appear to regulate including inflammatory pathways such as the ILK pathway and the 
mTor signalling pathway as well as genes that highly correlated with cell death, cell 
movement and cellular proliferation. Whilst the results of the ilomastat tablet microarray 
have highlighted an unwanted response in the form of a foreign body reaction, it has 
also highlighted specific targets that could potentially be modulated through combined 
therapeutic intervention. Further studies will be required to determine whether the 
foreign body reaction can be prevented through either altered surgical technique, the 
use of additional theraputics or a change in formulation of the ilomastat tablet 
potentially requiring the use of excipients to improve the release rate. The benefits of 
ilomastat have previously been demonstrated when using a non-tablet delivery method, 
and the microarray profile of tissue treated with a single injection of ilomastat shows the 
potential pathways (such as the downregulation of key inflammatory genes) through 
which ilomastat may regulate the wound healing response outside of direct MMP 
inhibition. 
  
Chapter 7 General Discussion and Overall Conclusions 
  345 
Whilst classically drugs to control scarring have been delivered through peri-operative 
short-term sponge applications or post-operative subconjunctival injections, this study 
has demonstrated that drugs which had been previously developed into tablets exert a 
wide range of biological effects that stretch far beyond their perceived target.  
 
Whilst the 5-FU tablet had been previously developed by Dr. Ru, its biological 
effectiveness had never been demonstrated. Whilst a range of concentrations have 
over the past 20 years been tried both in-vitro and within the clinic itself, few have ever 
tried a prolonged, sustained dose of 5-FU at a lower dose than would be conventionally 
used. The results from the studies described within Chapter 3 it is clear that using the 
regimen described within this thesis (6 mg/ml for 8 hours) is at least as effective as 
current dosing strategies with the possibility of actually having an advantage in limiting 
the amount of initial cell death that takes place following administration. This cell death 
is one of the underlying causes of side effects associated with current cytotoxic use 
within the clinic and as such present the 5-FU tablet as a candidate for further 
investigation within a laboratory situation through the use of an in-vivo model of 
glaucoma filtration surgery. Complications are observed when using the current 
regimen in-vivo and as such it provides an ideal model to examine whether the 5-FU 
tablet can function as effectively, or better, in an in-vivo situation.  
Furthermore, this study has shown, for the first time, which pathways are altered upon 
the application of a second cytotoxic agent, MMC, 5 days into the wound healing 
processs in-vivo. Whilst this drug has been extensively used for over 20 years, this is 
the first study that documents the changes in gene expression within the tissue of the 
conjunctiva following GFS. Predictably, many genes had strong associations with 
apoptosis, although it was surprising to find that many were downregulated including 
those related to the 14-3-3 and p38 MAPK signalling pathways, suggestive of a 
response by cells within the tissue to limit the damage caused by the presence of this 
drug. Responses such as these have been previously documented following the use of 
anti-cancer agents where resistance builds up and demonstrates why some people 
may still suffer from failed glaucoma surgery due to scarring if a natural, albeit small, 
resistance to these cytotoxics exists within the body. The downregulation of both 
cytoskeletal genes (such as Wave and Actin) as well as many MMPs highlight however 
ways in which cells that do remain function, at least initially, poorly in the wound 
healing response. If it is these genes that, due to their downregulation, underlie why 
MMC functions outside of simple apoptosis then these genes present themselves as 
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candidate targets for future, novel, drugs. Correlations with multiple in-vitro studies, 
including those within this study, were also observed such as the downregulation of 
growth factor receptors again indicating targets that may be ideal targets for future 
drugs. 
 
The bevacizumab tablet was similarly demonstrated to function in-vitro at least as 
effectively as bevacizumab solution in inhibiting HUVEC proliferation, inhibiting gene 
expression and limiting the amount of sprouting and network formation seen in an in-
vitro model of “angiogenesis”. These results demonstrated that the actual fabrication of 
the bevacizumab tablet did not affect the integrity of the antibody and allowed it to 
remain fully functional when used in a biological model. Since these studies were 
undertaken, further work has now gone on to demonstrate that these tablets can work 
in an in-vivo model of glaucoma filtration surgery and perform better than single 
injections of bevacizumab (Khalili, 2011). Outside of angiogenesis, bevacizumab may 
also function to limit the activity of HTFs as, for the first time, this study has 
demonstrated the direct effects of VEGF on HTFs in-vitro. This study demonstrated 
VEGF can increase the rate of fibroblast proliferation, as well as being able to 
upregulate the gene expression of MMP-2 and MMP-9 as well as the actual protein 
levels of MMP-1, suggesting VEGF plays at least a small role in the wound healing 
response outside of angiogenesis and as such remains a valid target for groups 
pursuing anti-VEGF drugs as a drug to augment current treatments (Kahook, 2010; 
Mahdy, 2010). 
However, whether VEGF is the best target for controlling wound healing, or whether 
these effects are solely down to VEGF inhibition are still unknown. This study was able 
to demonstrate that, somewhat surprisingly, both trehalose and hyaluronic acid can 
play a role in limiting the proliferative ability of both HUVECs and HTFs, with trehalose 
also shown to limit the contractile ability of HTFs at high doses. To date, no studies 
have been undertaken that have investigate how trehalose releases from the tablet and 
so accurate studies as to the concentration within the tissue are unknown and require 
further study. Despite this, a number of groups are pursuing research into using only 
trehalose as an anti-scarring agent following glaucoma filtration surgery and the data 
from this study only aids in their argument (Takeuchi et al., 2010). 
 
Finally, this study explored the effects of the MMP inhibitor both in-vitro and in-vivo in 
order to understand both the downstream effects of MMP inhibition as well as the 
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effects of altering the delivery of the drug. Using in-vitro experiments, this study 
demonstrated that ilomastat could act beyond MMP inhibition through the inhibition of 
fibroblast proliferation, alter MMP gene and protein production and inhibit 
sprouting/vessel growth using a model of angiogenesis. These effects, though not 
completely surprising due to existing reports within the literature, illustrate the 
importance of understanding the roles of drugs outside of the initial target and the 
downstream consequences of protein inhibition. This study confirmed the previously, 
surprising, documented report that the addition of ilomastat can cause a 
downregulation of MMP expression (T. Wong, 2004). Typically, in reduction to protein 
in the extracellular matrix, a cell will respond by upregulating production of that 
particular protein, however in this case that does not occur. Reasons for this were not 
probed within this study, but further work may examine the mechanisms underlying this 
with clues provided by the in-vitro microarray such as the downregulation of the STAT6 
signalling, a pathway known to be critical for MMP-1 expression (5.1.2.1). A number of 
phenotypic changes were observed in the immunocytochemical staining and from the 
in-vitro microarray screening reasons behind these changes are present, such as the 
downregulation of ACTG2, CXCL12 and ACTA2. 
Aside from the in-vitro findings, from in-vivo analysis of filtering blebs five days after 
GFS an expected response was observed in operated but untreated tissue where the 
upregulation of MMPs, inflammatory genes and ECM proteins characterised the most 
highly altered genes. However in blebs treated with a single injection of ilomastat the 
downregulation of a number of pro-inflammatory genes was observed, with a number 
of correlations found between an in-vitro and in-vivo study of ilomastat including the 
downregulation of MMP-1, IL-1 and PLAU. This highlights a secondary for the ilomastat 
in being able to directly modulate the inflammatory response, demonstrating the 
benefits of administering the drug early in the wound healing response and not just at a 
later timepoint when MMPs are most active. 
However, despite these encouraging results the gene expression analysis of an 
ilomastat tablet treated bleb revealed a foreign body reaction-like response, with a 
number of genes upregulated that highly correlate with such a process including MMP-
12, MMP-13 and several heat shock proteins. Subsequent studies have seemingly 
confirmed this foreign body response to the tablet (Figure 6.36), suggesting that an 
alteration in the tablet formulation is required. Nonetheless, this does however suggest 
that the success of the ilomastat tablet that has previously been reported may have 
been because the tablet was acting as a spacer between the conjunctiva and sclera, 
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preventing sealing of the two layers and as such keeping a space into which aqueous 
humor can flow preventing surgical failure. Such spacer devices are not novel, with a 
number of groups reporting high success in their use (Sarkisian, 2010). As such, in the 
ongoing development of the ilomastat tablet thought could be directed toward designing 
an implant that has higher biocompatibility with only a small amount of drug 
interspersed throughout the implant that is released as the implant is degraded.  
Alternatively, this the study has highlighted a number of genes, which may act as a 
target for secondary theraputics in controlling this initial foreign body response 
including IL-1β and TNF-α. 
  
Overall, this study has highlighted the potential of a number of agents in controlling 
wound healing following glaucoma filtration surgery. However, in future experiments 
further questions must be asked as to the biocompatibility of the implant, as well as the 
effects of any excipients, before in depth in-vivo studies are undertaken. 
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9.1 An animated video demonstrating glaucoma filtration surgery 
Please refer to movie 9.1 found on the accompanying CD-ROM. 
9.2 In-vitro microarray differential gene expression list 
Please refer to Excel file 9.2 found on the accompanying CD-ROM. 
9.3 In-vitro microarray networks generated using IPA 
Please refer to Excel file 9.3 found on the accompanying CD-ROM. 
9.4  In-vivo Nanochip traces 
Please refer to PDF file 9.4 found on the accompanying CD-ROM. 
9.5 In-vivo microarray differential gene expression list 
Please refer to Excel file 9.5 found on the accompanying CD-ROM. 
9.6 In-vivo microarray networks generated using IPA 
Please refer to Excel file 9.6 found on the accompanying CD-ROM 
9.7 Microarray Background Information 
9.7.1 Introduction 
The genomic library of a eukaryotic cell resides within the 23 pairs of chromosomes 
made up of double helices of DNA which themselves are composed of complementary 
bound nucleotides arranged in a tightly coiled structure. The human genomic library is 
composed of 20,000 - 25,000 genes (as of September 2010 the NCBI record contains 
23,739 fully identified coding sequences), which are coded by particular segments 
along specific DNA strands (Ncbi, 2010a). This library provides the blueprint for the 
creation of functional proteins, with copies of these blueprints (genes) made by 
intracellular machinery to form messenger RNA (mRNA). The code contained within 
the sequence of mRNA is translated by the ribosome to create functional proteins. The 
regulation of the translational process from gene to protein is otherwise known as gene 
expression. An upregulation in gene expression typically results in an increase in 
protein, whereas a downregulation in gene expression typically results in a decrease in 
protein (Bichindaritz, 2010). Various tools are available to scientists to understand the 
functional state of a cell, whether it is in a diseased state or following drug treatment, 
through interrogation at either the genomic or protein level. However, many of these 
require the investigation of only one gene or protein per experiment. In 1995, Schena 
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and colleagues published a paper that would change scientists approach to 
understanding the changes in gene expression: the cDNA microarray (Schena et al., 
1995). Whilst microarrays had been under development for sometime, the publication 
of an in-house produced microarray allowed scientists to rapidly investigate the 
expression profiles of multiple genes in single experiments, at relatively low cost 
following initial set up (Southern, 2001). Since it’s inception various modifications to the 
microarray have resulted in the generation of different platforms, as summarised below. 
9.7.1.1 The principles of microarray technology 
Microarray technology allows the high throughput quantification of the expression 
levels of thousands of genes (up to the whole genome) in one single experiment. The 
primary idea behind the microarray is to exploit the complementary base pair binding 
that occurs between single stranded probes attached to a hardened surface and a 
labelled DNA/RNA fragment (referred to as a product or target). Upon the binding of the 
labelled target to it’s complementary probe, relative quantification of the expression 
levels of different genes can be calculated through a fluorescent detection system; with 
probes located at precise locations within the chip, it is possible to detect which genes 
are up- or down-regulated based upon the fluorescent profile of the array. During the 
development of the microarray chip two different approaches were used to manufacture 
the array itself. One method is based upon the physical deposition of cDNA probes 
onto a solid slide (spotted, ‘cDNA’ arrays) or the in-situ synthesis of oligonucleotide 
probes onto a solid surface (oligonucleotide arrays) (Fodor et al., 1991; Schena et al., 
1995). With this difference in chip fabrication a number of differences exist between the 
systems resulting in each method having its own pros and cons. 
9.7.1.2 The cDNA array 
The rapid uptake of microarray technology is widely acknowledged as being pioneered 
by the publication of Schena and colleagues in 1995, whereby pre-synthesised cDNA 
probes were printed onto predetermined locations (forming spots) on glass microscope 
slides (Schena et al., 1995). Each spot is typically 100 – 150 µm in diameter and is 
formed from a volume of 0.5 - 10 nl, with each equally spaced apart. Despite the 
advances in microarray technology, glass slides have remained the printing material of 
choice for cDNA arrays due to, amongst various reasons, their low cost, low 
background fluorescence and rigidity (Affara, 2003; Lyons, 2003). The formation of the 
cDNA probes usually occurs through the amplification (via PCR) of products derived 
from either cDNA clone sets or custom cDNA libraries (Wildsmith et al., 2001; A. S. 
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Wilson et al., 2002). Typically each probe is 0.2 – 1.2 kilobases (kb) in size with Heller 
and colleagues finding no significant differences in signal intensities between this 
range, suggesting that a probe as large as 1.2 kb functions as well as one 0.2 kb in 
size (Heller et al., 1997). However, these probes far exceed the size of the probes used 
in the oligonucleotide arrays and as such limit the number of probes, and thus spots, 
available per chip; today it is possible to print a maximum of around 20,000 – 30,000 
spots per chip (Junbai Wang, 2008; Gry et al., 2009). Whilst this allows for whole (or 
near whole) genomes to be spotted onto a single array this would allow only one probe 
per gene to be present (Churchill, 2002). Whilst the increased size of the probe offers 
an increased detection sensitivity compared to the much smaller oligonucleotides, 
higher levels of cross-hybridisation are observed; if two individual probes have similar 
sequence homologies it may result in failure to differentiate between two members of 
the same gene family, and thus a failure to specifically detect the individual genes. 
Heller and colleagues were able to demonstrate that high levels of cross hybridisation 
were observed in probes that shared a 70-90% sequence homology (Heller et al., 
1997). To this end, cDNA arrays are more typically composed of a two-probe design 
with more targeted gene selection required prior to the array fabrication. 
For gene expression analysis, the cDNA array, rather than measuring expression 
levels directly, measures the differential expression of any given gene through the 
difference in intensity level between red and green fluorescence (as described in 
9.7.1.4 and graphically represented in Figure 9.1). Whilst this has the benefit of being 
able to rapidly observe differences between two sample sets, such a set up requires a 
much more complex experimental design due to the number of increased variables 
present. One of the most important variables, is that of dye bias, or the increased 
binding of one colour dye over another, requiring true technical replicate dye swaps 
(the exposure of the same biological sample to each dye) which are run on separate 
arrays. Other variables that require careful monitoring include washing bias (the 
position of a single array on a multi-array slide means washing of the slide may not 
exactly be the same in an array at one end of the slide compared to the other) and 
hybridisation inconsistencies, such as one array at one end of the chip having 
increased hybridisation of targets to the probes compared to another array on a single 
slide. Whilst using more arrays to account for these variables can actually lead to 
improved detection rates, and improved quantification of gene expression, it also 
instantly begins, at minimum, doubling the number of arrays required. When multiple 
sample groups are present, the experimental design can rapidly increase in size, 
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requiring careful planning to combine technical efficiency, biological replicates and of 
course, cost. To overcome these problems, the cDNA microarrays have an advantage 
over the oligonucleotide arrays in that arrays can be created “in house”, resulting in a 
low cost for array construction. The arrays themselves can be very tightly targeted to 
small populations of genes known to be of interest rather than arraying a whole 
genome, which typically results in a large percentage of genes that do not, statistically, 
alter. However in-house fabrication can itself cause issues, such as spotting errors 
(inconsistent spot size due to inconsistent pipetting), and as such in house fabrication 
is now losing ground due to the high tech, and relatively low cost, options offered by 
companies such as Agilent (Lyons, 2003; Bammler et al., 2005). Where cDNA arrays 
once gave scientists the flexibility in quickly generating small microarrays capable of 
targeting a small subset of genes, it is now possible to design a custom arrays based 
upon annotated sequences available from a number of databases before submitting 
the design to a company such as Agilent for more accurate printing using either cDNA 
probes or alternatively, custom oligonucleotides. 
9.7.1.3 The oligonucleotide arrays 
The oligonucleotide array is generated by the in situ synthesis of oligonucleotides 
through either photolithography (as associated with Affymetrix) or inkjet printing (as 
associated with Agilent). The exact mechanisms of photolithography and inkjet printing 
are beyond the scope of this thesis but can be found within the original publications of 
these techniques (Fodor et al., 1993; Pease et al., 1994; Hughes et al., 2001). This “on 
chip” printing of small sized probes has allowed for the generation of arrays with 
multiple probes per single gene compared to the single probe setup often found on the 
cDNA array. The current GeneChip Human Gene 1.0 ST Array, developed by 
Affymetrix and designed for human gene expression analysis, contains probe sets (a 
group of probes that are designed for a single gene) covering 28,869 identified human 
genes [though some of these are now redundant as the genome has been updated – 
the latest Affymetrix GeneChips are based upon the publications of Human Genome 
revision 36 (Karolchik et al., 2008)]. Each GeneChip contains a median number of 26 
distinct probes per gene (that form the probe set), resulting in 764,886 distinct probes 
across the array with each probe 25-mer (base pairs) in size. Previous Affymetrix 
probesets contained one mismatch (MM) probe for each perfect match (PM) probe, 
whereby the 13th nucleotide in each MM probe was replaced with an incorrect 
nucleotide, scrambling the probe (for example, the replacement of a G with a C). The 
MM probe was used as part of the internal quality control checks, but as statistical 
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algorithms improved the MM probes were no longer used, rendering them redundant; 
replacing the MM probes are approximately 20,000 generic background probes that 
some QC models take into account, as well as an increase in probe numbers per probe 
set. Along with the background probes a series of internal control probes also exist on 
the array that allow troubleshooting during the hybridisation process. The GeneChip 
platform offers only one array per slide, and only sample per array; rather than using a 
competitive binding strategy as in the cDNA arrays (as well as the Agilent 
Oligonucleotide arrays) the Affymetrix arrays measure absolute mRNA levels of single 
samples, using a single fluorescent dye, and require multiple chips to compare 
between samples. Similar to the generation of the Affymetrix GeneChips are Agilent’s 
SurePrint gene expression microarrays, which differ from the photolithographic 
produced Affymetrix chips in such a way that individual nucleotides are inkjet printed 
into spots and probes built up to a final length of 60-mer; this technology allows for very 
rapid, flexible, array fabrication allowing groups the flexibility to generate microarrays of 
their own design. 
The use of oligonucleotide arrays offers a number of advantages over cDNA arrays 
including the speed in which arrays can be fabricated, improved specificity due to an 
increased number of probes per gene, as well as a high level of reproducibility. 
However, the array is dependent on the known genomic sequence in order to generate 
the probe sets. Whilst full sequencing has occurred for a number of organisms, many 
that are used in research are still incomplete meaning that in some occasions the 
cDNA array may benefit the user. Whilst advantages are present, several 
disadvantages are also associated with these arrays including their cost (GeneChips 
are traditionally more expensive per array due to only allowing the use of single 
samples per array) as well as a lower sensitivity and binding affinity when compared to 
the cDNA arrays (although this is countered through the presence of multiple probes). 
9.7.1.4 Hybridisation 
In order to detect changes in gene expression, be it relative or absolute, samples must 
first be labelled to allow such detection before being hybridised to the array. Initially 
samples of RNA are isolated from either tissue or cell samples before being quality 
assessed (QC). Passing QC leads to one, or more, of a number of steps producing 
either labelled RNA or labelled cDNA. The Agilent platform utilises the fluorescent 
cyanine dyes Cy-3 and Cy-5 to detect changes in gene expression, with two samples 
hybridised to a single array (one labelled Cy3 and the other Cy5). Based upon the 
principle of competitive binding, if any one gene is upregulated in the sample labelled 
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Cy-3, increased binding of the Cy-3 labelled target to that probe will be seen and when 
the array is scanned the spot will appear green. If equal expression were observed the 
dot would appear yellow due to an equal binding of both red and green-labelled targets. 
Whilst this two-dye approach is essential for cDNA microarrays, it is possible to use 
either a single- or two-dye approach on Agilent’s oligonucleotide arrays, allowing the 
generation of an absolute level of gene expression. A graphical representation of a 
two-colour microarray is shown in Figure 9.1. 
9.7.1.5 Image processing 
Following hybridisation the array is washed and transferred to a scanning machine 
where the chip is analysed using confocal microscopy, resulting in an image displaying 
the distribution of fluorescence across the array. A number of different scanners are 
available with subsequently outputting a number of different files (the differences 
between Agilent and Affymetrix are discussed below). The image of the slide that is 
produced is manually inspected to look for any misalignment features using built in 
alignment probes, before the final image is exported together with values expression 
values assigned to each probe. Following the extraction of the raw data the 
downstreatm data analysis can be undertaken beginning with post-hybridisation quality 
control checks. 
9.7.1.6 Data analysis 
The raw data collected from the scanning of the array must, before any differential 
expression analysis takes place, be quality assessed to ensure its integrity. The 
unprocessed raw data is subject to both technical and sample variation that will have 
occurred during the processing of the array; it is therefore critical that the raw data be 
put through a series of processing methods to create data which is accurate, 
particularly when comparing groups of samples. In brief, the samples collected are 
subject to a multi-step process of background correction and normalisation followed by 
the output of statistical analysis of the normalised data providing each gene with a fold 
change value as well as p-value; for two-group comparison the most common 
approach for the statistical analysis is through the use of a modified t-test with a 
Bayesian approach (G. K. Smyth, 2004). The exact methods, and algorithms, that are 
used differ slightly for single colour and two colour microarrays and these differences 
are explained within their own sections (2.11.1.3 and 2.11.2.3 respectively). 
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Figure 9.1 – A graphical representation of a two-colour microarray. 
Each microarray contains thousands of spots, with each spot representing a particular gene. Probes that 
reside in each spot are hybridised to their targets (labelled cDNA) and when scanned with a confocal laser 
the cyanine-labelled targets, and thus spots, appear red, green or yellow. Red spots indicate the 
upregulation of the gene within the sample labelled red, whereas yellow spots indicate the gene has 
neither been upregulated nor downregulated with equal hybridisation of the two samples occurring.  
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Figure 9.2 – A graphical representation of quantile normalisation. 
Panel A shows the PM intensity distribution of a single sample following background correction. Panel B 
shows the cumulative distribution of these values, with panel C shown the cumulative distribution of the 
mean values of the quintiles from each array. Any one single probe value from sample A is matched to its 
position in the cumulative distribution which can be converted to the normalised value and plotted into a 
normalised PM intensity distribution graph (panel D). Image obtained from the supplementary material of 
the cited reference (Bolstad et al., 2003). 
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9.8 In-vitro microarray data 
 
 
Figure 9.3 – Images obtained during QC from the in-vitro ilomastat microarray experiment. 
Image A shows the box plots obtained following normalisation, with similar means and interquartile ranges 
clearly visible. Figure B shows the density of the probe intensities with all samples overlapping indicating 
that normalisation had produced comparable results. Images C and D show the MA plots for the control 
and ilomastat treated samples respectively. All samples had similar distribution with no significant 
deviation from the mean indicating good agreement between the biological replicates. 
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Figure 9.4 - Images obtained during QC from the in-vitro ilomastat microarray experiment. 
Image A shows the plot of the positive and negative control together with an area under the curve (AUC) 
plot. The AUC fell between 0.8 and 0.9 indicating there was good separation between the positive and 
negative controls. Images B and C show the polyA and BAC probeset graphs respectively. The probesets 
displayed expected results, with each of the probes having the expected rank order. 
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Figure 9.5 - The correlation plot showing the array-array intensity correlation between the 
samples.  
Samples from within the same groups all had high correlation coefficients with no outliers detected 
indicating high quality data. 
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Figure 9.6 – A volcano plot showing the genes altered in HTFs following 72 hours of treatment with 100 µM of ilomastat.  
Genes with a p value less than 0.05 and a fold change greater or lower than 1.5 are coloured green. The horizontal blue line indicates the p value cut off of 0.05. All values 
above this line therefore have a p value lower than 0.05. The vertical blue lines indicate the cut off for a fold change of ±1.5. Genes to the left or right of these lines have a fold 
change greater or lower than 1.5.
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9.9 In-vivo microarray normalisation data 
 
 
 
 
 
 
Figure 9.7 - Normalisation of the eight in-vivo array samples revealing a single outlier. 
During normalisation an outlier was observed in the array data, which coincided with a sample treated with 
MMC. It was decided to remove this array before continuing analysis. 
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Figure 9.8 - MA traces of the seven microarrays used for in-vivo gene expression analysis. 
Images A and B show the MA plots for in-vivo arrays pre and post normalisation respectively. All samples 
had similar distribution post normalisation with no significant deviation from the mean indicative of good 
agreement between the biological replicates. 
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Figure 9.9 - Box plots and probe intensity traces of the seven microarrays used for in-vivo gene 
expression analysis. 
Image A shows the box plots obtained following between-array normalisation, with similar means and 
interquartile ranges clearly visible. Figures B-D show the density of the probe intensities pre normalisation, 
following within-array normalisation and following between-array normalisation respectively. Figure D 
showed good overlapping of the samples indicative of normalisation having produced comparable results.
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